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Abstract 
 
 
In pre-historic times, the sun was revered as a source of physical strength and 
vitality. Following the discovery of vitamin D in the 1920’s and the role of UV-
light in its production, research has focused predominantly on its effects on bone 
and mineral homeostasis. However, emerging evidence supports broader effects 
of vitamin D in modulating the cell cycle, tissue development and the response to 
injury. At a tissue level, skeletal muscle underpins the emerging concept that 
vitamin D exerts functions beyond bone. This is unsurprising as muscle and bone 
arise together from embryonic mesoderm and interact via complex 
biomechanical and humoural factors during post-natal life. In the clinical setting, 
vitamin D deficiency leads to concurrent defects in bone and muscle. In addition 
to an increased risk of fracture, patients with vitamin D deficiency report muscle 
weakness, myalgia and have a greater risk of falls. Precise, bio-molecular effects 
of vitamin D on muscle are unclear and hampered by contradictory reports on the 
presence of the vitamin D receptor (VDR) in this tissue. This thesis sought to 
address this question by examining four different models of murine muscle and 
by employing a range of established and novel techniques. VDR was clearly 
detected in skeletal muscle in vivo but this depended on specific experimental 
conditions. In vitro, VDR activation led to an intriguing anabolic effect with 
doubling in the diameter of C2C12 myotubes and an anti-proliferative effect in 
C2C12 myocytes. Myogenic precursor cells, isolated using a novel technique, 
also expressed VDR and functional CYP27B1 on the basis of luciferase reporter 
studies. In vivo, mice lacking VDR displayed significantly lighter muscles, 
smaller muscle fibres and increased nuclei to fibre ratio compared to wild-type 
(WT) mice. These data, together with higher VDR levels found in muscle of 
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young mice, support a predominantly developmental and anabolic role for VDR 
in muscle. In this thesis, vitamin D effects were not confined to development. 
Adult VDR knockout (VDRKO) mice and mice with diet-induced vitamin D 
deficiency displayed reduced grip strength which progressed with age. They also 
displayed activation of atrophy genes, suggesting links between vitamin D and 
muscle ageing. In the absence of VDR, muscle fibres displayed reduced uptake 
and storage of 3H-25(OH)D3. In summary, this thesis reports the presence of 
VDR in murine muscle and diverse effects of vitamin D/VDR signals on muscle 
development, anabolism, strength and 25OHD uptake. These findings in muscle 
are consistent with emerging roles of VDR at other sites in tissue pleiotropy, 
cardiac regeneration and response to tissue fibrosis. To confirm these direct 
effects and settle the controversy of VDR’s expression in skeletal muscle, the 
generation of muscle-specific VDR knockout mice is an essential, next step. The 
use of chromatin immunoprecipitation (ChIP) assays to define the VDR cistrome 
in muscle cells will further clarify potential interactions of VDR with TGF-B and 
genomic effects at this site. On the basis of findings presented in this thesis, the 
vitamin D pathway holds promise in the treatment of muscle disorders and in 
enhancing muscle repair.        
 
 
 
 
 
Chapter 1 – Introduction, Hypothesis and Aims 
References for this chapter are listed at the end of the Chapter 10. Abbreviations in 
Chapters 1 and 10 are defined in the text in order of appearance.   
 
Introduction 
The association between vitamin D deficiency and muscle disease is long-standing. 
More than three hundred years ago, the English physician Daniel Whistler reported 
the combination of “flabby, toneless muscles” and “flexible, waxy bones” in young 
children with nutritional rickets (1). More recently, adults with vitamin D deficiency 
have been reported to display muscle wasting and weakness in association with 
defects in bone mineralisation (2, 3). Whilst vitamin D’s effects on bone are well 
characterised, its effects on muscle remain elusive and subject to debate. This takes 
place within the broader controversy of whether vitamin D exerts extra-skeletal 
effects at all (4, 5). Although the vitamin D receptor (VDR) is expressed in a range of 
tissues not involved in bone/mineral homeostasis, its precise role at these sites is not 
fully understood. Observations made in the laboratory – particularly relating to its 
anti-cancer and immune-modulatory effects – have not always translated into robust 
clinical findings (5).  
 
In its comprehensive report, the Institute of Medicine concluded that clinical evidence 
for an extra-skeletal role of vitamin D was “not yet compelling” (6). In the 
controversy that ensued, meta-analyses with different perspectives on the clinical data 
and conflicting guidelines on the optimal daily intakes of vitamin D and serum targets 
were published (7-10). This debate shows no sign of abating and highlights the need 
for greater understanding of vitamin D biology, serving as a basis upon which its 
purported, non-classical roles may be pursued in the clinic. 
 Beyond bone, there is biologic plausibility for a role of vitamin D in skeletal muscle. 
Muscle and bone share their ancestral origin in the common mesenchymal stem cell 
and arise together from embryonic mesoderm. Following the formation of bone by 
endochondral or intramembranous ossification, skeletal modeling and remodeling 
relies continually on mechanical signals from muscle (11). Myogenesis relies on its 
master regulator Pax3 that drives differentiation of mesenchymal precursor cells into 
myoblasts, which subsequently fuse to form multinucleated syncytia (12).  
 
In post-natal life, bone and muscle function in close proximity and are regulated by 
overlapping genes, growth factors and mechanical cues (13). Muscle is dependent 
upon calcium for contraction, insulin sensitivity, and cellular plasticity (2). Since 
vitamin D is essential for calcium homeostasis, this at least indirectly links vitamin D 
activity to muscle function. Therefore, for these reasons, muscle stands at the frontier 
of the emerging, debated concept of vitamin D’s extra-skeletal functions.  
 
The aim of this thesis was to elucidate mechanisms by which vitamin D affects 
skeletal muscle, in particular how it may regulate muscle development, morphology 
and gene expression. One particular difficulty is that changes in serum calcium and 
phosphate levels – under the systemic control of vitamin D –independently lead to 
muscle changes (2, 14). This has been a major confounding factor in human and 
animal studies assessing muscle effects of vitamin D (2, 14, 15). In this thesis, cell 
and mouse models were employed in which serum calcium and phosphate levels were 
controlled thereby avoiding confounding observed effects of vitamin D on muscle. 
Parameters with direct relevance to a clinical setting – strength, muscle fibre size and 
atrophy – were examined in response to changes in vitamin D, thereby adopting a 
translational approach to this important question. 
 
In the published literature review, a number of unifying themes and controversies 
arising from human clinical, animal and cell studies on vitamin D and muscle were 
presented (The Roles of Vitamin D in Skeletal Muscle: Form, Function, and 
Metabolism, Endocrine Reviews 2013; 34(1):33–83) (2). This review – cited > 80 
times since publication – outlined the central controversy in this field, namely 
whether skeletal muscle responds in a direct fashion to vitamin D via the local 
expression and activity of the vitamin D receptor (VDR) in muscle.  
 
The first original research article in this thesis employed a cell model of skeletal 
muscle, namely C2C12 cells, to examine the presence of vitamin D signalling 
components and direct effects of vitamin D on muscle cells (Vitamin D Signaling 
Regulates Proliferation, Differentiation, and Myotube Size in C2C12 Skeletal 
Muscle Cells, Endocrinology 2014; 155(2):347–357) (16). Using a luciferase 
reporter system, C2C12 muscle cells were shown to express functional CYP27B1. 
CYP27B1 is the enzyme responsible for conversion of 25-hydroxyvitamin D 
(25OHD) into the bioactive hormone, 1,25-dihydroxyvitamin D (1,25(OH)2D). 
C2C12 muscle cells also expressed VDR and this protein increased in a dose-
dependent fashion in response to its natural ligand, 1,25(OH)2D (1- 100 nM). 
Treatment of developing C2C12 muscle cells with 25OHD or 1,25(OH)2D resulted in 
anti-proliferative effects due to changes in cell cycle genes. In later stages of 
differentiation (i.e. following fusion of myoblasts into myotubes), an intriguing 
growth-promoting effect was consistently found. C2C12 myotubes treated with 
25OHD or 1,25(OH)2D doubled in association with profound down-regulation of 
myostatin, a member of the TGF-β superfamily that negatively regulates muscle 
mass. These novel findings provided prima facie evidence that vitamin D directly 
affects muscle and exerts effects on muscle development and anabolism in a cell line. 
However, an important limitation of this study is the uncertain correlation between in 
vitro responses to vitamin D and in vivo physiology.  
 
In the second original research article, the in vivo expression of VDR in skeletal 
muscle was examined by RT-PCR, western blot and immunohistochemistry (The 
Vitamin D Receptor (VDR) is Expressed in Skeletal Muscle of Male Mice and 
Modulates 25-Hydroxyvitamin D (25OHD) Uptake in Myofibers, Endocrinology 
2014; 155(9):3227-37) (17). Using the specific VDR-D6 antibody, particular 
methodological factors (i.e. hyperosmolar lysis buffer) and appropriate experimental 
controls, VDR was successfully detected in mouse muscle, albeit at low levels. In 
vivo, VDR was localised within muscle fibres in both the cytoplasm and nucleus. 
Intriguingly, substantially higher levels of VDR were found in muscle of younger 
mice suggesting a developmental role of VDR in muscle. As conclusive proof of 
functional presence, a novel physiological role of VDR was demonstrated in 
modulating the uptake of 25OHD within muscle fibres. Therefore, this work clearly 
demonstrated the presence of VDR in muscle and was published with accompanying 
editorial articles (i.e. News/Views and Counterpoint articles) (18, 19). These articles 
and the invited response to the Counterpoint article have been included in this thesis 
(20). 
 
The third manuscript, submitted for publication, examines functional effects of 
vitamin D and VDR on muscle strength and morphology (Vitamin D Receptor 
Ablation and Vitamin D Deficiency Result in Reduced Grip Strength, Altered 
Muscle Fibers and Increased Myostatin in Mice, Calcified Tissue International, 
Submitted). Diet-induced vitamin D deficiency led to progressive reductions in grip 
strength in mice and there was a significant dose-dependent effect of VDR on grip 
strength (i.e. VDR +/+ mice  > VDR +/- mice > VDR -/- mice). In the absence of 
altered serum calcium and phosphate levels, these findings supported a direct in vivo 
effect of vitamin D signalling on muscle strength. Developmental defects in skeletal 
muscle from VDR knockout (VDRKO) mice were also demonstrated. These included 
a reduction in muscle mass, reduction in muscle fibre size and increased nuclei to 
fibre ratio. To explain these changes, VDRKO mice showed altered expression of 
myogenic regulatory factors and increased myostatin. Consistent with changes 
reported in C2C12 cells, muscle fibre hyper-nuclearity may relate to altered cell cycle 
regulation of muscle precursors during embryogenesis in the absence of VDR. This 
manuscript therefore supports developmental effects of VDR on muscle and the 
influence of vitamin D and VDR on muscle strength.   
 
A research letter published in Endocrinology reported differences in the skeletal 
phenotype of VDRKO mice (“Direct Effects of VDR Ablation on Bone Mass”) (21). 
In response to a publication describing increased bone mineral density/mass in VDR 
heterozygote mice (VDR +/-) (22), no such difference was found on DXA scan in a 
group of 7 VDR heterozygote (VDR+/-) males and 14 WT littermates. Possible 
reasons for this discrepancy included the different genetic bases for these models (i.e. 
ablation of exon 2 vs. exon 3) and the presence of a biologically active mutant VDR 
protein in the former model (23). This highlights the complexity of VDR’s effects on 
bone and suggests that an integrated approach in examining musculoskeletal roles of 
VDR may yield further information.  
 
During this period of research, a contribution was made to another published work 
that described a novel technique to isolate muscle stem cells (i.e. satellite cells) from 
whole muscle (Grb10 deletion enhances muscle cell proliferation, differentiation 
and GLUT4 plasma membrane translocation. Journal of Cell Physiology 2014 
Nov;229(11):1753-6) (24). My contribution was in examining alterations in the cell 
cycle associated with ablation of Grb10 (growth-factor receptor-bound protein 10), in 
muscle stem cells. Techniques described in the study were also used in isolating 
muscle stem cells from VDRKO and WT mice, as described in this thesis (17). 
 
Three published review articles have been inserted in this thesis (Chapter 8). The first 
two articles present recent clinical data on vitamin D’s role in various aspects of 
muscle function, including insulin sensitivity, physical/athletic performance and age-
related muscle changes (Effects of vitamin D in skeletal muscle: falls, strength, 
athletic performance and insulin sensitivity, Clinical Endocrinology 2014; 80: 
169–181; and Vitamin D and muscle function in the elderly: the elixir of youth? 
Current Opinion in Clinical Nutrition and Metabolic Care 2014 Nov;17(6):546-50) 
(3, 25). The third of these articles discusses the integrated biology of muscle and bone 
and novel therapies for musculoskeletal diseases, including a section on vitamin D 
(Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One 
Stone? Current Osteoporosis Reports 2014;12(2):142-53) (26).  
 
Three additional review articles have been included in this thesis (Chapter 9). One, 
published in Molecular and Cellular Endocrinology, discusses the role of vitamin D 
in integrating musculoskeletal biology, specifically in development, ageing and 
injury. Another review on which I am co-author was published in Bone and covers 
integrated effects of vitamin D on bone-muscle interactions. Another review on which 
I am co-author was published in Nutrition and Dietary Supplements and discusses 
metabolic effects of vitamin C and D, particularly on the prevention of diabetes.  
 
Over the course of this thesis, these published and submitted works have addressed 
the question “does vitamin D directly affect skeletal muscle?” Using a basic model of 
muscle – C2C12 cells – the presence of an innate vitamin D endocrine system in these 
cells with distinct developmental and anabolic effects was found (16). To address the 
physiological relevance of these in vitro findings, the presence of VDR was examined 
in whole muscle in vivo. Here VDR was found to be present at low levels and its 
detection depended on a range of methodological factors (17). A novel role for VDR 
in the uptake of 25OHD in muscle fibres confirmed its presence and physiologic 
relevance at this site. Finally, in experiments examining muscle morphology, VDR 
exerted direct effects on muscle mass, fibre size and strength. Taken together, these 
findings indicate that vitamin D does directly affect skeletal muscle, supporting a 
predominantly developmental/pleiotropic function of VDR at this site and bringing 
closure to this long-standing controversy. 
 
 
 
 
Hypothesis 
To explain the phenomenon of impaired muscle function in subjects with vitamin D 
deficiency and VDR mutations, vitamin D plays a vital role in skeletal muscle 
morphology and physiology via local expression and activity of components of its 
signalling pathway.   
 
Aims 
The aims of this thesis were to: 
• investigate effects of vitamin D on skeletal muscle using a range of in vitro 
and in vivo mouse models. 
• determine whether the vitamin D receptor (VDR) is expressed in skeletal 
muscle and consider technical and methodological reasons for this 
controversy.  
• examine specific roles of vitamin D signalling, independent of calcium and 
phosphate, in skeletal muscle morphology, strength and development. 
• ascertain whether the vitamin D endocrine system holds promise in the 
management of debilitating muscle conditions, in particular age-related 
sarcopaenia and acquired myopathies. !
 
 
 
 
 
 
 
 
 
 !
Chapter 2 – Literature Review 
 
 
 
This chapter consists of a review of human clinical, animal and molecular studies 
examining effects of vitamin D in skeletal muscle. This was published in the 
February 2013 edition of Endocrine Reviews. The PhD candidate and primary 
author of this article, Christian Girgis, conducted the literature review, drew 
conclusions from the existing evidence-base and prepared the manuscript and 
figures for publication. This has been verified by co-authors (see Appendix). 
 
This review is presented in the current format (i.e. Times New Roman, font size 
12) for ease of reading and following this, in published pdf format. Figures, 
tables and references may be found within the published format.  
 
Abbreviations and spelling may differ between chapters, according to the 
specific guidelines of journals where these articles were published. 
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The Roles of Vitamin D in Skeletal Muscle: Form, Function and 
Metabolism (Endocrine Reviews 2013; 34: 33–83) 
 
Abstract  
Beyond its established role in bone and mineral homeostasis, there is emerging 
evidence that vitamin D exerts a range of effects in skeletal muscle. Reports of 
profound muscle weakness and changes in the muscle morphology of adults with 
vitamin D deficiency have long been described. These reports have been 
supplemented by numerous trials assessing the impact of vitamin D on muscle 
strength and mass and falls in predominantly elderly and deficient populations. 
At a basic level, animal models have confirmed that vitamin D deficiency and 
congenital aberrations in the vitamin D endocrine system may result in muscle 
weakness. To explain these effects, some molecular mechanisms by which 
vitamin D impacts on muscle cell differentiation, intracellular calcium handling, 
and genomic activity have been elucidated. There are also suggestions that 
vitamin D alters muscle metabolism, specifically its sensitivity to insulin, which 
is a pertinent feature in the pathophysiology of insulin resistance and type 2 
diabetes. We will review the range of human clinical, animal, and cell studies 
that address the impact of vitamin D in skeletal muscle, and discuss the 
controversial issues. This is a vibrant field of research and one that continues to 
extend the frontiers of knowledge of vitamin D’s broad functional repertoire.  
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I. Introduction 
In recent times, there has been a great deal of interest in vitamin D, with over 
1000 publications in PubMed in 2011 alone. A remarkable number of studies 
dealing with novel aspects of its biological activity and its potential to exert 
broad-ranging effects beyond calcium and mineral homeostasis have emerged 
(1– 4). Vitamin D deficiency is a highly prevalent condition in the developed 
world and in the populous regions of Asia, India, and the Middle East (5, 6). 
Significant downward trends in vitamin D status in U.S. population-based studies 
suggest that vitamin D deficiency/insufficiency is increasing in frequency (7, 8). 
Accordingly, health agencies including the International Osteoporosis 
Foundation, The Endocrine Society, and Institute of Medicine have recently 
outlined recommendations for the prevention of vitamin D deficiency and have 
called for further research to guide the field (9 –11). 
 
Beyond the classic effects on bone and calcium health, the effects of vitamin D 
are a matter of considerable debate and have been recently reviewed in detail 
(12). A recent Institute of Medicine report contended that the evidence in support 
of an extraskeletal role for vitamin D was “not yet compelling” (11). However, 
there is a large and expanding body of observational data about associations 
between vitamin D deficiency and diverse medical conditions, ranging from 
multiple sclerosis to malignancy (3). Reports of the presence of the vitamin D 
receptor (VDR) in almost every tissue strengthen the case in favor of direct 
extraskeletal functions (13). The effective use of active vitamin D and vitamin D 
analogs in the treatment of the skin disorder, psoriasis, demonstrate that skin is 
an extraskeletal target tissue for vitamin D. Long before the recognition of UV 
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radiation as an essential component in the synthesis of vitamin D, the sun’s rays 
were considered a source of physical strength and vitality. Ancient Egyptians 
revered the Sun-God, Amon-Rah, whose rays could make “a single man stronger 
than a crowd” (14). Herodotus recommended solaria in Ancient Greece as a cure 
for “weak and flabby muscles,” and ancient Olympians were instructed to lie 
exposed and train under the sun’s rays (15). In 1952, Spellberg (16), a German 
sports physiologist, conducted an extensive study examining the effects of UV 
irradiation on elite athletes. He informed the German Olympic Committee that 
UV irradiation had a “convincing effect” on physical performance. This was 
consistent with earlier studies that reported improvements in speed and 
endurance among students after treatment with sunlamps (17, 18). 
 
We have known for more than 30 yr that vitamin D exerts effects on muscle cells 
at a molecular level. In this journal in 1986, Ricardo Boland reviewed the effects 
of vitamin D on calcium handling, mineral homeostasis, and signaling pathways 
in muscle cells (19). Since that time, we have gained further insight in its effects 
on the regulation of cell survival (20), differentiation (21), and calcium handling 
(22). In more recent times, clinical studies have examined the effects of vitamin 
D supplementation on muscle function and falls in various populations (23, 24). 
However, the field is challenged by controversy. A recent report suggesting that 
VDR was not detectable in muscle has fueled the debate as to whether vitamin D 
effects on muscle are direct or indirect (25–27). The creation of the VDR 
knockout (VDRKO) mouse in 1997 gave a new focus to this question, which we 
will discuss (28). A continuing area of uncertainty stems from conflicting meta-
analyses of clinical studies examining the effect of vitamin D supplementation on 
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muscle strength and falls in older individuals (23, 29–31). In this review, 
molecular, animal, and human studies examining the various roles of vitamin D 
in muscle will be presented. We will discuss contentious issues that have made 
this a vibrant field of research and one that continues to extend the frontiers of 
our knowledge of vitamin D’s broad functional repertoire. 
 
 II. Background Physiology 
A. The vitamin D pathway 
The family of molecules known collectively as vitamin D are not true vitamins, 
which are defined as essential substances obtained exclusively from the diet. The 
misnomer is a remnant of the early work of a number of scientific pioneers from 
the 1900s. After inducing rickets in a group of dogs by keeping them indoors for 
prolonged periods, the British physician Sir Edward Mellanby (32) discovered 
that feeding them cod-liver oil cured them and attributed this to the recently 
identified vitamin (33). However, in 1922, McCollum et al. (34) showed that 
after heating and aerating cod-liver oil to destroy the vitamin A, it remained 
effective in the treatment of rickets but no longer cured night blindness. Mc-
Collum followed the sequential alphabetical designations and labeled the new 
substance “vitamine D.” In the 1920s, it was recognized that children with 
rickets had profound muscle weakness, and Alfred F. Hess (35) reported that 
exposing rachitic children to direct sunlight led to the “rapid disappearance” of 
their illness and improved “general vigor and nutrition.” This finding was the 
direct extension of earlier work by Huldschinsky (36), who achieved the same 
outcome with artificially produced UV light. After these seminal studies, Harry 
Goldblatt and Katherine Soames (37) reported in 1923 that the irradiation of 
! 7!
certain foodstuffs rendered them antirachitic. In 1926, Adolf Windaus et al. (38) 
identified the chemical structure of cholecalciferol (vitamin D3) as found in 
irradiated pig skin as well as the structure of its parent molecule, 7-
dehydrocholesterol. Windaus also isolated vitamins D1 and D2 and was awarded 
the 1928 Nobel prize for his work on sterols and vitamins. The nomenclature in 
the field is often confusing. Names, alternate names, and molecular structures of 
vitamin D and related molecules are shown in Fig. 1. The metabolic pathway of 
vitamin D, including the various steps in its activation and degradation, are 
depicted in Fig. 2. It was assumed that exposure of the skin to UV radiation 
drove the conversion of 7-dehydrocholesterol to cholecalciferol (step 1, Fig. 2). 
However, proof of this emerged more than 30 yr later with independent 
discoveries by two groups: Holick et al. (39) and Esvelt et al. (40). The photo-
production is subject to a variety of factors including amount of UV exposure 
(latitude, season, and use of sunscreen and clothing), ethnicity (skin 
pigmentation), and age (41–43).  
 
After the photochemical conversion of 7-dehydrocholesterol to pre-vitamin D3 
and its thermal isomerization to vitamin D3, it binds to the vitamin D-binding 
protein (DBP), and is transported to the liver where a hydroxyl group is attached 
at the carbon-25 atom (i.e. C-25) to generate 25-hydroxyvitamin D (25D) (step 2, 
Fig. 2). The importance of the liver in this first phase of hydroxylation was 
reported in 1969 by DeLuca and colleagues (44). A number of 25-hydroxylases 
have been reported including cytochrome P450 CYP27A1 and CYP2R1 (45, 46). 
CYP2R1 is probably the major enzyme required for 25-hydroxylation of vitamin 
D3, at least in humans (47, 48). A patient with classic rickets and low circulating 
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levels of 25D was found to have a homozygous mutation of the CYP2R1 gene, 
implying that other enzymes were unable to compensate (49). Much remains 
unknown about the 25-hydroxylase enzymes including the significance of their 
reported presence in skin, kidney, and intestine (50). These enzymes are 
generally considered to be constitutively expressed with little feedback 
regulation; however, this is unusual for the CYP family (50). In the absence of 
severe hepatic dysfunction, 25-hydroxylation of vitamin D is not usually rate 
limiting. However, in mild to moderate liver impairment, the associated fat 
malabsorption can cause vitamin D deficiency. In contrast, 1α-hydroxylation is 
the major rate-limiting step in synthesis of 1,25-dihydroxyvitamin D (1,25D) 
(step 3, Fig. 2). Synthesis of 1,25D is tightly regulated (51) and is mediated by 
the enzyme 1α-hydroxylase. Factors regulating 1α-hydroxylase in kidney are 
shown in Fig. 2. Due to its sequence similarity to CYP27A1, the gene encoding 
1α-hydroxylase was called CYP27B1 (52). CYP27B1 encodes the enzyme 
responsible for conversion of 25-hydroxyvitamin D (25OHD) into the bioactive 
hormone, 1,25-dihydroxyvitamin D (1,25(OH)2D). Its role was demonstrated in 
1998 by the development of rickets and reduced circulating 1,25D levels in four 
patients with gene mutations for this enzyme (53). Cyp27B1-null mice also 
develop rickets with reduced levels of circulating 1,25D (54). CYP27B1 mRNA 
is expressed in a number of vitamin D target tissues including kidney, skin, 
intestine, macrophages, and bone. Although its expression is relatively high in 
skin, the kidney is thought to be primarily responsible for circulating levels of 
1,25D (50). This is supported by 1,25D deficiency in people with renal failure 
(55, 56). However, this has not been conclusively proven with renal-specific 
CYP27B1 deletion. The presence of CYP27B1 in other cell types, especially 
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macrophages, is demonstrated by the fact that people with granulomatous 
diseases can have elevated 1,25D levels (57).  
 
Entry of 25D into the proximal renal tubular cells requires receptor-mediated 
uptake of DBP plus 25D at the brush border, degradation of DBP by legumain, 
and endocytic internalization and translocation of 25D to mitochondria (58). 
Megalin, a member of the low-density lipoprotein receptor family, is required for 
reabsorption of filtered DBP-bound 25D (59). It is in the mitochondria that 1α-
hydroxylation of 25D into its biologically active form, 1,25D, occurs (50). A 
number of factors contribute to the tight regulation of 1α-hydroxylase enzyme 
expression and activity in the kidney (Fig. 2). These include calcium, PTH, 
calcitonin, GH, IGF-I, and fibroblast growth factor 23 (FGF23). In addition, 
1,25D negatively regulates its own synthesis by suppressing 1α-hydroxylase 
expression in kidney and bone (60). There is also evidence to suggest that 
estrogen, progesterone, and prolactin may regulate 1α-hydroxylase activity (61, 
62). In macrophages, regulation of CYP27B1 is primarily cytokine mediated 
(63). 
 
The final important enzyme in the vitamin D endocrine system is 24-hydroxylase 
(CYP24A1). Found in nearly all cells and highly expressed by the kidney, 
CYP24A1 limits the amount of 1,25D in target tissues by converting 1,25D to 
inactive metabolites, including 1,24,25-(OH)3D and calcitroic acid and by 
converting 25D to 24,25(OH)2D (step 4, Fig. 2). In addition to 24-hydroxylation, 
this multicatalytic enzyme is able to catalyze side-chain hydroxylations at the 
C23 and C26 positions (64). Recently, mutations in CYP24A1 were reported in 
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six children with infantile hypercalcemia, thereby providing conclusive evidence 
of the importance of this enzyme in the in vivo regulation of vitamin D 
metabolism (65).  
 
The VDR, to which 1,25D binds to exert its biological effects, was described in 
1974 by Brumbaugh and Haussler (66). This is depicted in Fig. 3. Insights into 
the structure and function of this protein have been gained via the cloning and 
subsequent analysis of the recombinant protein (67), by x-ray crystallography 
(68) and molecular modeling using atomic coordinates of the protein x-ray 
structure (69). The protein comprises three distinct regions: an N-terminal dual 
zinc finger domain that binds to DNA (a characteristic feature of the steroid 
receptor family), a C-terminal domain that binds to 1,25D, and an extensive, 
unstructured region that links these two functional domains. Binding of 1,25D to 
VDR leads to conformational changes within the receptor that allows it to 
interact with its heterodimeric partner, retinoid X receptor (RXR) (Fig. 3) (70). 
VDR also forms homodimers that bind DNA and regulate gene expression (71). 
The liganded complex (i.e. 1,25D-VDR-RXR) binds to vitamin D response 
elements (VDRE) in the DNA (72). Classic VDRE are direct repeats of two 
hexameric core binding sites with a three-nucleotide separation (73, 74). 
However, numerous nonclassic sites have been proven to act as VDRE. VDR-
containing dimers interact with large coregulatory complexes required for gene 
modulation (70, 75). Although a number of coregulatory molecules have been 
characterized including the VDR interacting protein and the steroid receptor 
coactivator complex (SRC), the precise mechanisms by which these molecules 
operate are just beginning to emerge (76). The system is more complex, because 
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VDR is one of the few nuclear hormone receptors that has been clearly 
demonstrated to be able to regulate gene expression in the absence of ligand. 
Unliganded VDR dimers can bind to and regulate some genes, mostly to repress 
their expression. This is thought to be the mechanism for spontaneous hair loss in 
mice with mutations in VDR (77). Expression of the VDR in virtually every 
tissue and the diverse phenotypic changes in the VDRKO mouse are consistent 
with the wide spectrum of activity of the 1,25D-VDR endocrine system (13). As 
well as regulation of VDR, CYP27B1, and CYP24A1 (78, 79), the 1,25D-VDR-
RXR complex is involved in regulation of a variety of cellular functions 
including DNA repair, cell differentiation, apoptosis, metabolism, and oxidative 
stress (13). Its effects on calcium and mineral homeostasis are well established 
and, in brief, result from the transcriptional regulation of specific proteins within 
the intestine (calcium-binding proteins, calbindin D28k, and epithelial calcium 
channels), bone (osteocalcin, osteopontin, and receptor activator of nuclear 
factor-κ B ligand), and parathyroid glands (PTH) (80). These effects provide 
potential indirect routes for regulation of muscle function in addition to direct 
effects (Fig. 4). This review will focus on diverse effects of the vitamin D 
endocrine system on the functional and metabolic capacity of skeletal muscle as 
reported by a range of clinical and translational studies. We will also discuss the 
central role of skeletal muscle in our emerging understanding of the nongenomic 
capabilities of the VDR. 
 
B. Skeletal muscle physiology 
 Skeletal muscle is estimated to account for 42% of total body mass in males and 
35% in females (81). Its primary function is to generate force and to provide 
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locomotion. The functional units of skeletal muscle are the muscle fibers, 
themselves comprised of many myofibrils. Myofibrils are long cylindrical 
multinucleated cells that vary considerably in their morphological, biochemical, 
and physiological properties, thereby forming the basis of the well-known 
structural and functional diversity of skeletal muscle (82). This complexity 
causes difficulty in classifying muscle fibers. At one stage, one author described 
fiber classification as “showing an alarming trend toward the incomprehensible” 
(83). At this time, the most widely used classification is based on histochemical 
methods that determine the pH lability of myofibrillar ATPase activity and 
divides fibers into type I (low activity) and type II (high activity) with further 
subdivision into IIA, IIX, and IIB (84) depending on the expression of different 
myosin heavy chain (MHC) forms (summarized in Table 1). The reliance on 
oxidative or glycolytic metabolic pathways determines the contractile speed of 
these various fiber types. There is substantial evidence that muscle fibers are 
dynamic in their response to a variety of contractile and metabolic stimuli and 
are able to convert from one fiber type to another or undergo atrophy (84). Both 
vitamin D deficiency and age-related sarcopenia have been associated with 
preferential atrophy of type II (fast-twitch) fibers (84, 85). On a macroscopic 
scale, the generation of force by a muscle is dependent on several factors 
including size, fiber composition, and individual fiber functional capacity. The 
cross-sectional area is the sum of the individual, parallel fibers, themselves made 
up of thousands of individual myofibrils and other cell types (86). The sarcomere 
is the basic unit of contraction and is defined as the portion of the myofibril that 
lies between two bands, known as Z bands. Between successive Z bands, an 
array of myosin and actin molecules are intricately arranged to form alternating 
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filaments, suspended in the sarcoplasm and lying in close proximity to 
mitochondria, indicative of the significance of ATP in contraction. The role of 
calcium, also fundamentally important in the tight regulation of muscle 
contraction (87), will be discussed below. 
 
Apart from the generation of force, skeletal muscle is a highly metabolic tissue 
that produces and responds to a variety of hormones and factors, leading one 
author to describe it as a true endocrine organ (88). Exercise leads to the 
increased expression and secretion of a family of myokines including IL-6 and 
brain-derived neurotrophic factor that can stimulate glucose uptake and fat 
oxidation within muscle, lipolysis in adipocytes, and gluconeogenesis in 
hepatocytes via various autocrine, paracrine, and endocrine pathways (87, 89). 
Skeletal muscle is also responsive to a range of hormones including, but not 
limited to, insulin, IGF, glucocorticoids, thyroid hormones, and 1,25D, all of 
which exert influences on the differentiation, metabolism, and function of muscle 
via a number of established and evolving mechanisms. 
 
C. Calcium and muscle contraction 
 As well as regulating whole-body calcium homeostasis, there is also evidence 
that 1,25D increases calcium influx in muscle cells and thus may have both 
direct and indirect calcium-related effects on muscle (Fig. 4) (90). The sliding 
filament theory, first proposed in 1954 (91), describes the highly complex 
movement of actin and myosin filaments over each other. This and potential 
effects by which vitamin D may affect this model, based on data to be discussed, 
are depicted in Fig. 5. It is primarily the influx of calcium from the sarcoplasmic 
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reticulum (SR) and binding to the troponin-tropomyosin complex that results in 
the exposure of active binding sites on the actin filament and their engagement 
with the myosin heads (82). In the presence of ATP, contraction ensues as the 
myosin head tilts from an obtuse angle to the perpendicular, causing movement 
of myosin over actin filaments in a process named the power stroke, after which 
ADP and inorganic phosphate are released (86). The binding of new ATP to the 
myosin head causes its detachment from the active site of the actin filament and 
movement back into the obtuse position. 
 
D. Calcium and exercise-related glucose uptake 
Calcium plays a vital role in exercise-related glucose uptake by skeletal muscle. 
Vitamin D regulates calcium homeostasis, giving potential for indirect 
regulation. Exercise increases glucose transporter 4 (GLUT4) expression; after 
contraction, increased cytosolic calcium activates Ca2+/calmodulin-dependent 
protein kinase (CAMK) pathways and causes transcriptional up-regulation of 
myocyte enhancer factors 2A and 2D, which increase GLUT4 expression (92–
94). Exercise also increases GLUT4 translocation to the muscle cell membrane, 
independently of insulin. Activation of the AMP-kinase pathway contributes to 
this process (95). GLUT4 vesicle translocation and insertion into the cell 
membrane is a calcium- and ATP-dependent process (96). A putative mechanism 
for this is the synaptotagmins. They are calcium-sensitive proteins required for 
insertion of the GLUT4 proteins into the cell membrane, as demonstrated in 
adipocytes (97). Synaptotagmins in turn regulate Myo1c, an actin-filament-
attached protein that binds to and transports GLUT4 vesicles (98). Contraction-
induced calcium influx stimulates a range of signaling pathways that regulate 
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muscle differentiation and function (99, 100). These include myogenic 
transcription factors, myostatin, peroxisome proliferator-activated receptor-γ and 
utrophin A, mainly via CAMK and calcineurin-mediated pathways (82, 99, 101). 
These processes, generally referred to as excitation-transcription coupling, give 
rise to the plasticity and unique adaptive ability of muscle to alter vital 
components in its function, fiber type, and contractile force on demand. 
 
E. Calcium and insulin-stimulated glucose uptake 
 Skeletal muscle is responsible for approximately 85% of insulin-mediated 
glucose uptake in lean individuals (102). Insulin induces translocation of GLUT4 
to the cell surface, facilitating glucose uptake and clearance of circulating 
glucose. Insulin binds to the α -subunits of its receptor, activating a signaling 
cascade. This has been covered in many elegant reviews (103, 104). The 
mechanisms by which the activation of these proteins then leads to the insertion 
of GLUT4 protein into the cell membrane remain incompletely understood but 
have also been the subject of recent review (105). As with exercise, GLUT4 
vesicle translocation is ATP and calcium dependent. Pharmacological inhibition 
of calcium influx in muscle reduces insulin-mediated glucose uptake, 
independent of effects on Akt (96). Calcium regulates components of the 
proximal insulin signaling pathway such as the binding of calmodulin to insulin 
receptor substrate (IRS)-2 (106). Increases in calcium influx improved insulin-
mediated glucose uptake in isolated muscle fibers of both normal and insulin-
resistant mice (96). Calcium regulates cytoskeletal components involved in 
GLUT4 translocation (98). Studies on L6 myotubes reported significant 
increases in GLUT4 expression in response to caffeine-related increases in 
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intracellular calcium. The effects were negated by dantrolene, an inhibitor of SR 
calcium release (92). However, additional research examining the role of calcium 
in insulin sensitivity is needed. 
 
III. Vitamin D and Muscle: Cell Models 
 On a cellular level, a variety of mechanisms by which vitamin D impacts upon 
the function of skeletal muscle have been elucidated. These can be broadly 
divided into 1) genomic effects that arise from the binding of the 1,25D-VDR-
RXR heterodimer at specific nuclear receptors to influence gene transcription 
and 2) nongenomic effects that arise from a host of complex intracellular signal 
transduction pathways after binding of 1,25D to nonnuclear receptor. Over the 
past 30 yr, the majority of research in this area has mainly focused on the 
nongenomic effects of vitamin D on skeletal muscle, in particular its regulation 
of protein kinaseA(PKA)/cAMP, protein kinase B, protein kinase C (PKC), 
CAMK, and multiple MAPK pathways (90). 
 
A. VDR in muscle 
 After the discovery of the VDR in 1969 (107), the isolation of unoccupied 
1,25D receptors partitioned between the cytosol and cell nucleus in intestinal 
cells in 1980 raised the possibility of rapid, non-transcriptional pathways 
associated with this receptor (108). The rapidity, over minutes, with which 1,25D 
treatment resulted in changes in intracellular calcium transport in vascularized 
duodenal cells supported this possibility (109). Furthermore, it became apparent 
from studies that examined the binding properties of VDR isolated from the 
caveolae-enriched membrane fraction of chick intestinal cells that the cytosolic 
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receptors were identical to nuclear VDR (110). To confirm this, significant 
reductions in the capacity of [3-H]1,25D to bind to isolated caveolae-membrane 
fractions were reported in tissues obtained from VDRKO mice (110). Studies 
examining the Tokyo strain of VDRKO mice, in which the second zinc finger of 
the DNA-binding domain of VDR is ablated, reported some residual binding of 
1,25D in kidney cells (111). Treatment with 1,25D elicits rapid uptake of 
calcium within muscle cells in vitro and in vivo  (112). However, after 
transfection of muscle cells with anti-VDR antisense oligodeoxynucleotides 
(ODN), 1,25D-dependent mechanisms by which rapid calcium entry occurs, 
namely store operated calcium entry (SOCE) or capacitative calcium entry, are 
inhibited (113, 114), therefore implying a direct nongenomic role for VDR in 
calcium handling. The presence of the VDR has been reported in avian, murine, 
and human muscle cells on the basis of immunohistochemistry (20, 115), 
equilibrium binding studies (25), and detection of VDR mRNA by RT-PCR 
(real-time PCR) (21). However, these findings are subject to challenge due to the 
nonspecificity of many of the VDR antibodies (116). A recent paper that used a 
validated antibody (which did not show bands in VDRKO mice) did not find 
VDR expression in skeletal, cardiac, or smooth muscle by Western blot and 
immunohistochemistry (27). Differences in experimental conditions and the 
possibility of tight protein binding of VDR to DNA may have accounted for this 
finding. Moreover, low levels may be sufficient for significant function in 
muscle. Major studies examining the presence of VDR in muscle and the various 
techniques used have been summarized in Table 2. 
 
Another possibility is that there may be differences in the expression of VDR in 
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muscle in different species and throughout the various stages of muscle 
differentiation. In support of the latter, in vitro studies predominantly examine 
the activity of VDR within myoblasts and myotubes rather than fully 
differentiated adult cells. In vivo, VDR mRNA was reported in the muscle of 3-
wk-old wild-type mice but not in their 8-wk-old counterparts (21). The authors 
suggested a primary role for VDR in early muscle development (21). Thus, the 
expression of VDR within muscle over time requires further clarification. Within 
cultured chick myoblasts, VDR translocates from the nucleus to the cytoplasm 
quite rapidly (i.e. 1–10 min) after exposure to 1,25D (117). Intact microtubular 
transport and caveolae structure were essential as demonstrated by the disruption 
of VDR translocation by inhibition of these individual components in C2C12 
cells (i.e. with colchicine and methyl-β-cyclodextrin, respectively) (20). After a 
longer period of exposure to 1,25D, the VDR appears to translocate back to the 
nucleus to presumably carry out its role in transcriptional regulation. This 
shuttling of the VDR between cytoplasm and nucleus indicates its versatility in 
both rapid and genomic actions, depending on location (118). 
Coimmunoprecipitation analyses have also demonstrated direct binding of the 
VDR with a component of the tyrosine phosphorylation cascade, namely c-Src, 
under the influence of 1,25D (119). Transfection of muscle cells with three 
different anti-VDR antisense ODN inhibited 1,25D dependent dephosphorylation 
and subsequent activation of c-Src as assessed 15 min after treatment with 1,25D 
or vehicle (120). More recently, treatment of muscle cells with 1,25D resulted in 
VDR binding with c-Src, time-dependent increases in c-Src activity, and the 
redistribution of c-Src from the periplasma membrane zone, where it resides 
under basal conditions, to the cytoplasm and nucleus as seen on confocal 
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microscopy (20). There is also evidence that 1,25D induces the association 
between c-Src and c-myc, a transcription factor involved in cell growth and 
apoptosis. This evidence includes coimmunoprecipitation analyses that 
demonstrate 1,25D-mediated formation of complexes between c-Src and c-myc 
(20) and significant inhibition (i.e. 94%) of 1,25D-mediated c-myc tyrosine 
phosphorylation on immunoblot after transfection of muscle cells with anti-VDR 
antisense ODN (120) or treatment with PP1, a c-Src-specific inhibitor (120). 
Mechanistically, c-Src probably interacts with VDR and c-myc, both of which 
are hormone-dependent phosphotyrosine proteins, via its Src homology 2 
domain, but this requires further evaluation (121).  
 
A role for caveolin-1 in 1,25D-mediated activation of c-Src has also been 
suggested. Caveolin-1 belongs to a family of membrane-scaffolding proteins 
with potential roles in different disease phenotypes and binds to c-Src under 
basal conditions near the cell membrane. After treatment of C2C12 myoblasts 
with 1,25D, colocalization of caveolin-1 and c-Src was disturbed, and they were 
redistributed into cytoplasm and nucleus (20). Interestingly, when the caveolae 
structure was disrupted by methyl-β-cyclodextrin, 1,25D was not able to separate 
caveolin-1 from c-Src, preventing its activation and also preventing the nuclear 
translocation of VDR. Therefore, the caveolae and associated proteins appear to 
play an upstream role in the activation of c-Src. It also appears that 1,25D-
mediated activation of c-Src by VDR is a downstream regulator of several 
nongenomic effects of 1,25D in muscle, specifically involving differentiation and 
calcium homeostasis, which we will discuss. Apart from the specific ability of 
the VDR to translocate from nucleus to cytosol in response to 1,25D, 
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conformational changes within the highly flexible 1,25D molecule also 
determine the mediation of genomic and nongenomic actions via its receptor. It 
has been shown that the relatively planar 6-s-cis locked JN [1,25-(OH)2-
lumisterol3] displays nongenomic activity and that the 6-s-trans locked JB [1,25-
(OH)2-dihydrotachysterol3] possesses predominantly genomic activity on 
binding the VDR (69). By molecular modeling of the VDR using atomic 
coordinates of the protein x-ray structure and computer docking, specific binding 
sites on the VDR that determine its functional activity have been reported (122, 
123). Interestingly, the pockets that, respectively, mediate the regulation of 
nongenomic and genomic responses overlap and therefore result in mutually 
exclusive conformational forms of the VDR. It has been suggested that the 
unbound VDR may possibly exist in the cytoplasm as multiple, equilibrating 
receptor conformations according to standard statistical distribution (69). Also 
intriguing, a potential role for 25D in binding the alternative pocket and initiating 
intracellular calcium flux has recently been reported (123). 
 
Apart from the VDR, it is also possible that other cytosol receptors may be 
responsible for the rapid actions of 1,25D in muscle. Contrary to an earlier 
report, it does not appear that annexin II binds to 1,25D in a physiologically 
relevant manner (124, 125). Recent data have suggested a role for membrane-
associated rapid response steroid binding in potentially inducing rapid effects of 
1,25D in muscle, but further assessment is required (126). 
 
B. Calcium homeostasis 
Although the nongenomic regulation of intracellular calcium by 1,25D has been 
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well characterized in cultured myoblasts and myotubes, it has also been 
confirmed by in vivo studies on chicks and in vitro assessment of differentiated 
soleus muscle samples. Studies report a time- and dose-dependent increase in 
intracellular muscle calcium uptake in response to 1,25D. The use of particular 
agents and antisense oligonucleotides to block components of the signal 
transduction pathway has led to the elucidation of specific step-wise mechanisms 
by which vitamin D influences intracellular calcium homeostasis (127–129). 
These have been depicted in Fig. 6. 
 
First, the rapid mobilization of calcium from the SR into the cytosol relies on 
1,25D-dependent activation of two components of the signal transduction 
pathway, namely c-Src and phosphoinositide-3 kinase. These in turn lead to the 
activation of phospholipase C-γ, the rapid production of inositol triphosphate 
(IP3) and the first of two phases of diacylglycerol (DAG) synthesis from the 
membrane phosphoinositides (22, 130). It is IP3 that then mediates the rapid 
movement of calcium from the SR into the cytosol (130). In the continued 
presence of 1,25D, two additional processes are then involved in the more 
sustained phase of calcium entry from the extracellular compartment, namely 
SOCE and L-type voltage-dependent calcium channel (VDCC) entry 
mechanisms. SOCE relies on several factors including IP3-dependent calcium 
release from the SR that activates calmodulin, CAMKII, and PKC, the latter also 
being activated by a by-product of a previous reaction, namely DAG (131). The 
particular channels responsible for SOCE have been identified as the transient 
receptor potential-canonical-like proteins. Interestingly, a direct role of the VDR 
in activating these channels has been suggested by the coimmunoprecipitation of 
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both molecules after treatment with 1,25D in chick skeletal muscle cells (113). 
 
Apart from its reported role in SOCE, evidence supports vital additional roles for 
PKC in 1,25D-dependent calcium homeostasis in muscle. Rapid translocation of 
PKC-α from the cytosol to the cell membrane after the in vitro treatment of chick 
soleus muscle and cultured rat and chick myoblasts with 1,25D (132, 133) and 
marked reduction in intracellular calcium influx after selective knockout of PKC-
α by the use of specific antisense oligonucleotides have been described (128). 
Furthermore, PKC also activates VDCC-mediated calcium entry as evidenced by 
the rapid stimulation of 45-Ca2+ uptake by cultured myoblasts after treatment 
with PKC activators, namely DAG and phorbol 12-myristate 13-acetate, 
inhibited by the addition of nifedipine, an L-type VDCC blocker (133). PKC-α 
may also have a role in the 1,25D-dependent activation of the ERK1/2 signaling 
pathway as will be discussed in Section III.D on proliferation and differentiation. 
 
VDCC-mediated calcium entry also relies on 1,25D-dependent activation of the 
cAMP/PKA pathway. Very rapid increases (within 30 sec) in the levels of 
adenylyl cyclase (AC) and cAMP levels, together with increased PKA activity, 
occur in differentiated muscle cells and cultured myotubes after 1,25D treatment 
(127, 134). These studies also report that 1,25D stimulation of VDCC- 45-Ca2+ 
entry can be mimicked by treatment with dibutyryl cAMP and abolished by 
specific inhibitors of AC and PKA. Another mechanism is emerging by which 
PKC and cAMP/PKA pathways may cross talk in the regulation of VDCC-
mediated calcium flux (90). The preliminary data indicates an increase in the 
cAMP content of myoblasts after treatment with a PKC activator, phorbol 12-
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myristate 13-acetate, which may stem from the phosphorylation of Gαi that is 
mediated by PKC in other cells (133). Furthermore, the phosphorylation of Gαi 
in myoblast membranes after treatment with 1,25D is likely to be essential in the 
stimulation of AC activity as evidenced by the effects of abolishing G protein 
regulatory pathways on 1,25D mediated AC activity (134).  
 
In summary, 1,25D induces changes in intracellular calcium levels in cultured 
muscle cells initially via rapid IP3-dependent calcium shifts from the SR to the 
cytosol followed by processes resulting in extracellular calcium influx via the 
activation of SOCE and VDCC activity. These mechanisms are evident in both 
immature myoblasts and differentiated myotubes, suggesting a potential role for 
rapid calcium influx in muscle cell differentiation and contraction, respectively 
(19). In support of this inference, an interesting report from 1974 described a 
direct correlation between in vivo skeletal muscle dysfunction and demonstrable 
defects in intracellular calcium handling (136). A group of rabbits, rendered 
vitamin D deficient by dietary methods, were found to be substantially weaker 
and hypotonic compared with their vitamin D-replete counterparts and in vitro, 
displayed significant reductions in calcium uptake in the SR on isolation from 
psoas muscle. 
 
C. Phosphate homeostasis 
 Phosphate is an essential substrate in the production of ATP and in protein 
synthesis. There is early evidence demonstrating that phosphate uptake in muscle 
may be influenced by 25D (19, 137). The administration of 25D to vitamin D-
deficient, phosphate-deplete rats resulted in a significant increase in the in vitro 
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concentration of [32-P]phosphate in muscle cells, followed by the stimulation of 
phosphate-dependent metabolic processes including ATP synthesis in these cells 
(137). This effect was not reproduced by the repletion of phosphate in these rats. 
The abolition of 1α-hydroxylase activity by nephrectomy had no effect on 25D-
mediated phosphate uptake, implying a direct role of the prehormone in this 
process. Another study reported the specificity of 25D on in vitro phosphate 
uptake of differentiated muscle cells with the absence of such effects after 1,25D 
and 24,25-(OH)2D treatment (138–140). Another study demonstrated the 
specific transport of [32-P]phosphate across muscle plasma membranes after in 
vivo vitamin D repletion and 32-P labeling of vitamin D deficient chicks (141). 
This finding was later confirmed by an increase in vesicle phosphate transport in 
muscle cells via the isolation of highly purified sarcolemma vesicles in vitamin 
D-deficient chicks treated with vitamin D (19). The direct effect on phosphate 
uptake may be mediated via a sodium-dependent mechanism as reported by 
studies on cultured muscle cells (138, 139). 
 
D. Proliferation and differentiation 
 There is evidence that 1,25D activates components of the MAPK family in 
cultured myoblasts, thereby influencing the expression of genes involved in 
cellular proliferation and differentiation. The majority of research in this area has 
focused on the effects of 1,25D on the ERK1/2 signaling pathway. The initial 
activation of c-Src by 1,25D, previously described as an apparent gateway to the 
nongenomic effects of 1,25D in muscle, results in the rapid activation of Raf-1 
by the phosphorylation of its serine residue, which relies on the involvement of 
Ras and PKC-α (142, 143). Raf-1 then leads to the activation of MAPK kinase, 
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which activates ERK1/2, after which the phosphorylation of a range of proteins 
and transcription factors including cAMP response element-binding protein and 
Elk-1 and the increased expression of other proteins relevant to cell proliferation 
and differentiation, namely c-myc and c-fos, take place (144, 145). Another 
MAPK activated by1,25D in cultured myoblasts is p38. Rapid c-Src-dependent 
stimulation of MAPK kinases MKK3 and 6 and p38 was demonstrated in C2C12 
myoblasts after treatment with 1,25D (146). After this, p38-dependent activation 
of MAPK2 and subsequent phosphorylation of heat-shock protein 27 was 
demonstrated. Heat shock protein 27 has an important role through its 
association with the actin microfilament system and cytoskeletal remodeling of 
muscle cells (146, 147). More recently, 1,25D-mediated AKT phosphorylation in 
differentiating C2C12 cells was also shown to occur via c-Src, p38, MAPK and 
phosphoinositide-3 kinase pathways (148). Although little is known about its 
exact activity in this context, a third member of the MAPK family, namely c-Jun 
N-terminal kinase-1/2, is also phosphorylatively activated by 1,25D 
inC2C12myoblasts (146). Therefore, an intricate system of nongenomic 
regulatory responses to 1,25D may control cellular proliferation and 
differentiation of muscle cells, although the relative role of each component 
remains unclear. 
 
A variety of genomic responses to 1,25D have also recently been elucidated. 
Apart from being the first to describe the presence of VDR within muscle cells, 
Simpson et al. (25) also demonstrated dose-dependent reduction in the 
proliferation of G-8 myoblast cells that were treated with 1,25D and a 
commensurate reduction in DNA synthesis, suggesting that genomic responses to 
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1,25D gave rise to the down-regulation in myoblast proliferation and enhanced 
differentiation into myotubes. 
In a recent study, treatment of C2C12 myoblasts with 1,25D for 7 d as opposed 
to vehicle resulted in increased mRNA and protein expression of transcription 
factors known to enhance myogenesis, namely myogenic differentiation antigen, 
desmin, myogenin, and IGF-II and the reduced expression of proliferating cell 
nuclear antigen and myostatin, which, respectively, enhance cell proliferation 
and negatively regulate muscle mass (118). Morphologically, cells treated with 
1,25D for 10 d displayed significantly increased muscle fiber size and diameter, 
as indicated by staining for MHC type II a late myogenic marker. These changes 
were associated with VDR-induced genomic mechanisms as evidenced by 
significant increases in the expression of the receptor by 1 d of 1,25D treatment 
and its nuclear translocation at 4d as opposed to its persistent location in the 
cytoplasm of cells treated with vehicle. However, these findings stand in contrast 
to an earlier report that described the down-regulation of myogenin and 
myogenic transcription factor 5 (myf5) at an mRNA level in C2C12 myoblasts 
treated with 1,25D for 48 and 96 h compared with those treated with vehicle 
(21). Furthermore, this coincided with the reduced expression of neonatal forms 
of MHC, suggesting myoblast maturation in cells treated with 1,25D. It is 
possible that differences in study design may have accounted for these 
contradictory findings, specifically pertaining to myogenin expression. Different 
durations of treatment, and daily vs. single treatment regimens were employed in 
these studies (21, 118). 
 
In another study Artaza and Norris (390), vitamin D treatment of mesenchymal 
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stem cells resulted in increased expression of follistatin, an antagonist of 
myostatin, and caused down-regulation of TGF-β. These vitamin D-mediated 
changes in gene expression imply that it has a potential role in the inhibition of 
fibrosis and, perhaps, the promotion of myogenesis and osteogenesis in 
mesenchymal stem cells. 
 
In a recent study, European sea bass treated with various doses of dietary 
cholecalciferol from 9–44 d after hatching demonstrated dose-dependent effects 
in the gene expression of a number of myogenic transcription factors and dose-
dependent increases in white muscle fiber size and number (149). 
 
Although vitamin D has clear effects on muscle differentiation, more research is 
needed to elucidate the nature of these mechanisms. It is also important to note 
that the overlapping functions and complex regulatory pathways determining the 
activity of myogenic transcription factors are themselves something of a mystery 
although recently reviewed in detail (150). 
 
E. Muscle contractile proteins 
 There is evidence that vitamin D may play a role in the regulation of key 
components in the cytoskeletal structure of muscle cells. As discussed in Section 
II.B, the complex interaction between actin and myosin, two cytoskeletal 
proteins, forms the basis of understanding muscle contraction (Fig. 5). Similar 
proteins play a potential role in intracellular trafficking and, potentially, GLUT4 
translocation. Significant reductions in components of the actomyosin-troponin 
complex in the skeletal muscle of vitamin D-deficient rats and rabbits have been 
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reported in two separate studies, although in the latter, this may not have been 
directly related to 1,25D because in vivo administration of ethane-1-hydroxy-1,1-
diphosphate in doses known to inhibit 1,25D had no effect on these components 
of the cytoskeleton (151, 152). A study also reported an increase in the muscle 
concentrations of actin and troponin C in chicks replete with vitamin D as 
opposed to their vitamin D-deficient counterparts (141). Taken together, these 
reports suggest a direct role for 25D in the up-regulation of these muscle 
contractile proteins (141, 151). Furthermore, the direct role of 25D in phosphate 
homeostasis, as discussed, and the recent demonstration of direct binding 
between 25D and the alternative pocket of the VDR with subsequent biological 
effects in COS-1 kidney cells suggest that reconsideration of the ability of 25D to 
generate biological responses in vivo may be in order (123). 
 
F. Phospholipid composition 
 Phospholipids, a class of lipids that reside within the cell membrane, have been 
implicated in a variety of signal transduction pathways, including insulin 
signaling and calcium handling, and play a role in cell membrane function 
including caveolae. Alterations in phospholipid composition have been 
associated with insulin-resistant states (153). There is also evidence of a direct 
role of 1,25D in the regulation of the phospholipid metabolic pathway. A study 
reported higher relative concentrations of phospholipids in the muscle SR 
membranes of vitamin D-replete vs. -deficient animals (141). There were also 
significant changes in the levels of particular phospholipids, specifically an 
increased concentration of phosphatidylcholine and decreases in 
phosphatidylethanolamine, in the sarcolemma vesicles of vitamin D-replete vs. 
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deficient chicks (141). Another study suggested that 1,25D treatment led to the 
activation of specific methylation pathways that leads to the conversion of 
phosphatidylethanolamine to phosphatidylcholine in muscle cells (154). This is 
likely to represent a genomic effect as 1,25D-mediated binding of [3-H]glycerol 
and [14-C]ethanolamine to phosphatidylcholine in cultured myoblasts was 
inhibited by the action of actinomycin D, an inhibitor of DNA synthesis. 
Although the precise significance of genomic 1,25D-mediated influences on 
phospholipid composition remains uncertain, potential influences on calcium 
handling, cell proliferation, and insulin signaling merit further consideration. 
 
G. Bone-muscle cross talk and vitamin D 
 It is well established that muscle strength and muscle mass are important 
determinants of bone density, bone geometry, and fracture risk. Vitamin D 
therefore plays a key role in bone metabolism not only through its direct effects 
mediated by the VDR in osteoblasts and its effects on calcium absorption by the 
intestines but also through its effects on muscle fiber size and muscle function 
noted above. Interestingly, during growth, serum 25D levels have been found to 
be negatively associated with the accrual of bone mineral content in girls (155), 
and 25D levels decrease as lean mass increases (156). These observations raise 
the possibility that muscle tissue may require additional vitamin D during growth 
and that an important function of vitamin D on bone mass accrual may be 
mediated by the effects of vitamin D on accumulation of lean mass, which has 
been documented to precede gains in bone (157). Another pertinent consideration 
is the role of FGF23, a protein whose regulation is closely linked to phosphate 
homeostasis and the activation of vitamin D (step 3, Fig. 2). Although 1,25D up-
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regulates the expression of FGF23 by osteocytes and osteoblasts, FGF23 inhibits 
1,25D synthesis and stimulates its breakdown (158). Therefore, FGF23 excess, 
as seen in those with oncogenic or X-linked hypophosphatemic osteomalacia, 
leads to reduced 1,25D and phosphate levels and is also associated with muscle 
weakness. In Hyp mice, a model of X-linked hypophosphatemic rickets, the 
administration of neutralizing FGF23 antibodies increased 1,25D and phosphate 
levels as well as leading to improvements in grip strength and spontaneous 
movement (159). Therefore, the FGF23-vitamin D feedback loop presents 
another layer of complexity when assessing effects on muscle function. 
 
H. Cell models and molecular pathways for insulin signaling and diabetes 
1. Insulin signaling in cell models 
 Treatment of U-937 human promonocytic cells with 1,25D leads to time- and 
dose-dependent increases in the mRNA expression of insulin receptors, as shown 
in two separate studies (160, 161). In the second study, 1,25D treatment also 
resulted in an increase in VDR expression, suggesting that the accompanying 
increases in insulin-mediated [14-C]2-deoxyglucose uptake and [125-I]insulin 
binding in these cells resulted from the activation of genomic pathways. The 
authors also reported a putative VDRE in the human insulin receptor gene 
promoter on the basis of luciferase assays on transfected plasmid constructs 
(162). However, differences in insulin signaling mechanisms between skeletal 
muscle and immune cells, with the reliance of the latter on GLUT1 rather than 
GLUT4 transporters for glucose uptake, may limit extrapolation of these results. 
In a recent study, differentiated C2C12 muscle cells were rendered insulin 
resistant and atrophic by treatment with free fatty acids (FFA) (163). However, 
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coadministration of 1,25D with FFA resulted in significant dose- and time-
dependent increases in the insulin-mediated uptake of [3-H]2-deoxyglucose 
compared with cells that had received FFA alone. This effect of 1,25D was 
initially observed at 12 h and reached stability at 36 h, at which point complete 
reversal of the FFA-mediated insulin resistance was observed (using 10 nM 
1,25D). In addition, 1,25D treatment prevented muscle atrophy as demonstrated 
by significantly increased myotube diameter in cells that had been cotreated with 
1,25D and FFA as opposed to those receiving FFA alone. To account for these 
effects on insulin resistance, the authors reported that 1,25D treatment reversed a 
number of FFA-induced abnormalities in the insulin-signaling pathway. At a 
protein level, 1,25D significantly inhibited FFA-induced serine phosphorylation 
of IRS-1 and increased the tyrosine phosphorylation of IRS-1 and the 
phosphorylation of Akt. In addition, the FFA-mediated activation of c-Jun N-
terminal kinase, a protein with a significant role in insulin resistance, was 
significantly reversed by 1,25D treatment. Thus, this report provided the first 
demonstration of a direct effect of 1,25D in the restoration of key components of 
the insulin-signaling pathway in an established cellular model of insulin 
resistance. 
 
2. Arachidonic acid (AA) release 
Apart from direct effects on the composition of membrane phospholipids as 
discussed earlier, there is evidence that 1,25D leads indirectly to the release of 
AA by a process involving deacylation of membrane-bound phosphatidylcholine 
(164). This is relevant because levels of AA, a polyunsaturated fatty acid, in 
skeletal muscle correlate inversely with insulin resistance in humans. AA may 
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also modulate the function of membrane insulin receptors and glucose 
transporters and may influence the action of insulin by acting as a precursor for 
the generation of second messengers such as DAG (90). AA also plays a central 
role in inflammation, with the production of both pro- and antiinflammatory 
metabolites that may also have potential effects on insulin signaling. In chick 
myoblasts, 1,25D treatment resulted in dose-dependent increases in the release of 
[3-H]AA, but the effect appeared to be dependent on the influx of extracellular 
calcium and the indirect activation of phospholipaseA2 by PKC (164). More 
research is needed to clarify the possibilities that arise from an effect of 1,25D on 
AA release and its availability for intracellular processes. 
 
3. Caveolin-I mediated insulin sensitivity 
 Some data suggests that vitamin D may play a role in caveolin-I mediated 
insulin sensitivity (165). Caveolin-I, a scaffolding protein within the caveolar 
membrane, has recently been shown to play an important role in insulin 
sensitivity. Its selective down-regulation in the skeletal muscle of wild-type mice 
and its reduced expression in JYD mice, an age-dependent type 2 diabetes 
model, were associated with significant impairments in insulin sensitivity (166). 
VDR is present within the caveolae, appears in close proximity to caveolin-1 on 
confocal microscopy after treatment of ROS 17/2.8 cells with 1,25D (110) and 
relies on caveolin-I for the mediation of nongenomic effects within skeletal 
muscle cells (20), all supporting a close association between vitamin D and 
caveolin-I and raising the question as to whether vitamin D might also have an 
impact on caveolin-I mediated insulin sensitivity. Perhaps the strongest evidence 
to support this possibility is the combination of marked insulin resistance and 
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vitamin D resistance in humans with homozygous nonsense caveolin-1 
mutations, otherwise known as Berardinelli-Seip congenital lipodystrophy (167). 
Future research may address this intriguing conceptual link. 
 
IV. Vitamin D and Muscle: Studies in Animal Models 
A. VDRKO mice 
 The VDRKO mouse model has provided valuable insights into the biological 
function of the vitamin D endocrine system and, specifically, the genomic 
activity of the transcription factor VDR (13). The role of vitamin D in the 
development, morphology, and function of skeletal muscle has been made 
clearer by studies on this mouse model. The earliest form of the VDRKO mouse, 
generated by targeted ablation of the DNA encoding the second zinc finger of the 
DNA-binding domain, was described in 1997 (28). Mice appeared 
phenotypically normal at birth, despite known expression of the VDR in fetal life 
in wildtype mice, but became hypocalcemic with secondary hyperparathyroidism 
around weaning (21 d) and developed alopecia associated with large dermal cysts 
by 4 wk of age and rickets and growth retardation by d 35. The initial lack of 
hypocalcemia is considered to be due to the early presence of nonsaturable 
1,25D-independent mechanisms of intestinal calcium absorption. However, when 
1,25D-dependent mechanisms take over, mice require a high calcium (2%), 
phosphorus (1.25%), and lactose (20%) rescue diet for survival. The alopecia is 
interesting, because people with mutations in VDR (vitamin D-resistant rickets) 
also develop alopecia (168, 169). 
 
1. Muscle morphology and development 
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 A study in 2003 described histological changes in the muscles of VDRKO mice 
directly before and after the development of hypocalcemia. At 3wk of age, 
samples taken from the quadriceps muscle of VDRKO mice displayed a wider 
degree of variability in fiber diameter in addition to significant reductions in the 
size of both type I and II fibers compared with those in wild-type mice (21). By 8 
wk of age, generalized atrophy of type I and II muscle fibers had worsened in the 
VDRKO mice, suggesting progression due to the absence of the VDR or the 
additional effect of systemic biochemical changes that had not been present at 3 
wk. These changes were also reported in VDRKO mice on a high-calcium, -
phosphorus, and -lactose rescue diet, suggesting that the absence of VDR was the 
predominant cause rather than systemic biochemical changes. Neither 
degenerative nor necrotic changes were observed in VDRKO skeletal muscle, 
and similar results were obtained in a range of other muscle groups in this model, 
suggesting a diffuse effect of the VDR on skeletal muscle morphology. Impaired 
regulation in the expression of particular myogenic transcription factors, known 
to control muscle phenotype, was reported as an explanation for these findings. 
On immunohistochemistry, Northern blot, and RTPCR analyses, the expression 
of myf5, myogenin, and E2A was significantly higher in quadriceps samples of 
3- and 8-wk-old VDRKO mice compared with age-matched wild-type mice. 
Persistent expression of immature forms of MHC was also found in the small 
muscle fibers of VDRKO mice but not in their type II muscle fibers. The 
expression of two other myogenic transcription factors, namely MyoD and 
MRF4, were not particularly affected in VDRKO mice. Although these data 
support a role for vitamin D in the regulation of muscle development, precise 
genomic mechanisms by which the VDR influences myogenesis are unclear, and 
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the issue is further complicated by the failure to identify negative VDRE in the 
promoter region of the genes encoding myf5 and myogenin (170, 171). 
 
2. Muscle strength and functional assessment 
A number of studies have examined muscle strength and performance in 
VDRKO mice. These investigations rarely assess muscle function in isolation, 
with results being potentially influenced by a range of other factors including 
cardiovascular endurance, balance, and the ability to learn new skills. 
Furthermore, behavioral differences between VDRKO and wild-type mice have 
been reported, which may confound the assessment of some tests (172). 
Nevertheless, these studies provide an indication of the functional motor deficits 
associated with loss of VDR by testing swimming ability and motor 
coordination. 
 
a. Forced swim test analysis.  Three studies have described differences in the 
swimming behavior of VDRKO mice. In one study comparing six VDRKO mice 
with 10 wildtype and heterozygote mice that were shaved to account for 
alopecia-related alterations in buoyancy, severe impairment of swimming was 
seen in the knockout mice (173). Baseline levels of locomotor, sensory, and 
vestibular activity were similar. On swim testing, they were observed to swim in 
a predominantly vertical position, had a significantly greater number of sinking 
episodes, and displayed stereotypic rotations and catatonic-like upper limb 
spasms. In another study, a significantly greater number of sinking episodes were 
seen among eight VDRKO mice compared with six wild-type controls (174). 
However, on being given a stimulus, they showed no impairment in ability to 
! 36!
move down a 1-m laneway or in reaching a visible platform. However, VDRKO 
mice did display greater fatigue after the swim based upon differences in rearing 
and grooming behavior. The authors hypothesized that this was due to the 
reduced availability of calcium in VDRKO mice after exercise. A third study 
reported that abnormal patterns of swimming behavior among VDRKO mice 
were more marked in older (5–13 months) rather than younger knockouts (175). 
Interestingly, no such impairment in swimming ability was seen among a group 
of 11 1α-hydroxylase (Cyp27B1)-knockout mice (175). That suggests the 
intriguing possibility that there might be vitamin D-independent effects of VDR 
upon muscle function (175). 
 
b. Tests of motor coordination.  The time taken for a mouse to fall off a device 
that rotates at fixed speeds and in acceleration is considered to indicate its degree 
of motor coordination (174). In one study, VDRKO mice stayed on a rotating 
device for a significantly shorter time than wild-type mice on both the 
accelerating and fixed-speed rotarod tests (174). On gait assessment, VDRKO 
mice took significantly shorter steps and traveled a shorter distance than wild-
type mice when placed in an open field for 5 min. Significantly shorter retention 
times on accelerated rotarod testing were confirmed in another group of 12-
month-old VDRKO mice compared with age-matched wild-type mice (175). 
These 12-month-old mice demonstrated similar impairments in muscle 
coordination in tilting box and tilting tube tests, which measure the latency and 
the angle at which the animal displaces off a device that, respectively, tilts or 
rotates at different angles. However, no differences were found in 6-month-old 
VDRKO mice. 
! 37!
 
In another study, the vertical screen test that measures the time taken for a mouse 
to fall from a screen that becomes suddenly vertical while the mouse rests on it in 
a horizontal position (i.e. retention time) was employed (173). VDRKO mice 
demonstrated markedly shorter retention times compared with both wild-type 
and heterozygous groups, implying impaired motor coordination or strength.  
 
In summary, VDRKO mice demonstrate notable defects in their overall motor 
performance with significant impairments in their ability to remain afloat while 
swimming and shorter stride length and impaired motor coordination and balance 
on rotarod, rotating tube, and tilting box tests. Although the effect of alopecia 
was accounted for in one study, other biochemical and behavioral changes in 
VDRKO mice together with the widespread expression of the VDR in the central 
nervous system, vestibular system, and spinal cord under normal conditions 
make direct assessment of its role in muscle function difficult in this setting 
(175). Nevertheless, it is clear that the overall motor function of these mice is 
impaired and that further work is needed to clarify the individual components 
that may account for this. 
 
B. Other animal models 
Although the VDRKO mouse model has provided valuable insights into the 
biological activity of vitamin D, it is more accurate to consider this as a model of 
type II vitamin D-dependent rickets rather than vitamin D deficiency. Studies 
have examined muscle function in animals rendered vitamin D deficient by a 
range of dietary and other methods (176). In a study from 1978, vitamin D-
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deficient male Sprague-Dawley rats demonstrated significantly prolonged times 
to peak tension and recovery times in electrically stimulated soleus muscle 
contraction compared with vitamin D-replete rats on normal chow (177). These 
changes normalized after vitamin D repletion. In contrast, no impairments were 
noted in rats rendered phosphate deficient or calcium deficient 10 d before 
experimentation. A study from 1979 examined muscle function in chicks raised 
from hatching on a vitamin D-deficient diet (178). Significant reductions in the 
tension generated by the triceps surae during stimulation of the posterior tibial 
nerve compared with that in vitamin D-replete chicks were found. This occurred 
independently of calcium and phosphate levels. The authors found no difference 
in the histological appearance of muscle samples but did isolate reduced muscle 
mitochondrial calcium levels. This was independent of serum calcium levels and 
was proposed as the mechanism by which vitamin D deficiency affected muscle 
contraction force. Four weeks after the commencement of a vitamin D deficient 
diet, rats displayed marked skeletal muscle hypersensitivity on calf compression 
compared with those fed a normal diet (179). This finding was not related to 
hypocalcemia but was rather accelerated by increased dietary calcium and was 
accompanied by early impairments in balance on a beam-walk test to assess the 
frequency of foot slips. Histologically, vitamin D-deficient rats displayed 
increased numbers of presumptive nocioceptor axons in skeletal muscle, 
providing an explanation for their hyperalgesic phenotype. In contrast to these 
studies, a recent report questioned the primary role of vitamin D, rather than 
biochemical changes associated with vitamin D deficiency, in resulting in 
myopathy (176). In 58 male Wistar rats that were rendered vitamin D, 
phosphorus, and calcium deficient by dietary methods and housing under 
! 39!
incandescent lighting, muscle strength of the soleus as assessed by a force 
transducer detecting isometric contraction was significantly reduced compared 
with that in replete controls (176). The authors concluded that phosphorus 
deficiency was the primary culprit on the basis of several findings. These 
included a direct independent correlation between phosphorus levels and the 
reduction in soleus muscle force in these animals, complete restoration in slow-
twitch muscle force after dietary repletion with phosphorus despite persistent 
vitamin D deficiency and similar measures of muscle function among 
phosphorus-replete rats that were either vitamin D deficient or replete. Similarly, 
there was no difference in muscle contraction among rats that were calcium 
deficient and replete, in which vitamin D and phosphorus levels were within the 
reference range. The central importance of phosphorus in the production of ATP, 
essential for muscle contraction, was considered as the explanation for these 
findings. 
 
Therefore, the difficulty in differentiating the effects of severe vitamin D 
deficiency from those of hypocalcemia and hypophosphatemia in the 
development of muscle pathology is common to animal and human clinical 
studies. However, cell lines and tissue culture enable study of direct effects, and 
these studies date back to the 1970s. 
 
C. Animal studies on insulin sensitivity and diabetes 
Although vitamin D deficiency has been associated with more aggressive disease 
among nonobese diabetic mice (180), a model for type 1 diabetes, few animal 
trials have addressed the role of vitamin D in insulin resistance. In one study of 
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ob/ob mice, an obese type 2 diabetes model, significant improvements in 
hyperglycemia and hyperinsulinemia in response to treatment with 1α-
hydroxyvitaminD3 (1α-OHD3) were observed (181). In another study of aged 
rats with type 2 diabetes and insulin resistance that received 25D, 1α-OHD3, or 
no treatment, serum 1,25D levels correlated positively with the glucose infusion 
rate on euglycemic clamp studies at the end of the 12-wk treatment period (182), 
suggesting a potential role in insulin sensitivity. However, the main focus of this 
study was the demonstration of bone loss among insulin-resistant rats attributed 
to a reduction in their renal 1α-hydroxylase activity.  
 
D. Summary: vitamin D and muscle function in animal studies 
Congenital absence of the VDR in VDRKO mice is associated with atrophy of 
both type I and type II fibers, poor musculoskeletal performance in behavioral 
tests, and marked changes in gait. Vitamin D deficiency induced in rats has also 
been found to alter muscle function when compared with vitamin D-replete 
animals. Together, these studies using animal models provide additional 
evidence that vitamin D plays an important role in muscle physiology. However, 
they do not separate the effects of muscle vs. whole-body deletion of VDR. 
Biochemical abnormalities in these mouse models may once again confound 
these findings (Fig. 4). A similar question has been recently answered in relation 
to cardiac muscle; mice with specific deletion of VDR in cardiac muscle 
displayed significant cardiac hypertrophy, similar to that seen in whole-body 
VDRKO mice (183). Specific deletion of VDR in skeletal muscle using Cre-Lox 
technology will be required to clarify this question. 
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V. VDR Polymorphisms and Muscle Function 
Several single-nucleotide polymorphisms (SNP) in the gene encoding the VDR 
have been associated with a range of phenotypic characteristics including muscle 
strength. These have been summarized in Table 3. 
 
A. FokI polymorphism 
The FokI polymorphism of the VDR gene is a T/C transition in exon 2 of the 
VDR gene that results in a shorter 424-amino-acid protein with enhanced 
transactivation capacity using a reporter gene assay (184). Although this greater 
VDR activity might suggest improved muscle strength in light of some of the 
clinical data, the FokI polymorphism is associated with reduced muscle strength 
in two studies in men (185, 186). It is interesting to speculate that increased VDR 
function could increase CYP24A1 expression and thereby degradation of 1,25D. 
Among 302 Caucasian men (aged 58–93 yr), those who were homozygous for 
the FokI polymorphism displayed significantly lower fat-free mass and 
appendicular muscle mass on dual-energy x-ray absorptiometry (DXA) scanning 
(185). Furthermore, men with this polymorphism demonstrated a 2.17-fold 
higher risk of sarcopenia (defined by appendicular fat-free mass < 7.26 kg/m2), 
independent of age. Lower fat-free mass was associated with significantly lower 
quadriceps muscle strength. Differences in quadriceps strength were not 
significant after adjusting for fat-free mass, suggesting that the difference was 
mediated by altered muscle mass. In another study that included 107 patients 
with stable chronic obstructive pulmonary disease and 104 healthy, age-matched 
controls, homozygosity for the FokI polymorphism was associated with reduced 
quadriceps strength compared with heterozygosity or control subjects (186). The 
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difference became more significant in a model that adjusted for age, sex, forced 
expiratory volume in 1 sec (FEV1), fat-free mass, and angiotensin-converting 
enzyme genotypes. There was no evidence that the presence or absence of lung 
disease affected the relation between FokI genotype and quadriceps strength. 
Among 240 women (41.5 ± 13.2 yr), those with the FokI polymorphism (FF) 
had weaker isometric knee extensor strength (P<0.05 for both 90° and 120° 
incline) vs. those who were heterozygous (Ff) or lacking the polymorphism (ff) 
(187). However, on adjusting for age, height, and total fat-free mass, the 
differences were no longer significant, again suggesting that the polymorphism 
may be affecting muscle mass. 
 
B. BsmI polymorphism 
The data are less consistent for the BsmI polymorphism. This SNP is located in 
the 3’ region of the VDR gene, known to play an important role in the regulation 
of gene expression (188). In a group of 121 nonobese, healthy women over 70 yr 
of age, the bb genotype was associated with 23% higher quadriceps strength and 
7% higher wrist strength compared with those with the BB genotype (189). 
However, among the 380 obese women over the age of 70 in this same study, no 
effect was found. Conversely, a study of 175 young healthy women (age range 
20–39 yr) in Belgium found that those with the bb genotype had lower hamstring 
strength on dynamometer and lower fat-free mass on DXA compared with the 
BB genotype (190). The difference in hamstring strength became of borderline 
significance after adjustment for age, fat mass, and lean mass. Interestingly, the 
significance of another polymorphism known to be in linkage disequilibrium 
with the BsmI B allele, namely the polyadenosine repeat (ss genotype), was 
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associated with higher hamstring strength and greater body weight and fat mass 
compared with those with LL genotype in this study. Among 109 healthy female 
university students in China (age around 19–21 yr), those with the bb genotype 
of the BsmI polymorphism displayed significantly lower peak torque in 
concentric knee flexors at a specific setting on the isokinetic dynamometer than 
the combined BB and Bb group (P<0.03) (191). However, when this parameter 
was tested at other settings, namely 120°/sec and 30°/sec, the differences were 
not statistically significant. When examining another polymorphism at the ApaI 
site, peak torque in eccentric knee extensors at 120°/sec was significantly lower 
in the AA homozygous group compared with the aa and Aa groups. In a study of 
253 men (54.9 ± 10.2 yr), Bt homozygotes (i.e. those with BB genotype at the 
Bsm I site and tt genotype at an associated polymorphism site, namely Taq I) had 
higher isometric quadriceps strength at 150° on isokinetic dynamometer than b 
or T allele carriers without and with adjustment for confounding factors (P<0.01 
after adjustment) (187). However, no such association was found when this same 
parameter was tested at 90° or 120° or when assessing knee flexor strength. 
Among 120 Turkish men (>65 yr), knee extensor strength on dynamometer was 
significantly higher in those with BB homozygosity at the Bsm I site than in the 
Bb/bb group, but no significant association between muscle mass and strength 
was found (192). 
 
Two population studies examining the rate of falls suggest that the bb genotype 
of the Bsm I polymorphism may be protective against falls. In a study from Italy 
that included 259 community-dwelling older patients (>80 yr of age), the rate of 
falls differed according to Bsm I genotype with more seen among those with BB 
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or bb genotype on multivariate analysis (193). Data collected from two separate 
population cohorts of older women, namely the Aberdeen Prospective 
Osteoporosis Screening Study (APOSS) and Osteoporosis and Ultrasound study 
(OPUS), also identified a greater incidence of self-reported recurrent falls among 
those with the BB genotype of the Bsm I polymorphism compared with those 
with the bb genotype (194). Significant differences in function with greater ease 
in rising from a chair were seen in bb homozygotes compared with carriers of the 
B allele. These studies failed to demonstrate an association between Fok 1 
polymorphisms and balance or muscle power measurements. Apart from VDR 
polymorphisms, a recent population based study that involved 153 men and 596 
women (65–101 yr) reported an association between SNP in the CYP27B1 gene 
(i.e. – 1260 and + 2838) and the risk of fracture over a 2.2-yr follow-up period 
(195). There was no difference in the risk of falls among subjects, and muscle 
strength was not examined. There are limitations in the interpretation of these 
data. Larger studies to assess the association between muscle strength and 
genetic polymorphisms are needed, and more functional studies of effects on 
VDR function are required. 
 
C. VDR polymorphisms and insulin resistance/type 2 diabetes 
 Particular polymorphisms in the gene encoding the VDR may be associated with 
the development of insulin resistance and type 2 diabetes among certain 
populations. However, once again, the data are inconclusive due to the generally 
small sample size in these studies and the variability in the populations and 
examined endpoints. These studies have been summarized in Table 3. 
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VI. Vitamin D and Muscle: Human Studies 
A. Myopathy 
 Rickets and osteomalacia have been associated with muscle weakness and 
hypotonia for centuries (196, 197). Weakness affecting the proximal lower limb 
musculature was reported in a group of adults with osteomalacia who responded 
to high-dose vitamin D therapy in the 1960s (198). The paper did not report 
whether all patients responded or whether responses were complete. In addition 
to general weakness, more specific proximal muscle deficits are commonly 
described, including difficulty rising from a seated or squat position, ascending a 
flight of stairs, or lifting objects (199–201). Changes in gait, often described as 
waddling or penguin-like in appearance, are widely reported and are possibly a 
combined result of bone pain, muscle pain, and proximal weakness (199, 202). 
However, the classic pattern of proximal weakness seen in vitamin D deficiency 
is not specific. Many endocrine and metabolic disorders including renal failure, 
hyperparathyroidism, hypophosphatemia, Cushing’s syndrome, and 
hyperthyroidism as well as glucocorticoid therapy may display similar clinical 
features (203, 204). Electromyographic changes seen in vitamin D-deficient 
subjects with muscle weakness confirm myopathy, but without specific features 
(201). In the reports of myopathy with vitamin D deficiency, many subjects had 
multiple biochemical abnormalities involving calcium, phosphate, and PTH that 
co-corrected with vitamin D repletion, making it difficult to assess the individual 
role of each component in the development of osteomalacic myopathy (205). 
These observations formed the basis for the belief that myopathy in these 
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subjects was not directly related to vitamin D deficiency but rather a general 
result of osteomalacia and its associated biochemical abnormalities (206).  
 
Observational and uncontrolled treatment studies 
The reversibility of myopathy with vitamin D supplementation has been 
described in some case series (200, 207, 208). A recent series described the 
presence of progressive muscle weakness among young vitamin D-deficient 
veiled women from Saudi Arabia [90% had 25D< 8 ng/ml (20 nmol/liter)] (205). 
Some women required a wheelchair. Substantial improvements followed 3 
months of vitamin D and calcium supplementation (800 IU and 1200 mg daily, 
respectively). Wheelchair-bound patients walked independently by the end of the 
study. In another case series, five patients with myopathy resulting in wheelchair 
use were treated with vitamin D2 (50,000 IU weekly) (209). At baseline, they 
were deficient [25D 5–13 ng/ml (12–32 nmol/liter)] with secondary 
hyperparathyroidism (intact PTH range 13–89 pmol/ liter). Treatment resulted in 
marked improvements in strength, pain, and mobility within 4–6 wk, despite 
persisting hyperparathyroidism. The authors suggested that this indicated a role 
for vitamin D independent of PTH. A study assessing vitamin D-deficient 
women [25D<7 ng/ml [17 nmol/liter)] vs. controls with higher levels [25D>19 
ng/ml (47 nmol/liter)] reported an independent association between 25D levels 
and maximal voluntary knee extension force (208). No correlations were found 
for PTH or total or bone-specific alkaline phosphatase. 
 
A common theme in these case series that describe patients with muscle pain and 
weakness is the high rate of initial misdiagnosis. The diagnoses of diabetic 
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neuropathy, general debility, motor neuron disease, orthopedic disorders, 
psychiatric conditions, or inherited myopathy were described before the 
recognition of vitamin D deficiency (205, 209, 210). The nonspecific clinical 
features of vitamin D-deficiency myopathy, the wide range of severity from mild 
weakness to debilitating pain and immobility, and low index of suspicion may 
contribute to the frequent delay in the diagnosis. We are not aware of any reports 
of muscle biopsy or muscle function studies in people with mutations in VDR. 
 
B. Myalgia and vitamin D deficiency 
 People with vitamin D deficiency and proximal myopathy (i.e. weakness of the 
proximal musculature arising from muscle pathology) often have associated 
proximal myalgia (i.e. muscle pain) (198). Many authors have also proposed that 
low vitamin D is associated with more diffuse muscle pain (211–213). However, 
this is controversial, and other studies do not support this (214–216). The issue is 
made more difficult because osteomalacia is associated with bone pain and 
microfractures, making causal discrimination of the source of pain challenging. 
Because it is conceptually obvious that people with muscle pain may be less 
likely to exercise, go out, and carry out normal outside activities of daily living, 
establishing cause and effect is important. Ideally, demonstrating a therapeutic 
response would clarify the issue. 
 
1. Observational studies 
A cross-sectional study of 3075 men from eight European centers found that 
those who reported chronic widespread pain (8.6%) were more likely to have low 
25D levels [<15 ng/ml (37.5 nmol/liter]) (217). However, the relationship was 
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attenuated by adjusting for age, season, activity, and other factors. Ninety-three 
percent of 153 patients who were being assessed for persistent, nonspecific 
musculoskeletal pain in Minneapolis were vitamin D deficient [mean 25D 12 
ng/ml [30 nmol/liter)] (211). All African-American, East African, Hispanic, and 
American Indian patients had 25D below 20 ng/ml (50 nmol/liter) as did 82% of 
Caucasian patients. None had fibromyalgia or medical conditions known to 
decrease production, absorption, or hydroxylation of vitamin D. This study did 
not include a control group of similar ethnicity. The propensity for particular 
ethnic groups, including those migrating from Asia and the Indian subcontinent 
to Western countries, to develop myalgia and bone pain as the primary 
manifestation of vitamin D deficiency has been reported since the 1970s (218, 
219). A study describing 33 mostly Somalian female asylum seekers with 
musculoskeletal pain and low 25D [<8.5 ng/ml [21 nmol/liter)] found that 
vitamin D and calcium supplementation led to the symptom resolution in 22 
(66.7%) by 3 months (220). The authors noted a 2.5-yr mean lag time between 
symptom onset and diagnosis. There was no control group. A study from the 
United Arab Emirates found that 86% of patients who were initially diagnosed 
with fibromyalgia or nonspecific muscle pain were vitamin D deficient. The 
majority reported improvement in response to supplementation (221). Another 
study compared cultural differences in the reporting of muscle pain among South 
Asians (i.e. Indian, Pakistani, and Bangladeshi) and white Europeans living in 
England (212). Reporting of widespread pain was significantly more common in 
the 1945 South Asians. However, in the 137 South Asians in whom 25D was 
measured, there was no association between deficiency and pain. 
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A report describing myalgia in six women who had migrated to the Netherlands 
considered vitamin D deficiency [<8 ng/ml (20 nmol/liter) in 5 patients] to be the 
cause. There was a lengthy lag period (7–103 months) from the onset of 
symptoms to diagnosis (222). In three cases, misdiagnosis led to treatment with 
prednisone, estrogen, or cholecystectomy. Vitamin D and calcium 
supplementation was effective in reversing the myalgia in each case. 
 
2. Case-control studies 
Muscle pain was recently proposed as a marker for vitamin D deficiency among 
Aboriginal Australians (223). A case-control study of eight urban Aboriginal 
patients with muscle pain and eight matched Aboriginal controls without pain 
reported significantly lower vitamin D levels among those with pain [17 vs. 23 
ng/ml (41 vs. 58 nmol/liter), P<0.017]. Wide cultural and gender differences in 
the reporting of pain, subjective features in the diagnosis of fibromyalgia, and the 
presence of other features known to affect vitamin D status among patients with 
persistent pain syndromes confound the assessment of the role of vitamin D 
deficiency in muscle pain. Also, the observational nature of these studies does 
not equip them to address the question of causality. 
 
3. Randomized controlled trials (RCT) for myalgia 
We identified only one randomized placebo-controlled trial of supplementation 
where treatment of muscle pain appeared to be the primary endpoint. The study 
examined people with diffuse muscle pain (214). Fifty subjects with 25D below 
20 ng/ml (50 nmol/liter) at baseline were randomized to placebo or vitamin D2  
50,000 IU weekly for 3 months. There was no benefit of treatment. The authors 
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note that 50% of the placebo group achieved normal vitamin D levels during the 
study; however, the improvement in pain scores was not substantial for either 
group. Using the PowerStat program (224), we calculate that the study had 80% 
power with α of 0.05 to detect a difference of ±19 in pain score. The baseline 
visual analog pain score in the treatment group was high at 67 ± 23, so if there is 
any benefit, it is probably smaller than this. 
 
4. Summary: myalgia 
Vitamin D deficiency with osteomalacia is associated with muscle pain that in 
most cases resolves with treatment. The pain is more commonly located in large 
proximal muscle groups rather than displaying diffuse distribution (198, 222, 
225, 226) and is often associated with bone pain and other features of 
osteomalacia and myopathy (205, 208). Thus, for pain (proximal or diffuse) in 
patients without osteomalacia, other etiologies should also be considered. In 
patients with diffuse pain, without obvious osteomalacia, the data remain 
inconclusive. There are strong associations, but the only RCT found no 
convincing benefit of supplementation. The trial was adequately powered to 
detect a clinically meaningful change in pain score. There are no RCT examining 
specific treatment of proximal muscle pain. Larger randomized placebo-
controlled trials should be carried out, preferably with stratification by baseline 
vitamin D status, in people with fibromyalgia and in people with proximal 
myalgia. There is no evidence to support supplementation for myalgia in people 
with normal levels. 
 
C. Fibromyalgia 
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 Fibromyalgia is not purely a muscle disorder, but there are a number of studies 
examining the potential association between it and vitamin D. Myalgia was 
examined in a cross-sectional study of 6824 white, middle-aged subjects living in 
the United Kingdom. A significant association between fibromyalgia, defined by 
the American College of Rheumatology criteria, and 25D was found among 
women (227). However, no such association was found in men, although they 
reported similar rates of pain (11.4% for men, 12.5%for women). No association 
with myalgia was found. In two separate case-control studies of patients with 
fibromyalgia from the United States and Brazil, no statistically significant 
differences were found in 25D levels (214, 228). In contrast, another case-control 
study that examined 40 premenopausal women with fibromyalgia and 37 
controls found a significantly higher proportion of vitamin D deficiency [25D<8 
ng/ml (20 nmol/liter)] among women with fibromyalgia (229). However, this 
was not adjusted for physical activity, smoking, or body mass index (BMI). 
Fibromyalgia symptoms did not differ depending on the vitamin D status. A 
subset of deficient patients who received supplementation (eight of 18) reported 
subjective improvement that persisted at 3 months; however, 10 of 18 did not. 
One placebo-controlled study examining the effect of vitamin D on fibromyalgia 
was identified (230). In that study of 138 patients with fibromyalgia, the subset 
of 100 patients with mild to moderate vitamin D deficiency and insufficiency 
[25D 10–25 ng/ml (25–62.5 nmol/liter)] who were randomized to receive 
vitamin D3  (50,000 IU weekly) showed significant improvement over 8 wk vs. 
placebo-treated controls. However, this did not persist at 1 yr, and in the same 
study, the subset of 38 people with severe deficiency [25D <10 ng/ml (25 
nmol/liter)] who received vitamin D in an unblinded fashion did not report any 
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improvement at either 8 wk or 1 yr (230). 
 
Overall, there is conflicting evidence regarding the possibility of an association 
between low vitamin D and fibromyalgia, and clearly, having fibromyalgia may 
have an impact on time spent outdoors/exercising. The data from the one 
randomized placebo-controlled trial do not provide a clear answer, because the 
most deficient subjects did not benefit, but less deficient subjects did. More 
research is needed in this area. 
 
D. Drug-related myopathy and vitamin D 
1. Aromatase inhibitors 
The effect of vitamin D supplementation on myalgia due to a drug class, namely 
aromatase inhibitors, has been recently reported. For this class, there is both 
observational and randomized controlled data, and myalgia is a very common 
side effect. An observational study found significantly less musculoskeletal pain 
among 60 women on letrozole who had achieved median25Dlevels over 66 
ng/ml (165 nmol/liter) compared with women with levels below 66 ng/ml (165 
nmol/liter) (19 vs. 52%) after weekly supplementation with 50,000 IU vitamin 
D3 for 12 wk (231). In a double-blind RCT, 60 patients with early-stage breast 
cancer with new or worsening musculoskeletal pain on aromatase inhibitor 
therapy were randomized to receive either high-dose vitamin D supplementation 
at a regimen that depended on their baseline 25D or placebo (232). Those with 
25D of 10–19 ng/ml (25–47 nmol/liter) received 50,000 IU vitamin D2 for 16 
wk, whereas those with 25D of 20–29 ng/ml (50–72 nmol/liter) received 50,000 
IU for 8wk (232). There were significant improvements in pain at 2 months in 
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the vitamin D group vs. placebo on the basis of several indices. Therapy was 
decreased from weekly to monthly after 2 months in most subjects. The 
beneficial effects did not remain at the 4- and 6-month visits. There was evidence 
of a dose-response effect; women who were more deficient had greater benefits, 
and in that subgroup, the beneficial effect was seen across the whole study 
period. 
 
2. 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) 
A number of reports suggest that vitamin D deficiency may potentiate myopathy 
in patients on lipid lowering statin therapy (3-hydroxy-3-methyl-
glutarylcoenzyme A reductase inhibitors) (233–242). These reports are both 
anecdotal and based on case series and cross-sectional studies. Not all studies 
have confirmed this relationship (237). 
 
Cross-sectional and cohort studies.   
Among a group of 621 statin-treated patients, the 128 who reported myalgia had 
lower serum 25D (238). Levels were low [defined as <32 ng/ml (80 nmol/liter) 
in that study] in 64% of myalgic patients vs. 43% of the others. A subset of 38 of 
the 82 25D-deficient myalgic patients were treated with 50,000 IU/wk of vitamin 
D2 for 12wk (unblinded) while continuing statins, and 35 had their myalgia 
resolve. The three nonresponders achieved similar vitamin D levels. A 
prospective study of 150 statin-intolerant patients with 25D below 32 ng/ml (80 
nmol/liter) reported that 83% were free of myalgia and no longer statin intolerant 
after approximately 8 months of vitamin D2 treatment (50,000 IU twice weekly 
for 3 wk and then 50,000 IU weekly) (240). However, treatment had little effect 
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on elevated creatine phosphokinase (CPK). However, not all studies find an 
association. A retrospective study of 6808 statin users found no correlation 
between 25D levels, myalgia, or CPK levels (242). A smaller study of 129 
patients on statins also found no difference in the 25D levels of those with and 
without myalgia (237). 
 
Some hypotheses have been proposed regarding mechanisms by which vitamin 
D deficiency may potentiate statin-induced myalgia. The suggestion that statins 
may reduce vitamin D synthesis by inhibition of synthesis of its cholesterol 
precursor has not been supported by clinical studies (243, 244). The enzyme 
CYP34 demonstrates in vitro 25-hydroxylase activity (245), and it has been 
speculated that vitamin D deficiency may lead to preferential shunting or use of 
this enzyme for vitamin D hydroxylation, reducing its availability to metabolize 
(deactivate) statins (239). This hypothesis could be tested by measuring statin 
levels in vitamin D-deficient and vitamin D-sufficient individuals matched for 
the presence or absence of myopathy and/or CPK levels. Although an association 
between a polymorphism of the solute carrier organic anion transporter family 
member 1B1 gene (SLCO1B1) and statin-induced myalgia was reported, no 
interaction between vitamin D deficiency and genotype was found in a group of 
46 patients on statin therapy (241). 
 
These studies of statin myalgia/myopathy are interesting; however, their 
unblinded nature and lack of control groups are particular limitations, especially 
given the well known placebo effect in pain studies. At this time, the evidence of 
an association between vitamin D deficiency and statin-related myalgia is 
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derived from observational studies and small series. Obviously, people who 
experience pain with muscle movement may be less likely to be participating in 
outdoor activities and may therefore make less vitamin D than their pain-free 
counterparts. Randomized placebo-controlled studies are needed. In the 
meantime, we suggest treating deficient patients because of the known bone and 
calcium benefits. There is at present no evidence to support treating people on 
statins who have normal vitamin D status. 
 
3. Summary: drug-related myopathy and vitamin D 
 Myalgia has been observed in patients receiving statins or aromatase inhibitors. 
A number of these studies reveal that patients on statins who suffer from myalgia 
are also vitamin D deficient, and vitamin D supplementation might improve 
symptoms of myalgia in these patients. These findings suggest that vitamin D 
deficiency may potentiate statin-induced myalgia, but the molecular mechanisms 
underlying the interaction between vitamin D, statin treatment, and muscle 
function have not been elucidated. Based on the limited data, we recommend 
treating all deficient subjects who are receiving statins or aromatase inhibitors. 
The only RCT in patients taking aromatase inhibitor used high-dose therapy. If 
this is used, patients should be monitored for hypercalcemia and hypercalciuria. 
 
E. Falls and vitamin D 
Approximately 30% of community-dwelling people over the age of 65 fall each 
year, and approximately 20% of these require medical attention (246). Falls pose 
a substantial risk to an aging population, are a major risk factor for fracture and 
other injury, and impact negatively on quality of life (247). Therefore, 
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identifying reversible factors is important. In older individuals, falls are closely 
related to sarcopenia (loss of muscle mass), loss of muscle tone, and a range of 
conditions that contribute to the complex syndrome of frailty (248). This issue 
has also recently been discussed in an Endocrine Society statement on 
extraskeletal roles of vitamin D (12). 
 
1. Falls: observational studies 
There is a seasonal variation in the incidence of falls, with more occurring in 
winter among older women. This raises the suggestion of a putative role for 
vitamin D in the occurrence of falls (249), although other factors such as 
decreased daylight and increased likelihood of slipping on wet or icy surfaces 
could also explain the differences. The possibility that vitamin D deficiency, 
which is highly prevalent in frail and older individuals, may contribute to falls 
has been examined by a number of studies. These are summarized in Table 4. In 
1619 women in low-level and high-level residential care (mean age 84 yr), a 
significant inverse association between serum 25D levels and the incidence of 
falls over approximately 5 months was reported. The authors estimated a 20% 
reduction in falls risk with doubling vitamin D status on analysis of log[25D] 
levels (250). A similar sized study of 1231 community-dwelling individuals 
identified baseline 25D as a predictor for falls over a 1-yr period, particularly 
among those 65–75 yr of age (251). Those with 25D levels below 10 ng/ml (25 
nmol/liter) displayed the highest risk of recurrent falls. However, in a smaller 
study, although older individuals who fell had significantly lower 25D levels vs. 
the overall group of 83 subjects, this was not significant on multivariate analysis 
(252). 
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The possibility that 25D does not directly contribute to falls but is rather an 
associative marker of frailty remains a potential limitation in the interpretation of 
these observational data. As in the situation with myalgia, it is obvious that 
people who fall may spend less time outdoors and thereby have lower exposure 
to solar UV radiation. The other issue is that malnutrition is very common in 
elderly persons, affecting up to 40% of those living in institutions, and may 
contribute simultaneously to vitamin D deficiency and frailty. 
 
2. Falls: interventional studies 
Interventional studies seeking to examine the effects of vitamin D 
supplementation or UV exposure on the risk of falls among older individuals 
have been performed and are summarized in Table 5. 
 
a. Sunlight therapy    
In a study of 602 residents of aged-care facilities, those who complied with a 
daily regimen of increased sunlight exposure had fewer falls than those 
randomized to the control group (253). Compliance was surprisingly poor despite 
the use of sunlight officers who visited the facilities (median adherence was 
26%). Thus, on intention-to-treat analysis, the study was underpowered, and no 
effects were seen. The authors concluded that vitamin D supplementation was a 
more practical approach to reduce falls in residential care. It should also be noted 
that sunlight exposure during the early morning hours rather than at midday 
when UV levels are highest might not have been sufficiently effective in the 
synthesis of vitamin D. 
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b. Intervention studies: non-placebo controlled 
The combination of daily 400 IU vitamin D3 plus 1000 mg calcium reduced 
severe falls requiring admission in 5063 community-dwelling city residents 
above the age of 66 yr in Denmark (254). The number needed to treat was nine. 
 
c. Intervention studies: placebo controlled 
A reduced incidence of falls, regardless of baseline 25D, was seen in a 
randomized trial of vitamin D supplementation (255). Among 625 older residents 
of assisted-living facilities, those who received calcium (600mgdaily) and 
vitaminD2 (initially 10,000 IU once weekly and then 1,000 IU daily) for 2 yr had 
a lower rate of falls compared with those receiving calcium alone. However, the 
rate of ever falling was not different, implying that the benefits were among 
repeat fallers. On subgroup analysis of compliant participants (defined as taking 
>50% of the doses, n=540) the risk of ever falling was also significantly lower. 
The number needed to treat to prevent one fall per year was eight, similar to the 
above open-label study. A 3-yr double-blinded randomized study examined 
combined supplementation with vitamin D3  (700 IU) and calcium citrate malate 
(500 mg) vs. placebo in 445 community-dwelling older individuals (256). By 
intention-to treat analysis, combined therapy was not effective. A subgroup 
analysis of the women found a significant reduction in the incidence of falls that 
was most pronounced in those who were less active. Inter-gender differences in 
muscle mass were postulated to lead to greater susceptibility for falls among this 
particular group. The trial was not originally powered to detect effect 
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modification by sex and activity levels, and falls were also a secondary outcome. 
The primary outcome examined bone density, which was significantly improved 
(257). In another study, 242 community-dwelling older individuals were 
randomized to receive calcium (1000 mg daily) with or without vitamin D3 (800 
IU daily) for 1 yr and then followed 8 months without treatment but continuing 
blinding to treatment (258). On intention-to-treat analysis, subjects on dual 
supplementation reported 27% fewer falls at 1 yr and 39% fewer falls at 20 
months. Among 122 older women in long-stay geriatric care who received 
calcium (1200 mg/d) with or without vitamin D3  (800 IU/d), those on dual 
supplementation had significantly fewer falls during the 12-wk treatment period 
compared with the preceding 6-wk observation period. There was no difference 
in the proportion who fell at all, but people who fell the most appeared to obtain 
the greatest benefit (259). In a particularly vulnerable group, namely older 
individuals with poststroke hemiplegia, a significant reduction in the number of 
falls per person and the total number of repeat fallers was seen among 48 women 
receiving vitamin D2  (1000 IU daily) vs. controls who received placebo for 2 yr 
(85). The study included biopsies of the unaffected side and reported that the 
baseline proportion and diameter of type II muscle fibers were significant 
independent predictors for falls over the 2 yr. In demonstrating significant 
improvements in these parameters in a subset of individuals who received 
vitamin D supplementation for 2 yr, they offered a mechanistic explanation for 
the reduction in falls. By contrast, recurrent fallers were the least likely to benefit 
from supplementation in another study (260). Community dwelling ambulant 
older women were randomized to receive calcium citrate (1000 mg daily) and 
either vitamin D2  (1000 IU) or placebo for 1 yr. After adjusting for height, 
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which was not equal at baseline, the vitamin D group had a 19% lower risk of a 
single fall compared with controls. The effect was most pronounced in 
winter/spring rather than in summer/autumn. It was calculated that 25D levels 
over 22 ng/ml (54 nmol/liter) were adequate for the benefit. The results were not 
statistically significant without height correction. Another study that specifically 
targeted vitamin D insufficient older individuals [25D <20 ng/ml (50 nmol/liter)] 
reported that 800 IU vitamin D3 and 1200 mg calcium daily decreased falls per 
subject compared with the 148 controls who received calcium alone (261). One 
noncompliant individual was excluded from analysis. The authors propose that 
the mechanism relates to a significant improvement in body sway at 8 wk (261, 
262). Sagittal body sway improved with treatment, but frontal sway improved in 
both groups (261). 
 
d. Negative randomized studies and falls. 
A number of randomized studies have also failed to demonstrate an effect of 
vitamin D supplementation upon falls. Among 354 older persons in The 
Netherlands who were randomized to receive vitamin D3  (400 IU) or placebo 
for 28 wk, impaired mobility was the major predictor of falls, and vitamin D 
treatment had no significant effect (263). This study had marked patient 
heterogeneity with inclusion of both institutionalized and community-dwelling 
persons. A positive effect of vitamin D supplementation on falls risk was 
reported by Broe et al. (264) among the subgroup of 124 nursing home residents 
receiving high-dose vitamin D (800 IU/d) but not in the 600-, 400-, or 200-IU 
groups. The risk of falling was lower if those receiving 800 IU vitamin D2 were 
compared with the combined group of smaller doses (200, 400, or 600 IU) and 
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placebo. There was no suggestion of a normal dose-response curve with the 
lower doses actually having nonsignificantly higher fall rates compared with 
placebo (0 IU, 44%; 200 IU, 58%; 400 IU, 60%; 600 IU, 60%; 800 IU, 20%). A 
large study of 5292 subjects over 70 yr of age with a recent minimal-trauma 
fracture did not find a beneficial effect of 800 IU of vitaminD3 on falls over 26–
62 months (265). Falls were a secondary endpoint with information collected 
only for the week before each 4-monthly questionnaire. Compliance (patients 
taking 80% or more of tablets) was poor (<45% at 2 yr); however, there was also 
no benefit if only compliant patients were examined. Baseline levels were 
measured in approximately 1% of patients (n=60) and were 15.2 ng/ml (38 
nmol/liter). Another study in 3314 older women living in nursing homes did not 
find fewer falls among those randomized to receive a combination of vitamin D3  
(800 IU), calcium (1000 mg), and a falls prevention leaflet over 25 months 
compared with those receiving the leaflet alone (266). Falls were also a 
secondary outcome in this study. 
 
In reaction to generally poor adherence to daily regimens of vitamin D 
supplementation as described by a number of these reports, other studies have 
examined the efficacy of infrequent high-dose vitamin D supplementation. In one 
widely reported study of 2256 community dwelling women over 70 yr of age, an 
annual oral dose of 500,000 IU of vitamin D3 for 3–5 yr appeared to increase the 
risk of falls, particularly in the first 3 months after the vitamin D dose (267). The 
median baseline 25D concentration was 21.2 ng/ml (53 nmol/liter), and 1 month 
after treatment, the median was 48 ng/ml (120 nmol/liter). Another study using 
300,000 IU, given annually by im injection, reported no effect on falls among 
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9440 older individuals (268). No benefit was observed in any subgroup. 
 
3. Meta-analyses and falls 
 Substantial heterogeneity among these randomized trials with regard to 
differences in study populations, variable treatment durations, and regimens of 
supplemental vitamin D and whether or not calcium was coadministered together 
with inconsistencies in the identification and analysis of falls among studies (e.g. 
falls per subject, number of falls, and number of fallers) makes collective 
assessment of these data difficult. Nevertheless, several meta-analyses have been 
published and are the subject of debate (23, 29, 30, 269–272). Most recently, a 
meta-analysis reported on 26 randomized trials that enrolled 45,782 participants, 
mainly elderly females (23). Studies were not excluded for lack of double 
randomization or strict definition of falls; hence, there were a substantially larger 
number of included individuals than in earlier meta-analyses. Vitamin D use was 
associated with statistically significant reduction in the risk of falls. However, 
there was no difference among those receiving higher doses (>800 IU) vs. lower 
doses. Vitamin D appeared to be effective in both community dwelling and 
institutionalized people and in those receiving vitamin D2 or D3 . Perhaps 
reassuringly, the reduction in falls was most prominent in patients who were 
vitamin D deficient at baseline. Studies in which calcium was coadministered 
with vitamin D showed a greater effect than those where vitamin D alone was 
given. Falls reduction in studies without calcium coadministration did not reach 
statistical significance. Calcium alone was the placebo in most of the 
combination studies. Therefore, despite substantial heterogeneity among studies, 
vitamin D supplementation is probably effective in conjunction with calcium in 
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the prevention of falls among older individuals. The positive impact of vitamin D 
and calcium supplementationon fall prevention appears to be best among those 
who are vitamin D deficient at baseline. We recommend consideration of vitamin 
D plus calcium therapy in people over 65 yr of age with baseline deficiency. 
However, appropriate supplemental dose of vitamin D and target serum levels 
required to prevent falls remain hotly debated issues. 
 
F. Muscle strength and physical performance 
 Many studies have examined the specific effects of vitamin D on measures of 
muscle function and physical performance. Comparing these studies is made 
very difficult by the variety of outcome measures used to assess muscle function. 
 
1. Observational studies 
A number of cross-sectional studies have reported associations between 25D 
levels and various parameters related to muscle function including handgrip, 
lower limb strength, balance, 6-min walk distance, and gait speed (273–275), 
although not all such studies have supported the association after multivariate 
adjustment (276, 277). These are summarized in Table 6. In a population-based 
study of 4100 ambulatory adults aged over 60 yr, an association between serum 
25D and lower-extremity function assessed by 8-ft. walk and the repeated sit-to-
stand test (STST) was reported (278). The improvements were modest: 3.9% 
worsening in STST and 5.6% in 8-ft. walk comparing the lowest vs. the highest 
quintiles of 25D. Interestingly, a trend toward impaired function with longer 
STST was seen in patients with high normal 25D [>48 ng/ml (120 nmol/liter)] 
vs. lower levels [16–38 ng/ml (40–94 nmol/liter)]. 
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Significantly poorer physical performance was seen in 1234 older individuals 
among those with 25D below 10 ng/ml (25 nmol/liter) and 10–20 ng/ml (25–50 
nmol/liter) vs. those higher than 30 ng/ml (75 nmol/liter) (279). In a subgroup of 
979 participants followed over 3 yr, those with lower 25D levels had 
significantly higher risk of decline in physical performance compared with those 
with levels above 30 ng/ml (75 nmol/liter). Those in the intermediate 25D group 
of 20–30 ng/ml (50–75 nmol/liter) did not display significantly greater rates of 
decline. In a prospective study of 1008 older individuals in the Netherlands, 
baseline 25D below 10 ng/ml (25 nmol/liter) was associated with poorer grip 
strength and reduced muscle mass on DXA after 3 yr compared with people with 
normal levels [>20 ng/ml (50 nmol/liter)] (280). Those in the intermediate 25D 
group of 10–20 ng/ml (25–50 nmol/liter) demonstrated significantly greater 
losses of muscle mass without difference in grip strength vs. those with 25D over 
20 ng/ml (50 nmol/liter). An accelerated rate of decline in physical performance 
over 2.5 yr on timed up and go tests (TUAG) and timed STST were seen among 
769 older women with lower baseline 25D (281). However, low 25D levels are 
associated with frailty (273), so a range of factors not included in adjustment 
models may confound data interpretation. A recent study of 714 Chinese men 
(>65 yr) found no association between baseline 25D levels and changes in 
performance measures or appendicular skeletal muscle mass over 4 yr (282). 
These men were not vitamin D deficient [mean baseline 25D 31 ng/ml (78 
nmol/liter)]. 
 
2. Nonrandomized studies 
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 Few studies have examined the effect of vitamin D supplementation on muscle 
function in younger people. Glerup et al.  (208) reported a case-control study in 
which 55 veiled Arabic women with a mean age of 32 and severe vitamin D 
deficiency [mean 25D 3 ng/ml (7 nmol/liter)] were compared with 22 Danish 
women of similar age but higher 25D levels [19 ng/ml (47 nmol/liter)]. At 
baseline, all parameters of muscle function were significantly lower in the Arabic 
women. Baseline 25D levels were independently associated with maximal 
voluntary knee extension. After vitamin D repletion, the Arabic women 
displayed significant improvements in parameters of muscle function at 3 and 6 
months. At 6 months, a subgroup that was retested showed no difference in 
electrically stimulated muscle function vs. Danish controls. Subjective 
improvements in muscle and deep bone pain were reported by the treated Arabic 
women. 
 
3. Randomized controlled studies 
The randomized controlled studies are summarized in Table 7. Two studies 
discussed in Section VI.E and Table 6 [Bischoff et al . (259) and Pfeifer et al . 
(258)] reported improvements in muscle function as well as decreased falls in 
those randomized to receive supplemental vitamin D. Over a 12-wk treatment 
period, those on calcium and vitamin D demonstrated significant improvements 
in the summed score of knee flexor and extensor strength, grip strength, and 
TUAG compared with those receiving calcium alone (259). Significant 
improvements were reported in quadriceps strength and TUAG in another study 
with reduced falls after 12 months of dual supplements compared with calcium 
alone (258). 
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A two by two randomized study of patients treated with calcium 800 mg with or 
without resistance training, with or without vitaminD400 IU daily for 9 months 
found that vitamin D improved physical performance (283). Quadriceps strength, 
physical performance test, and TUAG were significantly improved by vitamin D 
and by resistance training, with an additive benefit in the group that received 
both (283). In a study of 139 ambulatory older subjects with a history of falls and 
vitamin D deficiency [25D <12 ng/ml (30 nmol/liter)], treatment with vitamin 
D2  (600,000 IU im) had a significant effect on aggregate functional performance 
time but no effect on either falls or quadriceps strength at 6 months follow-up vs. 
placebo (284). Among 56 institutionalized persons over 60 yr of age, those 
randomized to receive calcium and vitamin D (two doses of 150,000 IU then 
90,000 IU monthly) demonstrated significant improvements in maximal 
isometric strength of hip flexors and knee extensors after 6 months (285). 
Subgroup analysis demonstrated greater improvements in muscle function 
among subjects with lower baseline 25D levels [<20 ng/ml (50 nmol/liter)]. 
Similarly, among 302 older, community-dwelling women, those in the lowest 
tertile of 25D levels who received daily calcium (1000 mg) and vitamin D2  
(1000 IU) displayed the most pronounced improvements in lower limb muscle 
function over 1 yr as opposed to those on calcium alone (286). Among 69 
postmenarcheal adolescent females, those randomized to receive 150,000 IU 
vitamin D2 orally every 3 months for 1 yr demonstrated significant 
improvements in movement efficiency, a composite of jump height and velocity 
measured by mechanography, compared with baseline (287). Additionally, at 
baseline, higher 25D levels correlated with greater jumping velocity. In a short 
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study of 42 postmenopausal women, 12 wk treatment with 1α-OHD3  (0.5 µg) 
and calcium led to significant improvements in quadriceps strength compared 
with those receiving calcium alone (288). 
 
4. Muscle strength and function: negative studies 
 In a study of 70 vitamin D-deficient women [25D 8–20 ng/ml (20–50 
nmol/liter)], 6 months of vitamin D and calcium (400 IU and 500 mg) had no 
effect on grip or knee strength vs. calcium alone. Baseline 25D levels showed an 
inverse correlation with these parameters of muscle function (289). In a study of 
686 community-dwelling women over 70 yr, treatment with oral vitaminD3  
(150,000 IU every 3 months) for a 9-month period had no significant effect on 
falls or hand grip strength compared with placebo (290). However, a randomly 
selected subgroup of 40 participants had a mean baseline 25D of 26 ng/ml (66 
nmol/liter), suggesting that the group at large were vitamin D sufficient. Other 
studies have failed to demonstrate improvements in muscle strength after vitamin 
D supplementation, regardless of baseline vitamin D status (291–295), as 
summarized in Table 7. A multicenter study of 243 frail, older patients reported 
no difference in parameters of physical performance between those randomized 
to receive a single dose of 300,000 IU of vitamin D vs. placebo (291). There was 
no effect in the subset with low baseline 25D levels [<12 ng/ml (30 nmol/liter)] 
despite significant improvements in25Dlevels. Some studies have examined 
other forms of vitamin D, namely 1,25D and 1α-OHD3, with variable effects. 
Among 98 older subjects with mild renal impairment, 1,25D (0.5 µg daily) 
resulted in no improvement over a 6-month period vs. placebo, and some 
subjects on 1,25D developed hypercalciuria and required dose reduction (294). 
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One negative study examined 179 vitamin D-deficient adolescent females in 
Lebanon. Those randomized to receive vitamin D3  (doses of 1,400 or 14,000 
IU/wk) did not demonstrate improved grip strength but did have greater increases 
in lean mass, bone area, and total hip bone mineral content vs. placebo after 1 yr 
(295). Two studies have examined the effects of combining vitamin D 
supplementation with high-resistance training on muscle strength in older 
individuals (283, 293). In one study of 180 community-dwelling males (50–79 
yr), those randomized to receive an intensive program of resistance training three 
times per week demonstrated improvements in strength. Those randomized to 
receive fortified milk alone (containing vitamin D 800IU, calcium1000mg, and 
protein 13.2 g daily) demonstrated no additional improvements (293). Those 
receiving high-resistance training with vitamin D (400 IU) and calcium (800 mg) 
over a 9-month period showed improvements in TUAG but not in quadriceps 
strength compared with those who received resistance training and calcium 
(283). 
 
5. Meta-analyses of muscle function 
In one meta-analysis, the substantial variability in the parameters of muscle 
function among studies, use of measures without established validity or 
reliability, and lack of blinded outcome assessments were cited as reasons for 
inability to pool data (30). 
 
On assessing 17 RCT involving 5072 participants, there was no significant effect 
of vitamin D supplementation on grip strength or proximal lower limb strength in 
adults with 25D levels over 10 ng/ml (25 nmol/liter) at baseline (24). However, 
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for adults with deficiency [25D <10 ng/ml (25 nmol/liter)], a beneficial effect on 
hip muscle strength was found. In another meta-analysis of 16 RCT, in which 
baseline 25D levels were below 20 ng/ml (50 nmol/liter) in 11 studies, the 
authors noted the publication of a greater number of studies that showed no 
effect rather than a beneficial effect of vitamin D supplementation on muscle 
function and that there were no obvious characteristics to differentiate studies 
with positive and negative findings (296). 
 
In a more recent meta-analysis of 13 RCT involving elderly subjects who were 
predominantly vitamin D deficient or insufficient, vitamin D supplementation 
with 800–1000 IU daily was associated with improvements in lower extremity 
strength and balance (297). The metaanalysis included only randomized trials of 
older individuals in whom baseline and posttreatment parameters of muscle 
function were assessed. Trials in younger individuals (295) or those that included 
muscle training as part of the treatment were not included (293). This meta-
analysis found no effect on gait. 6.  
 
Summary: vitamin D, muscle strength, and physical performance 
Although some data suggest a beneficial effect of vitamin D supplementation on 
muscle function, particularly in vulnerable populations and those with low 
baseline vitamin D levels (208, 286), the evidence base is limited by highly 
heterogeneous studies that assess muscle function by different methods. Hence, 
larger studies that use standardized, reproducible assessments of muscle strength 
and double-blinded treatment regimens are necessary to clarify this important 
issue and guide recommendations. Such studies should ideally consider baseline 
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vitamin D status and confirm adequate replacement is achieved by a rise in 25D 
to the normal range. 
G. Muscle morphology and electromyography (EMG)  
Several reports, dating back to the 1970s, have characterized the morphological 
appearance of skeletal muscle among vitamin D-deficient subjects and thus 
provided some evidence in support of a direct role for vitamin D in the 
morphology and development of muscle.  
 
1. Open-label studies 
In 1974, a case series of 13 patients with various degrees of proximal myopathy 
in the context of chronic renal failure was described (203). Ten of the 13 patients 
displayed significantly shorter mean action potential durations of the deltoid and 
quadriceps muscles on EMG. They also displayed moderate atrophy of type II 
(i.e. fast twitch) muscle fibers on the basis of myofibrillar ATPase staining and 
degenerative changes on electron microscopy with small foci of fiber necrosis, 
lytic vacuoles, and Z-band degeneration in four patients. Although vitamin D 
levels were not determined, because this was before the era of the standardized 
assay, substantial improvement in muscle strength after im vitamin D treatment 
in a proportion of the patients was reported. In another series of four uremic 
patients, the finding of type II muscle fiber atrophy was linked to vitamin D 
deficiency on the basis of significantly elevated PTH levels (298). 
 
In 1975, gluteal muscle biopsies of 12 patients with laboratory evidence of 
osteomalacia displayed nonspecific muscle fiber atrophy (299). A distinction was 
made between patients with isolated nutritional deficiency in whom biopsy 
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changes were mild compared with those with an additional condition including 
hyperparathyroidism, hyperthyroidism, or uremia who also demonstrated 
myofibrillar degeneration and infiltration with amorphous material. One year 
later, Irani (201) reported a case series of 15 women with nutritional 
osteomalacia who demonstrated significantly shorter motor unit action potentials 
and a greater proportion of polyphasic potentials on EMG compared with 
controls. Muscle biopsies from those with osteomalacia demonstrated 
nonspecific muscle fiber atrophy. Complete resolution in EMG changes after a 5-
wk course of high-dose vitamin D supplementation (600,000 IU of vitamin D2  
weekly or fortnightly) was noted in the three patients who were retested. In 1979, 
two patients with osteomalacia demonstrated type II muscle fiber atrophy in 
addition to scattered necrosis and derangement of the intermyofibrillar network 
on muscle biopsy (300). Eleven patients with a condition described as bone loss 
of aging had muscle biopsies from the vastus lateralis before and after treatment 
with 1α-OHD3 and calcium for 3–6 months (301). The predominant finding was 
an increase in the proportion and cross-sectional size of fasttwitch type IIa fibers. 
Measures of the oxidative capacity of muscle, succinate dehydrogenase, and total 
phosphorylase activity were low at baseline and increased with treatment. 
Lactate dehydrogenase activity, a measure of anaerobic metabolism, did not 
change. Interestingly, the proportion of type IIb fibers (very-fast-twitch fibers) 
decreased significantly with treatment. This was the first report to demonstrate 
changes in muscle morphology and oxidative capacity after treatment of 
presumably vitamin D-deficient subjects with a vitamin D analog.  
 
Three years later, Young et al.  (302) confirmed these findings by demonstrating 
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significant increases in the proportion of type II muscle fibers in biopsies of the 
vastus lateralis muscle after 3 months of vitamin D supplementation among 12 
patients with osteomalacia. In association with these findings, quadriceps muscle 
strength also improved significantly using an isodynamic dynamometer. 
However, this body of evidence dating back to the 1970s may be confounded by 
the many biochemical abnormalities associated with renal failure and 
osteomalacia such as hyperparathyroidism and disturbances in calcium and 
phosphate levels. These provide indirect mechanisms that may independently 
alter muscle function (Fig. 4). Nevertheless, the changes in muscle morphology 
and performance after vitamin D supplementation in these subjects are important 
preliminary observations. Recent studies have reported an association between 
significantly higher skeletal muscle fat content and vitamin D deficiency. In one 
study of 90 postpubertal females in California, the proportion of muscle fat, 
assessed by comparing the attenuation signal of a 2-cm2 section of the rectus 
femoris with the adjacent sc fat on computed tomography, was found to strongly 
correlate in an inverse fashion with serum 25D levels (303). This was 
independent of body mass or computed tomography measures of sc and visceral 
fat. The percentage of muscle fat was significantly lower in women with normal 
vs. subnormal serum 25D levels. In another study of 366 older patients receiving 
magnetic resonance imaging (MRI) of one shoulder for the investigation of 
potential rotator cuff injury, a correlation between higher fatty infiltration of 
rotator cuff muscles and lower serum levels of 25D was reported (304). After 
multivariate linear regression analysis, this association remained statistically 
significant in two muscle groups (i.e. supraspinatus and infraspinatus muscles) 
but only among those whose MRI also demonstrated a full-thickness rotator cuff 
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tear (228 patients). A third study using MRI of the thigh in 20 older subjects also 
reported an inverse correlation between muscular fatty degeneration and 25D 
(305). Interestingly, selective and near-total fatty degeneration of at least one 
muscle was observed among 11 vitamin D-deficient patients [25D <20 ng/ml (50 
nmol/liter)]. A recent cross-sectional study demonstrated a positive correlation 
between 1,25D levels and total skeletal muscle mass as measured on DXA 
among subjects younger than 65 yr (306). This was supported by greater 
isometric knee extension moment in women with higher 1,25D levels. However, 
no association was found between 25D levels and muscle mass or strength or in 
those over 65 yr of age. Among 26 subjects with chronic kidney disease, thigh 
muscle cross-sectional area on MRI correlated significantly with a model 
including 1,25D levels, calcium levels, and daily physical activity (307). 
Functional parameters assessing gait and proximal musculature also 
independently correlated with 1,25D. 
 
Although a majority of highly trained adolescent male ballet dancers had low 
vitamin D levels [25D <20 ng/ml (50 nmol/liter) in nine of 16 study 
participants], there was no correlation between 25D, body composition on DXA, 
or reports of muscle injury in this study (308). 
 
2. EMG and muscle biopsies: randomized study 
A study that randomized 96 elderly women with poststroke hemiplegia and 
severe vitamin D deficiency [<10 ng/ml (25 nmol/liter)] to vitamin D2 (1000 IU 
daily) or placebo for 2 yr reported significant and dramatic increases in the 
proportion and diameter of type II muscle fibers (85). These parameters 
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deteriorated significantly in the placebo group.  
 
3. EMG and muscle biopsies: summary 
In summary, it appears that vitamin D deficiency results in significant and 
reversible changes in EMG and type II muscle fiber atrophy, the latter being an 
independent predictor for falls in one study (85). However, the changes are 
nonspecific, being similar to those seen in other conditions. Although fatty 
infiltration in skeletal muscle has been suggested by three recent studies, these 
are crosssectional and based on imaging modalities that may not be validated for 
the assessment of muscle fat. Muscle becomes fatty with disuse, and thus this 
measure may be confounded by decreased exercise associated with both 
increased muscle lipid and lower vitamin D. These modalities are not equipped 
to identify intracellular fat, perhaps of greater pathophysiological significance. 
 
H. Insulin sensitivity and glucose handling 
A broad range of epidemiological and randomized clinical studies together with 
specific research on molecular pathways and animal models have drawn links 
between vitamin D and insulin sensitivity. This is relevant to the topic of vitamin 
D and muscle because under normal physiological conditions, skeletal muscle is 
responsible for approximately 85% of whole-body insulin-mediated glucose 
uptake (102). Insulin resistance, a highly prevalent condition that contributes to 
the pathogenesis of type 2 diabetes, is primarily due to defective insulin-
stimulated glucose uptake in skeletal muscle resulting from the production of 
various inflammatory mediators, adipokines, and FFA by adipocytes in 
predominantly overnourished and obese individuals (309). However, in 
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recognizing the complex processes involved in insulin resistance, a number of 
reversible factors with potential etiological relevance to this condition are being 
considered. One of these factors is vitamin D deficiency. In this section, we will 
review human clinical studies that examine the association between vitamin D 
status and insulin sensitivity. 
 
1. Cross-sectional studies: vitamin D and insulin sensitivity 
Studies have examined the association between parameters of insulin resistance 
and vitamin D status in nondiabetic individuals. In one report, 25D was inversely 
correlated with the homeostasis model assessment of insulin resistance (HOMA-
IR) among 214 Arab-American men, but no such association was found among 
the 317 women of the same ethnicity included in this study (310). Among 808 
nondiabetic participants of the Framingham Offspring Study, plasma 25D 
concentrations were inversely associated with fasting insulin concentrations and 
HOMA-IR after adjustment for age, sex, and BMI (311). 
 
A similar association between 25D levels and HOMA-IR was found in a group 
of 712 subjects at risk of diabetes (312). Among 1941 adolescents who 
participated in the National Health and Nutrition Examination Survey from 
2001–2006, adjusted concentrations of insulin were significantly higher among 
male subjects who were vitamin D deficient [<20 ng/ml (50 nmol/liter)] 
compared with those with higher vitamin D levels [>30 ng/ml (75 nmol/liter)], 
suggesting a potential role vitamin D status in insulin sensitivity (313). 
 
However, a recent study that employed the gold-standard technique in the 
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assessment of insulin sensitivity, namely the hyperinsulinemic-euglycemic 
clamp, found that the association between insulin sensitivity in 39 nondiabetic 
subjects and 25D levels become nonsignificant after adjustment for other factors 
including BMI (314). Similarly, among 381 nondiabetic university students in 
Lebanon and 510 nondiabetic subjects from a largely obese ethnic minority in 
Canada (i.e. Canadian Cree), the inverse association between 25D levels and 
HOMA-IR also became nonsignificant after adjustment for BMI in addition to 
other factors (315, 316). In another study of 126 healthy young adults, there was 
a significant association between 25D levels and insulin sensitivity on a 
hyperglycemic clamp study that remained after adjustment for a range of factors 
(317). Therefore, it is clear that the inverse correlation between 25D and BMI, as 
reported in a number of studies (314, 318), may particularly confound the 
assessment of these observational data. In fact, a recent study suggests that it 
may be more accurate to consider adiposity rather than BMI per se as the 
particular confounding factor (319). In a study of 1882 nondiabetic individuals, it 
was the inclusion of a computed tomography measure of visceral adiposity rather 
than BMI and waist circumference in the multivariate analysis that caused the 
inverse association between vitamin D status and markers of insulin resistance, 
namely HOMA-IR and log insulin levels, to be insignificant (319). Several 
mechanisms associating vitamin D deficiency with obesity have been proposed, 
including the great capacity of adipose tissue to store vitamin D (80, 320) and the 
avoidance of sunlight exposure and outdoor activity among potentially self-
conscious, obese individuals (320). 
 
In confirmation of the former mechanism, a study of 116 obese women reported 
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that fat mass measured by isotope dilution method was a strong predictor of 
serum 25D levels both 5 yr before and 10 yr after bilio-pancreatic diversion 
surgery and that vitamin D levels did not correlate with insulin sensitivity at 
either time on the basis of the euglycemic-hyperinsulinemic clamp studies (321). 
The impact of PTH, which has an inverse relation to vitamin D status and is also 
associated with diabetes (322), has been addressed in a small number of studies. 
A study including 15 subjects with secondary hyperparathyroidism (serum PTH 
6.4 pmol/liter) and 15 controls found that after adjustment for BMI, age, and sex, 
serum 25D levels were significantly associated with the insulin sensitivity index 
on a 3-h hyperglycemic clamp, but PTH levels were not (323). Similarly, a 
significant adjusted association between 25D and fasting insulin was reported in 
a study of 654 adult subjects from Canada, but PTH was not associated with this 
parameter after multivariate adjustment (324). 
 
Apart from insulin resistance of skeletal muscle, the pathophysiology of type 2 
diabetes comprises a range of other factors. Vitamin D may play a role in these 
other processes with cross-sectional studies and meta-analyses reporting an 
association between vitamin D deficiency/insufficiency and the incidence of 
diabetes in various populations (325–328). However, not all studies confirm this 
observation, and there is substantial heterogeneity between studies in their design 
and adjustment for confounders (329–331). 
 
2. Prospective studies: vitamin D and insulin sensitivity 
Observational studies have examined the relationship between 25D and the 
prospective risk of developing insulin resistance. In the prospective Ely study 
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(1990–2000), baseline 25D levels of 524 nondiabetic men and women were 
inversely associated with the 10-yr risk of insulin resistance, on the basis of 
HOMA-IR and fasting insulin after adjustment for a range of factors including 
age, sex, BMI, and calcium and PTH levels (332). Each 10-ng/ml (25 nmol/liter) 
increase in baseline 25D was associated with a significant decrease in HOMA-IR 
score (i.e. 0.16 U) at 10 yr. 
 
In a recent study that assessed 5200 participants of the Australian Diabetes, 
Obesity, and Lifestyle (AusDiab) study, lower baseline 25D levels were 
associated with a higher risk of developing diabetes over the 5-yr follow-up 
period (333). After adjustment for a range of factors, the authors reported that 
each 10-ng/ml (25 nmol/liter) increment in serum 25D was associated with a 
24% reduced 5-yr risk of diabetes. Regarding insulin resistance, a positive and 
independent association with HOMA-IR at 5 yr was also reported. In contrast to 
an earlier report (334), no association between dietary calcium intake and 
diabetes risk or the follow-up homeostasis model assessment of insulin 
sensitivity score was found (333). Apart from insulin resistance, a number of 
studies have also reported an association between baseline 25D levels and the 
long-term risk of diabetes (334–336). However, not all such studies have 
supported this association (337–339). 
 
3. Interventional studies: vitamin D and insulin sensitivity 
Mixed results have emerged from a number of interventional studies that have 
sought to address the impact of vitamin D supplementation on glucose 
homeostasis and parameters of insulin sensitivity. There was no difference in 
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parameters of glucose homeostasis among 238 postmenopausal women who 
were randomized to receive 2 yr of treatment with vitamin D3 (2000 IU daily) or 
lα-OHD3  (0.25 µg daily) or 1 yr of treatment with 1,25D (0.25–0.50 µg) daily 
vs. placebo (340). Similarly, no differences in insulin-mediated glucose uptake 
on the euglycemic clamp study were found in18 healthy males randomized to 
receive either 1,25D 1.5 µg daily or placebo; however, treatment in this study 
was only 7 d (341). Studies examining subjects at risk of diabetes have suggested 
improvements in glucose homeostasis with vitamin D supplementation. In three 
studies, significant improvements were reported in insulin sensitivity, insulin 
secretion, and/or the disposition index in subjects at risk of diabetes who were 
randomized to receive supplemental vitamin D3 and calcium (2000 IU and 500 
mg, respectively) vs. calcium alone for 16 wk, high-dose vitamin D3 (120,000 
IU) every 2wk vs. placebo for 6 wk, and vitamin D3 and calcium (700 IU and 
500mgdaily, respectively) vs. placebo for 3 yr (342–344). 
 
A double-blind randomized trial of 81 South Asian women living in New 
Zealand who were found to be both insulin resistant on HOMA-IR and vitamin D 
deficient [25D 20 ng/ml (50 nmol/liter)] reported significant reductions in insulin 
resistance and fasting insulin levels among those randomized to receive vitamin 
D3  (4000 IU daily) vs. placebo for 6 months (345). In a recent randomized trial 
including 90 diabetic subjects, those randomized to receive vitamin D-fortified 
yogurt twice daily (each containing 500 IU) or vitamin D- and calcium fortified 
yogurt demonstrated improved glycemic control on glycated hemoglobin 
(HbA1c) and improved insulin resistance on HOMA-IR compared with those 
receiving plain yogurt for 12 wk (346). Importantly, an inverse correlation was 
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observed between changes in serum 25D and HOMA-IR in this study. In another 
study, 10 females with type 2 diabetes who were predominantly vitamin D 
deficient reported a significant reduction in a marker of peripheral insulin 
resistance after 1 month of vitamin D3 supplementation (1332 IU daily) (347). 
However, this study had no control group. Conversely, a number of small studies 
have failed to demonstrate any benefits in association with vitamin D 
supplementation in patients with type 2 diabetes. In 20 diabetic subjects, a 
randomized trial reported no improvements in fasting or stimulated glucose, 
insulin, C-peptide, or glucagon concentrations among those receiving 1,25D (1 
µg daily) for 4 d vs. placebo (348). Among 28 Asian Indian patients with type 2 
diabetes, those randomized to receive vitamin D supplementation for 4 wk did 
not demonstrate a significant difference in markers of insulin resistance (i.e.  
fasting insulin, post-oral glucose tolerance test serum insulin levels, and HOMA-
IR) compared with those receiving placebo (349). Similarly, in 32 diabetic 
subjects, 6 months of supplemental vitamin D (40,000 IU/wk) had no effect on 
fasting insulin, C-peptide, or HbA1c levels compared with baseline or those 
receiving placebo (350). It is probably reasonable to conclude that these studies 
were underpowered to answer the question in either direction. In one case series 
of three British Asians with diabetes and vitamin D deficiency [25D <6 ng/ml 
(15 nmol/liter)], high-dose vitamin D supplementation (300,000 IU im) was 
associated with subsequent deterioration in glycemic control on HbA1c and 
progression of insulin resistance on fasting insulin resistance index (351). Recent 
post hoc analyses of eight trials including participants with normal glucose 
tolerance at baseline and three small trials of patients with established type 2 
diabetes demonstrated no effect of vitamin D supplementation on glycemic 
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outcomes (352). However, two trials examining patients with baseline glucose 
intolerance reported improvements in insulin resistance among those receiving 
vitamin D supplementation (349, 350). A recent study of 95 adults also 
demonstrated an improvement in insulin sensitivity amongst patients with pre-
diabetes who were randomized to receive calcium carbonate (1200 mg d) and 
vitamin D supplementation (2000 to 6000 IU d) versus placebo (Gagnon C, Daly 
RM, Carpentier A et al. PLoS One. 2014 Oct 9;9(10):e109607). 
 
4. Summary: vitamin D and insulin sensitivity 
Substantial differences in study design, duration, and type of vitamin D 
supplementation and the particular populations studied in these trials make 
collective assessment of these results difficult. Although some large trials 
suggest a beneficial effect of vitamin D supplementation in the reduction of 
insulin resistance, others do not. Furthermore, to ascertain whether the potential 
glycemic benefits of supplemental vitamin D are more pronounced in those with 
vitamin D deficiency or poor glycemic control at baseline, larger trials of longer 
duration are necessary. More than 20 trials are currently under way to address 
this question (www.clinicaltrials.gov). 
 
VII. Conclusions 
See Table 8 for conclusions. In his 1922 publication on the cure of rickets by 
sunlight, Alfred Hess (35) remarked that “although we have realized the 
importance of light in the growth of plant life, we have [until now] accorded it 
too little significance in the development of animal life.” Since that time, we 
have come a long way in recognizing the role of UV radiation in the 
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photochemical synthesis of vitamin D, the role of vitamin D in calcium and 
mineral homeostasis, and the similarity of 1,25D to members of the steroid 
family with their cholesterol precursor, carbon-ringed structures, and ability to 
bind to specific nuclear receptors in the genomic mediation of developmental and 
functional effects. Although steroid hormones are known to exert diverse effects 
in multiple organs and tissues, a role for vitamin D beyond its predominant 
effects on bone and mineral homeostasis has been hotly contested. Muscle stands 
at the frontier of the emerging concept of vitamin D’s extraskeletal role because 
it shares its ancestral origin with bone in the common mesenchymal stem cell 
and relies heavily on intracellular calcium handling for contraction, insulin 
sensitivity, and cellular plasticity (99). In this review, we have adopted a 
multilayered approach in examining evidence from human clinical studies as 
well as reports on animal and cell models to piece together the current 
knowledge of vitamin D’s effects in skeletal muscle. The broad evidence base is 
generally in favor of a role for vitamin D in the development and function of 
skeletal muscle. The strongest evidence comes from studies that report distinct 
morphological changes in the muscle of vitamin D-deficient subjects, others that 
describe significant impairments in the muscle function of VDRKO mice, and 
molecular studies that have mapped out the various intracellular responses of 
cultured muscle cells to vitamin D (129, 173, 174). As a result, we have come 
closer to answering the perennial question as to whether vitamin D’s influence 
on muscle is direct or indirect, and the answer appears to be both. 
 
Outstanding questions remain, including the precise role of vitamin D in muscle 
differentiation, the possibility of specific biological activity of 25D in muscle, 
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and the current controversy regarding the in vivo presence of the VDR in muscle 
tissue. 
 
In the clinical domain, observations of reversible myopathy in subjects with 
severe vitamin D deficiency have been reported for some time. Cross-sectional 
data reporting a high prevalence of vitamin D deficiency among subjects with 
falls, muscle weakness, and insulin resistance are also present (211, 274, 327). 
However, confounding variables are a caveat in the interpretation of this 
circumstantial evidence. Furthermore, the demonstration of unequivocal 
improvements in muscle function among subjects with mild to moderate degrees 
of vitamin D deficiency randomized to receive vitamin D supplementation has 
been elusive. Possible reasons for this include heterogeneity in study design and 
supplemental regimens and the general lack of large-scale trials to address this 
issue. These challenges and others remain to be addressed.  
 
There is reasonable evidence from cellular, animal, and at least some human 
studies that muscle responds to vitamin D. Although molecular pathways by 
which vitamin D acts on the myocyte have been identified, there is scope for 
more clarification. Studies are also needed to clarify the therapeutic potential of 
vitamin D in the treatment of age-related sarcopenia and perhaps other 
myopathies. In the meantime, it would be prudent for clinicians to seek and 
manage vitamin D deficiency in individuals at risk of these conditions. 
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Beyond its established role in bone and mineral homeostasis, there is emerging evidence that vitamin D exerts
a range of effects in skeletal muscle. Reports of profound muscle weakness and changes in the muscle mor-
phology of adults with vitamin D deficiency have long been described. These reports have been supplemented
by numerous trials assessing the impact of vitamin D on muscle strength and mass and falls in predominantly
elderly and deficient populations. At a basic level, animal models have confirmed that vitamin D deficiency and
congenital aberrations in the vitamin D endocrine system may result in muscle weakness. To explain these
effects, some molecular mechanisms by which vitamin D impacts on muscle cell differentiation, intracellular
calcium handling, and genomic activity have been elucidated. There are also suggestions that vitamin D alters
muscle metabolism, specifically its sensitivity to insulin, which is a pertinent feature in the pathophysiology of
insulin resistance and type 2 diabetes. We will review the range of human clinical, animal, and cell studies that
address the impact of vitamin D in skeletal muscle, and discuss the controversial issues. This is a vibrant field of
researchandonethat continues toextendthe frontiersofknowledgeofvitaminD’sbroadfunctional repertoire.
(Endocrine Reviews 34: 33–83, 2013)
I. Introduction
II. Background Physiology
A. The vitamin D pathway
B. Skeletal muscle physiology
C. Calcium and muscle contraction
D. Calcium and exercise-related glucose uptake
E. Calcium and insulin-stimulated glucose uptake
III. Vitamin D and Muscle: Cell Models
A. VDR in muscle
B. Calcium homeostasis
C. Phosphate homeostasis
D. Proliferation and differentiation
E. Muscle contractile proteins
F. Phospholipid composition
G. Bone-muscle cross talk and vitamin D
H. Cell models and molecular pathways for insulin
signaling and diabetes
IV. Vitamin D and Muscle: Studies in Animal Models
A. VDRKO mice
B. Other animal models
C. Animal studies on insulin sensitivity and diabetes
D. Summary: vitamin D and muscle function in ani-
mal studies
V. VDR Polymorphisms and Muscle Function
A. FokI polymorphisms
B. BsmI polymorphisms
C. VDRpolymorphisms and insulin resistance/type 2
diabetes
VI. Vitamin D and Muscle: Human Studies
A. Myopathy
B. Myalgia and vitamin D deficiency
C. Fibromyalgia
D. Drug-related myopathy and vitamin D
E. Falls and vitamin D
F. Muscle strength and physical performance
ISSN Print 0163-769X ISSN Online 1945-7189
Printed in U.S.A.
Copyright © 2013 by The Endocrine Society
doi: 10.1210/er.2012-1012 Received February 28, 2012. Accepted July 11, 2012.
First Published Online November 20, 2012
Abbreviations: AA, Arachidonic acid; AC, adenylyl cyclase; BMI, body mass index; CAMK,
Ca2!/calmodulin-dependent protein kinase; CPK, creatine phosphokinase; CYP, cyto-
chrome P450; 1,25D, 1,25-dihydroxyvitamin D; 25D, 25-hydroxyvitamin D; DAG, diacyl-
glycerol; DBP, vitamin D-binding protein; DEXA, dual-energy x-ray absorptiometry; EMG,
electromyography; FFA, free fatty acid; FGF23, fibroblast growth factor 23;GLUT4, glucose
transporter 4; HbA1c, glycated hemoglobin; HOMA-IR, homeostasis model assessment of
insulin resistance; IP3, inositol triphosphate; IRS, insulin receptor substrate; MHC, myosin
heavy chain; MRI, magnetic resonance imaging; myf5, myogenic transcription factor 5;
ODN, oligodeoxynucleotides; 1!-OHD3, 1!-hydroxyvitamin D3; PKA, protein kinase A;
PKC, protein kinase C; RCT, randomized controlled trial; RXR, retinoid X receptor; SNP,
single-nucleotide polymorphism; SOCE, store-operated calcium entry; SR, sarcoplasmic
reticulum; SRC, steroid receptor coactivator complex; STST, sit-to-stand test; TUAG, timed
up and go test; VDCC, voltage-dependent calcium-channel; VDR, vitamin D receptor;
VDRE, vitamin D response element; VDRKO, VDR knockout.
R E V I E W
Endocrine Reviews, February 2013, 34(1):33–83 edrv.endojournals.org 33
G. Muscle morphology and electromyography (EMG)
H. Insulin sensitivity and glucose handling
VII. Conclusions
I. Introduction
In recent times, there has been a great deal of interest invitamin D, with over 1000 publications in PubMed in
2011 alone. A remarkable number of studies dealing with
novel aspects of its biological activity and its potential to
exert broad-ranging effects beyond calcium and mineral
homeostasis have emerged (1–4). Vitamin D deficiency is
a highly prevalent condition in the developedworld and in
the populous regions of Asia, India, and the Middle East
(5, 6). Significant downward trends in vitamin D status in
U.S. population-based studies suggest that vitamin D de-
ficiency/insufficiency is increasing in frequency (7, 8). Ac-
cordingly, health agencies including the International Os-
teoporosis Foundation, The Endocrine Society, and
Institute of Medicine have recently outlined recommen-
dations for the prevention of vitamin D deficiency and
have called for further research to guide the field (9–11).
Beyond the classic effects on bone and calcium health,
the effects of vitaminDare amatter of considerable debate
and have been recently reviewed in detail (12). A recent
Institute ofMedicine report contended that the evidence in
support of an extraskeletal role for vitaminDwas “not yet
compelling” (11).However, there is a large and expanding
body of observational data about associations between
vitaminDdeficiencyanddiversemedical conditions, rang-
ing from multiple sclerosis to malignancy (3). Reports of
the presence of the vitamin D receptor (VDR) in almost
every tissue strengthen the case in favor of direct extraskel-
etal functions (13). The effective use of active vitamin D
and vitamin D analogs in the treatment of the skin disor-
der, psoriasis, demonstrate that skin is an extraskeletal
target tissue for vitamin D.
Long before the recognition of UV radiation as an es-
sential component in the synthesis of vitamin D, the sun’s
rays were considered a source of physical strength and
vitality. Ancient Egyptians revered the Sun-God, Amon-
Rah, whose rays could make “a single man stronger than
a crowd” (14). Herodotus recommended solaria in An-
cient Greece as a cure for “weak and flabbymuscles,” and
ancient Olympians were instructed to lie exposed and
train under the sun’s rays (15).
In 1952, Spellberg (16), a German sports physiologist,
conducted an extensive study examining the effects of UV
irradiation on elite athletes. He informed the German
Olympic Committee that UV irradiation had a “convinc-
ing effect” on physical performance. This was consistent
with earlier studies that reported improvements in speed
and endurance among students after treatment with sun-
lamps (17, 18).
We have known for more than 30 yr that vitamin D
exerts effects on muscle cells at a molecular level. In this
journal in 1986, Ricardo Boland reviewed the effects of
vitamin D on calcium handling, mineral homeostasis, and
signalingpathways inmuscle cells (19). Since that time,we
have gained further insight in its effects on the regulation
of cell survival (20), differentiation (21), and calciumhan-
dling (22). In more recent times, clinical studies have ex-
amined the effects of vitamin D supplementation on mus-
cle function and falls in various populations (23, 24).
However, the field is challenged by controversy. A re-
cent report suggesting that VDR was not detectable in
muscle has fueled the debate as to whether vitamin D ef-
fects onmuscle are direct or indirect (25–27). The creation
of the VDR knockout (VDRKO) mouse in 1997 gave a
new focus to this question, which we will discuss (28). A
continuing area of uncertainty stems from conflicting
meta-analyses of clinical studies examining the effect of
vitaminD supplementation onmuscle strength and falls in
older individuals (23, 29–31).
In this review, molecular, animal, and human studies
examining the various roles of vitaminD inmuscle will be
presented. We will discuss contentious issues that have
made this a vibrant fieldof researchandone that continues
to extend the frontiers of our knowledge of vitamin D’s
broad functional repertoire.
II. Background Physiology
A. The vitamin D pathway
The family of molecules known collectively as vitamin
D are not true vitamins, which are defined as essential
substances obtained exclusively from the diet. The mis-
nomer is a remnant of the early work of a number of
scientific pioneers from the 1900s.
After inducing rickets in a group of dogs by keeping
them indoors for prolonged periods, the British physician
Sir Edward Mellanby (32) discovered that feeding them
cod-liver oil cured them and attributed this to the recently
identified vitaminA (33).However, in 1922,McCollum et
al. (34) showed that after heatingandaerating cod-liver oil
to destroy the vitamin A, it remained effective in the treat-
ment of rickets but no longer cured night blindness. Mc-
Collum followed the sequential alphabetical designations
and labeled thenewsubstance“vitamineD.” In the1920s,
it was recognized that children with rickets had profound
muscle weakness, and Alfred F. Hess (35) reported that
exposing rachitic children to direct sunlight led to the
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“rapid disappearance” of their illness and improved “gen-
eral vigor and nutrition.” This finding was the direct ex-
tension of earlier work by Huldschinsky (36), who
achieved the same outcome with artificially produced UV
light.
After these seminal studies, Harry Goldblatt and Kath-
erine Soames (37) reported in 1923 that the irradiation of
certain foodstuffs rendered them antirachitic. In 1926,
AdolfWindaus et al. (38) identified the chemical structure
of cholecalciferol (vitamin D3) as found in irradiated pig
skin as well as the structure of its parent molecule, 7-de-
hydrocholesterol. Windaus also isolated vitamins D1 and
D2 andwas awarded the 1928Nobel prize for hiswork on
sterols and vitamins. The nomenclature in the field is often
confusing. Names, alternate names, and molecular struc-
tures of vitaminD and relatedmolecules are shown in Fig.
1. The metabolic pathway of vitamin D, including the
various steps in its activation and degradation, are de-
picted in Fig. 2.
It was assumed that exposure of the skin to UV radia-
tion drove the conversion of 7-dehydrocholesterol to
cholecalciferol (step 1, Fig. 2). However, proof of this
Figure 1.
Figure 1. Summary of the molecular structures and various names of vitamin D and its related compounds (molecular structures taken from
PubChem Public Chemical Database www.ncbi.nlm.nih.gov/pccompound).
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emerged more than 30 yr later with independent discov-
eries by twogroups:Holick et al. (39) andEsvelt et al. (40).
The photo-production is subject to a variety of factors
including amount of UV exposure (latitude, season, and
use of sunscreen and clothing), ethnicity (skin pigmenta-
tion), and age (41–43). After the photochemical conver-
sion of 7-dehydrocholesterol to pre-vitamin D3 and its
thermal isomerization to vitamin D3, it binds to the vita-
min D-binding protein (DBP), and is transported to the
liver where a hydroxyl group is attached at the carbon-25
atom (i.e. C-25) to generate 25-hydroxyvitamin D (25D)
(step 2, Fig. 2). The importance of the liver in this first
phase of hydroxylation was reported in 1969 by DeLuca
and colleagues (44). A number of 25-hydroxylases have
been reported including cytochrome P450 CYP27A1 and
CYP2R1 (45, 46). CYP2R1 is probably themajor enzyme
required for 25-hydroxylation of vitamin D3, at least in
humans (47, 48). A patient with classic rickets and low
circulating levels of 25Dwas found to have a homozygous
mutation of the CYP2R1 gene, implying that other en-
zymes were unable to compensate (49).
Much remains unknown about the 25-hydroxylase
enzymes including the significance of their reported
presence in skin, kidney, and intestine (50). These en-
zymes are generally considered to be constitutively ex-
pressed with little feedback regulation; however, this is
unusual for theCYP family (50). In the absence of severe
hepatic dysfunction, 25-hydroxylation of vitamin D is
not usually rate limiting. However, in mild to moderate
liver impairment, the associated fat malabsorption can
cause vitamin D deficiency.
In contrast, 1!-hydroxylation is themajor rate-limiting
step in synthesis of 1,25-dihydroxyvitamin D (1,25D)
(step 3, Fig. 2). Synthesis of 1,25D is tightly regulated (51)
and is mediated by the enzyme 1!-hydroxylase. Factors
regulating 1!-hydroxylase in kidney are shown in Fig. 2.
Due to its sequence similarity to CYP27A1, the gene en-
coding 1!-hydroxylase was calledCYP27B1 (52). Its role
was demonstrated in 1998 by the development of rickets
and reduced circulating 1,25D levels in four patients with
gene mutations for this enzyme (53). Cyp27B1-null mice
also develop rickets with reduced levels of circulating
1,25D (54).
CYP27B1 mRNA is expressed in a number of vitamin
D target tissues including kidney, skin, intestine, macro-
phages, and bone. Although its expression is relatively
high in skin, the kidney is thought to be primarily respon-
sible for circulating levels of 1,25D (50). This is supported
by 1,25D deficiency in people with renal failure (55, 56).
However, this has not been conclusively proven with re-
nal-specificCYP27B1deletion.Thepresence ofCYP27B1
in other cell types, especially macrophages, is demon-
Figure 2.
Figure 2. Summary of the vitamin D pathway. Steps are discussed in the text. Molecular structures and alternate names for each of the compounds
are found in Fig. 1.
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strated by the fact that people with granulomatous dis-
eases can have elevated 1,25D levels (57).
Entry of 25D into the proximal renal tubular cells re-
quires receptor-mediated uptake of DBP plus 25D at the
brush border, degradation of DBP by legumain, and en-
docytic internalization and translocation of 25D to mito-
chondria (58). Megalin, a member of the low-density li-
poprotein receptor family, is required for reabsorption of
filtered DBP-bound 25D (59). It is in the mitochondria
that 1!-hydroxylation of 25D into its biologically active
form, 1,25D, occurs (50). A number of factors contribute
to the tight regulation of 1!-hydroxylase enzyme expres-
sion and activity in the kidney (Fig. 2). These include cal-
cium, PTH, calcitonin, GH, IGF-I, and fibroblast growth
factor23 (FGF23). In addition, 1,25Dnegatively regulates
its own synthesis by suppressing 1!-hydroxylase expres-
sion in kidney and bone (60). There is also evidence to
suggest that estrogen, progesterone, and prolactin may
regulate 1!-hydroxylase activity (61, 62). In macro-
phages, regulation of CYP27B1 is primarily cytokine me-
diated (63).
The final important enzyme in the vitaminD endocrine
system is 24-hydroxylase (CYP24A1). Found in nearly all
cells and highly expressed by the kidney, CYP24A1 limits
the amount of 1,25D in target tissues by converting 1,25D
to inactive metabolites, including 1,24,25-(OH)3D and
calcitroic acid and by converting 25D to 24,25(OH)2D
(step 4, Fig. 2). In addition to 24-hydroxylation, this mul-
ticatalytic enzyme is able to catalyze side-chain hydroxy-
lations at the C23 and C26 positions (64). Recently, mu-
tations in CYP24A1 were reported in six children with
infantile hypercalcemia, thereby providing conclusive ev-
idence of the importance of this enzyme in the in vivo
regulation of vitamin D metabolism (65).
The VDR, to which 1,25D binds to exert its biological
effects, was described in 1974 by Brumbaugh and
Haussler (66). This is depicted in Fig. 3. Insights into the
structure and function of this protein have been gained via
Figure 3.
Figure 3. Classic vitamin D signaling pathway. Vitamin D binds to its receptor, which dimerizes, preferentially with RXR. This complex binds to
VDRE in the DNA to regulate transcription.
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the cloning and subsequent analysis of the recombinant
protein (67), by x-ray crystallography (68) and molecular
modeling using atomic coordinates of the protein x-ray
structure (69). The protein comprises three distinct re-
gions: anN-terminal dual zinc finger domain that binds to
DNA (a characteristic feature of the steroid receptor fam-
ily), a C-terminal domain that binds to 1,25D, and an
extensive, unstructured region that links these two func-
tional domains.
Binding of 1,25D to VDR leads to conformational
changes within the receptor that allows it to interact with
its heterodimeric partner, retinoid X receptor (RXR) (Fig.
3) (70). VDR also forms homodimers that bind DNA and
regulate gene expression (71). The liganded complex (i.e.
1,25D-VDR-RXR) binds to vitamin D response elements
(VDRE) in theDNA (72). Classic VDRE are direct repeats
of two hexameric core binding sites with a three-nucle-
otide separation (73, 74). However, numerous nonclassic
sites have been proven to act as VDRE.
VDR-containing dimers interact with large coregula-
tory complexes required for gene modulation (70, 75).
Although a number of coregulatory molecules have been
characterized including the VDR interacting protein and
the steroid receptor coactivator complex (SRC), the pre-
cisemechanisms bywhich thesemolecules operate are just
beginning to emerge (76). The system is more complex,
because VDR is one of the few nuclear hormone receptors
that has been clearly demonstrated to be able to regulate
gene expression in the absence of ligand.UnligandedVDR
dimers can bind to and regulate some genes, mostly to
repress their expression. This is thought to be the mech-
anism for spontaneous hair loss in mice with mutations in
VDR (77). Expression of the VDR in virtually every tissue
and the diverse phenotypic changes in the VDRKOmouse
are consistent with the wide spectrum of activity of the
1,25D-VDR endocrine system (13).
As well as regulation ofVDR,CYP27B1, andCYP24A1
(78, 79), the 1,25D-VDR-RXR complex is involved in reg-
ulation of a variety of cellular functions including DNA
repair, cell differentiation, apoptosis, metabolism, and oxi-
dative stress (13). Its effects on calcium andmineral homeo-
stasis are well established and, in brief, result from the tran-
scriptional regulationof specific proteinswithin the intestine
(calcium-binding proteins, calbindin D28k, and epithelial
calcium channels), bone (osteocalcin, osteopontin, and re-
ceptor activator of nuclear factor-"B ligand), and parathy-
roid glands (PTH) (80). These effects provide potential in-
direct routes for regulation ofmuscle function in addition to
direct effects (Fig. 4).
This review will focus on diverse effects of the vitamin
D endocrine system on the functional and metabolic ca-
pacity of skeletal muscle as reported by a range of clinical
and translational studies. We will also discuss the central
role of skeletal muscle in our emerging understanding of
the nongenomic capabilities of the VDR.
B. Skeletal muscle physiology
Skeletalmuscle is estimated to account for 42%of total
body mass in males and 35% in females (81). Its primary
function is to generate force and to provide locomotion.
The functional units of skeletal muscle are the muscle fi-
bers, themselves comprised of many myofibrils. Myofi-
brils are long cylindrical multinucleated cells that vary
considerably in their morphological, biochemical, and
physiological properties, thereby forming the basis of the
well-known structural and functional diversity of skeletal
muscle (82). This complexity causes difficulty in classify-
ing muscle fibers. At one stage, one author described fiber
classification as “showing an alarming trend toward the
incomprehensible” (83).
At this time, themostwidely used classification is based
on histochemical methods that determine the pH lability
ofmyofibrillarATPase activity anddivides fibers into type
I (low activity) and type II (high activity) with further sub-
division into IIA, IIX, and IIB (84) depending on the ex-
pression of different myosin heavy chain (MHC) forms
(summarized in Table 1). The reliance on oxidative or
glycolytic metabolic pathways determines the contractile
speed of these various fiber types. There is substantial ev-
idence that muscle fibers are dynamic in their response to
a variety of contractile and metabolic stimuli and are able
to convert from one fiber type to another or undergo at-
rophy (84). Both vitaminDdeficiency and age-related sar-
copenia have been associated with preferential atrophy of
type II (fast-twitch) fibers (84, 85).
On a macroscopic scale, the generation of force by a
muscle is dependent on several factors including size, fiber
composition, and individual fiber functional capacity.The
cross-sectional area is the sum of the individual, parallel
fibers, themselves made up of thousands of individual
myofibrils and other cell types (86). The sarcomere is the
basic unit of contraction and is defined as the portion of
the myofibril that lies between two bands, known as Z
bands. Between successive Z bands, an array of myosin
and actin molecules are intricately arranged to form al-
ternating filaments, suspended in the sarcoplasmand lying
in close proximity to mitochondria, indicative of the sig-
nificance of ATP in contraction. The role of calcium, also
fundamentally important in the tight regulation of muscle
contraction (87), will be discussed below.
Apart from the generation of force, skeletal muscle is a
highly metabolic tissue that produces and responds to a
variety of hormones and factors, leading one author to
describe it as a true endocrine organ (88). Exercise leads to
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the increased expression and secretion of a family of myo-
kines including IL-6 and brain-derived neurotrophic fac-
tor that can stimulate glucose uptake and fat oxidation
within muscle, lipolysis in adipocytes, and gluconeogen-
esis in hepatocytes via various autocrine, paracrine, and
endocrine pathways (87, 89). Skeletal muscle is also re-
sponsive to a range of hormones including, but not limited
to, insulin, IGF, glucocorticoids, thyroid hormones, and
1,25D, all of which exert influences on the differentiation,
metabolism, and function of muscle via a number of es-
tablished and evolving mechanisms.
C. Calcium and muscle contraction
Aswell as regulatingwhole-body calciumhomeostasis,
there is also evidence that 1,25D increases calcium influx
in muscle cells and thus may have both direct and indirect
calcium-related effects onmuscle (Fig. 4) (90). The sliding
filament theory, first proposed in 1954 (91), describes the
highly complex movement of actin and myosin filaments
over each other. This and potential effects by which vita-
minDmayaffect thismodel, basedondata tobediscussed,
are depicted in Fig. 5. It is primarily the influx of calcium
from the sarcoplasmic reticulum (SR) and binding to the
troponin-tropomyosin complex that results in the expo-
sure of active binding sites on the actin filament and their
engagementwith themyosin heads (82). In the presence of
ATP, contraction ensues as the myosin head tilts from an
obtuse angle to the perpendicular, causing movement of
myosin over actin filaments in a process named the power
Figure 4.
Figure 4. Direct and indirect effects of vitamin D on muscle. Data on direct effects come predominantly from in vitro studies and are yet to be
confirmed in vivo, where the presence of the VDR is currently under debate.
TABLE 1. Respective characteristics of muscle fiber types based on the current classification
Type I Type IIA Type IIX Type IIB
mATPase activity Low High High High
MHC type I-MHC IIa-MHC IIx-MHC (rodents), IIb-MHC (humans) IIb-MHC
Mitochondrial density High High Medium Low
Anatomic color Red Red White White
Energy source Oxidative Mainly oxidative Oxidative and glycolytic Mainly glycolytic
Activity Aerobic Anaerobic (long-term) Aerobic (short-term) Aerobic (short-term)
Contractile speed Slow Moderately fast Fast Very Fast
Resistance to fatigue High High Moderate Low
References are Schiffiano (353), Spagenburg and Booth (354), Berchtold et al. (82), and Brooke and Kaiser (83). mATPase, Myofibrillar ATPase.
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stroke, after which ADP and inorganic phosphate are re-
leased (86). The binding of new ATP to the myosin head
causes its detachment from the active site of the actin fil-
ament and movement back into the obtuse position.
D. Calcium and exercise-related glucose uptake
Calcium plays a vital role in exercise-related glucose up-
takeby skeletalmuscle.VitaminDregulates calciumhomeo-
stasis, giving potential for indirect regulation. Exercise in-
creases glucose transporter 4 (GLUT4) expression; after
contraction, increased cytosolic calcium activates Ca2!/cal-
modulin-dependent protein kinase (CAMK) pathways and
causes transcriptional up-regulation of myocyte enhancer
factors 2A and 2D, which increase GLUT4 expression (92–
94).Exercisealso increasesGLUT4translocationto themus-
cle cell membrane, independently of insulin. Activation of
the AMP-kinase pathway contributes to this process (95).
GLUT4 vesicle translocation and insertion into the cell
membrane is a calcium- and ATP-dependent process (96).
Aputativemechanism for this is the synaptotagmins.They
are calcium-sensitive proteins required for insertion of the
GLUT4 proteins into the cell membrane, as demonstrated
in adipocytes (97). Synaptotagmins in turn regulate
Myo1c, an actin-filament-attached protein that binds to
and transportsGLUT4vesicles (98). Contraction-induced
calcium influx stimulates a range of signaling pathways
that regulate muscle differentiation and function (99,
100). These include myogenic transcription factors, myo-
statin, peroxisome proliferator-activated receptor # and
utrophin A, mainly via CAMK and calcineurin-mediated
pathways (82, 99, 101). These processes, generally re-
ferred to as excitation-transcription coupling, give rise to
the plasticity and unique adaptive ability ofmuscle to alter
vital components in its function, fiber type, and contractile
force on demand.
E. Calcium and insulin-stimulated glucose uptake
Skeletal muscle is responsible for approximately 85%
of insulin-mediated glucose uptake in lean individuals
(102). Insulin induces translocation of GLUT4 to the cell
surface, facilitating glucose uptake and clearance of cir-
culating glucose. Insulin binds to the !-subunits of its re-
ceptor, activating a signaling cascade. This has been cov-
ered inmany elegant reviews (103, 104). Themechanisms
by which the activation of these proteins then leads to the
insertionofGLUT4protein into the cellmembrane remain
incompletely understood but have also been the subject of
recent review (105). As with exercise, GLUT4 vesicle
translocation is ATP and calcium dependent.
Pharmacological inhibition of calcium influx inmuscle
reduces insulin-mediated glucose uptake, independent of
effects on Akt (96). Calcium regulates components of the
proximal insulin signaling pathway such as the binding of
calmodulin to insulin receptor substrate (IRS)-2 (106). In-
creases in calcium influx improved insulin-mediated glu-
cose uptake in isolated muscle fibers of both normal and
Figure 5.
Figure 5. Potential roles of vitamin D in the sliding-filament model of muscle contraction. These potential effects, marked with an asterisk, include
the rapid flux of calcium ions from the SR to cytoplasm (319), the expression of actin and troponin-tropomyosin proteins (152, 153), and the
effects of vitamin D-mediated phosphate homeostasis on ATP (326).
40 Girgis et al. Vitamin D and Skeletal Muscle Endocrine Reviews, February 2013, 34(1):33–83
insulin-resistantmice (96). Calcium regulates cytoskeletal
components involved in GLUT4 translocation (98). Stud-
ies on L6 myotubes reported significant increases in
GLUT4 expression in response to caffeine-related in-
creases in intracellular calcium. The effects were negated
by dantrolene, an inhibitor of SR calcium release (92).
However, additional research examining the role of cal-
cium in insulin sensitivity is needed.
III. Vitamin D and Muscle: Cell Models
Onacellular level, avarietyofmechanismsbywhichvitamin
D impacts upon the function of skeletal muscle have been
elucidated. These can be broadly divided into 1) genomic
effects that arise from the binding of the 1,25D-VDR-RXR
heterodimer at specific nuclear receptors to influence gene
transcription and 2) nongenomic effects that arise from a
host of complex intracellular signal transduction pathways
after bindingof 1,25D tononnuclear receptor.Over the past
30yr, themajorityof research in this areahasmainly focused
on the nongenomic effects of vitamin D on skeletal muscle,
in particular its regulation of protein kinaseA (PKA)/cAMP,
protein kinase B, protein kinase C (PKC), CAMK, andmul-
tiple MAPK pathways (90).
A. VDR in muscle
After the discovery of the VDR in 1969 (107), the iso-
lation of unoccupied 1,25D receptors partitioned between
the cytosol andcell nucleus in intestinal cells in1980 raised
the possibility of rapid, nontranscriptional pathways as-
sociated with this receptor (108). The rapidity, over min-
utes, with which 1,25D treatment resulted in changes in
intracellular calcium transport in vascularized duodenal
cells supported this possibility (109). Furthermore, it be-
came apparent from studies that examined the binding
properties of VDR isolated from the caveolae-enriched
membrane fraction of chick intestinal cells that the cyto-
solic receptors were identical to nuclear VDR (110). To
confirm this, significant reductions in the capacity of
[3H]1,25D to bind to isolated caveolae-membrane frac-
tionswere reported in tissues obtained fromVDRKOmice
(110). Studies examining the Tokyo strain of VDRKO
mice, in which the second zinc finger of the DNA-binding
domainofVDR is ablated, reported some residual binding
of 1,25D in kidney cells (111).
Treatment with 1,25D elicits rapid uptake of calcium
within muscle cells in vitro and in vivo (112). However,
after transfection of muscle cells with anti-VDR antisense
oligodeoxynucleotides (ODN), 1,25D-dependent mecha-
nisms by which rapid calcium entry occurs, namely store-
operated calcium entry (SOCE) or capacitative calcium
entry, are inhibited (113, 114), therefore implying a direct
nongenomic role for VDR in calcium handling.
The presence of the VDR has been reported in avian,
murine, and human muscle cells on the basis of immuno-
histochemistry (20, 115), equilibrium binding studies
(25), and detection of VDR mRNA by RT-PCR (21).
However, these findings are subject to challenge due to the
nonspecificity of many of the VDR antibodies (116). A
recent paper that used a validated antibody (which did not
show bands in VDRKO mice) did not find VDR expres-
sion in skeletal, cardiac, or smoothmuscle byWesternblot
and immunohistochemistry (27). Differences in experi-
mental conditions and the possibility of tight protein bind-
ing of VDR to DNAmay have accounted for this finding.
Moreover, low levels may be sufficient for significant
function in muscle. Major studies examining the presence
of VDR in muscle and the various techniques used have
been summarized in Table 2.
Another possibility is that there may be differences in
the expression of VDR in muscle in different species and
throughout the various stages ofmuscle differentiation. In
support of the latter, in vitro studies predominantly ex-
amine the activity ofVDRwithinmyoblasts andmyotubes
rather than fully differentiated adult cells. In vivo, VDR
mRNA was reported in the muscle of 3-wk-old wild-type
mice but not in their 8-wk-old counterparts (21). The au-
thors suggested a primary role for VDR in early muscle
development (21). Thus, the expression of VDR within
muscle over time requires further clarification.
Within cultured chick myoblasts, VDR translocates
from the nucleus to the cytoplasm quite rapidly (i.e. 1–10
min) after exposure to 1,25D (117). Intact microtubular
transport and caveolae structure were essential as dem-
onstrated by the disruption of VDR translocation by in-
hibition of these individual components in C2C12 cells
(i.e. with colchicine and methyl-$-cyclodextrin, respec-
tively) (20). After a longer period of exposure to 1,25D,
the VDR appears to translocate back to the nucleus to
presumably carry out its role in transcriptional regulation.
This shuttling of the VDRbetween cytoplasm and nucleus
indicates its versatility in both rapid and genomic actions,
depending on location (118).
Coimmunoprecipitation analyses have also demon-
strated direct binding of theVDRwith a component of the
tyrosinephosphorylation cascade, namely c-Src, under the
influenceof1,25D(119).Transfectionofmuscle cellswith
three different anti-VDRantisenseODN inhibited 1,25D-
dependent dephosphorylation and subsequent activation
of c-Src as assessed 15 min after treatment with 1,25D or
vehicle (120). More recently, treatment of muscle cells
with 1,25D resulted in VDR binding with c-Src, time-de-
pendent increases in c-Src activity, and the redistribution
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of c-Src from the periplasma membrane zone, where it
resides under basal conditions, to the cytoplasm and nu-
cleus as seen on confocal microscopy (20). There is also
evidence that 1,25D induces the association between c-Src
and c-myc, a transcription factor involved in cell growth
and apoptosis. This evidence includes coimmunoprecipi-
tation analyses that demonstrate 1,25D-mediated forma-
tion of complexes between c-Src and c-myc (20) and sig-
nificant inhibition (i.e. 94%) of 1,25D-mediated c-myc
tyrosine phosphorylation on immunoblot after transfec-
tion of muscle cells with anti-VDR antisense ODN (120)
or treatment with PP1, a c-Src-specific inhibitor (120).
Mechanistically, c-Src probably interacts with VDR and
c-myc, both of which are hormone-dependent phospho-
tyrosine proteins, via its Src homology 2 domain, but this
requires further evaluation (121). A role for caveolin-1 in
1,25D-mediated activation of c-Src has also been sug-
gested. Caveolin-1 belongs to a family of membrane-scaf-
folding proteins with potential roles in different disease
phenotypes and binds to c-Src under basal conditions near
the cell membrane. After treatment of C2C12 myoblasts
with 1,25D, colocalization of caveolin-1 and c-Src was
disturbed, and theywere redistributed into cytoplasm and
nucleus (20). Interestingly, when the caveolae structure
was disrupted by methyl-$-cyclodextrin, 1,25D was not
able to separate caveolin-1 from c-Src, preventing its ac-
tivation and also preventing the nuclear translocation of
VDR. Therefore, the caveolae and associated proteins ap-
pear to play an upstream role in the activation of c-Src. It
also appears that 1,25D-mediated activation of c-Src by
VDR is a downstream regulator of several nongenomic
effects of 1,25D in muscle, specifically involving differen-
tiation and calcium homeostasis, which we will discuss.
Apart from the specific ability of the VDR to translocate
from nucleus to cytosol in response to 1,25D, conforma-
tional changeswithin thehighly flexible1,25Dmoleculealso
determine the mediation of genomic and nongenomic ac-
tions via its receptor. It has been shown that the relatively
planar 6-s-cis locked JN [1,25-(OH)2-lumisterol3] displays
nongenomic activity and that the 6-s-trans locked JB [1,
25-(OH)2-dihydrotachysterol3] possesses predominantly
genomic activity on binding the VDR (69). By molecular
modelingof theVDRusingatomiccoordinatesof theprotein
x-ray structure and computer docking, specific binding sites
on the VDR that determine its functional activity have been
reported (122, 123). Interestingly, the pockets that, respec-
tively, mediate the regulation of nongenomic and genomic
responses overlap and therefore result in mutually exclusive
conformational formsof theVDR. It hasbeen suggested that
the unbound VDR may possibly exist in the cytoplasm as
multiple, equilibrating receptor conformations according to
standard statistical distribution (69). Also intriguing, a po-
tential role for 25D in binding the alternative pocket and
initiating intracellular calcium flux has recently been re-
ported (123).
Apart from the VDR, it is also possible that other cy-
tosol receptors may be responsible for the rapid actions of
1,25D inmuscle. Contrary to an earlier report, it does not
appear that annexin II binds to 1,25D in a physiologically
relevant manner (124, 125). Recent data have suggested a
role formembrane-associated rapid response steroidbind-
TABLE 2. Major studies examining the presence of VDR in muscle (listed in chronological order)
Study Muscle cell type Method of detection Findings in muscle
Neville and DeLuca, 1966
(355)
Rat muscle extracts Tritium-labeled 1,25D Proportion of 1,25D localized to membrane
Stumpf et al. 1979 (356) Rat muscle extracts Tritium-labeled 1,25D, autoradiography 1,25D not localized in muscle
Simpson et al. 1985 (25) Cultured G8 and H9c2
myoblasts; rat longissimus
muscle
Equilibrium binding studies, chromatography VDR present
Costa et al. 1986 (26) Cloned human muscle cells (five
individuals)
Binding studies, chromatography, 24-hydroxylase
assay
VDR present
Boland et al. 1985 (357) Chick myoblast cells Density gradient analysis, saturation analysis VDR present
Sandgren et al. 1991 (358) Rat muscle extracts Immunoradiometric assay VDR absent
Buitrago et al. 2000, 2001
(119, 120)
Chick skeletal muscle cells Western blot VDR present
Boland et al. 2002 (145) Chick skeletal muscle cells Western blot VDR present
Buitrago and Boland 2010
(20)
C2C12 cell line Immunohistochemistry VDR present
Endo et al. 2003 (21) Mouse muscle extracts RT-PCR VDR mRNA present in muscle of 3-wk-old
mice but not 8-wk-old mice
Bischoff et al. 2001 (115) Human muscle extracts (20
people)
Immunohistochemistry (VDR-9A7 antibody) VDR present and decreases with age
Garcia et al. 2011 (118) C2C12 cell line RT-PCR, immunohistochemistry, Western blot
(VDR-C20 antibody)
VDR present
Wang and DeLuca 2011
(27)
Mouse and human muscle
extracts
RT-PCR, immunohistochemistry, Western blot
(VDR-D6 antibody)
VDR mRNA at a low level; protein for VDR
not detected (using D6 antibody); C20
antibody not specific
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ing in potentially inducing rapid effects of 1,25D in mus-
cle, but further assessment is required (126).
B. Calcium homeostasis
Although the nongenomic regulation of intracellular
calcium by 1,25D has been well characterized in cultured
myoblasts and myotubes, it has also been confirmed by in
vivo studies on chicks and in vitro assessment of differen-
tiated soleus muscle samples. Studies report a time- and
dose-dependent increase in intracellular muscle calcium
uptake in response to 1,25D. The use of particular agents
and antisense oligonucleotides to block components of the
signal transduction pathway has led to the elucidation of
specific step-wise mechanisms by which vitamin D influ-
ences intracellular calcium homeostasis (127–129). These
have been depicted in Fig. 6.
First, the rapid mobilization of calcium from the SR
into the cytosol relies on 1,25D-dependent activation of
two components of the signal transduction pathway,
namely c-Src andphosphoinositide-3kinase.These in turn
lead to the activation of phospholipase C%, the rapid pro-
duction of inositol triphosphate (IP3) and the first of two
phases of diacylglycerol (DAG) synthesis from the mem-
brane phosphoinositides (22, 130). It is IP3 that then me-
diates the rapidmovement of calcium from the SR into the
cytosol (130).
In the continuedpresenceof1,25D, twoadditional pro-
cesses are then involved in the more sustained phase of
calcium entry from the extracellular compartment,
namely SOCE and L-type voltage-dependent calcium-
channel (VDCC) entry mechanisms. SOCE relies on sev-
eral factors including IP3-dependent calcium release from
the SR that activates calmodulin, CAMKII, and PKC, the
latter also being activated by a by-product of a previous
reaction, namely DAG (131). The particular channels re-
sponsible for SOCE have been identified as the transient
receptor potential-canonical-like proteins. Interestingly, a
Figure 6.
Figure 6. Mechanisms by which vitamin D influences calcium homeostasis in cultured muscle cells. c-Src, cellular Src; PI3-kinase, phosphoinositide
3-kinase; PKA, protein kinase A; PLC-%, phospholipase C%.
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direct role of the VDR in activating these channels has
been suggested by the coimmunoprecipitation of both
molecules after treatment with 1,25D in chick skeletal
muscle cells (113).
Apart from its reported role in SOCE, evidence sup-
ports vital additional roles for PKC in 1,25D-dependent
calcium homeostasis in muscle. Rapid translocation of
PKC-! from the cytosol to the cell membrane after the in
vitro treatment of chick soleusmuscle and cultured rat and
chick myoblasts with 1,25D (132, 133) and marked re-
duction in intracellular calcium influx after selective
knockout of PKC-! by the use of specific antisense oligo-
nucleotides have been described (128). Furthermore, PKC
also activatesVDCC-mediated calciumentry as evidenced
by the rapid stimulation of 45Ca2! uptake by cultured
myoblasts after treatment with PKC activators, namely
DAG and phorbol 12-myristate 13-acetate, inhibited by
the addition of nifedipine, anL-typeVDCCblocker (133).
PKC-! may also have a role in the 1,25D-dependent
activation of the ERK1/2 signaling pathway as will be
discussed in Section III.D on proliferation and
differentiation.
VDCC-mediated calcium entry also relies on 1,25D-
dependent activation of the cAMP/PKA pathway. Very
rapid increases (within 30 sec) in the levels of adenylyl
cyclase (AC) and cAMP levels, together with increased
PKA activity, occur in differentiated muscle cells and cul-
tured myotubes after 1,25D treatment (127, 134). These
studies also report that 1,25D stimulation of VDCC-
45Ca2! entry canbemimickedby treatmentwithdibutyryl
cAMPandabolishedby specific inhibitorsofACandPKA.
Another mechanism is emerging by which PKC and
cAMP/PKA pathways may cross talk in the regulation of
VDCC-mediated calcium flux (90). The preliminary data
indicates an increase in the cAMP content of myoblasts
after treatment with a PKC activator, phorbol 12-myris-
tate13-acetate,whichmay stemfromthephosphorylation
of G!i that is mediated by PKC in other cells (133). Fur-
thermore, the phosphorylation of G!i in myoblast mem-
branes after treatment with 1,25D is likely to be essential
in the stimulationofACactivity as evidencedby the effects
of abolishing G protein regulatory pathways on 1,25D-
mediated AC activity (134).
In summary, 1,25D induces changes in intracellular cal-
cium levels in cultured muscle cells initially via rapid IP3-
dependent calcium shifts from the SR to the cytosol fol-
lowed by processes resulting in extracellular calcium
influx via the activation of SOCE and VDCC activity.
These mechanisms are evident in both immature myo-
blasts and differentiated myotubes, suggesting a potential
role for rapid calcium influx in muscle cell differentiation
and contraction, respectively (19). In support of this in-
ference, an interesting report from 1974 described a direct
correlation between in vivo skeletal muscle dysfunction and
demonstrabledefects in intracellularcalciumhandling(136).
A group of rabbits, rendered vitamin D deficient by dietary
methods, were found to be substantially weaker and hypo-
tonic compared with their vitamin D- replete counterparts
and in vitro, displayed significant reductions in calcium up-
take in the SR on isolation from psoas muscle.
C. Phosphate homeostasis
Phosphate is an essential substrate in the production of
ATP and in protein synthesis. There is early evidence dem-
onstrating that phosphate uptake in muscle may be influ-
enced by 25D (19, 137). The administration of 25D to
vitamin D-deficient, phosphate-deplete rats resulted in a
significant increase in the in vitro concentration of
[32P]phosphate in muscle cells, followed by the stimula-
tion of phosphate-dependent metabolic processes includ-
ing ATP synthesis in these cells (137). This effect was not
reproducedby the repletionofphosphate in these rats.The
abolition of 1!-hydroxylase activity by nephrectomy had
no effect on 25D-mediated phosphate uptake, implying a
direct role of the prehormone in this process. Another
study reported the specificity of 25Don in vitrophosphate
uptake of differentiated muscle cells with the absence of
such effects after 1,25D and 24,25-(OH)2D treatment
(138–140).
Another study demonstrated the specific transport of
[32P]phosphate across muscle plasma membranes after in
vivo vitamin D repletion and 32P labeling of vitamin D-
deficient chicks (141). This findingwas later confirmed by
an increase in vesicle phosphate transport in muscle cells
via the isolation of highly purified sarcolemma vesicles in
vitamin D-deficient chicks treated with vitamin D (19).
Thedirect effect onphosphateuptakemaybemediatedvia
a sodium-dependent mechanism as reported by studies on
cultured muscle cells (138, 139).
D. Proliferation and differentiation
There is evidence that 1,25D activates components of
theMAPK family in culturedmyoblasts, thereby influenc-
ing the expression of genes involved in cellular prolifera-
tion and differentiation. The majority of research in this
area has focused on the effects of 1,25D on the ERK1/2
signaling pathway. The initial activation of c-Src by
1,25D, previously described as an apparent gateway to the
nongenomic effects of 1,25D inmuscle, results in the rapid
activation of Raf-1 by the phosphorylation of its serine
residue,which relies on the involvement ofRas andPKC-!
(142, 143).
Raf-1 then leads to the activation of MAPK kinase,
which activates ERK1/2, after which the phosphorylation
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of a range of proteins and transcription factors including
cAMP response element-binding protein and Elk-1 and
the increased expression of other proteins relevant to cell
proliferation and differentiation, namely c-myc and c-fos,
take place (144, 145).
AnotherMAPKactivatedby1,25Dinculturedmyoblasts
is p38.Rapid c-Src-dependent stimulation ofMAPKkinases
MKK3 and 6 and p38 was demonstrated in C2C12 myo-
blasts after treatment with 1,25D (146). After this, p38-de-
pendent activation of MAPK2 and subsequent phosphory-
lation of heat-shock protein 27 was demonstrated. Heat-
shock protein 27 has an important role through its
association with the actin microfilament system and cyto-
skeletal remodeling of muscle cells (146, 147). More re-
cently, 1,25D-mediated AKT phosphorylation in differenti-
ating C2C12 cells was also shown to occur via c-Src, p38,
MAPK and phosphoinositide-3 kinase pathways (148).
Although little is known about its exact activity in this
context, a third member of the MAPK family, namely c-
Jun N-terminal kinase-1/2, is also phosphorylatively ac-
tivatedby1,25D inC2C12myoblasts (146).Therefore, an
intricate system of nongenomic regulatory responses to
1,25D may control cellular proliferation and differentia-
tion ofmuscle cells, although the relative role of each com-
ponent remains unclear.
A variety of genomic responses to 1,25D have also re-
cently been elucidated. Apart from being the first to de-
scribe the presence of VDR within muscle cells, Simpson
et al. (25) also demonstrated dose-dependent reduction in
the proliferation of G-8 myoblast cells that were treated
with 1,25D and a commensurate reduction in DNA syn-
thesis, suggesting that genomic responses to 1,25D gave
rise to the down-regulation in myoblast proliferation and
enhanced differentiation into myotubes.
In a recent study, treatment of C2C12 myoblasts with
1,25D for 7 d as opposed to vehicle resulted in increased
mRNA and protein expression of transcription factors
known to enhance myogenesis, namely myogenic differen-
tiation antigen, desmin, myogenin, and IGF-II and the re-
duced expression of proliferating cell nuclear antigen and
myostatin, which, respectively, enhance cell proliferation
and negatively regulate muscle mass (118). Morphologi-
cally, cells treatedwith1,25Dfor10ddisplayedsignificantly
increased muscle fiber size and diameter, as indicated by
staining for MHC type II a late myogenic marker. These
changes were associated with VDR-induced genomic mech-
anismsas evidencedbysignificant increases in theexpression
of the receptor by 1 d of 1,25D treatment and its nuclear
translocationat4dasopposedto itspersistent location in the
cytoplasm of cells treated with vehicle.
However, these findings stand in contrast to an earlier
report that described the down-regulation of myogenin
and myogenic transcription factor 5 (myf5) at an mRNA
level in C2C12 myoblasts treated with 1,25D for 48 and
96 h compared with those treated with vehicle (21). Fur-
thermore, this coincided with the reduced expression of
neonatal forms ofMHC, suggestingmyoblast maturation
in cells treatedwith 1,25D. It is possible that differences in
study design may have accounted for these contradictory
findings, specifically pertaining to myogenin expression.
Different durations of treatment, and daily vs. single treat-
ment regimens were employed in these studies (21, 118).
In another study Artaza and Norris (390), vitamin D
treatment of mesenchymal stem cells resulted in increased
expression of follistatin, an antagonist of myostatin, and
caused down-regulation of TGF-$. These vitamin D-me-
diated changes in gene expression imply that it has a po-
tential role in the inhibition of fibrosis and, perhaps, the
promotion of myogenesis and osteogenesis in mesenchy-
mal stem cells.
In a recent study, European sea bass treated with var-
ious doses of dietary cholecalciferol from 9–44 d after
hatching demonstrated dose-dependent effects in the gene
expression of a number of myogenic transcription factors
and dose-dependent increases in white muscle fiber size
and number (149).
Although vitamin D has clear effects on muscle differ-
entiation, more research is needed to elucidate the nature
of these mechanisms. It is also important to note that the
overlapping functions and complex regulatory pathways
determining the activity of myogenic transcription factors
are themselves something of a mystery although recently
reviewed in detail (150).
E. Muscle contractile proteins
There is evidence that vitamin D may play a role in the
regulation of key components in the cytoskeletal structure
of muscle cells. As discussed in Section II.B, the complex
interaction between actin and myosin, two cytoskeletal
proteins, forms the basis of understanding muscle con-
traction (Fig. 5). Similar proteins play a potential role in
intracellular trafficking and, potentially, GLUT4
translocation.
Significant reductions in components of the actomyo-
sin-troponin complex in the skeletal muscle of vitamin
D-deficient rats and rabbits have been reported in two
separate studies, although in the latter, this may not have
been directly related to 1,25D because in vivo adminis-
tration of ethane-1-hydroxy-1,1-diphosphate in doses
known to inhibit 1,25Dhadnoeffect on these components
of the cytoskeleton (151, 152). A study also reported an
increase in the muscle concentrations of actin and tro-
ponin C in chicks replete with vitamin D as opposed to
their vitamin D-deficient counterparts (141). Taken to-
Endocrine Reviews, February 2013, 34(1):33–83 edrv.endojournals.org 45
gether, these reports suggest a direct role for 25D in the
up-regulation of these muscle contractile proteins (141,
151). Furthermore, the direct role of 25D in phosphate
homeostasis, as discussed, and the recent demonstration
of direct binding between 25D and the alternative pocket
of the VDR with subsequent biological effects in COS-1
kidney cells suggest that reconsideration of the ability of
25D to generate biological responses in vivo may be in
order (123).
F. Phospholipid composition
Phospholipids, a classof lipids that residewithin the cell
membrane, have been implicated in a variety of signal
transduction pathways, including insulin signaling and
calcium handling, and play a role in cell membrane func-
tion including caveolae. Alterations in phospholipid com-
position have been associated with insulin-resistant states
(153). There is also evidence of a direct role of 1,25D in the
regulation of the phospholipid metabolic pathway.
A study reported higher relative concentrations of phos-
pholipids in the muscle SRmembranes of vitamin D-replete
vs. -deficient animals (141). There were also significant
changes in the levels of particular phospholipids, specifically
an increased concentration of phosphatidylcholine and de-
creases in phosphatidylethanolamine, in the sarcolemma
vesicles of vitamin D-replete vs. -deficient chicks (141). An-
other study suggested that 1,25D treatment led to the acti-
vation of specific methylation pathways that leads to the
conversion of phosphatidylethanolamine to phosphatidyl-
choline in muscle cells (154). This is likely to represent a
genomic effect as 1,25D-mediated binding of [3H]glycerol
and [14C]ethanolamine to phosphatidylcholine in cultured
myoblasts was inhibited by the action of actinomycin D, an
inhibitor of DNA synthesis. Although the precise signifi-
cance of genomic 1,25D-mediated influences on phospho-
lipid composition remains uncertain, potential influences on
calcium handling, cell proliferation, and insulin signaling
merit further consideration.
G. Bone-muscle cross talk and vitamin D
It is well established that muscle strength and muscle
mass are important determinants of bone density, bone
geometry, and fracture risk. Vitamin D therefore plays a
key role in bone metabolism not only through its direct
effects mediated by the VDR in osteoblasts and its effects
on calcium absorption by the intestines but also through
its effects on muscle fiber size and muscle function noted
above. Interestingly, during growth, serum 25D levels have
been found to be negatively associated with the accrual of
bonemineral content in girls (155), and 25D levels decrease
as lean mass increases (156). These observations raise the
possibility thatmuscle tissuemay require additional vitamin
D during growth and that an important function of vitamin
D on bone mass accrual may be mediated by the effects of
vitamin D on accumulation of lean mass, which has been
documented to precede gains in bone (157).
Another pertinent consideration is the role of FGF23, a
protein whose regulation is closely linked to phosphate
homeostasis and the activation of vitamin D (step 3, Fig.
2). Although 1,25Dup-regulates the expression of FGF23
by osteocytes and osteoblasts, FGF23 inhibits 1,25D syn-
thesis and stimulates its breakdown (158). Therefore,
FGF23 excess, as seen in thosewith oncogenic orX-linked
hypophosphatemic osteomalacia, leads to reduced 1,25D
and phosphate levels and is also associated with muscle
weakness. In Hyp mice, a model of X-linked hypophos-
phatemic rickets, the administration of neutralizing
FGF23 antibodies increased 1,25D and phosphate levels
as well as leading to improvements in grip strength and
spontaneous movement (159). Therefore, the FGF23-
vitamin D feedback loop presents another layer of com-
plexity when assessing effects on muscle function.
H. Cell models and molecular pathways for insulin
signaling and diabetes
1. Insulin signaling in cell models
Treatment of U-937 human promonocytic cells with
1,25D leads to time- and dose-dependent increases in the
mRNAexpression of insulin receptors, as shown in two sep-
arate studies (160, 161). In the second study, 1,25D treat-
ment also resulted in an increase in VDR expression, sug-
gesting that the accompanying increases in insulin-mediated
[14C]2-deoxyglucose uptake and [125I]insulin binding in
these cells resulted fromtheactivationof genomicpathways.
The authors also reported a putative VDRE in the human
insulin receptor gene promoter on the basis of luciferase as-
says on transfected plasmid constructs (162). However, dif-
ferences in insulin signaling mechanisms between skeletal
muscle and immune cells, with the reliance of the latter on
GLUT1rather thanGLUT4 transporters for glucoseuptake,
may limit extrapolation of these results.
In a recent study, differentiated C2C12 muscle cells
were rendered insulin resistant and atrophic by treatment
with free fatty acids (FFA) (163). However, coadminis-
trationof 1,25Dwith FFA resulted in significant dose- and
time-dependent increases in the insulin-mediated uptake
of [3H]2-deoxyglucose compared with cells that had re-
ceived FFA alone. This effect of 1,25D was initially ob-
served at 12 h and reached stability at 36 h, at which point
complete reversal of the FFA-mediated insulin resistance
was observed (using 10 nM 1,25D). In addition, 1,25D
treatment prevented muscle atrophy as demonstrated by
significantly increased myotube diameter in cells that had
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been cotreated with 1,25D and FFA as opposed to those
receiving FFA alone.
To account for these effects on insulin resistance, the
authors reported that 1,25D treatment reversed a number
of FFA-induced abnormalities in the insulin-signaling
pathway. At a protein level, 1,25D significantly inhibited
FFA-induced serine phosphorylation of IRS-1 and in-
creased the tyrosine phosphorylation of IRS-1 and the
phosphorylation of Akt. In addition, the FFA-mediated
activation of c-Jun N-terminal kinase, a protein with a
significant role in insulin resistance, was significantly re-
versed by 1,25D treatment. Thus, this report provided the
first demonstration of a direct effect of 1,25D in the res-
toration of key components of the insulin-signaling path-
way in an established cellular model of insulin resistance.
2. Arachidonic acid (AA) release
Apart from direct effects on the composition of mem-
brane phospholipids as discussed earlier, there is evidence
that 1,25D leads indirectly to the release of AA by a pro-
cess involving deacylation of membrane-bound phos-
phatidylcholine (164). This is relevant because levels of
AA, a polyunsaturated fatty acid, in skeletal muscle cor-
relate inverselywith insulin resistance in humans. AAmay
alsomodulate the function ofmembrane insulin receptors
and glucose transporters and may influence the action of
insulin by acting as a precursor for the generation of sec-
ondmessengers such as DAG (90). AA also plays a central
role in inflammation,with theproductionofbothpro- and
antiinflammatory metabolites that may also have poten-
tial effects on insulin signaling.
In chick myoblasts, 1,25D treatment resulted in dose-
dependent increases in the release of [3H]AA,but the effect
appeared to be dependent on the influx of extracellular
calciumand the indirect activationof phospholipaseA2by
PKC (164). More research is needed to clarify the possi-
bilities that arise fromaneffect of 1,25DonAArelease and
its availability for intracellular processes.
3. Caveolin-I mediated insulin sensitivity
Some data suggests that vitamin D may play a role in
caveolin-I mediated insulin sensitivity (165). Caveolin-I, a
scaffolding protein within the caveolar membrane, has
recently been shown to play an important role in insulin
sensitivity. Its selective down-regulation in the skeletal
muscle of wild-type mice and its reduced expression in
JYD mice, an age-dependent type 2 diabetes model, were
associated with significant impairments in insulin sensi-
tivity (166). VDR is present within the caveolae, appear in
close proximity to caveolin-1 on confocal microscopy af-
ter treatment of ROS 17/2.8 cells with 1,25D (110) and
relies on caveolin-I for the mediation of nongenomic ef-
fects within skeletal muscle cells (20), all supporting a
close association between vitamin D and caveolin-I and
raising the question as to whether vitamin D might also
have an impact on caveolin-I mediated insulin sensitivity.
Perhaps the strongest evidence to support this possibility
is the combination of marked insulin resistance and vitamin
D resistance in humans with homozygous nonsense caveo-
lin-1 mutations, otherwise known as Berardinelli-Seip con-
genital lipodystrophy (167). Future research may address
this intriguing conceptual link.
IV. Vitamin D and Muscle: Studies in
Animal Models
A. VDRKO mice
The VDRKO mouse model has provided valuable in-
sights into the biological function of the vitamin D endo-
crine system and, specifically, the genomic activity of the
transcription factorVDR(13).The role of vitaminD in the
development, morphology, and function of skeletal mus-
cle has been made clearer by studies on this mouse model.
The earliest form of the VDRKO mouse, generated by
targeted ablation of the DNA encoding the second zinc
finger of theDNA-binding domain,was described in 1997
(28). Mice appeared phenotypically normal at birth, de-
spite known expression of the VDR in fetal life in wild-
type mice, but became hypocalcemic with secondary hy-
perparathyroidism around weaning (21 d) and developed
alopecia associated with large dermal cysts by 4 wk of age
and rickets and growth retardation by d 35. The initial
lack of hypocalcemia is considered to be due to the early
presenceofnonsaturable1,25D-independentmechanisms
of intestinal calcium absorption. However, when 1,25D-
dependent mechanisms take over, mice require a high cal-
cium (2%), phosphorus (1.25%), and lactose (20%) res-
cue diet for survival. The alopecia is interesting, because
people with mutations in VDR (vitamin D-resistant rick-
ets) also develop alopecia (168, 169).
1. Muscle morphology and development
A study in 2003 described histological changes in the
muscles of VDRKOmice directly before and after the de-
velopment of hypocalcemia.At 3wkof age, samples taken
from the quadriceps muscle of VDRKO mice displayed a
wider degree of variability in fiber diameter in addition to
significant reductions in the size of both type I and II fibers
compared with those in wild-type mice (21). By 8 wk of
age, generalized atrophy of type I and II muscle fibers had
worsened in theVDRKOmice, suggestingprogressiondue
to the absence of the VDR or the additional effect of sys-
temic biochemical changes that had not been present at 3
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wk. These changes were also reported in VDRKOmice on
ahigh-calcium, -phosphorus, and -lactose rescue diet, sug-
gesting that the absence of VDR was the predominant
cause rather than systemic biochemical changes. Neither
degenerative nor necrotic changes were observed in
VDRKO skeletal muscle, and similar results were ob-
tained in a range of other muscle groups in this model,
suggesting a diffuse effect of the VDR on skeletal muscle
morphology.
Impaired regulation in the expression of particular
myogenic transcription factors, known to control muscle
phenotype, was reported as an explanation for these find-
ings. On immunohistochemistry, Northern blot, and RT-
PCRanalyses, the expressionofmyf5,myogenin, andE2A
was significantly higher in quadriceps samples of 3- and
8-wk-old VDRKO mice compared with age-matched
wild-type mice. Persistent expression of immature forms
of MHC was also found in the small muscle fibers of
VDRKO mice but not in their type II muscle fibers. The
expression of two other myogenic transcription factors,
namelyMyoD andMRF4, were not particularly affected
in VDRKO mice.
Although these data support a role for vitamin D in the
regulation of muscle development, precise genomicmech-
anisms by which the VDR influences myogenesis are un-
clear, and the issue is further complicated by the failure to
identify negative VDRE in the promoter region of the
genes encoding myf5 and myogenin (170, 171).
2. Muscle strength and functional assessment
A number of studies have examined muscle strength
and performance in VDRKO mice. These investigations
rarely assess muscle function in isolation, with results be-
ing potentially influenced by a range of other factors in-
cluding cardiovascular endurance, balance, and the ability
to learn new skills. Furthermore, behavioral differences
between VDRKO andwild-typemice have been reported,
which may confound the assessment of some tests (172).
Nevertheless, these studies provide an indication of the
functional motor deficits associated with loss of VDR by
testing swimming ability and motor coordination.
a. Forced swim test analysis. Three studies have described
differences in the swimming behavior of VDRKOmice.
In one study comparing six VDRKOmice with 10 wild-
type and heterozygote mice that were shaved to account
for alopecia-related alterations in buoyancy, severe im-
pairment of swimming was seen in the knockout mice
(173). Baseline levels of locomotor, sensory, and ves-
tibular activity were similar. On swim testing, they were
observed to swim in a predominantly vertical position,
had a significantly greater number of sinking episodes,
and displayed stereotypic rotations and catatonic-like
upper limb spasms.
In another study, a significantly greater numberof sink-
ing episodes were seen among eight VDRKO mice com-
pared with six wild-type controls (174). However, on be-
ing given a stimulus, they showed no impairment in ability
to move down a 1-m laneway or in reaching a visible plat-
form. However, VDRKOmice did display greater fatigue
after the swim based upon differences in rearing and
grooming behavior. The authors hypothesized that this
was due to the reduced availability of calcium in VDRKO
mice after exercise.
A third study reported that abnormal patterns of swim-
mingbehavior amongVDRKOmiceweremoremarked in
older (5–13 months) rather than younger knockouts
(175). Interestingly, no such impairment in swimming
ability was seen among a group of 11 1!-hydroxylase
(Cyp27B1)-knockout mice (175). That suggests the in-
triguing possibility that there might be vitamin D-inde-
pendent effects of VDR upon muscle function (175).
b. Tests ofmotor coordination.The time taken for amouse to
fall off a device that rotates at fixed speeds and in accel-
eration is considered to indicate its degree of motor co-
ordination (174). In one study, VDRKOmice stayed on
a rotating device for a significantly shorter time than
wild-type mice on both the accelerating and fixed-speed
rotarod tests (174). On gait assessment, VDRKO mice
took significantly shorter steps and traveled a shorter
distance than wild-type mice when placed in an open
field for 5 min.
Significantly shorter retention times on accelerated ro-
tarod testing were confirmed in another group of 12-
month-old VDRKO mice compared with age-matched
wild-type mice (175). These 12-month-old mice demon-
strated similar impairments inmuscle coordination in tilt-
ing box and tilting tube tests, which measure the latency
and the angle at which the animal displaces off a device
that, respectively, tilts or rotates at different angles. How-
ever, no differences were found in 6-month-old VDRKO
mice.
In another study, the vertical screen test that measures
the time taken for a mouse to fall from a screen that be-
comes suddenly vertical while the mouse rests on it in a
horizontal position (i.e. retention time) was employed
(173). VDRKO mice demonstrated markedly shorter re-
tention times comparedwith bothwild-type andheterozy-
gous groups, implying impaired motor coordination or
strength.
In summary, VDRKO mice demonstrate notable de-
fects in their overall motor performance with significant
impairments in their ability to remain afloat while swim-
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ming and shorter stride length and impaired motor coor-
dination and balance on rotarod, rotating tube, and tilting
box tests. Although the effect of alopecia was accounted
for in one study, other biochemical and behavioral
changes in VDRKO mice together with the widespread
expression of the VDR in the central nervous system, ves-
tibular system, and spinal cord under normal conditions
make direct assessment of its role in muscle function dif-
ficult in this setting (175). Nevertheless, it is clear that the
overall motor function of these mice is impaired and that
further work is needed to clarify the individual compo-
nents that may account for this.
B. Other animal models
Although theVDRKOmousemodel has providedvalu-
able insights into the biological activity of vitamin D, it is
more accurate to consider this as a model of type II
vitamin D-dependent rickets rather than vitamin D de-
ficiency. Studies have examined muscle function in an-
imals rendered vitamin D deficient by a range of dietary
and other methods (176). In a study from 1978, vitamin
D-deficient male Sprague-Dawley rats demonstrated
significantly prolonged times to peak tension and re-
covery times in electrically stimulated soleus muscle
contraction compared with vitamin D-replete rats on
normal chow (177). These changes normalized after vi-
tamin D repletion. In contrast, no impairments were
noted in rats rendered phosphate deficient or calcium
deficient 10 d before experimentation.
A study from 1979 examinedmuscle function in chicks
raised from hatching on a vitamin D-deficient diet (178).
Significant reductions in the tension generated by the tri-
ceps surae during stimulation of the posterior tibial nerve
compared with that in vitamin D-replete chicks were
found. This occurred independently of calcium and phos-
phate levels. The authors found no difference in the his-
tological appearance of muscle samples but did isolate
reduced muscle mitochondrial calcium levels. This was
independent of serum calcium levels and was proposed as
the mechanism by which vitamin D deficiency affected
muscle contraction force.
Four weeks after the commencement of a vitamin D-
deficient diet, rats displayed marked skeletal muscle hy-
persensitivity on calf compression compared with those
fed a normal diet (179). This finding was not related to
hypocalcemia but was rather accelerated by increased di-
etary calcium andwas accompanied by early impairments
in balance on a beam-walk test to assess the frequency of
foot slips. Histologically, vitamin D-deficient rats dis-
played increased numbers of presumptive nocioceptor ax-
ons in skeletal muscle, providing an explanation for their
hyperalgesic phenotype.
In contrast to these studies, a recent report questioned
the primary role of vitamin D, rather than biochemical
changes associated with vitamin D deficiency, in resulting
in myopathy (176). In 58 male Wistar rats that were ren-
dered vitamin D, phosphorus, and calcium deficient by
dietarymethods and housing under incandescent lighting,
muscle strength of the soleus as assessed by a force trans-
ducer detecting isometric contractionwas significantly re-
duced compared with that in replete controls (176). The
authors concluded that phosphorusdeficiencywas thepri-
mary culprit on the basis of several findings. These in-
cluded adirect independent correlationbetweenphospho-
rus levels and the reduction in soleus muscle force in these
animals, complete restoration in slow-twitchmuscle force
after dietary repletion with phosphorus despite persistent
vitaminDdeficiency and similarmeasures ofmuscle func-
tion among phosphorus-replete rats that were either vita-
min D deficient or replete. Similarly, there was no differ-
ence in muscle contraction among rats that were calcium
deficient and replete, in which vitamin D and phosphorus
levels were within the reference range. The central impor-
tance of phosphorus in the production of ATP, essential
formuscle contraction, was considered as the explanation
for these findings.
Therefore, the difficulty in differentiating the effects of
severe vitamin D deficiency from those of hypocalcemia
and hypophosphatemia in the development of muscle pa-
thology is common to animal and human clinical studies.
However, cell lines and tissue culture enable studyofdirect
effects, and these studies date back to the 1970s.
C. Animal studies on insulin sensitivity and diabetes
Although vitamin D deficiency has been associated
with more aggressive disease among nonobese diabetic
mice (180), a model for type 1 diabetes, few animal trials
have addressed the role of vitamin D in insulin resistance.
Inone studyofob/obmice, anobese type2diabetesmodel,
significant improvements in hyperglycemia and hyperin-
sulinemia in response to treatment with 1!-hydroxyvita-
minD3 (1!-OHD3)were observed (181). In another study
of aged ratswith type 2diabetes and insulin resistance that
received 25D, 1!-OHD3, or no treatment, serum 1,25D
levels correlated positively with the glucose infusion rate
on euglycemic clamp studies at the end of the 12-wk treat-
ment period (182), suggesting a potential role in insulin
sensitivity. However, the main focus of this study was the
demonstration of bone loss among insulin-resistant rats
attributed to a reduction in their renal 1!-hydroxylase
activity.
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D. Summary: vitamin D and muscle function in
animal studies
Congenital absence of the VDR in VDRKO mice is
associated with atrophy of both type I and type II fibers,
poor musculoskeletal performance in behavioral tests,
andmarked changes in gait. VitaminDdeficiency induced
in rats has also been found to alter muscle function when
comparedwithvitaminD-replete animals.Together, these
studies using animal models provide additional evidence
that vitamin D plays an important role in muscle physi-
ology.However, they do not separate the effects ofmuscle
vs. whole-body deletion of VDR. Biochemical abnormal-
ities in thesemousemodelsmayonceagain confound these
findings (Fig. 4). A similar question has been recently an-
swered in relation to cardiac muscle; mice with specific
deletion of VDR in cardiac muscle displayed significant
cardiac hypertrophy, similar to that seen in whole-body
VDRKO mice (183). Specific deletion of VDR in skeletal
muscle using Cre-Lox technology will be required to clar-
ify this question.
V. VDR Polymorphisms and Muscle Function
Several single-nucleotide polymorphisms (SNP) in the
gene encoding the VDRhave been associatedwith a range
of phenotypic characteristics including muscle strength.
These have been summarized in Table 3.
A. FokI polymorphism
The FokI polymorphism of the VDR gene is a T/C tran-
sition in exon 2 of the VDR gene that results in a shorter
424-amino-acid protein with enhanced transactivation ca-
pacity using a reporter gene assay (184). Although this
greater VDR activity might suggest improved muscle
strength in light of some of the clinical data, the FokI poly-
morphism is associatedwith reducedmuscle strength in two
studies in men (185, 186). It is interesting to speculate that
increased VDR function could increase CYP24A1 expres-
sion and thereby degradation of 1,25D.
Among 302 Caucasian men (aged 58–93 yr), those who
were homozygous for the FokI polymorphismdisplayed sig-
nificantly lower fat-freemass and appendicularmusclemass
on dual-energy x-ray absorptiometry (DEXA) scanning
(185). Furthermore, men with this polymorphism demon-
strated a 2.17-fold higher risk of sarcopenia (defined by ap-
pendicular fat-free mass"7.26 kg/m2), independent of age.
Lower fat-free mass was associated with significantly lower
quadricepsmuscle strength.Differences in quadriceps strength
werenot significant after adjusting for fat-freemass, suggesting
that the difference was mediated by altered muscle mass.
In another study that included 107 patients with stable
chronic obstructive pulmonary disease and 104 healthy,
age-matched controls, homozygosity for the FokI poly-
morphism was associated with reduced quadriceps
strength comparedwithheterozygosity or control subjects
(186). The difference became more significant in a model
that adjusted for age, sex, forced expiratory volume in 1
sec (FEV1), fat-free mass, and angiotensin-converting en-
zyme genotypes. There was no evidence that the presence
or absence of lung disease affected the relation between
FokI genotype and quadriceps strength.
Among 240 women (41.5 # 13.2 yr), those with the
FokI polymorphism (FF) had weaker isometric knee ex-
tensor strength (P"0.05 forboth90° and120° incline)vs.
those whowere heterozygous (Ff) or lacking the polymor-
phism (ff) (187). However, on adjusting for age, height,
and total fat-free mass, the differences were no longer sig-
nificant, again suggesting that the polymorphism may be
affecting muscle mass.
B. BsmI polymorphism
The data are less consistent for the BsmI polymor-
phism. This SNP is located in the 3$ region of the VDR
gene, known to play an important role in the regulation of
gene expression (188). In a group of 121 nonobese,
healthy women over 70 yr of age, the bb genotype was
associated with 23% higher quadriceps strength and 7%
higher wrist strength compared with those with the BB
genotype (189). However, among the 380 obese women
over the age of 70 in this same study, no effect was found.
Conversely, a study of 175 young healthy women (age
range 20–39 yr) in Belgium found that those with the bb
genotype had lower hamstring strength on dynamometer
and lower fat-free mass on DEXA compared with the BB
genotype (190). The difference in hamstring strength be-
came of borderline significance after adjustment for age,
fat mass, and lean mass. Interestingly, the significance of
another polymorphism known to be in linkage disequi-
librium with the BsmI B allele, namely the polyadenosine
repeat (ss genotype),wasassociatedwithhigherhamstring
strength and greater body weight and fat mass compared
with those with LL genotype in this study.
Among 109 healthy female university students in China
(age around 19–21 yr), those with the bb genotype of the
BsmI polymorphism displayed significantly lower peak
torque in concentric knee flexors at a specific setting on the
isokineticdynamometer thanthecombinedBBandBbgroup
(P% 0.03) (191). However, when this parameter was tested
atothersettings,namely120°/secand30°/sec, thedifferences
were not statistically significant. When examining another
polymorphismat theApaI site, peak torque in eccentric knee
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TABLE 3. Studies assessing the relation between VDR polymorphisms, falls, muscle function, and markers of
insulin sensitivity
Study (Ref.) other n, Sex, Age
Polymorphisms
and groups Outcome and adjustments Findings and effects
Studies of muscle strength or
function
Barr et al. (359) 3145 BsmI Falls (self-reported) More falls OR 1.5 (1.01–2.3)
APOSS F, 54 BB, Bb vs. bb Adj: age, Ht, Wt, 25D, month
OPUS 2374 BsmI Falls, leg force, STST More falls,2STST
F, 67 BB, Bb vs. bb Adj: age, Ht, Wt, 25D, month OR % 1.3 (1.03–1.6)
Geusens et al. (189) 121 BsmI Quadriceps strength Stronger by 23%
Normal F, &70 bb vs. BB Adj: age, calcium, BMD
Obese 380 BsmI Quadriceps strength No difference
F, &70 bb vs. BB Adj: age, calcium, BMD
Windelinckx et al. (187)
Female 240 FokI Knee force No difference
F, 42 FF,Ff vs. Ff vs. ff Adj: age, Ht, FFM
Male 253 BsmI ! TaqI: BB!tt vs. tt
vs. b/T
Quadriceps strength Stronger
M, 55 Adj: age, Ht, FFM P % 0.01
Roth et al. (185) 302, M 58–93 FokI FFM, Grip, AMM Reduced FFM
Caucasian FF vs. Ff /ff Adj: age, fat, activity
Onder et al. (193) 259 BsmI Falls Decreased falls
CommD M, F, &80 BB/Bb vs. bb Adj: age, sex, ADL, co-morbidities OR % 0.14
(0.03–0.66)
Hopkinson et al. (186) 211 FokI Quadriceps strength Weaker in all (41 vs. 46 kg)
107 COPD, M, F FF vs. Ff and ff Adj: age, sex, FFM, ACE
104 Normal '62 BsmI bb/ Bb vs. BB Quadriceps strength Stronger in COPD
Grundberg et al. (190) 175 BsmI BB vs. bb Hamstring strength, FFM Both lower
F, 20–39 Adj: age, fat mass, FFM HS: r % (0.18
Polyadenosine repeat LL
vs. ss
Hamstring strength, FFM Trend lower
Adj: nil
Bahat et al. (192)
Turkish
120
M, &65
BsmI BB vs. bb Quadriceps and hamstring strength,
knee torque
Weaker
Adj:Nil
Wang et al. (191) 109 BsmI: BB vs. bb Hamstring strength Lower: 11%
Chinese F, 21 ApaI: AA vs. aa /Aa Adj: nil Lower: 29%
Studies of diabetes and glucose
homeostasis
Oh and Barrett-Connor (360) 1545 BsmI: bb vs. BB HOMA-IR 1HOMA, normal
242 DM M, F, 72 Adj: nil
ApaI: aa vs. AA T2D incidence. Adj: nil 1T2D
FPG, IGT Adj: nil 1FPG,1IGT
Ortlepp et al. (361) 1539 BsmI FPG 0.2 mM1FPG in less active!
Aircrew M, F, 33 BB vs. Bb or bb Adj: nil
Malecki et al. (362) 548 FokI, ApaI, BsmI, TaqI T2D No differences
Polish 308 T2D M, F, Adj: nil
Ye et al. (363) 452 TaqI TT vs. Tt/tt BMI at onset T2D BMI 29 vs. 32
309 T2D M, F, 62 Adj: nil
BsmI, Tru9I, ApaI T2D Adj: nil No association
Bid et al. (364) 260 Foki, BsmI, TaqI T2D FFBbTt OR % 4.0 (0.6–24.7)
Indian 100 T2D M, F, 49 Combinations Adj: nil
Speer et al. (365) 216, M, F BsmI Postprandial C-peptide 1C-peptide in T2DM and
obese
29 T2D 18–83 BB vs. Bb and bb Adj: nil
Filus et al. (366) 176, M, 52 FokI: FF/Ff vs. ff Fasting insulin. Adj: nil 1insulin
Polish BsmI: BB vs. bb BMI Adj: nil 1BMI
Each section is listed in order of number of participants, highest to lowest. ACE, Angiotensin converting enzyme genotype; Adj, adjustments; AMM, appendicular
muscle mass; ADL, activities of daily living; APOSS, Aberdeen Prospective Osteoporosis Screening Study; COPD, chronic obstructive pulmonary disease; F, female; FFM,
fat-free mass; FPG, fasting plasma glucose; Ht, height; IGT, impaired glucose tolerance; M, male; N, normal group; OPUS, Osteoporosis and Ultrasound Study; OR, odds
ratio; PP, postprandial; T2D, type 2 diabetes mellitus; Wt, weight.
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extensors at 120°/sec was significantly lower in the AA ho-
mozygous group compared with the aa and Aa groups.
In a study of 253men (54.9#10.2 yr), Bt homozygotes
(i.e. those with BB genotype at the BsmI site and tt geno-
type at an associated polymorphism site, namely TaqI)
had higher isometric quadriceps strength at 150° on iso-
kinetic dynamometer than b or T allele carriers without
and with adjustment for confounding factors (P % 0.01
after adjustment) (187). However, no such association
was found when this same parameter was tested at 90° or
120° or when assessing knee flexor strength.
Among 120 Turkish men (&65 yr), knee extensor
strengthondynamometerwas significantlyhigher in those
with BB homozygosity at the BsmI site than in the Bb/bb
group, but no significant associationbetweenmusclemass
and strength was found (192).
Two population studies examining the rate of falls sug-
gest that the bb genotype of the BsmI polymorphism may
be protective against falls. In a study from Italy that in-
cluded 259 community-dwelling older patients (&80 yr of
age), the rate of falls differed according to BsmI genotype
with more seen among those with BB or bb genotype on
multivariate analysis (193).
Data collected from two separate population cohorts of
olderwomen, namely the Aberdeen ProspectiveOsteoporo-
sis Screening Study (APOSS) and Osteoporosis and Ultra-
sound study (OPUS), also identified a greater incidence of
self-reported recurrent falls among those with the BB geno-
type of the BsmI polymorphism compared with those with
the bb genotype (194). Significant differences in function
with greater ease in rising from a chair were seen in bb ho-
mozygotescomparedwithcarriersof theBallele.These stud-
ies failed to demonstrate an association between Fok1 poly-
morphisms and balance or muscle power measurements.
Apart fromVDR polymorphisms, a recent population-
based study that involved 153 men and 596 women (65–
101 yr) reported an association between SNP in the
CYP27B1 gene (i.e. (1260 and !2838) and the risk of
fracture over a 2.2-yr follow-up period (195). There was
no difference in the risk of falls among subjects, and mus-
cle strengthwas not examined. There are limitations in the
interpretation of these data. Larger studies to assess the
associationbetweenmuscle strength andgenetic polymor-
phisms are needed, and more functional studies of effects
on VDR function are required.
C. VDR polymorphisms and insulin
resistance/type 2 diabetes
Particular polymorphisms in the gene encoding the
VDR may be associated with the development of insulin
resistance and type 2 diabetes among certain populations.
However, once again, the data are inconclusive due to the
generally small sample size in these studies and the vari-
ability in the populations and examined endpoints. These
studies have been summarized in Table 3.
VI. Vitamin D and Muscle: Human Studies
A. Myopathy
Rickets and osteomalacia have been associated with
muscle weakness and hypotonia for centuries (196, 197).
Weakness affecting the proximal lower limb musculature
was reported in a group of adults with osteomalacia who
responded to high-dose vitamin D therapy in the 1960s
(198). The paper did not report whether all patients re-
sponded or whether responses were complete.
In addition to general weakness, more specific proxi-
mal muscle deficits are commonly described, including
difficulty rising from a seated or squat position, ascending
a flight of stairs, or lifting objects (199–201). Changes in
gait, often described as waddling or penguin-like in ap-
pearance, arewidely reported andarepossibly a combined
result of bone pain, muscle pain, and proximal weakness
(199, 202). Pictures of a child with rickets demonstrates
the potentially profound effects of vitamin D deficiency
(Fig. 7). However, the classic pattern of proximal weak-
ness seen in vitamin D deficiency is not specific. Many
endocrine andmetabolic disorders including renal failure,
hyperparathyroidism, hypophosphatemia,Cushing’s syn-
drome, and hyperthyroidism as well as glucocorticoid
therapy may display similar clinical features (203, 204).
Electromyographic changes seen in vitamin D-deficient
subjects with muscle weakness confirm myopathy, but
without specific features (201). In the reports of myop-
athy with vitamin D deficiency, many subjects had mul-
tiple biochemical abnormalities involving calcium,
phosphate, and PTH that co-corrected with vitamin D
repletion,making it difficult to assess the individual role
of each component in the development of osteomalacic
myopathy (205). These observations formed the basis
for the belief that myopathy in these subjects was not
directly related to vitamin D deficiency but rather a
general result of osteomalacia and its associated bio-
chemical abnormalities (206).
Observational and uncontrolled treatment studies
The reversibility of myopathy with vitamin D supple-
mentation has been described in some case series (200,
207, 208). A recent series described the presence of pro-
gressive muscle weakness among young vitamin D-defi-
cient veiled women from Saudi Arabia [90% had 25D "
8 ng/ml (20 nmol/liter)] (205). Some women required a
wheelchair. Substantial improvements followed 3months
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of vitamin D and calcium supplementation (800 IU and
1200 mg daily, respectively). Wheelchair-bound patients
walked independently by the end of the study.
In another case series, five patients with myopathy re-
sulting in wheelchair use were treated with vitamin D2
(50,000 IUweekly) (209). At baseline, they were deficient
[25D % 5–13 ng/ml (12–32 nmol/liter)] with secondary
hyperparathyroidism (intact PTH range % 13–89 pmol/
liter). Treatment resulted in marked improvements in
strength, pain, and mobility within 4–6 wk, despite per-
sisting hyperparathyroidism. The authors suggested that
this indicated a role for vitamin D independent of PTH.
A study assessing vitamin D-deficient women [25D %
7 ng/ml [17 nmol/liter)] vs. controls with higher levels
[25D% 19 ng/ml (47 nmol/liter)] reported an independent
association between 25D levels and maximal voluntary
knee extension force (208). No corre-
lations were found for PTH or total or
bone-specific alkaline phosphatase.
A common theme in these case series
that describe patients withmuscle pain
and weakness is the high rate of initial
misdiagnosis. The diagnoses of dia-
betic neuropathy, general debility,mo-
tor neuron disease, orthopedic disor-
ders, psychiatric conditions, or
inheritedmyopathywere described be-
fore the recognition of vitamin D defi-
ciency (205, 209, 210). The nonspe-
cific clinical features of vitamin
D-deficiency myopathy, the wide
range of severity from mild weakness
to debilitating pain and immobility,
and low index of suspicion may con-
tribute to the frequent delay in the
diagnosis.
We are not aware of any reports of
muscle biopsy ormuscle function stud-
ies in people with mutations in VDR.
B. Myalgia and vitamin D deficiency
People with vitamin D deficiency
and proximalmyopathy (i.e.weakness
of the proximal musculature arising
from muscle pathology) often have as-
sociated proximal myalgia (i.e.muscle
pain) (198). Many authors have also
proposed that low vitamin D is associ-
ated with more diffuse muscle pain
(211–213).However, this is controver-
sial, and other studies do not support
this (214–216).The issue ismademore
difficult because osteomalacia is asso-
ciated with bone pain and microfractures, making causal
discrimination of the source of pain challenging. Because
it is conceptually obvious that people with muscle pain
may be less likely to exercise, go out, and carry out normal
outside activities of daily living, establishing cause and
effect is important. Ideally, demonstrating a therapeutic
response would clarify the issue.
1. Observational studies
A cross-sectional study of 3075 men from eight Euro-
pean centers found that those who reported chronic wide-
spread pain (8.6%) were more likely to have low 25D
levels ["15 ng/ml (37.5 nmol/liter]) (217). However, the
relationship was attenuated by adjusting for age, season,
activity, and other factors.
Figure 7.
Figure 7. Images of a child with rickets. These images of a 2-yr-old child with rickets display
widening of the metaphyseal regions in the left wrist (A) and both ankles (B). The x-ray of the
left wrist shows widening of the radial and ulnar metaphases with typical moth-eaten
appearance of the physis and rarefaction of the metacarpal and phalangeal bones (C) with
subsequent improvement after 3 months of treatment with cholecalciferol (D). These bone
deformities are due to impaired mineralization of bone at a critical stage in its development.
Muscle weakness, wasting, and hypotonia are also widely reported features of rickets, but
their mechanism is unclear. Images are courtesy of Associate Professor Craig Munns,
Childrens’ Hospital Westmead, Sydney, Australia.
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Ninety-three percent of 153 patients who were being
assessed for persistent, nonspecific musculoskeletal pain
inMinneapolis were vitamin D deficient [mean 25D% 12
ng/ml [30 nmol/liter)] (211). All African-American, East
African,Hispanic, andAmerican Indian patients had 25D
below20 ng/ml ("50 nmol/liter) as did 82%ofCaucasian
patients. None had fibromyalgia or medical conditions
known to decrease production, absorption, or hydroxy-
lation of vitamin D. This study did not include a control
group of similar ethnicity.
The propensity for particular ethnic groups, including
those migrating from Asia and the Indian subcontinent to
Western countries, to develop myalgia and bone pain as
the primary manifestation of vitamin D deficiency has
been reported since the 1970s (218, 219). A study describ-
ing 33 mostly Somalian female asylum seekers with mus-
culoskeletal pain and low 25D ["8.5 ng/ml [21 nmol/
liter)] found that vitamin D and calcium supplementation
led to the symptom resolution in 22 (66.7%) by 3 months
(220). The authors noted a 2.5-yr mean lag time between
symptom onset and diagnosis. There was no control
group. A study from the United Arab Emirates found that
86% of patients who were initially diagnosed with fibro-
myalgia or nonspecific muscle pain were vitamin D defi-
cient. The majority reported improvement in response to
supplementation (221). Another study compared cultural
differences in the reporting of muscle pain among South
Asians (i.e. Indian, Pakistani, and Bangladeshi) and white
Europeans living in England (212). Reporting of wide-
spread pain was significantly more common in the 1945
South Asians. However, in the 137 South Asians in whom
25Dwas measured, there was no association between de-
ficiency and pain.
A report describing myalgia in six women who had
migrated to the Netherlands considered vitamin D defi-
ciency ["8 ng/ml ("20 nmol/liter) in 5 patients] to be the
cause. There was a lengthy lag period (7–103 months)
from the onset of symptoms to diagnosis (222). In three
cases, misdiagnosis led to treatment with prednisone, es-
trogen, or cholecystectomy. Vitamin D and calcium sup-
plementationwas effective in reversing themyalgia in each
case.
2. Case-control studies
Muscle pain was recently proposed as a marker for
vitaminDdeficiency amongAboriginalAustralians (223).
A case-control study of eight urban Aboriginal patients
with muscle pain and eight matched Aboriginal controls
without pain reported significantly lower vitaminD levels
among those with pain [17 vs. 23 ng/ml (41 vs. 58 nmol/
liter), P % 0.017].
Wide cultural and gender differences in the reporting of
pain, subjective features in the diagnosis of fibromyalgia,
and the presence of other features known to affect vitamin
D status among patients with persistent pain syndromes
confound the assessment of the role of vitamin D defi-
ciency in muscle pain. Also, the observational nature of
these studies does not equip them to address the question
of causality.
3. Randomized controlled trials (RCT) for myalgia
We identified only one randomized placebo-controlled
trial of supplementation where treatment of muscle pain
appeared to be the primary endpoint. The study examined
people with diffuse muscle pain (214). Fifty subjects with
25D below 20 ng/ml (50 nmol/liter) at baseline were ran-
domized to placebo or vitamin D2 50,000 IU weekly for 3
months. There was no benefit of treatment. The authors
note that 50% of the placebo group achieved normal vi-
tamin D levels during the study; however, the improve-
ment in pain scores was not substantial for either group.
Using the PowerStat program (224), we calculate that the
study had 80%powerwith! of 0.05 to detect a difference
of#19 in pain score. The baseline visual analog pain score
in the treatment group was high at 67 # 23, so if there is
any benefit, it is probably smaller than this.
4. Summary: myalgia
Vitamin D deficiency with osteomalacia is associated
with muscle pain that in most cases resolves with treat-
ment. The pain is more commonly located in large prox-
imal muscle groups rather than displaying diffuse distri-
bution (198, 222, 225, 226) and is often associated with
bone pain and other features of osteomalacia and myop-
athy (205, 208).
Thus, for pain (proximal or diffuse) in patients without
osteomalacia, other etiologies should also be considered.
In patients with diffuse pain, without obvious osteoma-
lacia, the data remain inconclusive. There are strong as-
sociations, but the only RCT found no convincing benefit
of supplementation. The trial was adequately powered to
detect a clinically meaningful change in pain score.
There are no RCT examining specific treatment of
proximal muscle pain. Larger randomized placebo-con-
trolled trials should be carried out, preferably with strat-
ification by baseline vitamin D status, in people with fi-
bromyalgia and in peoplewith proximalmyalgia. There is
no evidence to support supplementation for myalgia in
people with normal levels.
C. Fibromyalgia
Fibromyalgia is not purely a muscle disorder, but there
are a number of studies examining the potential associa-
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tion between it and vitamin D. Myalgia was examined in
a cross-sectional study of 6824 white, middle-aged subjects
living in the United Kingdom. A significant association be-
tween fibromyalgia, defined by the American College of
Rheumatology criteria, and 25D was found among women
(227). However, no such association was found in men, al-
though they reported similar rates of pain (11.4% for men,
12.5%forwomen).Noassociationwithmyalgiawas found.
In two separate case-control studies of patients with
fibromyalgia from the United States and Brazil, no statis-
tically significant differences were found in 25D levels
(214, 228).
In contrast, another case-control study that examined 40
premenopausal women with fibromyalgia and 37 controls
found a significantly higher proportion of vitamin D defi-
ciency [25D" 8 ng/ml (20 nmol/liter)] among women with
fibromyalgia (229).However, thiswasnotadjustedforphys-
ical activity, smoking, or body mass index (BMI). Fibromy-
algia symptoms did not differ depending on the vitamin D
status. A subset of deficient patients who received supple-
mentation (eight of 18) reported subjective improvement
that persisted at 3 months; however, 10 of 18 did not.
One placebo-controlled study examining the effect of
vitamin D on fibromyalgia was identified (230). In that
study of 138 patients with fibromyalgia, the subset of 100
patients with mild to moderate vitamin D deficiency and
insufficiency [25D % 10–25 ng/ml (25–62.5 nmol/liter)]
who were randomized to receive vitamin D3 (50,000 IU
weekly) showed significant improvement over 8 wk vs.
placebo-treated controls. However, this did not persist at
1 yr, and in the same study, the subset of 38 people with
severe deficiency [25D "10 ng/ml (25 nmol/liter)] who
received vitamin D in an unblinded fashion did not report
any improvement at either 8 wk or 1 yr (230).
Overall, there is conflicting evidence regarding the pos-
sibility of an association between low vitamin D and fi-
bromyalgia, and clearly, having fibromyalgiamayhave an
impact on time spent outdoors/exercising. The data from
the one randomized placebo-controlled trial do not pro-
vide a clear answer, because themost deficient subjects did
not benefit, but less deficient subjects did. More research
is needed in this area.
D. Drug-related myopathy and vitamin D
1. Aromatase inhibitors
The effect of vitamin D supplementation on myalgia
due to a drug class, namely aromatase inhibitors, has been
recently reported. For this class, there is both observa-
tional and randomized controlled data, and myalgia is a
very common side effect.
An observational study found significantly less muscu-
loskeletal pain among 60 women on letrozole who had
achievedmedian25D levels over 66ng/ml (165nmol/liter)
compared with women with levels below 66 ng/ml (165
nmol/liter) (19 vs. 52%) after weekly supplementation
with 50,000 IU vitamin D3 for 12 wk (231).
In a double-blind RCT, 60 patients with early-stage
breast cancerwith neworworseningmusculoskeletal pain
on aromatase inhibitor therapy were randomized to re-
ceive either high-dose vitaminD supplementation at a reg-
imen that depended on their baseline 25D or placebo
(232). Thosewith 25Dof 10–19 ng/ml (25–47 nmol/liter)
received 50,000 IU vitamin D2 for 16 wk, whereas those
with 25D of 20–29 ng/ml (50–72 nmol/liter) received
50,000 IU for 8wk (232). Therewere significant improve-
ments in pain at 2 months in the vitamin D group vs.
placebo on the basis of several indices. Therapy was de-
creased from weekly to monthly after 2 months in most
subjects. The beneficial effects did not remain at the 4- and
6-month visits. There was evidence of a dose-response ef-
fect;womenwhoweremore deficient had greater benefits,
and in that subgroup, the beneficial effect was seen across
the whole study period.
2. 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase
inhibitors (statins)
A number of reports suggest that vitamin D defi-
ciency may potentiate myopathy in patients on lipid-
lowering statin therapy (3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase inhibitors) (233–242). These
reports are both anecdotal and based on case series and
cross-sectional studies. Not all studies have confirmed
this relationship (237).
Cross-sectional and cohort studies. Among a group of 621
statin-treated patients, the 128who reportedmyalgia had
lower serum 25D (238). Levels were low [defined as"32
ng/ml ("80 nmol/liter) in that study] in 64% of myalgic
patients vs. 43% of the others. A subset of 38 of the 82
25D-deficient myalgic patients were treated with 50,000
IU/wkof vitaminD2 for 12wk (unblinded)while continuing
statins, and 35 had their myalgia resolve. The three nonre-
sponders achieved similar vitamin D levels.
A prospective study of 150 statin-intolerant patients
with 25D below 32 ng/ml (80 nmol/liter) reported that
83% were free of myalgia and no longer statin intolerant
after approximately 8 months of vitamin D2 treatment
(50,000 IU twice weekly for 3 wk and then 50,000 IU
weekly) (240). However, treatment had little effect on el-
evated creatine phosphokinase (CPK).
However, not all studies find an association. A retro-
spective study of 6808 statin users found no correlation
Endocrine Reviews, February 2013, 34(1):33–83 edrv.endojournals.org 55
between 25D levels, myalgia, or CPK levels (242). A
smaller study of 129 patients on statins also found no
difference in the 25D levels of those with and without
myalgia (237).
Some hypotheses have been proposed regarding mech-
anisms by which vitamin D deficiency may potentiate sta-
tin-induced myalgia. The suggestion that statins may re-
duce vitamin D synthesis by inhibition of synthesis of its
cholesterol precursor has not been supported by clinical
studies (243, 244). The enzyme CYP34 demonstrates in
vitro 25-hydroxylase activity (245), and it has been spec-
ulated that vitamin D deficiency may lead to preferential
shunting or use of this enzyme for vitamin D hydroxyla-
tion, reducing its availability to metabolize (deactivate)
statins (239). This hypothesis could be tested by measur-
ing statin levels in vitamin D-deficient and vitamin D-suf-
ficient individuals matched for the presence or absence of
myopathy and/or CPK levels.
Although an association between a polymorphism of
the solute carrier organic anion transporter family mem-
ber 1B1 gene (SLCO1B1) and statin-inducedmyalgiawas
reported, no interactionbetween vitaminDdeficiency and
genotype was found in a group of 46 patients on statin
therapy (241).
These studies of statin myalgia/myopathy are interest-
ing; however, their unblinded nature and lack of control
groups are particular limitations, especially given thewell-
known placebo effect in pain studies. At this time, the
evidence of an association between vitamin D deficiency
and statin-related myalgia is derived from observational
studies and small series. Obviously, people who experi-
ence pain with muscle movement may be less likely to be
participating inoutdoor activities andmay thereforemake
less vitaminD than their pain-free counterparts. Random-
ized placebo-controlled studies are needed. In the mean-
time, we suggest treating deficient patients because of the
known bone and calcium benefits. There is at present no
evidence to support treating people on statins who have
normal vitamin D status.
3. Summary: drug-related myopathy and vitamin D
Myalgia has been observed in patients receiving statins or
aromatase inhibitors. A number of these studies reveal that
patients on statins who suffer frommyalgia are also vitamin
D deficient, and vitamin D supplementation might improve
symptoms of myalgia in these patients. These findings sug-
gest that vitaminDdeficiencymay potentiate statin-induced
myalgia, but the molecular mechanisms underlying the in-
teraction between vitamin D, statin treatment, and muscle
functionhavenotbeen elucidated.Basedon the limiteddata,
we recommend treating all deficient subjectswho are receiv-
ing statinsor aromatase inhibitors.TheonlyRCT inpatients
taking aromatase inhibitor used high-dose therapy. If this is
used, patients should be monitored for hypercalcemia and
hypercalciuria.
E. Falls and vitamin D
Approximately 30% of community-dwelling people
over the age of 65 fall each year, and approximately 20%
of these require medical attention (246). Falls pose a sub-
stantial risk to an aging population, are amajor risk factor
for fracture and other injury, and impact negatively on
quality of life (247). Therefore, identifying reversible fac-
tors is important. In older individuals, falls are closely
related to sarcopenia (loss of muscle mass), loss of muscle
tone, and a range of conditions that contribute to the com-
plex syndrome of frailty (248). This issue has also recently
been discussed in an Endocrine Society statement on ex-
traskeletal roles of vitamin D (12).
1. Falls: observational studies
There is a seasonal variation in the incidence of falls,
with more occurring in winter among older women. This
raises the suggestion of a putative role for vitaminD in the
occurrence of falls (249), although other factors such as
decreased daylight and increased likelihood of slipping on
wet or icy surfaces could also explain the differences. The
possibility that vitaminDdeficiency, which is highly prev-
alent in frail and older individuals, may contribute to falls
has been examined by a number of studies. These are sum-
marized in Table 4.
In 1619 women in low-level and high-level residential
care (mean age 84 yr), a significant inverse association
between serum 25D levels and the incidence of falls over
approximately 5 months was reported. The authors esti-
mated a 20% reduction in falls riskwith doubling vitamin
D status on analysis of log[25D] levels (250). A similar-
sized study of 1231 community-dwelling individuals iden-
tified baseline 25D as a predictor for falls over a 1-yr pe-
riod, particularly among those 65–75 yr of age (251).
Those with 25D levels over 10 ng/ml (25 nmol/liter) dis-
played the highest risk of recurrent falls.
However, in a smaller study, althougholder individuals
who fell had significantly lower 25D levels vs. the overall
group of 83 subjects, this was not significant on multivar-
iate analysis (252).
The possibility that 25D does not directly contribute to
falls but is rather an associative marker of frailty remains
a potential limitation in the interpretation of these obser-
vational data. As in the situation with myalgia, it is obvi-
ous that peoplewho fall may spend less time outdoors and
thereby have lower exposure to solar UV radiation. The
other issue is that malnutrition is very common in elderly
persons, affecting up to40%of those living in institutions,
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and may contribute simultaneously to vitamin D defi-
ciency and frailty.
2. Falls: interventional studies
Interventional studies seeking to examine the effects of
vitamin D supplementation or UV exposure on the risk of
falls amongolder individuals havebeenperformedandare
summarized in Table 5.
a. Sunlight therapy. In a study of 602 residents of aged-care
facilities, those who complied with a daily regimen of in-
creased sunlight exposure had fewer falls than those ran-
domized to the control group (253). Compliance was sur-
prisingly poor despite the use of sunlight officers who
visited the facilities (median adherence was 26%). Thus,
on intention-to-treat analysis, the study was underpow-
ered, and no effectswere seen. The authors concluded that
vitamin D supplementation was a more practical ap-
proach to reduce falls in residential care. It should also be
noted that sunlight exposure during the early morning
hours rather than at midday when UV levels are highest
might not have been sufficiently effective in the synthesis
of vitamin D.
b. Interventionstudies:non-placebocontrolled.Thecombina-
tion of daily 400 IU vitamin D3 plus 1000 mg calcium
reduced severe falls requiring admission in 5063 com-
munity-dwelling city residents above the age of 66 yr in
Denmark (254). The number needed to treat was nine.
c. Intervention studies: placebo controlled. A reduced inci-
dence of falls, regardless of baseline 25D, was seen in a
randomized trial of vitamin D supplementation (255).
Among 625 older residents of assisted-living facilities,
thosewho received calcium (600mgdaily) and vitaminD2
(initially 10,000 IU once weekly and then 1,000 IU daily)
for 2 yr had a lower rate of falls compared with those
receiving calcium alone. However, the rate of ever falling
was not different, implying that the benefits were among
TABLE 4. Observational studies assessing the longitudinal effect of vitamin D levels on falls/muscle function (listed in
order of number of study participants, highest to lowest)
Study (Ref.)
N, Sex, Age, Duration,
Predictors Outcomes Main results Risk Adjustments
Faulkner et al. (367) Quadriceps & grip strength,
walk speed, falls, others
No associations IRR % 0.70, Age, clinic, season, Ht, ETOH,
activity, BMI, education, ethnicity,
smoking, creatinine, comorb,
drugs, Ca.
9526, F, 70
4 yr vitamin D supplement
Faulkner et al. (367) 1 1,25D (40–80 vs. 7–26 pg/ml),2falls
1 25D associated with2 grip strength389, F, 70
4 yr, basal 25D, 1,25D, PTH
Flicker et al. (250) Falls: staff-reported 1 log)25D*2 falls HR % 0.74 Wt, cognition, drugs, past Colles
fracture, wandering behavior1619, F, 84, assisted care (0.59–0.94)
145–168 d, basal 25D
Snidjer et al. (251) Falls: self-reported 25D "10 ng/ml1 risk &2 falls OR % 1.78 Age, sex, ETOH, region, season,
activity, education, smoking1231, M, F, &65 (1.06–2.99)
1 yr 25D "10 ng/ml1 risk &3 falls OR % 2.23
Basal 25D (1.17–4.25)
Visser et al. (280)
1008, M, F, &65
3 yr, basal 25D
Grip strength
ASMM (DEXA)
25HD "10 ng/ml vs. &20 greater risk of
a decline
OR % 2.57
(1.4–4.7)
Activity, BMI, season, creatinine,
smoking, comorb
Visser et al. (280) 25HD "10 vs. &20 ng/ml greater risk of
sarcopenia
OR % 2.17
(0.73–6.33)331, M,F, &65
3 yr, basal 25D
Wicherts et al. (279)
939, M, F, &65
3 yr,
Basal 25D
Score: TCST, tandem stand,
walking
25D "10 ng/ml1 risk of2 in score
25D 10–20 ng/ml1 risk of2 in score
OR % 2.21
(1.0–4.87)
OR % 2.01
(1.06–3.81)
Age, sex, co-morb, ETOH, BMI,
urbanization
Dam et al. (281)
769, M, F, 75
2.5 yr
Basal 25D
TUAG,
TCST,
grip strength
" 25D "32 vs. &115 ng/ml1 decline in
TUAG, TCST
! 25D "36 vs. &49 ng/ml poorer grip
20 vs. 8% decline
32.1 vs. 34.1 kg
Age, sex, BMI, activity, ETOH,
estrogen use
Chan (282) ASMM, grip, walk speed,
others
No associations Age, BMI, ETOH, comorb, smoking,
diet, activity, season, PTH714, M, &65
4 yr
Basal 25D
Verreault et al. (368) Strength (hip, knee, grip),
walking speed and TCST
No associations Age, race, BMI, education, baseline
scores, comorb628, M, F, &65
3 yr
Basal 25D
ASMM, Appendicular skeletal muscle mass; Ca, calcium intake; comorb, comorbid conditions; ETOH, alcohol intake; HR, hazard ratio; Ht, height; IRR, incidence rate
ratio; OR, odds ratio; TCST, timed chair stand tests; Wt, weight.
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TABLE 5. Interventional studies assessing the effects of vitamin D supplementation on the incidence of falls (listed in
order of number of study participants, highest to lowest)
Study (Ref.), Positive vs.
Negative, Duration,
Basal 25D, Other
n, Sex,
Age Vitamin D (IU), Ca (mg)
Outcome
Proven 125D,
Adjustments
Main Results,
RR/OR/HR/IRR/
NNT where given
Larsen et al. (254) 9605 D3 400 ! Ca 1000 vs. home visit Severe falls, not proven 12% decrease
Positive 3 yr
NR
F
&66
vs. nil Adj: age, marital status,
intervention
RR % 0.88; (0.79–0.98)
NNT 9
Arden et al. (369) 6641 D2 im, 300,000/yr vs. placebo Falls, fracture, knee pain No change
Negative 3 yr M, F Not proven
NR &75 Adj: treatment
Grant et al. (265) 5292 D3 ! Ca 1000 vs. Fracture, falls No change
Negative 24–62 months M, F D3 800 vs. 1 Proven HR % 0.97
15 ng/ml (n % 16) Post
fracture
&70 placebo Adj: minimization variables
Law et al. (370) 3717 D2 100,000/3 months vs. placebo Fracture, falls;1 proven
Adj: age, sex, time in the trial,
cluster
No change
RR % 1.09Negative 10 months M, F
19 ng/ml (47) (n % 16).
Inst
85
Porthouse et al. (266)
Negative 25 months
NR. Inst
3314
M, F
&70
D3 800 ! Ca 1000 ! leaflet vs. leaflet Fracture, falls, QOL
Not proven
Adj: practice
No change
Chapuy et al. (371)
Positive 18 months
13–16 ng/ml. Inst
3270
M, F
84
D3 800 ! Ca 1200 vs. Ca alone Fracture, 25OHD, PTH
Yes
Adj:nil
99% fracture from a fall
2 fracture. Falls risk NR
Sanders et al. (267) 2256 D3 500,000/yr vs. placebo Fracture, falls;1 proven Higher falls and fracture
Adverse 4–6 yr
20 (49)
F
&70
Adj: nil RR % 1.15 (1.02–1.30) RR
fracture % 1.26 (1.0–
1.59)
Glendenning et al. (290) 686 D3 150,000 /3m vs. placebo Falls, TUAG, grip No changes
Negative 9 months F 1 Proven OR % 1.06
26 ng/ml (n % 40) 77 Adj: age, falls, follow-up
Flicker et al. (255)
Positive, post hoc
subgroup. 2 yr
"24 (89%). Inst
625
M, F
83
D2 10,000/wk ! Ca 600 then D2 1,000/d
! Ca vs. Ca alone
Fracture, falls
Not proven
Adj: Wt, cognition, drugs, level of
care, wandering
Compliant2 falls risk
IRR % 0.63 (0.48–0.82)
Sambrook et al. (253)
Positive, post hoc
subgroup. 12 m
13 ng/ml. NH
602
M, F
&70
Extra 30–40 min/d sunlight ! Ca 600 vs.
nil
Change in 25OHD and falls
Not proven
Adj: age, sex, falls, balance,
comorb, cognition,
incontinence, care level
Compliant2falls risk
IRR % 0.52 (0.31–0.88)
Chapuy et al. (372) 583 D3 800 ! Ca 1200 vs. Fracture, 25OHD, PTH No change
Negative 2 yr F D3 800 vs. placebo vs. Ca alone 1 Proven
"20 (79%). Inst 85 Adj: nil
Gallagher et al. (373) 489 1,25D 0.5'g/d vs. placebo# E/P Falls 2 falls. CrCl " or &60
Positive 3 yr F Not proven RR % 0.47 (0.29–0.78)
31–33 ng/ml 66–77 Adj: age, Wt, Ht, drugs, basal
25D and Ca absorption,
comorb, smoking
RR % 0.70 (0.51–0.96)
Bischoff-Ferrari et al. (256).
Positive, women only.
3 yr
27–33 ng/ml
445
M, F
&65
D3 700 ! Ca 500 vs. Ca alone Falls (self-report);1 proven
Adj: age, sex, BMI, Ca intake,
CrCl, comorb, basal 25D and
PTH, activity, ETOH, smoking
2 falls, women only
OR % 0.54 (0.30–0.97)
Dawson-Hughes et al. (257)
Positive fracture, adverse
falls ". 3 yr
27–33 ng/ml
389
M, F
&65
D3 700 ! Ca 500 vs. Ca alone Fracture, falls (self-report), BMD
1 Proven
Adj: nil
1 falls in women
2 fracture
(nonvertebral)
Falls data not shown
Dukas et al. (374)
Positive, post hoc
subgroup. 36 wk
28–30 ng/ml
378
M, F
&70
1 'g 1!(OHD3 daily vs. placebo Falls
Not proven
Adj: age, BMI, sex falls, activity,
CCMI, drugs, heart rate, Ca
intake, biochemistry
Ca intake &512 mg/d
2 fallers
OR % 0.46 (0.22–0.99)
CrCl " 65,2falls
OR % 0.29 (0.09–0.88)
(Continued)
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repeat fallers. On subgroup analysis of compliant partic-
ipants (defined as taking&50%of the doses, n% 540) the
risk of ever falling was also significantly lower. The num-
ber needed to treat to prevent one fall per year was eight,
similar to the above open-label study.
A 3-yr double-blinded randomized study examined
combined supplementation with vitamin D3 (700 IU) and
calcium citrate malate (500 mg) vs. placebo in 445 com-
munity-dwelling older individuals (256). By intention-to-
treat analysis, combined therapy was not effective. A sub-
group analysis of thewomen found a significant reduction
in the incidence of falls thatwasmost pronounced in those
who were less active. Inter-gender differences in muscle
mass were postulated to lead to greater susceptibility for
falls among this particular group. The trial was not orig-
inally powered to detect effect modification by sex and
activity levels, and falls were also a secondary outcome.
The primary outcome examined bone density, which was
significantly improved (257). In another study, 242 com-
munity-dwelling older individuals were randomized to re-
ceive calcium (1000mg daily) with or without vitamin D3
(800 IUdaily) for 1 yr and then followed8monthswithout
TABLE 5. Continued
Study (Ref.), Positive vs.
Negative, Duration,
Basal 25D, Other
n, Sex,
Age Vitamin D (IU), Ca (mg)
Outcome
Proven 125D,
Adjustments
Main Results,
RR/OR/HR/IRR/
NNT where given
Graafmans et al. (263) 354 D3 400 vs. placebo Falls (self-reported) No change
Negative. 28 wk M, F Not proven OR % 1
NR. NH &70 Adj: nil
Prince et al. (260) 302 D2 1000 ! Ca 1000 vs. Ca alone Falls (self-report) Cal # D2 risk
Positive 1 yr F 70–90 1 Proven OR % 0.61 (0.37–0.99)
"24 ng/ml Adj: Ht
Pfeifer et al. (258)
Positive. 12 ! 8 months
"31 ng/ml
242
M, F
77
D3 800 ! Ca 1000 vs. Ca alone Falls, quad strength, sway, TUAG
1 Proven
Adj: nil
2 falls RR % 0.73 (0.54–
0.96)1strength,
2sway,2TUAG
Burleigh et al. (375) 205 D3 800 ! Ca 1200 vs. Ca alone Falls (staff report) No change
Negative 30 d M, F Not proven RR % 0.82
8.8. ng/ml AGU 84 Adj: nil
Berggren et al. (376)
Trend 1 yr
NR. fracture NOF
199
M, F
82
D3 800 ! Ca 1000 ! falls
prevention vs. normal care
Falls
Not proven
Adj: dementia and depression
Trend to2 falls, P % 0.063
IRR % 0.64 (0.40–1.02)
Harwood et al. (377)
Positive 1 yr
'12 ng/ml. fracture hip
150
F
81
D2 300,000 im ! Ca 1000 vs. D3
800 ! Ca vs. Ca
Falls, 25D, PTH
1 Proven
Adj: age, fracture, BMD,
biochemistry, prefracture
mobility
2 falls
0.48 (0.26–0.90)
Pfeifer et al. (262)
Positive 1 yr
"20 ng/ml
148
F
74
D3 800 ! Ca 1200 vs. Ca alone Falls, body sway
1 Proven
Adj: nil
2 falls in calcium!D group
0.24 vs. 0.45.2 sway
Broe et al. (264) 124 D2 200, 400, 600, or 800 or placebo Falls (staff report) 800 IU2 falls vs. all others
Positive, post hoc
subgroup. 5 months
M, F
89
1 Only in the 800 group
Adj: age, multivitamin use
IRR % 0.28 (0.11–0.75)
19.5 ng/ml NH
Bischoff et al. (259)
Positive 6w ! 12 wk
"31 ng/ml. Inst
122
F
85
D3 800 ! Ca 1200 vs. Ca alone Falls, TUAG, knee ! grip strength
1 Proven
Adj: age, falls, basal 1,25D and
25D, observation time
2 falls, muscle function
improved
OR% 49% (14–71%)
Sato et al. (85) 96 D2 1000 vs. placebo Falls, strength, biopsy 2 falls, increased type II fibers
Positive 8 w ! 2 yr F 1 Proven RR % 0.6 (0.4–0.8)
"10 ng/ml 74 Adj: falls, age, Ht, Wt, BMI,
strength, basal 25D, 1,25D,
PTH, biopsy, walking aid
Sato et al. (378) Positive
fracture Negative falls.
18 months 11 ng/ml
96
M, F
71
1 'g 1!(OHD3 vs. placebo Fracture, falls, BMD, PTH
Only 1,25D
Adj: nil
2 nonvertebral fracture,
falls no change
Doses for vitamin D and calcium are daily and oral unless stated otherwise. Adj:, Adjusted for; AGU, acute geriatric unit; BI, Barthel index; CCMI, Charlson comorbity
index; CrCl, creatinine clearance (ml/min); E/P, estrogen plus progesterone; ETOH, alcohol use; F, female; HR, hazard ratio; Ht, height; Inst, institutionalized; IRR,
incidence rate ratio; ITT, intention-to-treat analysis; M, male; NA, not applicable; NH, nursing home; NR, not reported; OR, odds raito; PASE, physical activity scale for
the elderly; QOL, quality of life; RR, relative risk; Wt, weight.
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treatment but continuing blinding to treatment (258). On
intention-to-treat analysis, subjects on dual supplementa-
tion reported 27% fewer falls at 1 yr and 39% fewer falls
at 20 months.
Among 122 older women in long-stay geriatric care
who received calcium (1200 mg/d) with or without vita-
min D3 (800 IU/d), those on dual supplementation had
significantly fewer falls during the12-wk treatmentperiod
compared with the preceding 6-wk observation period.
There was no difference in the proportion who fell at all,
but people who fell the most appeared to obtain the great-
est benefit (259).
In a particularly vulnerable group, namely older individ-
uals with poststroke hemiplegia, a significant reduction in
thenumberof falls per personand the total numberof repeat
fallers was seen among 48 women receiving vitamin D2
(1000 IU daily) vs. controls who received placebo for 2 yr
(85). The study included biopsies of the unaffected side and
reported that the baseline proportion anddiameter of type II
muscle fibers were significant independent predictors for
falls over the 2 yr. In demonstrating significant improve-
ments in these parameters in a subset of individuals who
received vitamin D supplementation for 2 yr, they offered a
mechanistic explanation for the reduction in falls.
Bycontrast, recurrent fallerswerethe least likely tobenefit
from supplementation in another study (260). Community-
dwellingambulantolderwomenwere randomized to receive
calcium citrate (1000mg daily) and either vitaminD2 (1000
IU) or placebo for 1 yr.After adjusting for height,whichwas
not equal at baseline, the vitaminD group had a 19% lower
risk of a single fall compared with controls. The effect was
most pronounced in winter/spring rather than in summer/
autumn. It was calculated that 25D levels over 22 ng/ml (54
nmol/liter) were adequate for the benefit. The results were
not statistically significant without height correction.
Another study that specifically targeted vitamin D-
insufficient older individuals [25D "20 ng/ml (50 nmol/
liter)] reported that 800 IU vitamin D3 and 1200 mg cal-
cium daily decreased falls per subject compared with the
148 controls who received calcium alone (261). One non-
compliant individual was excluded from analysis. The au-
thors propose that the mechanism relates to a significant
improvement in body sway at 8 wk (261, 262). Sagittal
body sway improved with treatment, but frontal sway
improved in both groups (261).
d. Negative randomized studies and falls. A number of ran-
domized studies have also failed to demonstrate an effect
of vitamin D supplementation upon falls.
Among 354 older persons in The Netherlands who
were randomized to receive vitamin D3 (400 IU) or pla-
cebo for 28wk, impairedmobilitywas themajor predictor
of falls, and vitamin D treatment had no significant effect
(263). This study had marked patient heterogeneity with
inclusion of both institutionalized and community-dwell-
ing persons.
A positive effect of vitamin D supplementation on falls
riskwas reported by Broe et al. (264) among the subgroup
of 124nursinghome residents receivinghigh-dose vitamin
D (800 IU/d) but not in the 600-, 400-, or 200-IU groups.
The risk of falling was lower if those receiving 800 IU
vitamin D2 were compared with the combined group of
smaller doses (200, 400, or 600 IU) and placebo. There
was no suggestion of a normal dose-response curve with
the lower doses actually having nonsignificantly higher
fall rates compared with placebo (0 IU, 44%; 200 IU,
58%; 400 IU, 60%; 600 IU, 60%; 800 IU, 20%).
A large study of 5292 subjects over 70 yr of age with a
recent minimal-trauma fracture did not find a beneficial
effect of 800 IU of vitaminD3 on falls over 26–62months
(265). Falls were a secondary endpoint with information
collected only for the week before each 4-monthly ques-
tionnaire. Compliance (patients taking 80% or more of
tablets) was poor ("45%at 2 yr); however, therewas also
nobenefit if only compliant patientswere examined. Base-
line levelsweremeasured in approximately 1%of patients
(n % 60) and were 15.2 ng/ml (38 nmol/liter).
Another study in 3314 older women living in nursing
homes did not find fewer falls among those randomized to
receive a combination of vitamin D3 (800 IU), calcium
(1000 mg), and a falls prevention leaflet over 25 months
compared with those receiving the leaflet alone (266).
Falls were also a secondary outcome in this study.
In reaction to generally poor adherence to daily regi-
mens of vitamin D supplementation as described by a
number of these reports, other studies have examined the
efficacy of infrequent high-dose vitamin D supplementa-
tion. In one widely reported study of 2256 community-
dwelling women over 70 yr of age, an annual oral dose of
500,000 IU of vitamin D3 for 3–5 yr appeared to increase
the risk of falls, particularly in the first 3 months after the
vitamin D dose (267). The median baseline 25D concen-
tration was 21.2 ng/ml (53 nmol/liter), and 1 month after
treatment, the median was 48 ng/ml (120 nmol/liter).
Another study using 300,000 IU, given annually by
im injection, reported no effect on falls among 9440
older individuals (268). No benefit was observed in any
subgroup.
3. Meta-analyses and falls
Substantial heterogeneity among these randomized tri-
als with regard to differences in study populations, vari-
able treatment durations, and regimens of supplemental
vitaminDandwhether ornot calciumwas coadministered
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together with inconsistencies in the identification and
analysis of falls among studies (e.g. falls per subject, num-
ber of falls, and number of fallers) makes collective as-
sessment of these data difficult. Nevertheless, several
meta-analyses have been published and are the subject of
debate (23, 29, 30, 269–272).
Most recently, ameta-analysis reported on 26 random-
ized trials that enrolled 45,782 participants, mainly el-
derly females (23). Studies were not excluded for lack of
double randomization or strict definition of falls; hence,
there were a substantially larger number of included in-
dividuals than in earliermeta-analyses. VitaminDusewas
associated with statistically significant reduction in the
risk of falls. However, there was no difference among
those receiving higher doses (&800 IU) vs. lower doses.
Vitamin D appeared to be effective in both community-
dwelling and institutionalized people and in those receiv-
ing vitamin D2 or D3. Perhaps reassuringly, the reduction
in falls was most prominent in patients who were vitamin
D deficient at baseline. Studies in which calcium was co-
administered with vitamin D showed a greater effect than
those where vitamin D alone was given. Falls reduction in
studies without calcium coadministration did not reach
statistical significance. Calcium alone was the placebo in
most of the combination studies.
Therefore, despite substantial heterogeneity among stud-
ies, vitamin D supplementation is probably effective in con-
junctionwith calcium in the prevention of falls among older
individuals. The positive impact of vitamin D and calcium
supplementationonfallpreventionappears tobebestamong
those who are vitamin D deficient at baseline. We recom-
mend consideration of vitamin D plus calcium therapy in
people over 65 yr of age with baseline deficiency. However,
appropriate supplemental dose of vitamin D and target se-
rum levels required to prevent falls remain hotly debated
issues.
F. Muscle strength and physical performance
Many studies have examined the specific effects of vi-
taminD onmeasures of muscle function and physical per-
formance. Comparing these studies is made very difficult
by the variety of outcome measures used to assess muscle
function.
1. Observational studies
A number of cross-sectional studies have reported as-
sociations between 25D levels and various parameters re-
lated to muscle function including handgrip, lower limb
strength, balance, 6-min walk distance, and gait speed
(273–275), although not all such studies have supported
the association after multivariate adjustment (276, 277).
These are summarized in Table 6.
In a population-based study of 4100 ambulatory adults
aged over 60 yr, an association between serum 25D and
lower-extremity function assessed by 8-ft. walk and the
repeated sit-to-stand test (STST) was reported (278). The
improvementsweremodest: 3.9%worsening in STSTand
5.6% in 8-ft. walk comparing the lowest vs. the highest
quintiles of 25D. Interestingly, a trend toward impaired
function with longer STST was seen in patients with high
normal 25D [&48 ng/ml (120 nmol/liter)] vs. lower levels
[16–38 ng/ml (40–94 nmol/liter)].
Significantly poorer physical performance was seen in
1234 older individuals among those with 25D below 10
ng/ml (25 nmol/liter) and 10–20 ng/ml (25–50 nmol/liter)
vs. those higher than 30 ng/ml (75 nmol/liter) (279). In a
subgroup of 979 participants followed over 3 yr, those
with lower 25D levels had significantly higher risk of de-
cline in physical performance compared with those with
levels above 30 ng/ml (75 nmol/liter). Those in the inter-
mediate 25Dgroupof20–30ng/ml (50–75nmol/liter) did
not display significantly greater rates of decline.
In a prospective study of 1008 older individuals in the
Netherlands, baseline 25D below 10 ng/ml (25 nmol/
liter) was associated with poorer grip strength
and reduced muscle mass on DEXA after 3 yr compared
with people with normal levels [&20 ng/ml (50 nmol/
liter)] (280). Those in the intermediate 25D group of
10–20 ng/ml (25–50 nmol/liter) demonstrated signifi-
cantly greater losses of muscle mass without difference
in grip strength vs. those with 25D over 20 ng/ml (50
nmol/liter).
An accelerated rate of decline in physical performance
over 2.5 yr on timed up and go tests (TUAG) and timed
STSTwere seen among769olderwomenwith lower base-
line 25D (281). However, low 25D levels are associated
with frailty (273), so a range of factors not included in
adjustment models may confound data interpretation.
A recent study of 714 Chinese men (&65 yr) found
no association between baseline 25D levels and cha-
nges in performance measures or appendicular skeletal
muscle mass over 4 yr (282). These men were not vita-
min D deficient [mean baseline 25D % 31 ng/ml (78
nmol/liter)].
2. Nonrandomized studies
Few studies have examined the effect of vitamin D sup-
plementation on muscle function in younger people. Gle-
rup et al. (208) reported a case-control study in which 55
veiled Arabic women with a mean age of 32 and severe
vitamin D deficiency [mean 25D% 3 ng/ml (7 nmol/liter)]
were compared with 22 Danish women of similar age but
higher 25D levels [19 ng/ml (47 nmol/liter)]. At baseline,
all parameters of muscle functionwere significantly lower
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in the Arabic women. Baseline 25D levels were indepen-
dently associatedwithmaximal voluntary knee extension.
After vitamin D repletion, the Arabic women displayed
significant improvements in parameters of muscle func-
tion at 3 and 6months. At 6 months, a subgroup that was
retested showed no difference in electrically stimulated
muscle function vs. Danish controls. Subjective improve-
ments in muscle and deep bone pain were reported by the
treated Arabic women.
3. Randomized controlled studies
The randomized controlled studies are summarized
in Table 7. Two studies discussed in Section VI.E and
Table 6 [Bischoff et al. (259) and Pfeifer et al. (258)]
reported improvements in muscle function as well as
decreased falls in those randomized to receive supple-
mental vitaminD.Over a 12-wk treatment period, those
on calcium and vitamin D demonstrated significant im-
provements in the summed score of knee flexor and
extensor strength, grip strength, and TUAG compared
with those receiving calcium alone (259). Significant
improvementswere reported in quadriceps strength and
TUAG in another study with reduced falls after 12
months of dual supplements compared with calcium
alone (258).
A twoby two randomized studyofpatients treatedwith
calcium 800 mg with or without resistance training, with
orwithout vitaminD400 IUdaily for 9months found that
vitamin D improved physical performance (283). Quad-
riceps strength, physical performance test, and TUAG
were significantly improved by vitamin D and by resis-
tance training, with an additive benefit in the group that
received both (283).
In a study of 139 ambulatory older subjects with a his-
tory of falls and vitaminD deficiency [25D"12 ng/ml (30
nmol/liter)], treatment with vitamin D2 (600,000 IU im)
had a significant effect on aggregate functional perfor-
mance time but no effect on either falls or quadriceps
strength at 6 months follow-up vs. placebo (284).
Among 56 institutionalized persons over 60 yr of age,
those randomized to receive calcium and vitamin D (two
doses of 150,000 IU then 90,000 IU monthly) demon-
strated significant improvements in maximal isometric
strength of hip flexors and knee extensors after 6 months
(285). Subgroup analysis demonstrated greater improve-
TABLE 6. Cross-sectional studies assessing the correlation between vitamin D levels and muscle function (listed in
order of number of study participants, highest to lowest)
Study (Ref.) n Sex
Age
(yr)
Positive or
negative Other Muscle function tests Findings Adjustments
Bischoff-Ferrari et al.
(278)
4100 M, F 60–90 Positive Ambulatory 8-ft. walk, repeated STST 25D 40–94 nmol/liter, better
function vs. "40 nmol/liter
Sex, age, BMI, ethnicity, SES, Ca
intake, comorb, walking device,
month, activity
Wicherts et al. (279) 1234 M, F &65 Positive Ambulatory Physical performance score Poorer with 25D "25 and
25–50 vs. &75 nmol/liter
Age, sex, chronic diseases,
urbanization, BMI, ETOH
Gerdhem et al. (379) 986 F 78 Positive Ambulatory Gait speed, Romberg test, thigh
strength, activity
25D correlated with all
outcomes (activity threshold
87 nmol/liter)
BMI, weight, height, BMD, hours
spent outdoors, activity
Houston et al. (275) 976 F &65 Positive Ambulatory SPPB (walk speed, STST,
balance), grip
25D "10 ng/ml,2 SPPB; 25D
"20 ng/ml,2 grip
SES, smoking, BMI, activity,
cognition, season
Marantes et al. (306) 667 M, F 21–97 Positive post hoc,
subgroup
Lean mass, muscle mass, grip
strength, knee extension
25D, no associations;2 1,25D
correlated with2 muscle
mass and knee strength in
"65-yr-old F
Age, height, activity, season of the
baseline visit, fat mass
Annweiler et al.
(380)
440 F &70 Negative CommD Handgrip and quadriceps
strength
No significant associations Age, chronic diseases, BMI, Ca use,
activity, serum Ca, CrCl
Beauchet et al. (381) 411 M, F 70 Positive, one
measure
Ambulatory STV, sway, grip strength, other 25D "25 nmol/liter, worse STV
only
Age, sex, drugs, cognition, falls last
year
Mowé et al. (382) 349 M, F 70–91 Positive, some
measures
Hosp (70%), CommD Falls, grip and proximal
strength, walking
25D correlated with strength,
activity, and absence of falls
BMI, age, serum albumin, heart
disease
Bischoff et al. (277) 319 M, F 74–77 Positive Ambulatory Leg extension power 1,25D correlated with leg
extension power
Age, sex, BMI, 1,25D, PTH, 25D
Stein et al. (252) 83 M, F 84 Negative NH, hostel Falls before 25D measurement 25D not significant; higher
PTH,1 falls
Multivariate analysis
Boxer et al. (273) 60 M, F 77 Positive CF 6-min walk, frailty markers 25D levels correlated with both
measures
Age, sex, free T, DHEAS, 25D, PTH,
hsCRP, IL-6, cortisol/DHEAS
ratio, and NTpro-BNP
Mastaglia et al.
(274)
54 F 71 Positive, some
measures
Ambulatory Walk speed, STST, balance, leg
strength
25D &20 ng/ml, greater knee
and hip strength.
Nil
Ducher et al. (308) 16 M 10–19 Negative Ballet dancers Injury, DEXA No correlations Nil
CF, Cardiac failure (ejection fraction "40%); CommD, community dwelling; comorb, comorbid conditions; CrCl, creatinine clearance; DHEAS, dehydroepiandrosterone
sulfate; ETOH, alcohol use; free T, percent free testosterone; Hosp, recently hospitalized; hsCRP, high-sensitivity C-reactive protein; NH, nursing home; NT-proBNP, N-
terminal pro-brain natritretic peptide; SES, socioeconomic status; SPPB, short physical performance battery; STV, stride time variability.
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ments inmuscle function among subjects with lower base-
line 25D levels ["20 ng/ml (50 nmol/liter)].
Similarly, among 302 older, community-dwelling
women, those in the lowest tertile of 25D levels who re-
ceived daily calcium (1000 mg) and vitamin D2 (1000 IU)
displayed the most pronounced improvements in lower
limb muscle function over 1 yr as opposed to those on
calcium alone (286).
Among 69 postmenarcheal adolescent females, those
randomized to receive 150,000 IU vitaminD2 orally every
3months for 1 yr demonstrated significant improvements
in movement efficiency, a composite of jump height and
velocity measured by mechanography, compared with
baseline (287).Additionally, at baseline, higher 25D levels
correlated with greater jumping velocity.
In a short study of 42 postmenopausal women, 12 wk
treatment with 1!-OHD3 (0.5 'g) and calcium led to sig-
nificant improvements in quadriceps strength compared
with those receiving calcium alone (288).
4. Muscle strength and function: negative studies
In a study of 70 vitamin D-deficient women [25D %
8–20 ng/ml (20–50 nmol/liter)], 6 months of vitamin D
and calcium (400 IU and 500 mg) had no effect on grip or
knee strength vs. calcium alone. Baseline 25D levels
showed an inverse correlation with these parameters of
muscle function (289).
In a study of 686 community-dwelling women over
70 yr, treatment with oral vitamin D3 (150,000 IU every
3months) for a 9-month period had no significant effect
on falls or hand grip strength compared with placebo
(290). However, a randomly selected subgroup of 40
participants had a mean baseline 25D of 26 ng/ml (66
nmol/liter), suggesting that the group at large were vi-
tamin D sufficient.
Otherstudieshave failed todemonstrate improvements in
muscle strength after vitaminD supplementation, regardless
of baseline vitamin D status (291–295), as summarized in
Table 7. A multicenter study of 243 frail, older patients re-
ported no difference in parameters of physical performance
between those randomized to receive a single dose of
300,000 IU of vitamin D vs. placebo (291). There was no
effect in the subset with low baseline 25D levels ["12 ng/ml
(30nmol/liter)] despite significant improvements in25D lev-
els. Some studies have examined other forms of vitamin D,
namely 1,25D and 1!-OHD3, with variable effects. Among
98older subjectswithmild renal impairment, 1,25D (0.5'g
daily) resulted in no improvement over a 6-month period vs.
placebo, and some subjects on 1,25D developed hypercalci-
uria and required dose reduction (294).
One negative study examined 179 vitamin D-deficient
adolescent females in Lebanon. Those randomized to re-
ceive vitaminD3 (doses of 1,400 or 14,000 IU/wk) did not
demonstrate improved grip strength but did have greater
increases in lean mass, bone area, and total hip bone min-
eral content vs. placebo after 1 yr (295).
Two studies have examined the effects of combining
vitamin D supplementation with high-resistance training
on muscle strength in older individuals (283, 293). In one
study of 180 community-dwellingmales (50–79 yr), those
randomized to receive an intensive program of resistance
training three timesperweekdemonstrated improvements
in strength. Those randomized to receive fortified milk
alone (containingvitaminD800 IU, calcium1000mg,and
protein13.2gdaily) demonstratednoadditional improve-
ments (293). Those receiving high-resistance trainingwith
vitamin D (400 IU) and calcium (800 mg) over a 9-month
period showed improvements in TUAG but not in quad-
riceps strength compared with those who received resis-
tance training and calcium (283).
5. Meta-analyses of muscle function
In one meta-analysis, the substantial variability in
the parameters of muscle function among studies, use of
measures without established validity or reliability, and
lack of blinded outcome assessments were cited as rea-
sons for inability to pool data (30).
On assessing 17 RCT involving 5072 participants,
there was no significant effect of vitamin D supplementa-
tion on grip strength or proximal lower limb strength in
adults with 25D levels over 10 ng/ml (25 nmol/liter) at
baseline (24). However, for adults with deficiency [25D
"10 ng/ml (25 nmol/liter)], a beneficial effect on hipmus-
cle strength was found.
In another meta-analysis of 16 RCT, in which baseline
25D levels were below20 ng/ml (50 nmol/liter) in 11 stud-
ies, the authors noted the publication of a greater number
of studies that showed no effect rather than a beneficial
effect of vitamin D supplementation on muscle function
and that there were no obvious characteristics to differ-
entiate studies with positive and negative findings (296).
In a more recent meta-analysis of 13 RCT involving
elderly subjects who were predominantly vitamin D defi-
cient or insufficient, vitamin D supplementation with
800–1000 IU daily was associated with improvements in
lower extremity strength and balance (297). The meta-
analysis included only randomized trials of older individ-
uals in whom baseline and posttreatment parameters of
muscle function were assessed. Trials in younger individ-
uals (295) or those that includedmuscle training as part of
the treatment were not included (293). This meta-analysis
found no effect on gait.
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6. Summary: vitamin D, muscle strength, and
physical performance
Although some data suggest a beneficial effect of vita-
min D supplementation on muscle function, particularly
in vulnerable populations and those with low baseline vi-
tamin D levels (208, 286), the evidence base is limited by
highly heterogeneous studies that assess muscle function
by different methods. Hence, larger studies that use stan-
dardized, reproducible assessmentsofmuscle strengthand
double-blinded treatment regimens are necessary to clar-
ify this important issue and guide recommendations. Such
studies should ideally consider baseline vitamin D status
and confirm adequate replacement is achieved by a rise in
25D to the normal range.
G. Muscle morphology and electromyography (EMG)
Several reports, dating back to the 1970s, have char-
acterized the morphological appearance of skeletal
muscle among vitamin D-deficient subjects and thus
provided some evidence in support of a direct role for
vitamin D in the morphology and development of
muscle.
TABLE 7. Interventional studies assessing the effects of vitamin D supplementation on muscle function (listed in
order of number of study participants, highest to lowest)
Study (Ref.) n Sex Age (yr) Positive or negative Duration Basal 25D )ng/ml (nmol/liter)*
Brunner et al. (383) 33,067 F 50–79 Negative 7 yr NR
Zhu et al. (286) 302 F 70–90 Positive, post hoc subgroup 1 yr 18 (44)
Latham et al. (291) 243 M, F 80 Negative 6 months 17 (42)
Lips et al. (384) 226 M, F &70 Positive, one measure 16 wk 6–20 (15–50)
Kukuljan et al. (293) 180 M 50–79 Negative 18 months 34 (86)
El-Hajj et al. (295) 179 F 10–17 Positive, one measure 1 yr 14 (35)
Dhesi et al. (284) 139 M, F &65 Positive, three measures 6 months &12 (30)
Johnson et al. (385) 109 M, F &60 Negative 6 months NR
Witham et al. (386) 105 M, F &70 Negative 20 wk "20 (50)
Grady et al. (294) 98 M, F &69 Negative 6 months 24 (60)
Bunout et al. (283) 96 M, F &70 Positive, one measure 9 months 12 (30)
Glerup et al. (208) 77 F 32–36 Positive 3–6 months A (n % 55), 7 (17); D, 42 (104)
Ward et al. (287) 73 F 41–74 Positive, one measure 1 yr "15 (37.5)
Janssen et al. (289) 70 F &65 Negative, baseline correlated 6 months 8–20 (20–50)
Kenny et al. (387) 65 M 76 Negative 6 months 26 (65)
Corless et al. (292) 63 M, F 82 Negative 40 wk 17.2 (43)
Moreira-Pfrimer et al. (285) 56 M, F &60 Positive 6 months 40–46 (100–115)
Songpatanasilp et al. (288) 42 F &65 Positive 12 wk "30 (75)
Gupta et al. (388) 40 M, F 32 Positive 6 months 8–10 (21–25)
Gloth et al. (389) 32 M, F &65 Positive, post hoc subgroup 6 months "15 (37.5)
Doses for vitamin D and calcium are daily and administered orally (unless stated otherwise). A, Arab women; AFPT, aggregate functional performance time; CF, cardiac
failure; CrCl, creatinine clearance; CRT, choice reaction time; CommD, community dwelling; D, Danish women; FEFA, frail elderly functional assessment score; Hosp, in
hospital; ITT, intention-to-treat analysis; LSGC, long-stay geriatric care units; MCT, modified Cooper test; MRS, magnetic resonance spectroscopy; Quads, quadriceps
strength; PAS, physical activity/performance score; TST, to stand test; WHI, Women’s Health Initiative.
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1. Open-label studies
In1974, a case series of13patientswithvariousdegrees
of proximal myopathy in the context of chronic renal fail-
ure was described (203). Ten of the 13 patients displayed
significantly shorter mean action potential durations of
the deltoid and quadriceps muscles on EMG. They also
displayed moderate atrophy of type II (i.e. fast twitch)
muscle fibers on the basis of myofibrillar ATPase staining
and degenerative changes on electron microscopy with
small foci of fiber necrosis, lytic vacuoles, and Z-band
degeneration in four patients. Although vitamin D levels
were not determined, because thiswas before the era of the
standardized assay, substantial improvement in muscle
strength after im vitamin D treatment in a proportion of
the patients was reported. In another series of four uremic
patients, the finding of type II muscle fiber atrophy was
linked to vitamin D deficiency on the basis of significantly
elevated PTH levels (298).
In 1975, gluteal muscle biopsies of 12 patients with
laboratory evidenceofosteomalaciadisplayednonspecific
muscle fiber atrophy (299). A distinction was made be-
tween patients with isolated nutritional deficiency in
TABLE 7. Continued
Other Vitamin D and Ca/other Outcomes Adjustments Main results
WHI study D3 400 ! Ca 1000 mg vs. placebo Grip, 6-m walk, chair-STS,
exercise
Age, WHI group No improvement
CommD D2 1000 ! Ca 1000 or Ca alone Ankle, knee, hip strength, TUAG NR Lowest basal tertile1 hip and
TUAG
Adverse outcomes,
frail
D3 300,000 by 1 ! exercise vs.
placebo
Knee strength, balance, TUAG,
4-m walk, falls
NR Higher rates of injury with
intervention
Ambulatory D3 8400/wk vs. placebo Body sway, PAS Basal sway and
25D
Subgroup1 basal sway
improved
CommD Milk ! D3 800 ! Ca 1000 mg vs.
placebo # exercise
Sway, step test, lateral
pulldown, leg and bench
press
NR No effect
School D3 1400 vs. D3 14,000/wk vs.
placebo
Grip, lean mass NR No effect
Falls D2 600,000 im once vs. placebo CRT, AFPT, quadriceps strength,
falls
NR AFPT, CRT, and sway improved
CommD D 2000 vs. placebo Muscle function in arm and leg NR No effect
CF D3 100,000, by 2 or placebo 6-min walk, QOL, activity,
function
NR No effect
Ambulatory 1,25D 0.5 'g or placebo Quads, grip strength Age, sex, CrCl,
strength
No effect
Ambulatory D3 400 ! Ca 800 mg vs. Ca alone Quads, TUAG, walk speed, other Compliance Walk speed increased
D2 100,000 im by 6 ! 4–600/d !
Ca 8–1200 vs. nil in Danes
Knee extensors NR Arabic women improved
School Four doses of D2 150,000 Jumping, grip, weight, muscle
strength
NR Jump efficiency improved
CommD D3 400 ! Ca 500 mg vs. nil Grip and lower limb strength,
TUAG, MCT
NR No effect
CommD D3 1000 ! Ca 500 mg vs. nil Grip and leg strength, PAS,
supine TST, TUAG, 6-ft. walk,
balance
NR No effect
Hosp D2 9000 vs. nil ADL score with walking up stairs
and on flat
NR No effect
Frail, LSGC Ca 1000 ! D3 150,000 by 2 !
90,000/month by 4 vs. Ca !
placebo
Hip flexor and knee extensor
strength
NR Both improved
1!(OHD3 (0.5 'g) ! Ca 1500
mg vs. Ca/Placebo
Quadriceps strength Baseline strength Improved quadriceps strength
Asian Ca 1000 mg ! D3 60,000/wk, 12
doses
Grip and calf strength,
respiratory pressures, 6-min
walk, MRS
Age, sex, basal
measures
Improved grip and calf strength
and 6-min walk
Frail, CommD, NH Ca (no dose) ! D2 400 or Ca !
D2 100,000/3 months or Ca
alone
FEFA score NR Subgroup increase 25D &3
ng/ml D improved
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whom biopsy changes were mild compared with those
with an additional condition including hyperparathyroid-
ism, hyperthyroidism, or uremia who also demonstrated
myofibrillar degeneration and infiltration with amor-
phous material.
One year later, Irani (201) reported a case series of 15
women with nutritional osteomalacia who demonstrated
significantly shorter motor unit action potentials and a
greater proportion of polyphasic potentials on EMGcom-
pared with controls. Muscle biopsies from those with os-
teomalacia demonstrated nonspecific muscle fiber atro-
phy. Complete resolution in EMG changes after a 5-wk
course of high-dose vitamin D supplementation (600,000
IU of vitamin D2 weekly or fortnightly) was noted in the
three patients who were retested. In 1979, two patients
with osteomalacia demonstrated type II muscle fiber at-
rophy in addition to scattered necrosis and derangement
of the intermyofibrillar network on muscle biopsy (300).
Eleven patients with a condition described as bone loss
of aging had muscle biopsies from the vastus lateralis be-
fore and after treatment with 1!-OHD3 and calcium for
3–6 months (301). The predominant finding was an in-
crease in the proportion and cross-sectional size of fast-
twitch type IIa fibers. Measures of the oxidative capacity
of muscle, succinate dehydrogenase, and total phosphor-
ylase activity were low at baseline and increased with
treatment. Lactate dehydrogenase activity, a measure of
anaerobic metabolism, did not change. Interestingly, the
proportion of type IIb fibers (very-fast-twitch fibers) de-
creased significantly with treatment. This was the first re-
port to demonstrate changes in muscle morphology and
oxidative capacity after treatment of presumably vitamin
D-deficient subjects with a vitamin D analog.
Three years later, Young et al. (302) confirmed these
findings by demonstrating significant increases in the pro-
portion of type II muscle fibers in biopsies of the vastus
lateralis muscle after 3 months of vitamin D supplemen-
tation among 12 patients with osteomalacia. In associa-
tion with these findings, quadriceps muscle strength also
improved significantly using an isodynamic dynamome-
ter. However, this body of evidence dating back to the
1970s may be confounded by the many biochemical ab-
normalities associatedwith renal failure andosteomalacia
such as hyperparathyroidism and disturbances in calcium
and phosphate levels. These provide indirect mechanisms
that may independently alter muscle function (Fig. 4).
Nevertheless, the changes in muscle morphology and per-
formance after vitamin D supplementation in these sub-
jects are important preliminary observations.
Recent studies have reported an association between
significantly higher skeletal muscle fat content and vita-
min D deficiency. In one study of 90 postpubertal females
in California, the proportion of muscle fat, assessed by
comparing the attenuation signal of a 2-cm2 section of the
rectus femoris with the adjacent sc fat on computed to-
mography, was found to strongly correlate in an inverse
fashion with serum 25D levels (303). This was indepen-
dent of body mass or computed tomography measures of
sc and visceral fat. The percentage of muscle fat was sig-
nificantly lower in women with normal vs. subnormal se-
rum 25D levels.
In another study of 366 older patients receiving mag-
netic resonance imaging (MRI) of one shoulder for the
investigation of potential rotator cuff injury, a correlation
between higher fatty infiltration of rotator cuff muscles
and lower serum levels of 25D was reported (304). After
multivariate linear regression analysis, this association re-
mained statistically significant in two muscle groups (i.e.
supraspinatus and infraspinatus muscles) but only among
those whose MRI also demonstrated a full-thickness ro-
tator cuff tear (228 patients).
A third studyusingMRIof the thigh in20older subjects
also reported an inverse correlation between muscular
fatty degeneration and 25D (305). Interestingly, selective
and near-total fatty degeneration of at least one muscle
was observed among11vitaminD-deficient patients [25D
"20 ng/ml (50 nmol/liter)].
A recent cross-sectional study demonstrated a positive
correlation between 1,25D levels and total skeletalmuscle
mass asmeasured onDEXAamong subjects younger than
65 yr (306). This was supported by greater isometric knee
extension moment in women with higher 1,25D levels.
However, no association was found between 25D levels
and muscle mass or strength or in those over 65 yr of age.
Among 26 subjects with chronic kidney disease, thigh
muscle cross-sectional area on MRI correlated signifi-
cantlywith amodel including 1,25D levels, calcium levels,
and daily physical activity (307). Functional parameters
assessing gait and proximal musculature also indepen-
dently correlated with 1,25D.
Although a majority of highly trained adolescent male
ballet dancers had low vitamin D levels [25D "20 ng/ml
(50 nmol/liter) in nine of 16 study participants], there was
no correlation between 25D, body composition on
DEXA, or reports of muscle injury in this study (308).
2. EMG and muscle biopsies: randomized study
A study that randomized 96 elderly women with post-
stroke hemiplegia and severe vitamin D deficiency ["10
ng/ml (25 nmol/liter)] to vitamin D2 (1000 IU daily) or
placebo for 2 yr reported significant and dramatic in-
creases in the proportion and diameter of type II muscle
fibers (85). These parameters deteriorated significantly in
the placebo group.
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3. EMG and muscle biopsies: summary
In summary, it appears that vitaminDdeficiency results
in significant and reversible changes in EMG and type II
muscle fiber atrophy, the latter being an independent pre-
dictor for falls in one study (85).However, the changes are
nonspecific, being similar to those seen in other condi-
tions. Although fatty infiltration in skeletal muscle has
been suggested by three recent studies, these are cross-
sectional and based on imagingmodalities thatmay not be
validated for the assessment of muscle fat. Muscle be-
comes fatty with disuse, and thus this measure may be
confounded by decreased exercise associated with both
increased muscle lipid and lower vitamin D. These mo-
dalities are not equipped to identify intracellular fat, per-
haps of greater pathophysiological significance.
H. Insulin sensitivity and glucose handling
Abroad range of epidemiological and randomized clin-
ical studies together with specific research on molecular
pathways and animal models have drawn links between
vitamin D and insulin sensitivity. This is relevant to the
topic of vitaminDandmuscle because under normal phys-
iological conditions, skeletal muscle is responsible for ap-
proximately 85% of whole-body insulin-mediated glu-
cose uptake (102).
Insulin resistance, a highly prevalent condition that
contributes to the pathogenesis of type 2 diabetes, is pri-
marily due to defective insulin-stimulated glucose uptake
in skeletalmuscle resulting from the production of various
inflammatory mediators, adipokines, and FFA by adi-
pocytes in predominantly overnourished and obese indi-
viduals (309). However, in recognizing the complex pro-
cesses involved in insulin resistance, anumberof reversible
factors with potential etiological relevance to this condi-
tion are being considered. One of these factors is vitamin
Ddeficiency. In this section,wewill reviewhuman clinical
studies that examine the association between vitamin D
status and insulin sensitivity.
1. Cross-sectional studies: vitamin D and insulin sensitivity
Studies have examined the association between param-
eters of insulin resistance and vitamin D status in nondi-
abetic individuals. In one report, 25D was inversely cor-
related with the homeostasis model assessment of insulin
resistance (HOMA-IR) among 214 Arab-American men,
but no such associationwas found among the 317women
of the same ethnicity included in this study (310). Among
808 nondiabetic participants of the Framingham Off-
spring Study, plasma 25D concentrations were inversely
associated with fasting insulin concentrations and
HOMA-IR after adjustment for age, sex, and BMI (311).
A similar association between 25D levels and HOMA-IR
was found in a group of 712 subjects at risk of diabetes
(312).
Among 1941 adolescents who participated in the Na-
tional Health and Nutrition Examination Survey from
2001–2006, adjusted concentrations of insulin were sig-
nificantly higher among male subjects who were vitamin
D deficient ["20 ng/ml (50 nmol/liter)] compared with
those with higher vitamin D levels [&30 ng/ml (75 nmol/
liter)], suggesting a potential role vitamin D status in in-
sulin sensitivity (313).
However, a recent study that employed the gold-stan-
dard technique in the assessment of insulin sensitivity,
namely the hyperinsulinemic-euglycemic clamp, found
that the association between insulin sensitivity in 39 non-
diabetic subjects and 25D levels become nonsignificant
after adjustment for other factors including BMI (314).
Similarly, among 381 nondiabetic university students in
Lebanon and 510 nondiabetic subjects from a largely
obese ethnic minority in Canada (i.e.Canadian Cree), the
inverse association between 25D levels and HOMA-IR
also became nonsignificant after adjustment for BMI in
addition to other factors (315, 316). In another study of
126 healthy young adults, there was a significant associ-
ation between 25D levels and insulin sensitivity on a hy-
perglycemic clamp study that remained after adjustment
for a range of factors (317).
Therefore, it is clear that the inverse correlation between
25DandBMI, as reported in anumberof studies (314, 318),
may particularly confound the assessment of these observa-
tionaldata. Infact,arecentstudysuggests that itmaybemore
accurate to consider adiposity rather than BMI per se as the
particular confounding factor (319). In a study of 1882non-
diabetic individuals, it was the inclusion of a computed to-
mographymeasureofvisceraladiposity rather thanBMIand
waist circumference in the multivariate analysis that caused
the inverse association between vitamin D status and mark-
ers of insulin resistance, namely HOMA-IR and log insulin
levels, to be insignificant (319).
Several mechanisms associating vitamin D deficiency
with obesity have been proposed, including the great ca-
pacity of adipose tissue to store vitamin D (80, 320) and
the avoidance of sunlight exposure and outdoor activity
amongpotentially self-conscious, obese individuals (320).
In confirmation of the former mechanism, a study of 116
obese women reported that fat mass measured by isotope
dilution method was a strong predictor of serum 25D lev-
els both 5 yr before and 10 yr after bilio-pancreatic diver-
sion surgery and that vitamin D levels did not correlate
with insulin sensitivity at either time on the basis of the
euglycemic-hyperinsulinemic clamp studies (321).
The impact of PTH, which has an inverse relation to
vitaminDstatus and is alsoassociatedwithdiabetes (322),
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has been addressed in a small number of studies. A study
including 15 subjects with secondary hyperparathyroid-
ism (serum PTH &6.4 pmol/liter) and 15 controls found
that after adjustment for BMI, age, and sex, serum 25D
levels were significantly associated with the insulin sensi-
tivity index on a 3-h hyperglycemic clamp, but PTH levels
were not (323). Similarly, a significant adjusted associa-
tion between 25D and fasting insulin was reported in a
studyof654adult subjects fromCanada, butPTHwasnot
associated with this parameter after multivariate adjust-
ment (324).
Apart from insulin resistance of skeletal muscle, the
pathophysiology of type 2 diabetes comprises a range of
other factors. Vitamin D may play a role in these other
processes with cross-sectional studies and meta-analyses
reporting an association between vitamin D deficiency/
insufficiency and the incidence of diabetes in various pop-
ulations (325–328). However, not all studies confirm this
observation, and there is substantial heterogeneity be-
tween studies in their designandadjustment for confound-
ers (329–331).
2. Prospective studies: vitamin D and insulin sensitivity
Observational studies have examined the relationship
between 25D and the prospective risk of developing in-
sulin resistance.
In the prospective Ely study (1990–2000), baseline
25D levels of 524 nondiabetic men and women were in-
versely associated with the 10-yr risk of insulin resistance,
on the basis of HOMA-IR and fasting insulin after adjust-
ment for a range of factors including age, sex, BMI, and
calcium and PTH levels (332). Each 10-ng/ml (25 nmol/
liter) increase in baseline 25D was associated with a sig-
nificant decrease inHOMA-IR score (i.e. 0.16U) at 10 yr.
In a recent study that assessed 5200 participants of the
Australian Diabetes, Obesity, and Lifestyle (AusDiab)
study, lower baseline 25D levels were associated with a
higher risk of developing diabetes over the 5-yr follow-up
period (333). After adjustment for a range of factors, the
authors reported that each 10-ng/ml (25 nmol/liter) incre-
ment in serum 25D was associated with a 24% reduced
5-yr risk of diabetes. Regarding insulin resistance, a pos-
itive and independent association with HOMA-IR at 5 yr
was also reported. In contrast to an earlier report (334), no
association between dietary calcium intake and diabetes
risk or the follow-up homeostasis model assessment of
insulin sensitivity score was found (333).
Apart from insulin resistance, a number of studies have
also reported an association between baseline 25D levels
and the long-term risk of diabetes (334–336). However,
not all such studies have supported this association
(337–339).
3. Interventional studies: vitamin D and insulin sensitivity
Mixed results have emerged from a number of inter-
ventional studies that have sought to address the impact of
vitamin D supplementation on glucose homeostasis and
parameters of insulin sensitivity.
There was no difference in parameters of glucose ho-
meostasis among 238 postmenopausal women who were
randomized to receive 2 yr of treatment with vitamin D3
(2000 IU daily) or l!-OHD3 (0.25 'g daily) or 1 yr of
treatment with 1,25D (0.25–0.50 'g) daily vs. placebo
(340). Similarly, no differences in insulin-mediated glu-
cose uptake on the euglycemic clamp study were found in
18 healthy males randomized to receive either 1,25D 1.5
'g daily or placebo; however, treatment in this study was
only 7 d (341).
Studies examining subjects at risk of diabetes have sug-
gested improvements in glucose homeostasis with vitamin
D supplementation. In three studies, significant improve-
ments were reported in insulin sensitivity, insulin secre-
tion, and/or the disposition index in subjects at risk of
diabetes who were randomized to receive supplemental
vitamin D3 and calcium (2000 IU and 500 mg, respec-
tively) vs. calcium alone for 16 wk, high-dose vitamin D3
(120,000 IU) every 2wk vs. placebo for 6wk, and vitamin
D3 and calcium (700 IUand500mgdaily, respectively) vs.
placebo for 3 yr (342–344).
A double-blind randomized trial of 81 South Asian
women living inNewZealandwhowere found to be both
insulin resistant on HOMA-IR and vitamin D deficient
[25D "20 ng/ml (50 nmol/liter)] reported significant re-
ductions in insulin resistance and fasting insulin levels
among those randomized to receive vitamin D3 (4000 IU
daily) vs. placebo for 6 months (345).
Inarecentrandomizedtrial including90diabeticsubjects,
those randomized to receivevitaminD-fortifiedyogurt twice
daily (each containing 500 IU) or vitamin D- and calcium-
fortified yogurt demonstrated improvedglycemic control on
glycated hemoglobin (HbA1c) and improved insulin resis-
tance on HOMA-IR compared with those receiving plain
yogurt for 12 wk (346). Importantly, an inverse correla-
tion was observed between changes in serum 25D and
HOMA-IR in this study.
In another study, 10 females with type 2 diabetes who
were predominantly vitamin D deficient reported a signif-
icant reduction in amarker of peripheral insulin resistance
after 1 month of vitamin D3 supplementation (1332 IU
daily) (347). However, this study had no control group.
Conversely, a number of small studies have failed to
demonstrate any benefits in association with vitamin D
supplementation in patients with type 2 diabetes. In 20
diabetic subjects, a randomized trial reported no improve-
ments in fasting or stimulated glucose, insulin, C-peptide,
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or glucagon concentrations among those receiving 1,25D
(1 'g daily) for 4 d vs. placebo (348). Among 28 Asian
Indian patients with type 2 diabetes, those randomized to
receive vitamin D supplementation for 4 wk did not dem-
onstrate a significant difference in markers of insulin re-
sistance (i.e. fasting insulin, post-oral glucose tolerance
test serum insulin levels, and HOMA-IR) compared with
those receiving placebo (349). Similarly, in 32 diabetic
subjects, 6 months of supplemental vitamin D (40,000
IU/wk) had no effect on fasting insulin, C-peptide, or
HbA1c levels compared with baseline or those receiving
placebo (350). It is probably reasonable to conclude that
these studieswereunderpowered toanswer thequestion in
either direction.
In one case series of three British Asians with diabetes
and vitamin D deficiency [25D"6 ng/ml (15 nmol/liter)],
high-dose vitamin D supplementation (300,000 IU im)
was associated with subsequent deterioration in glycemic
control onHbA1c andprogression of insulin resistance on
fasting insulin resistance index (351).
Recent post hoc analyses of eight trials including par-
ticipants with normal glucose tolerance at baseline and
three small trials of patients with established type 2
diabetes demonstrated no effect of vitamin D supple-
mentation on glycemic outcomes (352). However, two
trials examining patients with baseline glucose intoler-
ance reported improvements in insulin resistance
among those receiving vitamin D supplementation
(349, 350).
4. Summary: vitamin D and insulin sensitivity
Substantial differences in study design, duration, and
typeof vitaminDsupplementationand theparticular pop-
ulations studied in these trials make collective assessment
of these results difficult.Although some large trials suggest
a beneficial effect of vitamin D supplementation in the
reduction of insulin resistance, others do not. Further-
more, to ascertain whether the potential glycemic benefits
of supplemental vitamin D are more pronounced in those
with vitamin D deficiency or poor glycemic control at
baseline, larger trials of longer duration are necessary.
More than20 trials are currently underway to address this
question (www.clinicaltrials.gov).
VII. Conclusions
See Table 8 for conclusions.
In his 1922 publication on the cure of rickets by sun-
light, Alfred Hess (35) remarked that “although we have
realized the importance of light in the growth of plant life,
wehave [until now]accorded it too little significance in the
development of animal life.” Since that time, we have
come a longway in recognizing the role of UV radiation in
the photochemical synthesis of vitamin D, the role of vi-
taminD in calcium andmineral homeostasis, and the sim-
ilarity of 1,25D tomembers of the steroid familywith their
cholesterol precursor, carbon-ringed structures, and abil-
ity to bind to specific nuclear receptors in the genomic
mediation of developmental and functional effects.
Although steroid hormones are known to exert diverse
effects in multiple organs and tissues, a role for vitamin D
beyond its predominant effects on bone and mineral ho-
meostasis has been hotly contested. Muscle stands at the
frontier of the emerging concept of vitamin D’s extraskel-
etal role because it shares its ancestral origin with bone in
the common mesenchymal stem cell and relies heavily on
TABLE 8. Conclusions and outstanding questions
Conclusions
Vitamin D exerts rapid and genomic effects in primary muscle cells and cell lines. These effects relate to intracellular calcium handling,
differentiation and contractile protein composition.
In vivo, it is not clear whether VDR is expressed in adult skeletal muscle.
Whole-body VDRKO mice and vitamin D-deficient animals display significant defects in muscle function and development.
In humans, single nucleotide polymorphisms in the gene encoding VDR have been associated with differences in muscle strength.
Changes in muscle morphology in humans with severe vitamin D deficiency have been reported since the 1970’s.
Proximal myopathy and muscle pain in subjects with severe vitamin D deficiency resolve following vitamin D supplementation.
Associations between vitamin D deficiency, muscle weakness and falls are confounded by factors including frailty and lower exposure to
sunlight. Clinical parameters of muscle function are not standardized making data aggregation difficult.
Randomized data suggest that vitamin D supplementation may reduce falls in older individuals but not all studies support this conclusion.
The recommended dose of vitamin D supplementation and vitamin D targets remain hotly contested issues.
Outstanding questions
Does the VDR exist in fully differentiated adult muscle and does it have physiological relevance at this site? Or rather, as suggested by in vitro
studies, is its role predominantly related to the function of immature muscle cells such as in myogenesis?
Are changes in muscle function and morphology directly related to vitamin D or indirectly to its effects in calcium and mineral homeostasis?
Does skeletal muscle possess the ability to 1-!-hydroxylate 25D at any stage in its development?
As suggested by studies on phosphate handling in myocytes, does 25D itself exert direct effects on muscle?
Is vitamin D deficiency or its reversal an important consideration among those with other muscle disorders such as congenital dystrophies and
acquired immune-related myositis?
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intracellular calciumhandling for contraction, insulin sen-
sitivity, and cellular plasticity (99).
In this review, we have adopted a multilayered ap-
proach in examining evidence fromhuman clinical studies
as well as reports on animal and cell models to piece to-
gether the current knowledgeof vitaminD’s effects in skel-
etal muscle. The broad evidence base is generally in favor
of a role for vitamin D in the development and function of
skeletal muscle.
The strongest evidence comes from studies that report
distinct morphological changes in the muscle of vitamin
D-deficient subjects, others that describe significant im-
pairments in the muscle function of VDRKO mice, and
molecular studies that have mapped out the various in-
tracellular responses of cultured muscle cells to vitamin D
(129, 173, 174). As a result, we have come closer to an-
swering the perennial question as to whether vitamin D’s
influence on muscle is direct or indirect, and the answer
appears to be both.
Outstanding questions remain, including the precise
role of vitamin D in muscle differentiation, the possibility
of specific biological activity of 25D in muscle, and the
current controversy regarding the in vivo presence of the
VDR in muscle tissue.
In the clinical domain, observations of reversible my-
opathy in subjects with severe vitamin D deficiency have
been reported for some time. Cross-sectional data report-
ing a high prevalence of vitamin D deficiency among sub-
jectswith falls,muscleweakness, and insulin resistanceare
also present (211, 274, 327). However, confounding vari-
ables are a caveat in the interpretation of this circumstan-
tial evidence. Furthermore, the demonstration of unequiv-
ocal improvements in muscle function among subjects
with mild to moderate degrees of vitamin D deficiency
randomized to receive vitamin D supplementation has
been elusive. Possible reasons for this include heterogene-
ity in study design and supplemental regimens and the
general lackof large-scale trials to address this issue.These
challenges and others remain to be addressed.
There is reasonable evidence from cellular, animal, and
at least some human studies that muscle responds to vi-
tamin D. Althoughmolecular pathways by which vitamin
D acts on the myocyte have been identified, there is scope
formore clarification. Studies are alsoneeded to clarify the
therapeutic potential of vitaminD in the treatment of age-
related sarcopenia and perhaps other myopathies. In the
meantime, it would be prudent for clinicians to seek and
manage vitaminDdeficiency in individuals at risk of these
conditions.
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Chapter 3 – Effects of vitamin D in C2C12 muscle cells 
 
 
 
This chapter consists of an original article that was published in the February 
edition of Endocrinology (2014; 155: 347–357). The primary author and PhD 
candidate, Christian Girgis, carried out the majority of experiments described in 
this work (>90%), drafted manuscripts and responses to reviewers. This has 
been verified by co-authors (see Appendix). To date, this article has been cited 
> 10 times since publication.  
 
The main findings of this work include: 
• novel effects of 1,25(OH)2D in C2C12 muscle cell proliferation,  
differentiation and myotube formation. 
• elucidation of mechanisms underlying the anti-proliferative effect of 
1,25(OH)2D in C2C12 cells (i.e. modulation of cell cycle genes 
including myc, post-translational effects of Rb).  
• the presence of functional CYP27B1 in C2C12 cells using a luciferase 
reporter system and demonstration of morphologic changes in C2C12 
cells in response to 25OHD.  
• anabolic effects of vitamin D on C2C12 myotube size and profound 
inhibition of myostatin, a negative regulator of muscle mass. 
Vitamin D Signaling Regulates Proliferation,
Differentiation, and Myotube Size in C2C12 Skeletal
Muscle Cells
Christian M. Girgis, Roderick J. Clifton-Bligh, Nancy Mokbel, Kim Cheng,
and Jenny E. Gunton
Garvan Institute of Medical Research (C.M.G., N.M., K.C., J.E.G.), Sydney, New South Wales 2010,
Australia; Faculty of Medicine (C.M.G., R.J.C.-B., J.E.G.), University of Sydney, Sydney, New South Wales
2008, Australia; The Kolling Institute of Medical Research (R.J.C.-B.) and Royal North Shore Hospital
(R.J.C.-B.), Sydney, New South Wales 2065, Australia; Department of Endocrinology and Diabetes
(J.E.G.), Westmead Hospital, Sydney, New South Wales 2145, Australia; and St Vincent’s Clinical School
(J.E.G.), University of New South Wales, Sydney, New South Wales 2052, Australia
Vitamin D deficiency is linked to a range of muscle disorders including myalgia, muscle weakness,
and falls. Humans with severe vitamin D deficiency and mice with transgenic vitamin D receptor
(VDR) ablation have muscle fiber atrophy. However, molecular mechanisms by which vitamin D
influences muscle function and fiber size remain unclear. A central question is whether VDR is
expressed in skeletal muscle and is able to regulate transcription at this site. To address this, we
examined key molecular andmorphologic changes in C2C12 cells treated with 25-hydroxyvitamin
D (25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)2D). As well as stimulating VDR expression,
25(OH)D and 1,25(OH)2D dose-dependently increased expression of the classic vitamin D target
cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24A1), demonstrating the presence
of an autoregulatory vitamin D-endocrine system in these cells. Luciferase reporter studies dem-
onstrated that cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1) was functional
in these cells. Both 25OHD and 1,25(OH)2D altered C2C12 proliferation and differentiation. These
effects were related to the increased expression of genes involved in G0/G1 arrest (retinoblastoma
protein [Rb], 1.3-fold; ATM, 1.5-fold, both P ! .05), downregulation of mRNAs involved in G1/S
transition, including myc and cyclin-D1 (0.7- and 0.8-fold, both P ! .05) and reduced phosphory-
lation of Rb protein (0.3-fold, P ! .005). After serum depletion, 1,25(OH)2D (100nM) suppressed
myotube formation with decreased mRNAs for key myogenic regulatory factors (myogenin, 0.5-
fold; myf5, 0.4-fold, P ! .005) but led to a 1.8-fold increase in cross-sectional size of individual
myotubes associated with markedly decreased myostatin expression (0.2-fold, P! .005). These
data show that vitamin D signaling alters gene expression in C2C12 cells, with effects on
proliferation, differentiation, and myotube size. (Endocrinology 155: 347–357, 2014)
In addition to established effects in bone and mineralhomeostasis, vitaminD deficiency is linked to a range of
muscle disorders (1). These includemuscle weakness, my-
algia, and drug-related myopathy. Type II (fast-twitch)
muscle fibers atrophy in elderly individuals with vitamin
D deficiency, exacerbating their tendency to fall (2).
Evidence suggests that vitamin D plays a role in muscle
development (1). Children with vitamin D-deficient rick-
ets developprofoundmuscleweakness andhypotonia that
improves after sun exposure or vitamin D supplementa-
tion (3, 4). In animal studies, mice lacking the vitamin D
receptor (VDR)have smallermuscle fibers at 3weeks of age,
ISSN Print 0013-7227 ISSN Online 1945-7170
Printed in U.S.A.
Copyright © 2014 by the Endocrine Society
Received March 2, 2013. Accepted November 18, 2013.
First Published Online November 26, 2013
Abbreviations: 7AAD, 7-amino-actinomycin D; AB, Alamar Blue; BrdU, bromodeoxyuri-
dine; CYP24A1, cytochrome P450, family 24, subfamily A, polypeptide 1; CYP27B1, cy-
tochrome P450, family 27, subfamily B, polypeptide 1; DBP, Vitamin D-binding protein;
FITC, fluorescein isothiocyanate; MRF, myogenic regulatory factor; 25OHD, 25-hydroxyvi-
tamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; PI, propidium iodide; Rb, retinoblastoma
protein; VDR, vitamin D receptor.
C A L C I U M - R E G U L A T I N G H O R M O N E S
doi: 10.1210/en.2013-1205 Endocrinology, February 2014, 155(2):347–357 endo.endojournals.org 347
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 January 2014. at 16:37 For personal use only. No other uses without permission. . All rights reserved.
persistent expression of developmental muscle genes, and
impaired motor coordination throughout adulthood (5–7).
However, the precise mechanisms by which vitamin D
signaling influences muscle development and function are
unclear. Importantly, the issue of whether the VDR is ex-
pressed in skeletal muscle is contentious (1, 8, 9).
The aimof this studywas to assess the effects of vitamin
D in an in vitro model of skeletal muscle. C2C12 muscle
cells, a widely investigated model of myogenesis (10, 11),
were used. To determine whether vitamin D could have
direct effects on these cells, expressionand functionality of
key components of the vitamin D-endocrine system, spe-
cifically cytochrome P450, family 27, subfamily B, poly-
peptide 1 (CYP27B1), VDR, and cytochrome P450, fam-
ily 24, subfamily A, polypeptide 1 (CYP24A1), was
measured.We thenassessed effects of 25-hydroxyvitaminD
(25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)2D)
on C2C12 muscle cell proliferation and differentiation.
Materials and Methods
Cell culture
C2C12 cellswere propagated inDMEM-F12with 10%heat-
inactivated fetal calf serum at 37°C and 5% CO2. On reaching
70% confluence, cells were distributed into appropriate plates
for each assay and cultured in media with 10% fetal calf serum.
At 24 hours after seeding (day 1), cells were treated with 100nM
1,25(OH)2D, 100nM 25OHD, or vehicle (ethanol). The me-
dium was changed daily. From day 3 onward, serum was de-
creased from 10% to 2% and changed to horse serum to initiate
cell cycle exit and myogenic differentiation (ie, serum depletion)
(12, 13). Serum depletion has been previously used to examine
effects of different treatments on myogenic differentiation (14–
16). The 100nM dose of 1,25(OH)2D is usual for studies exam-
ining its effect on cell lines and primary cells (17–20). In some
assays specified below, additional doses of 1,25(OH)2D and
25OHD were used to assess dose responses.
Cell proliferation
Cell proliferationwasmeasuredby3methodsonday3before
serum starvation.
1) For cell counting, cells cultured in 6-well plates were dis-
lodged by trypsin and counted using a hemocytometer.
2) For Alamar Blue (AB) staining (Invitrogen), cells cultured
in 96-well plates were stained with AB (10% vol/vol). AB
is reduced in proliferating cells from resazurin to resorufin,
the latter being a fluorescent compound. Measurement of
AB fluorescence is therefore a marker of cell proliferation
and viability (21). In our study, fluorescence excitation at
544 nm and emission at 590 to 610 nmwas measured. AB
fluorescencewas determined at baseline and after 25OHD
or 1,25(OH)2D treatments as an index of cellular prolif-
eration over this period.
3) For bromodeoxyuridine (BrdU) incorporation, using a
fluorescein isothiocyanate (FITC) BrdU Flow Kit (BD
Pharmingen), BrdU (100 mmol/mL) was added on day 2
for 24 hours. Staining for BrdU and 7-amino-actinomycin
D (7AAD) was performed as described (22). Flow cyto-
metric data was acquired using a FACS Canto (BD Bio-
sciences), and fluorochromes/filters were BrdU FITC
B530/30 and 7AADR660/20. FlowJo software (Tree Star)
was then used to analyze these data.
Apoptosis and necrosis
AnnexinV and propidium iodide (PI) are establishedmarkers
for apoptosis and cell necrosis (23). Annexin V binds to phos-
Table 1. Primer Sequences
Gene Primer
Akirin-1
Forward ccacctttacccttcgacaa
Reverse taggcaagaaggcttcagga
ATM
Forward gagtgagacgggctgttacc
Reverse catgctgcctccttcttttc
Cyclin D1
Forward agtgcgtgcagaaggagatt
Reverse cacaacttctcggcagtcaa
Cyclophilin
Forward tggaccaaacacaaacggttcc
Reverse acattgcgagcagatggggtag
CYP24A1
Forward cccttctgcaagaaaactgc
Reverse ctcttgagggctctgattgg
CYP27B1
Forward ggctgcatctctacctgacc
Reverse cagctggaagtggtagctca
Desmin
Forward gtgaagatggccttggatgt
Reverse gtagcctcgctgacaacctc
p19
Forward tccattgaagaagggagtgg
Reverse accgtttagatggctgttgc
p27
Forward cagaatcataagcccctgga
Reverse tctgacgagtcaggcatttg
Myc
Forward gcccagtgaggatatctgga
Reverse atcgcagatgaagctctggt
Myf5
Forward aggaaaagaagccctgaagc
Reverse gcaaaaagaacaggcagagg
Myogenin
Forward ccttgctcagctccctca
Reverse tgggagttgcattcactgg
Myostatin
Forward ctgtaaccttcccaggacca
Reverse tcttttgggtgcgataatcc
Rb
Forward aacccagcagtgcgttatct
Reverse ggtgttcgaggtgaaccatt
TBP
Forward tatcactcctgccacaccag
Reverse atgatgactgcagcaaatcg
VDR
Forward ttggaaccctggtctcattc
Reverse ccctctattggtgcttccag
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phatidylserine that becomes exposed on the cell surface during
apoptosis, and PI is an intercalating agent that gains entry into
the cell via membrane defects during necrosis (23). On day 3,
cells cultured in 6-well plates were trypsinized and then re-
suspended in solution containing 10mM HEPES, 140mM
NaCl, 2.5mM CaCl2, and FITC-labeled annexin V antibody
(1:50 dilution; BD Pharmingen). After 30minutes incubation,
cells were treated with PI (1:50 dilution). Flow cytometric
data was acquired using a FACS Canto (BD Biosciences), and
fluorochromes/filters were annexin V FITC B530/30 and PI
B655lpor. FlowJo software (Tree Star) was then used to an-
alyze these data.
Vitamin D luciferase reporter studies
Plasmids for GAL-4-VDR, UASTK-Luciferase, and pcDNA
were generated by R.J.C.-B. (Kolling Institute). Plasmids were
transformed in chemically competent Top-10" E. coli (Invit-
rogen) and extracted using the Plasmid Mini Kit (QIAGEN)
according to the manufacturer’s protocols. C2C12 cells were
split into 24-well culture plates and transfected at a high den-
sity before adhesion as previously described (24). Lipo-
fectamine 2000 (Gibco)was used to transfect 800 ng ofGAL4-
VDR and 800 ng of UASTK-luciferase reporter into 21 wells
per plate. Cells were also transfected with 800 ng !-galacto-
sidase reporter to correct for transfection efficiency. The re-
maining 3wells were transfected with pcDNA empty vector as
negative control. Twenty-four hours after transfection,
growth medium was replaced with serum-free medium, and
cells were treated with 25OHD (1nM–100nM), 1,25(OH)2D
(1nM–100nM), or ethanol control (0.1% of media solution).
Twenty-four hours later, luciferase activitywas detected using
the Steady-Glo luciferase assay system (Promega) and lumi-
nometry on a microplate scintillation counter (Packard). In
this system, luciferase activity results from 1,25(OH)2D bind-
ing to GAL-4-VDR and subsequent activation of the UASTK-
luciferase gene via its GAL4 promoter. Detection of luciferase
activity after treatment with 25OHD therefore shows conver-
sion to 1,25(OH)2D. Luciferase readings were corrected for
!-galactosidase activity as a transfection control. This was de-
tected using the Galacto-Star System (Applied Biosystems).
Figure 1. Components of the vitamin D-endocrine system in C2C12 muscle cells. A, C2C12 cells express CYP27B1, VDR, CYP24A1, and DBP
mRNA as seen on semiquantitative PCR. Duplicates for each are shown. B, On RT-PCR, expression of VDR and CYP24A1 mRNA is stimulated in a
dose-dependent fashion by 48 hours treatment with 1,25(OH)2D (data are mean # SEM, n $ 3 per group). C and D, Western blots (C) and
densitometric quantitation (D) show that VDR expression (normalized for !-actin) increased 2.2-fold in response to 72 hours treatment with
1,25(OH)2D (P ! .005, n $ 6–8 per group). E and F, On RT-PCR, expression of VDR and CYP24A1 mRNA is stimulated in a dose-dependent
fashion by 24 hours treatment with 25(OH)D (data are mean # SEM, n $ 3 per group). *, P ! .05; **, P ! .005.
Table 2. Antibody Information
Protein
Target Name of Antibody Manufacturer, Catalog No.
Species and
Clonality Dilution
VDR VDR (D6) Santa Cruz Biotechnology, sc13133 Mouse monoclonal 1:1000
Total Rb RB (G3-245) BD Pharmingen, 554136 Mouse monoclonal 1:1000
Phospo-Rb Phospho-Rb (Ser807/811) Cell Signaling, 9308 Rabbit polyclonal 1:1000
c-myc c-myc (c19) Santa Cruz Biotechnology, sc788 Rabbit polyclonal 1:1000
!-Actin !-Actin (AC-74) Sigma Aldrich, A2228 Mouse monoclonal 1:20 000
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Real-time PCR
RNA was isolated using the RNeasy Mini-kit (QIAGEN),
and equal amounts were reverse transcribed using Superscript
III first strand kit (Invitrogen) as previously described (25,
26). Real-time quantitative PCR was performed in 384-well
plates. The protocol included melting for 10 minutes at 95°C
and 40 cycles of 2-step PCR including melting for 15 seconds
at 95°C and annealing for 1 minute at 60°C. Primers were
designed using Primer 3 and BLAST (National Library of
Medicine) and obtained from Invitrogen. Primer sequences
are listed in Table 1. Every plate included housekeeping genes
(TATA-box binding protein [TBP] and/or cyclophilin) for ev-
ery sample. Semiquantitative PCRwas also performed by sep-
aration of PCR products via agarose gel electrophoresis. Im-
ages were taken using a Gel Doc (Bio-Rad).
Western blot
Cell lysates (60 "g protein) were separated by SDS-PAGE as
previously reported (27). A 10% gel was used, proteins were
transferred to PVDFmembrane, and themembranewas blocked
with 5%skimmilk powder in PBS plus 0.1%Tween 20. Primary
antibody was applied overnight at 4°C. Washed membranes
were incubated for 1 hour at room temperature with 1:1000 of
horseradishperoxidase-conjugatedsecondaryantibodyinblocking
buffer.Afterwashing, immune-reactivebandswerevisualizedusing
enhanced chemiluminescence (Santa Cruz
Biotechnology) in a Bio-Rad chemilumi-
nescence detection system. Bands were
quantified using ImageJ (National Insti-
tutes of Health).
A list of primary antibodies, the dilu-
tions used, and manufacturers’ details
have been included in Table 2. The
VDR-D6 antibody was chosen for its
previously reported specificity (28) and
our own validation experiments that
confirm the absence of signal in VDR-
null tissues. The cell cycle antibodies tar-
geting retinoblastoma protein (Rb),
phospho-Rb, and c-myc have been
widely used in cancer studies and vali-
dated by Western blot in small interfer-
ing RNA knockdown cell models (29,
30). We used protein lysates of MCF-7
human breast cancer cells as positive
controlswhen assessing cell cycle protein
expression.
Statistical analysis
Statistics were calculated in Excel or
SPSS version 20. Unless otherwise spec-
ified, Student’s unpaired t test with un-
equal variance was used to compare 2
groups. ANOVA with post hoc testing
and Bonferroni correction was used
where multiple comparisons were made.
For all figures, data are presented as
mean # SEM. P values !.05 were con-
sidered significant.
Results
C2C12 cells express components of the vitamin
D-endocrine system
There is ongoing debate about whether the effects of vi-
tamin D on muscle are direct or indirect via effects in other
tissues. To determine whether direct effects were possible,
components of the vitamin D-endocrine system were mea-
sured in the absence or presence of 1,25(OH)2D or
25(OH)D.
At a transcript level, C2C12 myotubes express VDR,
CYP27B1, CYP24A1, and vitamin D-binding protein
(DBP) (Figure 1A). Expression of VDR increased in a
dose-dependent manner after 48 hours treatment with
1,25(OH)2D (P ! .005, Figure 1B). Translation of VDR
mRNA into protein was confirmed using the VDR-D6
antibody (SantaCruz). VDRprotein increased%2-fold by
72 hours (P ! .005, Figure 1, C and D), and, consistent
with functional vitamin D signaling, the classic VDR tar-
get geneCYP24A1wasmarkedly upregulated aswell (P!
.005, Figure 1B).
Figure 2. Effects of 25OHD in C2C12 muscle cells. A, 25OHD induced a dose-dependent
increase in luciferase activity in C2C12 cells transfected with GAL4-VDR (switch) and UASTK-
luciferase reporter (P ! .005, n $ 3–4 per group). Similar changes were observed in response to
1,25(OH)2D (P ! .005, n $ 3–4 per group). These findings imply the presence of functional
CYP27B1 in C2C12 cells converting 25OHD to 1,25(OH)2D. Negligible levels of luciferase activity
were detected in cells transfected with empty vector pcDNA. Cells were also transfected with
!-gal reporter; luciferase activity was corrected (corr.) for !-galactosidase activity as
transfection control. B, As further evidence of functional CYP27B1, 25OHD induced an
antiproliferative effect in C2C12 myoblasts. C, This effect was first noted after 72 hours of
treatment and was dose-dependent on cell counting using a hematocytometer (P ! .05, n $
3 per group in 6-well plates). D and E, After prolonged treatment with 25OHD throughout
differentiation, there were fewer myotubes (D) and these were larger in size compared with
control-cultured cells (E) (P ! .005). Fibers were counted, and diameter was assessed on
ImageJ (diameter measurement, 20 fibers randomly selected per field, 2 fields per sample).
*, P ! .05; **, P ! .005.
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C2C12 cells express functional CYP27B1
Apart from demonstrating the expression of CYP27B1
mRNA, we sought to determine whether this enzyme
was functional in C2C12 cells. After treatment with
25OHD, there were dose-dependent increases in VDR
and CYP24A1 mRNAs, strongly implying the local me-
tabolism of 25(OH)D into 1,25(OH)2D (Figure 1, E and
F). Further evidence of functional CYP27B1 protein was
sought. Luciferase reporter studies were performed in
C2C12 cells that were transfected with GAL4-VDR
(switch) and UASTK-luciferase reporter. After 24 hours
treatment with 25OHD, there was a dose-dependent in-
crease in luciferase activity (P! .05, Figure2A), indicating
the intracellular conversion of 25OHD to 1,25(OH)2Dby
functional CYP27B1 and the subsequent activation of lu-
ciferase expression via 1,25(OH)2D-bound GAL4-VDR.
In general, luciferase activity in response to 25OHD was
comparable to that seen with the same concentrations of
1,25(OH)2D (Figure 2A).Luciferase reporter studies have
been previously used to demonstrate functional CYP27B1
in other cell types (31).
25OHD and 1,25(OH)2D exert antiproliferative
effects in C2C12 myoblasts
After 72 hours treatment with 25OHD, there were vis-
ibly fewer myoblasts in culture compared with control-
cultured samples (Figure 2B). This antiproliferative effect
was seen at 48 hours in cells treated with 1,25(OH)2D
(Figure 3A), was dose-dependent
with both 25OHD and 1,25(OH)2D
(Figures 2C and 3B), and was con-
firmed with AB fluorescence (Figure
3C).
Decreased cell counts can be due
to decreased proliferation, increased
cell death, or both. Proliferationwas
assessed by flow cytometric analysis
of BrdU incorporation and 7AAD
staining.Myoblasts treatedwith 100
nM 1,25(OH)2D had a higher per-
centageof cells in quiescent phases of
the cell cycle (G0/G1) and a lower
proportion of cells in the active (S
andM) phases (Figure 4A). This sug-
gested that the antiproliferative ef-
fect of 1,25(OH)2D was associated
with cell cycle arrest.
1,25(OH)2D does not induce
apoptosis or necrosis in C2C12
myoblasts
In addition to the antiprolifera-
tive effect described above, the re-
duced cell number after 1,25(OH)2D treatment could be
due to increased cell death. To exclude this possibility,
flow cytometry analysis was performed. Treatment with
1,25(OH)2D had no effect on the proportion of apoptotic
or necrotic cells on annexin V and PI staining (Figure 4B).
In addition, there was no difference in the proportion of
cells in the pre-G0/G1 phases on BrdU incorporation and
7AAD staining (P $ .54, Figure 4A). As this phase con-
tains both dying and apoptotic cells, this further confirms
the lack of toxic effect of 1,25(OH)2D in this study.
1,25(OH)2D alters expression of cell cycle markers
To assess mechanisms by which 1,25(OH)2D exerted
its antiproliferative effect, mRNA levels of genes control-
ling the cell cycle were measured. Treatment of C2C12
myoblasts with 1,25(OH)2D (range 1nM–100nM) for 48
hours dose-dependently increased ATM and Rb and re-
duced c-myc and cyclin D1 mRNA levels (Figure 4D).
These genes control the G1-S restriction point, and the
described changes are consistent with cell cycle arrest as
seen in Figure 3A (32). VDR expression increased at the
48-hour time point (Figure 4D). Other cell cycle markers,
including p19 and p27, were unchanged by 1,25(OH)2D
treatment.
Treatment with 1,25(OH)2D (48 hours, 100nM) did
not alter levels of total Rb protein (Figure 4C). This
could be related to increased turnover of Rb or perhaps
Figure 3. Antiproliferative effect of 1,25(OH)2D on C2C12 myoblasts. A, There were notably
fewer myoblasts in culture after 48 hours of treatment with 1,25(OH)2D. B, This effect was dose
dependent and significant at 10nM and 100nM on cell counting using a hematocytometer (P !
.05, n $ 3 per group in 6-well plates). C) AB fluorescence assay also indicated a dose-dependent
antiproliferative effect of 1,25(OH)2D (P ! .05, n $ 4 per group). *, P ! .05; **, P ! .005.
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to delay between mRNA and protein synthesis. Inter-
estingly, despite similar total protein, there was reduced
phosphorylation of Rb protein (Figure 4C). Dephos-
phorylated Rb binds to critical regulatory proteins in-
cluding E2F transcription factors and induces cell cycle
arrest (32, 33).
Treatment with 1,25(OH)2D reduced c-myc (Figure
4C), a transcription factor that controls cell proliferation.
C-myc activity is frequently elevated in cancer (34). In
epithelium (35), the c-myc pathway represents a mecha-
nism by which 1,25(OH)2D and VDR influence prolifera-
tion, and decreased c-myc is likely to contribute to the de-
crease in proliferation.
25OHD and 1,25(OH)2D decrease myotube formation
On day 3, myogenic differentiation was induced by
changing 10% fetal calf serum to 2% horse serum. The
rationale for thiswas to examine effects of1,25(OH)2Don
myogenesis independent of its effects on proliferation, by
inducing cell cycle arrest in general. Continued treatment
with 1,25(OH)2D delayed myotube formation and re-
duced the number of myotubes by 38% from days 3 to 10
(P ! .05, Figure 5, A and C). This coincided with down-
regulation of myogenic regulatory factors (MRFs) myf5,
myogenin (Figure 5B), and desmin (data not shown). These
genes play central, overlapping roles in myogenesis, in-
fluencing cell cycle arrest andmyotube formation. Con-
Figure 4. Cell cycle effects of 1,25(OH)2D on C2C12 myoblasts. A, Representative fluorescence-activated cell sorting (FACS) plot of BrdU and
7AAD staining. 1,25(OH)2D treatment resulted in significantly more C2C12 cells in the quiescent phases of the cell cycle (ie, G0/G1 phases, 80.1%
# 1.5% vs 68.9% # 1.3%, mean # SEM from n $ 4 per group, P ! .05) and significantly fewer in the active phases of the cell cycle (ie, M and S
phases, 16.7% # 1.3% vs 25.9% # 2.1%, P ! .05). B, Representative FACS plot of annexin V and PI staining. In 4 experiments, 1,25(OH)2D
treatment had no effect in the proportion of cells that stained positively for annexin V (ie, Q1, 2.3% # 0.9% vs 2.0% # 0.3%, P $ .7), PI (ie, Q3,
4.3% # 0.9% vs 13.8% # 5.5%, P $ .2), or both (ie, Q2, 5.0% # 1.3% vs 4.8% # 1.0%, P $ .9). C, At a protein level, total Rb expression was
not significantly altered despite the mRNA findings. However, Rb phosphorylation and c-myc protein levels were significantly reduced by
1,25(OH)2D treatment (P ! .05, corrected for total protein [pr,] on Coomassie blue stain). D, On RT-PCR, 1,25(OH)2D treatment resulted in altered
mRNA expression of cell cycle genes in C2C12 cells. Specifically, Rb and ATM mRNA expression increased in a dose-dependent fashion whereas
cyclin D1 and myc expression decreased (P ! .05, n $ 3 per group). *, P ! .05; **, P ! .005.
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sistent with this, 1,25(OH)2D suppressed fusion of
C2C12 myocytes to form myotubes. Fewer myotubes
were also seen in response to 25OHD, indicating persis-
tent CYP27B1 function and conversion to 1,25(OH)2D
throughout C2C12 cell differentiation (Figure 2D).
25OHD and 1,25(OH)2D increase C2C12 myotube
diameter, and 1,25(OH)2D downregulates myostatin
Despite delayed proliferation and lower absolute num-
berofmyotubes, byday10, cells treatedwith1,25(OH)2D
weremarkedly larger (Figure 5, C andD, 1.8-fold increase
in cross-sectional area, P ! .005). A similar increase in
myotube size was also seen in response to 25OHD (Figure
2, D and E, 2-fold increase in cross-sectional area, P !
.005). Myostatin, a negative regulator of muscle mass,
was downregulated 10-fold on day 7 in response to
1,25(OH)2D (Figure 5B, P ! .005), providing a poten-
tial mechanism for the notable difference in myotube
size.
Discussion
The presence of a functional vitamin D system in C2C12
cells (Figures 1and2) implies that vitaminDsignalingmay
play a direct role inmuscle regulation.We found 3 distinct
effects of treating C2C12 cells with 25OHD and
1,25(OH)2D: 1) inhibition of proliferation (Figures 2 and
3), 2) inhibition of myotube formation during serum star-
vation (Figures 2 and5), and3) increased size of individual
Figure 5. Effects of 1,25(OH)2D on C2C12 myotube formation and size. A, At day 7, there were notably fewer myotubes in C2C12 cells treated
with 1,25(OH)2D. B, On RT-PCR, myogenin, myf5, and myostatin mRNA levels were significantly reduced by 1,25(OH)2D treatment throughout
differentiation induced by serum starvation. VDR mRNA levels increased, indicating that changes in MRF expression were due to 1,25(OH)2D-VDR
genomic activity. Increases in the expression of CYP24A1 confirms the presence of a vitamin D autoregulatory system in these cells, activated by
1,25(OH)2D-mediated VDR stimulation. The reference point for fold change is the day 3 control, error bars are #SEM, and n $ 3 per group. C, On
day 10, C2C12 myotubes treated with 1,25(OH)2D were notably larger in diameter. D, On image analysis, 1,25(OH)2D treatment led to a
significant reduction in myotube number (22 # 3.6 vs 35 # 1.9 myotubes per field, P ! .05) and increases in myotube diameter (56.8 # 4.3 vs
30.5 # 1.8 "m, P ! .005). Fibers were counted, and diameter was assessed on ImageJ (diameter measurement, 8 fibers randomly selected per
field, 3 fields per sample). *, P ! .05; **, P ! .005.
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myotubes (Figures 2 and 5). VDR stimulation was effec-
tive at various time points (Figures 4 and 5), again sug-
gesting a direct role in the transcriptional regulation of
muscle development. Transcription factors that are known
to regulate key steps in mammalian myogenesis have been
summarized in Figure 6, including those involved in myo-
blast commitment, proliferation, differentiation, and the
determination of muscle fiber size. Potential effects of
1,25(OH)2D and 25OHD on myogenesis based on this
work have also been depicted.
The antiproliferative effects of 1,25(OH)2D in muscle
cells were first described in 1985 (36). They are consistent
with antiproliferative effects of 1,25(OH)2D in a number
of other cells and tissues including skin (35), cancer cells
(37), and immune cells (38). We report a novel antiprolif-
erative effect of the prehormone 25OHD in C2C12 cells as-
sociated with the presence of functional CYP27B1 as dem-
onstrated by luciferase reporter studies.We also report, for
the first time, underlying mechanisms for the antiprolif-
erative effect of vitamin D signaling in C2C12 cells. By
direct regulation of cell cycle gene expression (ATM,myc,
Rb, and cyclin D1) and posttranslational Rb hypophos-
phorylation, 1,25(OH)2D promotes cell cycle arrest and
quiescence in C2C12 cells as displayed in BrdU/7AAD
flow cytometry analysis (Figure 4). The antiproliferative
effect of 1,25(OH)2Dwas not related to an increase in cell
death,making toxicity unlikely (Figure4).Consistentwith
this, treatment with 1,25(OH)2D markedly upregulated
CYP24A1,which degrades 1,25(OH)2D (Figures 1 and 5).
Another novel finding is the suppression of C2C12
myotube formation after 25OHD and 1,25(OH)2D treat-
ment and serum deprivation. These findings stand in con-
trast to the recent study by Garcia and colleagues (18).
Without serumstarvation, prolonged treatment ofC2C12
cells with 1,25(OH)2D resulted in a stimulatory effect on
myotube formation via increased expression of MRFs in
this earlier study (18). This discrepancy is interesting, be-
cause serum deprivation and prolonged confluent culture
represent 2 distinct models of myogenesis. The former re-
lies onwithdrawal ofmitogenic stimuli to induce cell cycle
arrest and myogenin expression (12), and the latter relies
on expression of endogenous IGFs (12, 39). Due to the
protracted nature of C2C12 myogenesis in high-serum
conditions, it is possible that Garcia et al (18) reporting a
stimulatory effect of 1,25(OH)2D on myogenesis corre-
sponds with earlier cell cycle arrest, as seen before serum
deprivation (ie, day 3) in our study.
In broader terms, the inhibitory effects of vitamin D
signaling on myocyte proliferation and myotube forma-
tion may indicate the promotion of cell quiescence and
protection from senescence. In a recent study, 1,25(OH)2D
(100nM) inhibited proliferation and delayed replicative
senescence of human mesenchymal stem cells on the basis
of ß-galactosidase staining and p16 expression, without
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affecting their clonogenic capacity (40). Another study
found direct links between the antiproliferative effect of
VDR and proteins involved in cell survival, namely FoxO
and Sirt1 (41). Thismay be particularly important inmus-
cle, in which age-related dysfunction of stem cells is di-
rectly related to downregulation of their quiescent, self-
renewing capacity (42).
A separate effect in this study, also seen with the high-
serummethod (18), was an anabolic effect of 25OHDand
1,25(OH)2D on myotube size. We saw a pronounced
downregulationofmyostatin, anegative regulatorofmus-
cle mass, and upregulation of an upstream transcription
factor, follistatin, has also been described (18). Effects of
1,25(OH)2D and VDR on the TGF-! family, of which
myostatin is a member, have also been demonstrated in
mesenchymal stem cells (43), skin (44), and liver (45),
suggesting widespread links between these pathways.
1,25(OH)2Dmay also have effects on fiber size via insulin
signaling pathways, relating specifically to insulin recep-
tor substrate-1 and Akt phosphorylation (46).
There are limitations to this study. Although C2C12
cells expressproteinsnecessary formuscle contractionand
display themorphology of individual fiber units, there are
striking differences between these cells and adult muscle,
particularly in their degree of maturation (47) and mode
of glucose transport (48).Therefore, effects inC2C12cells
donot always translate to adultmuscle. Second, treatment
of cellswith pharmacological doses of 1,25(OH)D in vitro
may not necessarily correspond with physiologic re-
sponses in vivo.Nevertheless, this in vitromodelmay pro-
vide insight into the role of the VDR in skeletal muscle
development and transcriptional events mediated by its
activation.
In vivo studies also support a role for vitamin D sig-
naling in the development of skeletal muscle. Mice with
deletion of VDRdisplayedmuscle fibers that were smaller
andmore variable in size thanwild-typemice (5). Thiswas
associatedwith higher expression ofmyf5, myogenin, and
E2A in quadriceps muscle of the knockouts. Myostatin
was not reported in this study (5). European sea bass that
received dietary vitamin D after hatching demonstrated
dose-dependent increases in white muscle fiber size and
differences in the expression of MRFs (49). In humans,
children born to vitamin D-deficient mothers displayed
significantly smaller arm-muscle area (50), and another
study reported a positive correlation between 1,25(OH)2D
levels and skeletal muscle mass on dual-energy x-ray ab-
sorptiometry scan in adults (51).
There are, however, no in vivo studies examining ef-
fects of vitamin D on muscle fiber number, an important
question given its in vitro effects onproliferation andmyo-
tube formation. Overexpression of c-myc in VDR-knock-
out mice is associated with the local development of co-
lonic epithelial hyperplasia and dysregulated epidermal
differentiation, leading to alopecia (35, 52). We have also
found that 1,25(OH)2D directly regulates c-myc expres-
sion in muscle cells, suggesting in vivo relevance in this
tissue. Other questions remain such as potential roles for
vitamin D in muscle regeneration, a process that closely
mimics muscle differentiation (53). Such a role has re-
cently been suggested by the upregulation of VDR in a
mouse model of muscle injury (54) and the modulation of
key angiogenic factors vascular endothelial growth factor
and fibroblast growth factor-1 inC2C12 cells treatedwith
1,25(OH)2D (55).
In summary, this work reports the presence of func-
tional CYP27B1 in C2C12 cells on the basis of luciferase
reporter studies andnovel effects of 25OHDinC2C12cell
proliferation and differentiation. This work also eluci-
dates novel effects of vitamin D signaling in C2C12 cell
cycle regulation, with effects in the expression and post-
translational modification of genes controlling G0/G1 ar-
rest and G1/S transition. This offers mechanistic insight
into the establishedantiproliferative effect of 1,25(OH)2D
in these cells. Independent of this effect, 1,25(OH)2D in-
hibited myogenesis by the suppression of MRFs and had
an anabolic effect on myotube formation, previously un-
reported findings in C2C12 cells after serum deprivation.
Taken together, these findings raise the possibility of a
direct effect of vitamin D on muscle. Further studies are
needed to examine developmental effects of vitamin D in
skeletal muscle and elucidate relevant signaling pathways
at this site.
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Chapter 4 – The vitamin D receptor and skeletal muscle 
 
 
This chapter consists of an original article that was published in the September 
edition of Endocrinology (2014; 155: 3227–3237). The primary author and PhD 
candidate, Christian Girgis, carried out the majority of experiments described in 
this work (>80%), drafted manuscripts and responses to reviewers. A 
component of this work (radiolabelled vitamin D uptake assay) was performed 
in collaboration with the laboratory of Prof. Rebecca Mason. To date, this 
article has been cited > 15 times since publication and in 2014, received the 
Endocrine Society Best of Basic Research Award.  
 
The main findings of this work include: 
• detection of VDR in four models of murine skeletal muscle by the use 
of four independent techniques (i.e. RT-PCR, western blot, 
immunohistochemistry, and radiolabelled vitamin D uptake assay).  
• experimental conditions and technical factors necessary for detection of 
VDR in muscle.  
• significantly higher levels of VDR in young muscle and isolated muscle 
cells corroborating with its purported role in muscle development and 
pleiotropy.  
• novel effect of VDR in the ligand-mediated uptake of 25OHD in 
primary muscle fibres. 
News/Views and Counterpoint articles published in the same edition as this 
article, together with our rebuttal to the Counterpoint, have also been included 
in this chapter.  
The Vitamin D Receptor (VDR) Is Expressed in
Skeletal Muscle of Male Mice and Modulates
25-Hydroxyvitamin D (25OHD) Uptake in Myofibers
Christian M. Girgis, Nancy Mokbel, Kuan Minn Cha, Peter J. Houweling,
Myriam Abboud, David R. Fraser, Rebecca S. Mason, Roderick J. Clifton-Bligh,
and Jenny E. Gunton
Garvan Institute of Medical Research (C.M.G., N.M., K.M.C., J.E.G.), Sydney, New South Wales,
Australia 2010; Faculties of Medicine (C.M.G., M.A., R.S.M., R.J.C.-B., J.E.G.) and Veterinary Science
(D.R.F.) University of Sydney, Sydney, New South Wales, Australia 2145; Bosch Institute (M.A., R.S.M.),
University of Sydney, Sydney, New South Wales, Australia 2006; Murdoch Childrens Research Institute
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Vitamin D deficiency is associated with a range of muscle disorders, including myalgia, muscle
weakness, and falls. Inhumans,polymorphismsof thevitaminDreceptor (VDR)geneareassociated
with variations in muscle strength, and in mice, genetic ablation of VDR results in muscle fiber
atrophy and motor deficits. However, mechanisms by which VDR regulates muscle function and
morphology remain unclear. A crucial question is whether VDR is expressed in skeletal muscle and
directly alters muscle physiology. Using PCR, Western blotting, and immunohistochemistry
(VDR-D6 antibody), we detected VDR inmurine quadricepsmuscle. Detection byWestern blotting
wasdependenton theuseofhyperosmolar lysis buffer. Levels ofVDR inmusclewere lowcompared
with duodenum and dropped progressively with age. Two in vitro models, C2C12 and primary
myotubes, displayed dose- and time-dependent increases in expression of both VDR and its target
gene CYP24A1 after 1,25(OH)2D (1,25 dihydroxyvitamin D) treatment. Primary myotubes also
expressed functional CYP27B1 as demonstrated by luciferase reporter studies, supporting an au-
toregulatoryvitaminD-endocrine systeminmuscle.Myofibers isolatedfrommice retainedtritiated
25-hydroxyvitamin D3, and this increased after 3 hours of pretreatment with 1,25(OH)2D (0.1nM).
No such response was seen in myofibers from VDR knockout mice. In summary, VDR is expressed
in skeletal muscle, and vitamin D regulates gene expression and modulates ligand-dependent
uptake of 25-hydroxyvitamin D3 in primary myofibers. (Endocrinology 155: 3227–3237, 2014)
The association between vitamin D deficiency andmus-cle disease is long standing. More than 300 years ago,
children with rickets were noted to demonstrate hypotonia
and muscle wasting (1). Adults with vitamin D deficiency
develop type 2 (ie, fast twitch) muscle fiber atrophy, muscle
weakness, andpain (2).VitaminDsupplementation reverses
these features and attenuates the risk of falls in older and
institutionalized individuals (3). Serum 25-hydroxyvitamin
D (25OHD) levels have also been positively correlated with
muscle function in young and old individuals (4, 5).
Precise mechanisms to explain vitamin D’s effects in
muscle are unclear. Biochemical abnormalities associated
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with vitamin D deficiency independently lead to muscle
disease. However, emerging evidence suggests that vita-
min Dmay play a direct role. In vitro studies demonstrate
various effects of 25OHD or 1,25(OH)2D on calcium
flux, intracellular signaling, and gene expression in
muscle cells in addition to uptake of 25OHD in muscle
fibers (6, 7).
ThevitaminDreceptor (VDR), amemberof thenuclear
receptor superfamily, regulates expression of numerous
genes involved in calcium/phosphate homeostasis and cel-
lular proliferation/differentiation in a predominantly li-
gand-dependent manner (2). The question of whether
skeletal muscle expresses VDR, and may therefore be a
direct target of 1,25(OH)2D, is controversial. Several
studies report the presence of VDR in muscle cell lines (6,
8–11), whereas others examining the in vivo presence of
VDR have yielded contradictory results (12–16).
In this study, we address the critical issue of whether
VDR is present in skeletal muscle and examine variations
in its expression in young and old mice. We also elucidate
a novel role of VDR in the ligand-mediatedmodulation of
25OHDuptake inmuscle fibers, further strengthening the
case in favor of its presence and function at this site.
Materials and Methods
Cell culture
Primary cellswere isolated fromthequadricepsof 3-week-old
male mice by explant culture as previously described (17). Ex-
plant cells were then trypsinized and sorted (Aria U2; Becton
Dickinson-BD) using a Neural Adhesion Cell Marker/CD56 an-
tibody (MEM-188;ThermoScientific/Pierce) aswehave recently
described (18). The enriched population of primary muscle cells
was then propagated in DMEM-F12with 20%heat-inactivated
fetal calf serum (FCS) and 10% Amniomax at 37°C and 5%
CO2. Serum depletion was used to induce myotube formation.
These primary myotubes differ from C2C12 myotubes, because
they are derived fromhealthy rather than dystrophicmuscle (19)
and are not subject to mutations arising due to immortalization.
Primary myotubes with a low passage count (ie, 5 and 6) were
used in these studies.
C2C12 myoblasts were propagated as previously reported
(10) inDMEM-F12with 10%heat-inactivated FCS at 37°C and
with 5% CO2. On reaching 80% confluence, cells were
trypsinized and subcultured in 6-well plates (30 000 cells per
well). To produce myotubes, after day 3, serum was decreased
from10%to2%,andFCSwas changed tohorse serumto initiate
cell cycle exit and myogenic differentiation (ie, serum depletion)
(20, 21). Six days after serum depletion, myotubes were fully
formed and were treated with 1,25(OH)2D (1 nM–100 nM) or
vehicle (ethanol). VDR mRNA and protein expression were
measured after 48 and 72 hours, respectively.
Animals and maintenance
C57BL/6male mice of different ages were used. Demay VDR
knockout (VDRKO) mice and their wild-type (WT) littermates
were maintained on a !-irradiated “rescue chow” (SF08-002;
Specialty Feeds) containing 2% calcium, 1.2%phosphorus, 0.2-
g/g lactose, and 1-IU vitamin D/g fromweaning. Rescue chow is
essential to normalize the blood mineral ion levels of VDRKO
mice (22). All procedures were approved by theGarvan Institute
Animal Ethics Committee (ethics protocol AEC 12/26). Animals
were euthanized with CO2, and hindlimb muscles were dis-
sected. Muscles were then sliced open and washed thoroughly
with PBS to reduce blood contamination. They were then snap
frozen in liquid nitrogen to be used at a later time for RNA and
protein isolation. Muscles to be used for histological examina-
tion were frozen in isopentone cooled in liquid nitrogen.
Real-time PCR
For C2C12 cells, RNA was isolated using RNeasy Mini kit
(QIAGEN). For whole muscle, samples were homogenized in
RLT solution (QIAGEN), treated with proteinase K solution,
and RNA was subsequently isolated using RNeasy Mini kit
(QIAGEN). Equal amounts of RNA were reverse transcribed
using Superscript III first strand kit (Invitrogen) as previously
described (23, 24). Real-time quantitative PCR (RT-PCR) was
performed in 384-well plates. The protocol included melting for
10minutes at 95°C and 40 cycles of 2-step PCR, including melt-
ing for 15 seconds at 95°C and annealing for 1 minute at 60°C.
Primers were designed using Primer 3 and BLAST (National Li-
brary of Medicine) and obtained from Invitrogen. Primer se-
quences were as previously published (10) with an additional
primer for VDR: forward, 5!-gtggacattggcatgatgaa-3! and re-
verse, 5!-ttacgtctgcacgaattgga-3!. Every plate included house-
keeping genes (TATA-box-binding protein, cyclophilin, and/or
18S) for every sample. For each experiment, a housekeeping gene
that did not differ significantly between groups was used to nor-
malize cycle threshold (CT) values. CT is the number of PCR
cycles at which fluorescence above background crosses a set
threshold. Relative expression levels were calculated by compar-
ing the logarithm of the difference of total cycle number and CT
for specific groups (ie, ""CT).
Semiquantitative PCR was also performed by separation of
PCR products via agarose gel electrophoresis. Images were cap-
tured using a Gel Doc (Bio-Rad) to determine the presence or
absence of mRNA transcripts.
Western immunoblotting
To isolate protein fromwholemuscle, 2 different lysis buffers
were used for comparison: 1) regular lysis buffer (RLB) contain-
ing 10mM Tris-HCL, 1% Triton X-100, 0.5% NP40, 150mM
NaCl, 10mM Na orthophosphate, 10mM Na pyrophosphate,
10mM Na orthovanadate, 100mM NaF, 1mM EDTA, 1mM
EGTA,andProtease InhibitorCocktail tablet (Roche) (pH7.45);
or 2) hyperosmolar lysis buffer (HLB) containing 6.7M urea,
10% glycerol, 10mM Tris-HCl, 1% sodium dodecyl sulfate,
1mM dithiothreitol, 1mM phenylmethylsulfonyl-fluoride, and
Protease InhibitorCocktail tablet (Roche).Wehypothesized that
HLB would be necessary in separating VDR from tight binding
to DNA. Samples were homogenized in respective buffers and,
after centrifugation, were sonicated. After further centrifuga-
tion, the supernatantwas transferred to a fresh tube, and protein
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concentrations were measured. Lysates (20- to 60-"g protein)
were separated by SDS-PAGE as previously reported (25). A
10% gel was used, proteins were transferred to polyvinylidene
fluoride, and the membrane was blocked with 5% skim milk
powder in PBS plus 0.1% Tween 20. Primary antibody was ap-
plied overnight at 4°C. Washed membranes were incubated for
1 hour at room temperature with 1:1000 of horseradish perox-
idase-conjugated secondary antibody in blocking buffer. After
washing, immune-reactivebandswerevisualizedusing enhanced
chemiluminescence (Santa Cruz Biotechnology, Inc) in a Bio-
Radchemiluminescencedetection system.Bandswerequantified
using ImageJ (National Institute of Health). The VDR-D6 anti-
body (sc13133; Santa Cruz Biotechnology, Inc) was chosen for
its previously reported specificity (26). Validation experiments
confirm the absence of signal in tissues from our VDRKOmice.
To correct for protein loading, membranes were additionally
probedwith#-actin antibody (A2228, 1:20 000; Sigma-Aldrich)
or total protein staining using Coomassie reagent. Protein ex-
tracted from duodenum and kidney was used a positive control
for detection of VDR.
Immunohistochemistry
Frozen 8-"m muscle sections from 3-week-old VDRKO or
WT mice were cut using a Cryostat (Leica) and mounted on
slides. Sections were simultaneously fixed and permeabilized by
incubation in 3% paraformaldehyde and 0.1% Triton X-100 in
PBS for 30 minutes. After thorough washing in PBS, sections
were then blocked with 2% BSA in PBS for 30 minutes. Sections
were then incubated inVDR-D6antibody (at adilutionof 1:100)
in PBS containing 2%BSA in a moist chamber at 4°C overnight.
The nextmorning, sectionswere blocked again in 2%BSA for 30
minutes at room temperature. They were then incubated in PBS
with secondary antibody Alexa Fluor 488-conjugated goat an-
timouse IgG (1:250; Molecular Probes). 4=,6-Diamidino-2-phe-
nylindole (DAPI) (1:150; Molecular Probes, Life Technologies)
was incubatedwith the secondary antibody to stain nuclei.Mus-
cle sections from 3-week-old VDRKO or WT mice were used.
Optimal antibody dilutions and incubation times were deter-
mined by earlier pilot experiments. For control sections, the pri-
mary or secondary antibody was omitted, and absence of signal
was confirmed. Images were taken using a fluorescent micro-
scope (Leica LAS Power-Mosaic). Duodenal sections from adult
WT mice were used as positive control.
Vitamin D luciferase reporter studies
In addition to VDR, we assessed the presence of functional
CYP27B1 in primary myotubes to further investigate an innate
vitaminD system in thismodel of skeletalmodel. The expression
construct Gal4-VDR was made by cloning the ligand-binding
domain of VDR downstream of the Gal4 DNA-binding domain
in pGL3Basic (Promega). Expression vectors for the Gal4-re-
sponsive reporter gene, UASTK-luciferase, and transfection
control reporter gene (#-galactosidase)were kind gifts fromPro-
fessorV.K.K.Chatterjee (University ofCambridge,UnitedKing-
dom). Plasmidswere transformed in “chemically competent: top
10”Escherichia coli (Invitrogen) andextractedusing thePlasmid
Mini kit (QIAGEN) according to the manufacturer’s protocols.
Primary myocytes were split into 96-well culture plates at high
density (30 000 cells per well) and transfected 1 day later (con-
fluence,#90%). Lipofectamine-2000 (Gibco)was used to trans-
fect 800 ng each of Gal4-VDR, UASTK-luciferase reporter, and
#-galactosidase reporter into 21 wells per plate. The remaining
3 wells were transfected with pcDNA empty vector as negative
control. Forty-eight hours after transfection, primary myocytes
had fused to form contractilemyotubes due to confluent culture.
These myotubes were subsequently treated in serum-free media
with 25OHD (1nM–100nM), 1,25(OH)2D (1nM–100nM), or
ethanol (0.1% of media solution) as indicated. Twenty-four
hours later, luciferase activity was detected using the Steady-Glo
Luciferase Assay system (Promega) and luminometry in a mi-
croplate scintillation counter (Packard). In this system, luciferase
activity results from 1,25(OH)2D binding to GAL-4-VDR and
subsequent activation of UASTK-luciferase gene via its GAL4
promoter. Detection of luciferase activity after treatment with
25OHD, therefore, indicates conversion to 1,25(OH)2D. Lu-
ciferase readings were corrected for #-galactosidase as a trans-
fection control. This was detected using the Galacto-Star System
(Applied Biosystems).
Effect of 1,25(OH)2D on tritiated 25OHD uptake in
muscle models
Apart from examining the presence of VDR in skeletal mus-
cle, we also sought to determine its functional significance.
Whole myofibers were isolated from the flexor digitorum brevis
muscle of euthanized WT and VDRKO mice, as previously de-
scribed (27). The isolated myofibers were cultured in 24-well
plates coated with 20-"g/mL laminin at a density of approxi-
mately 10–30 myofibers per well and maintained in DMEM
supplemented with 10% FCS. They were preincubated with
0.1nM 1,25(OH)2D or control for 3 hours. Uptake studies were
conductedby incubationofmyofiberswith25-[26,27 3H]OHD3
(PerkinElmer) at a concentration of 240 nCi/mL in DMEM sup-
plemented with 0.1M 1,25(OH)2D or control and 20% serum
replacement 1 (Sigma-Aldrich) for 4 hours. Fibers were washed
and lysed as described (7). Radioactivity was measured by scin-
tillation counting, and the results were expressed as counts per
minute per primary myofibers counted in each well. These stud-
ies were also performed in C2C12 myotubes, which were pre-
incubated for 1 hour with 50"M4,4!-diisothiocyanatostilbene-
2,2!-disulfonic acid (DIDS) or dimethyl sulfoxide control. DIDS
is a chloride channel blocker known to inhibit nongenomic ac-
tions of 1,25(OH)2D-VDR (28).
Statistical analysis
Statistics were calculated in Excel or SPSS version 20. Unless
otherwise specified, Student’s unpaired t test with unequal vari-
ance was used to compare 2 groups. ANOVA with post hoc
testing and Bonferroni correction was used where multiple com-
parisonsweremade. For all figures, data arepresentedasmean$
SEM. P % .05 was considered significant.
Results
VDR is expressed and declines during
differentiation in C2C12 muscle cells
To test whether VDR is expressed in a skeletal muscle
cell line, C2C12 cells were studied. These immortalized
cells are derived from dystrophic murine muscle and dif-
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ferentiate into multinucleated myotubes upon serum de-
pletion. C2C12 cells express VDR mRNA in addition to
mRNAs of vitamin D-related enzymes CYP27B1 encod-
ing 1-$-hydroxylase and CYP24A1 encoding 24-hydrox-
ylase (Figure 1A). The expression of VDR mRNA was
inducible, increasing in a dose-dependentmanner after 48
hours of treatment with its ligand, 1,25(OH)2D (P% .005)
(Figure1B).VDR expressiondropped sequentially throughout
differentiation but remained detectable throughout (P %
.005) (Figure 1C). Its expression was 0.4-fold lower in
fully differentiated myotubes compared with myoblasts.
This has also been reported in G8 and H9C2 muscle cell
lines (11). VDR protein was detectable in differentiated
C2C12myotubes and increasedmore than 2-fold after 72
hours of treatment with 1,25(OH)2D at a dose of 100nM
(P % .005) (Figure 1, D and E).
VDR and functional CYP27B1 are expressed in
primary myotubes
Primarymyotubes appear as elongated,multinucleated
syncytia akin to muscle fibers (Figure 2A). They express
cytoskeletal proteins necessary for contraction and may
contract spontaneously in culture. At a transcript level,
primary myotubes express VDR in addition to vitamin
D-related enzymes CYP27B1 and CYP24A1 (Figure 2,
B–D). The expression of VDR and its classic target gene,
CYP24A1, were inducible, increasing in a dose-dependent
manner after 48 hours treatment
with 1,25(OH)2D (P% .005) (Figure
2B). In a time-course study, expres-
sion ofVDRwas increasedby4hours
after treatment with 1,25(OH)2D
(100nM), and the increase was main-
tained at 8 and 16 hours (P % .005)
(Figure 2D).CYP24A1 also increased
significantly but not until 16 hours
(P % .005) (Figure 2D). There was
no regulation of CYP24A1 by
1,25(OH)2D in primary myotubes
from VDRKOmice (Figure 2D), con-
firming that this effect is mediated by
VDR.
Apart fromdemonstrating the ex-
pression of CYP27B1 mRNA (Fig-
ure 2C), we sought to determine
whether the enzyme encoded by this
gene (1-$-hydroxylase) was func-
tional in primary myotubes and
could convert25OHDto1,25(OH)2D.
Luciferase reporter studies were per-
formed in primary myotubes that
were transfected with GAL4-VDR
(switch), UASTK-luciferase reporter,
and#-galactosidase reporter (transfection control). After 24
hours of treatment with 25OHD, there was a dose-depen-
dent increase in luciferase activity (P% .05) (Figure 2E), in-
dicating the intracellular conversion of 25OHD to
1,25(OH)2D. This demonstrates functional 1-$-hydroxy-
lase converting 25OHD to 1,25(OH)2D and the subsequent
activation of luciferase expression via 1,25(OH)2D-bound
GAL4-VDR. Luciferase activity in response to 25OHDwas
comparablewiththat seenwith1,25(OH)2Dusedaspositive
control (Figure 2E). Doses of 25OHD used (5nM–100nM)
were substantially lower than those known to directly acti-
vate VDR independent of CYP27B1 (29). Luciferase re-
porter studies have been previously used to demonstrate
functional 1-$-hydroxylase in C2C12 myoblasts (10), but
this is the first report in primary contractile myotubes.
VDR transcript is detectable in skeletal muscle
WeperformedRT-PCRonwholemuscle extracts from
adult WT and VDRKOmice. VDR transcript was detect-
able inWT but not in VDRKOmuscle (Figure 3A). Levels
ofVDR transcript in (WT) skeletal muscle were low com-
pared with a classical site of VDR expression, the duode-
num (relative transcript levelswere obtained by correcting
for muscle VDR mRNA in Figure 3B). However, tran-
scription factors may be functionally active in the regula-
tion of gene expression at very low expression levels (30).
Figure 1. Components of the vitamin D-endocrine system in C2C12 muscle cells. A, C2C12
cells express CYP27B1, VDR, and CYP24A1 mRNA as seen on semiquantitative PCR. Duplicates
for each have been shown. B, Expression of VDR mRNA is stimulated in a dose-dependent
fashion by 48 hours of treatment with 1,25(OH)2D (data are mean $ SEM, n & 3 per group).
C, VDR mRNA drops sequentially during C2C12 differentiation from myoblasts to myotubes (P %
.005). Western blotting (D) and densitometric quantitation (E) show that VDR expression
(normalized for #-actin) increased 2.2-fold in response to 72 hours of treatment with 1,25(OH)2D
in C2C12 myotubes (P % .005, n & 3 per group).
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Therefore, this difference in transcript levels does not pre-
clude a functional role for VDR in muscle. To examine
this, we assessed differences in the expression of cell cycle
and calcium handling genes in WT and VDRKO muscle.
Thesepathwayswere chosenbecause theyare regulatedby
VDR in other organ systems (31). Significant increases in
the expression of sarcoplasmic reticulum calcium chan-
nels and an intracellular calcium-binding protein were
noted in VDRKO muscle (see figure 5 below). This was
unexpected because the opposite effect is seen in intes-
tine and kidney (32). This highlights the tissue-specific
nature of VDR regulation of calcium handling, which
has also been demonstrated in brain (33). Expression of
myc and cyclins were significantly higher in the muscle
of VDRKO mice, consistent with changes seen in skin
and intestine, indicating altered cell cycle regulation
(see Figure 5 below) (34).
VDR protein is detectable in skeletal muscle
We compared the effects of 2 different lysis solutions
upon the ability to detect VDR onWestern blotting under
the same experimental conditions. Protein bands were
barely detectable in lysates made using RLB (Figure 3C).
However, in HLB samples, bands
were detectable inWT but undetect-
able in muscle from VDRKO mice
(Figure 3C). HLB may facilitate re-
lease of DNA-bound proteins, in-
cluding VDR, and be more effective
for protein unfolding and denatur-
ation (35, 36). Similar urea-contain-
ing lysis buffer is used for the detec-
tion of heat-shock transcription
factors in muscle (37). These find-
ings denote the importance of spe-
cific conditions in the detection of
nuclear proteins expressed at low
levels in muscle, such as VDR. In
Western blottings comparing VDR
in muscle, duodenum, and kidney,
VDR detection in muscle required
relatively long exposure time (15
min) and greater amounts of muscle
protein per sample (ie, 50 vs 10 "g
for duodenum and kidney per lane)
(Figure 3D). However, it was
detectable.
VDR is detectable at higher
levels in cell models than whole
muscle
VDR expression levels differed
substantially between whole muscle
and in vitro models. Primary and C2C12 myotubes ex-
pressed significantly higher levels of VDR mRNA than
whole muscle (ie, #8- and #300-fold, respectively; P %
.005) (Figure 3B). The CT values for the real-time PCR
were 22.8$ 0.1 for C2C12 cells, 28.1$ 0.3 for primary
myotubes, and31.1$0.2 forprimarymuscle.At aprotein
level, there was approximately 10-fold more VDR in pri-
mary and C2C12myotubes compared with whole muscle
(P % .05) (Figure 3, E and F). This finding suggests that
VDRexpression is activated aftermuscle cell isolation and
immortalization, respectively. Alternatively, its presence
specifically within muscle fibers and not in other compo-
nents of whole muscle may possibly explain this
discrepancy.
VDR is detectable within muscle fibers
Skeletal muscle is a heterogeneous tissue composed of
myofibers, fibroblasts, immune cells, and adipocytes. We
therefore sought to determine whether the expression of
VDR in muscle was specifically located in muscle fibers.
On immunohistochemistry of muscle taken from young
WT mice, VDR was detected within muscle fibers and
Figure 2. Components of the vitamin D-endocrine system in primary myotubes. A, Primary
myotubes are elongated, multinucleated syncytia that contract in culture and resemble muscle
fibers. B, On RT-PCR, expression of VDR and CYP24A1 mRNA is stimulated in a dose-dependent
fashion by 48 hours of treatment with 1,25(OH)2D (mean $ SEM, n & 3 per group). C, Primary
myotubes express CYP27B1, VDR, and CYP24A1 mRNA as seen on semiquantitative PCR.
Duplicates for each have been shown. D, On RT-PCR, expression of VDR increases in a time-
dependent fashion after treatment with 100nM 1,25(OH)2D. An increase in CYP24A1 was first
noted at 16 hours in myotubes from WT mice, but this effect was absent in myotubes from KO
mice. E, 25OHD induced a dose-dependent increase in luciferase activity in primary myotubes
transfected with Gal4-VDR (switch) and UASTK-luciferase reporter (P % .005, n & 4–6 per
group). Similar changes were observed in response to 1,25(OH)2D (P % .005, n & 4–6 per
group). Luciferase activity was corrected for #-galactosidase activity as transfection control.
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partly localized to fiber nuclei as seen on DAPI counter-
staining (Figure 4, A–C). No signal was detected in
VDRKO muscle (Figure 4, D and E). As positive control,
VDR staining in duodenum of WT mice was performed
(Figure 4, F and G).
VDR expression in muscle is greater in young mice
VDR exerts pleiotropic effects in the development of
bone, skin, and the immune system (38, 39). Recent data
also suggest that upon activation, VDR regulates prolif-
eration and differentiation in C2C12 muscle cells (9, 10).
We therefore sought to determine whether the expression
of VDR in muscle was influenced by developmental age.
To do this,VDR transcript and protein were compared in
quadriceps muscles of mice of different ages, from new-
born pups to 3-month-old adults. VDR transcript levels
were significantly lower in the quadriceps muscles of
3-week-old mice (ie, postweaning) and 3-month-old mice
compared with newborn WT mice (0.7- and 0.14-fold,
respectively; P% .005 both) (Figure 5B). This indicated a
sequential drop in the expression of VDR in muscle
throughout development (ie, from newborn to 3 wk of
age) and intomaturity (ie, from3wk to3moofage).These
changes were also confirmed at a protein level. On West-
ern blotting, VDR protein was significantly lower in mus-
cles of 3-month-old mice compared with newborn pups
(0.4-fold difference; P% .005) (Figure 5, C and D). These
findings suggest the possibility of a role forVDR inmuscle
development and, perhaps, a different role in fully devel-
oped, adult muscles. This also denotes the importance of
age in the detection of VDR in skeletal muscle.
VDR modulates 1,25(OH)2D-modulated uptake of
25OHD in muscle
We have recently elucidated a novel role for skeletal
muscle in the net uptake of 25OHD (7). This occurs in a
time-dependent fashion and relies on the local expression
of megalin and cubilin, endocytotic receptors for the vi-
tamin D-binding protein (DBP).
WT myofibers preincubated with 1,25(OH)2D for 3
hours showed 40% higher net uptake of 3H-25OHD3
than WT myofibers preincubated with control solution
Figure 3. Detection of VDR in skeletal muscle on PCR and Western blotting. A, On semiquantitative PCR, VDR transcript is detectable in
quadriceps muscle from 3 adult WT mice. Muscle from 3 VDRKO mice was used as negative control. B, VDR transcript levels relative to whole
muscle (ie, fold difference; VDR mRNA levels divided by that in whole muscle) and absolute CT values are listed (mean $ SEM, n & 3 per group).
VDR transcript levels are markedly higher in duodenum (Duo.), the classic target of vitamin D action, compared with whole muscle and appreciably
higher in muscle cell models compared with whole muscle. C, Using VDR-D6 antibody on Western blotting, VDR was detected in quadriceps
muscle processed in HLB but hardly detected in samples processed in RLB (n & 9 per group, 60-"g protein/well, 7.2-fold higher detection; P %
.05). For negative control, VDRKO muscle sample processed in HLB was used (n & 3). D, Compared with Duo. and kidney (Kid.), VDR in muscle
required longer exposure time (15 min) and more protein loading (50 vs 10 "g per lane). Western blotting (E) and ImageJ densitometric
quantitation (F) show that VDR expression (normalized for total protein on Coomassie) is approximately 10-fold higher in primary myotubes (Prim.
MT) and C2C12 myotubes compared with whole muscle (n & 2 per group, P % .005, 20-"g protein/well). Samples used were processed in HLB.
TBP, TATA box binding protein.
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(Figure 6A). There was no increase in the uptake of 3H-
25OHD3 in VDRKO myofibers exposed to 1,25(OH)2D
(Figure 6). In addition, DIDS, an inhibitor of the non-
genomic effects of the VDR, reversed 1,25(OH)2D-medi-
ated increases in 3H-25OHD3uptake inC2C12myotubes
(Figure 6B). Together, these data indicate that VDRmod-
ulates ligand-mediated uptake of 25OHD in skeletal mus-
cle. This occurs via a nongenomic VDR mechanism and
confirms its presence at this site.
WT and VDRKO myofibers not treated with
1,25(OH)2D showed similar levels of net
3H-25OHD3
uptake. This suggests that VDR-independent processes
may also affect the retention of 25OHD in skeletal muscle
at baseline.
Discussion and conclusions
This study uses 4 models to investigate the presence of
VDR in skeletal muscle: C2C12 cells, primary myotubes,
mature muscle fibers, and whole muscle. This is the first
report of an innate vitaminD-endocrine system inprimary
muscle cells that possess functional CYP27B1, VDR, and
CYP24A1. We report 3 factors confounding VDR detec-
tion inmuscle. These include: 1) differences inVDR signal
on Western blotting depending on protein extraction
methods (Figure 3C); 2) age-related differences in VDR
expression in muscle (Figure 5, B–D); and 3) the augmen-
tation ofVDR inmuscle cellmodels comparedwithwhole
muscle (Figure 3E). Consistent with an earlier report (12),
VDRwas not detectable onWestern blotting after the use
of RLB in whole muscle. However, upon using a HLB,
VDRwas detectable but at a substantially lower level than
in duodenum and kidney (Figure 3D). As further evidence
of the functionalityofVDRinmuscle,wedemonstrated its
role inmodulating ligand-dependent uptake of 25OHD in
muscle fibers (Figure 6).
Contradictory reports regarding the presence of a
1,25(OH)2D-binding protein in muscle date back 4 de-
cades (summarized in Table 1). Before the discovery of
VDR in 1974 (40), Neville and DeLuca (41) reported the
localization of 3H-25OHD3 in the membrane of skeletal
muscle, but Stumpf et al (42) failed to identify the nuclear
localization of 3H- 1,25(OH)2D at this site. Studies using
anti-VDR antibodies were also conflicting, some report-
Figure 4. Detection of VDR in skeletal muscle on immunohistochemistry. Using VDR-D6 antibody, VDR was detected within muscle fibers of
young WT mice on immunohistochemistry (8-"m cross-sections, quadriceps) (A) and localized to fiber nuclei (white arrow) and cytoplasm (red
arrow) as seen on DAPI counterstaining (scale bars, 100 "m) (B). C, This is further demonstrated on higher magnification (scale bar, 50 "m; image
brightness adjusted to aid in visualizing the cytoplasm). D and E, No such signal was detected in muscle from age-matched VDRKO mice in which
DAPI staining was also performed. F and G, Duodenum (duo.) from adult WT mice was used as positive control and showed substantially greater
levels of VDR than muscle (scale bars, 100 "m).
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ing detection of VDR in skeletal muscle, which was not
confirmed by others (12–15, 43). In the notable work by
Wang et al (26), differences in the specificity of commer-
cially available VDR antibodies were reported. Using the
highly specific D6 antibody, VDRwas not detected in the
muscle of mature animals, but young animals were not
examined (12). Other studies were limited by reliance on
muscle cell models alone, use of nonvalidated VDR anti-
bodies, and/or lack of appropriate controls (Table 1). In a
recent randomized study of 21 older women with vitamin
Ddeficiency (mean25OHD,#45nmol/L), vitaminDsup-
plementation for 4 months resulted
in 30% increase in intramyonuclear
VDR staining and 10% increase in
muscle fiber size (16). However, the
specificity of the antibody used in
this study (VDR-NR1I1) is uncer-
tain, and it has not been validated by
the absence of signal in VDRKO tis-
sue (15).
VitaminDdeficiency is associated
with muscle weakness, abnormal
muscle physiology, and muscle mi-
tochondrial defects in humans and
animals (2, 44–49). VDR polymor-
phisms in humans are associated
with muscle strength and falls (2),
and VDR ablation in mice leads
to impaired motor coordination,
shorter stride length, and abnormal
swimming (50, 51). An important
question raised by these studies is
whether the effects of vitamin D in
muscle are direct or indirect. Our
findings in primary myotubes indi-
cate that direct effects are possible,
because these cells express functional CYP27B1 and re-
spond to 1,25(OH)2Dby activation ofVDRand its classic
target gene CYP24A1. We have also recently reported di-
rect effects of 25OHD and 1,25(OH)2D in C2C12muscle
cell proliferation and differentiation (10). The increase in
VDR after muscle cell isolation in this study is interesting
(Figure 3E). This is not unique tomuscle cells (52, 53) and
may result in amplified responses to vitamin D in vitro.
The relatively low levels of VDR in adult muscle do not
preclude a direct role in many of its physiological effects.
In liver, under normal circumstances, VDR is also ex-
pressed at levels which are so low that is it also difficult to
detect by Western blotting (43). Despite this, it has re-
cently been clearly demonstrated that VDR plays an im-
portant role in liver fibrosis (54).
We demonstrate here that VDR is necessary for
1,25(OH)2D-modulated uptake of 25OHD in freshly iso-
latedmuscle fibers (Figure 6A). These ex vivo experiments
differ from in vitro techniques, because whole muscle fi-
bers were used and experiments were performed directly
after isolation, excluding effects of long-term altered gene
expression. Whole muscle fibers responded significantly
to physiological levels of 1,25(OH)2D, validating the rel-
evance of this model. In addition to our previous descrip-
tion of skeletal muscle as an extravascular site for uptake
of 25OHD (7),we nowdemonstrate a role forVDR in this
process. This finding raises the pertinent question: What
Figure 5. Effects of VDRKO in muscle gene expression and age-related differences in muscle
VDR in WT mice. A, Muscle from WT vs VDRKO mice displayed significant differences in the
mRNAs of calcium-handling genes, including Serca2a, Serca2b, Serca3, and Calbindin-28K (Sc2a,
Sc2b, Sc3, and Cal.), and cell cycle regulatory genes, including myc and Cyclins D2, D3, and E1
(Cd2, Cd3, and Ce1). B, VDR transcript levels were significantly higher in muscles of newborn WT
mice compared with 3-week- and 3-month-old mice (n & 3 per group; P % .005). Using samples
prepared in HLB, Western blotting (C) and densitometric quantitation (D) demonstrated higher
VDR expression in muscles of newborn WT mice compared with 3-month-old mice (n & 4 per
group; P % .005). Muscle from newborn VDRKO mice was used as negative control. Pr, protein.
Figure 6. 3H-25OHD3 uptake in WT and VDRKO myofibers.
A, Preincubation of WT myofibers with 1,25(OH)2D resulted in 40%
greater 3H-25OHD3 uptake compared with WT myofibers preincubated
with control solution (P % .005). No such increase in 3H-25OHD3
uptake in response to 1,25(OH)2D was seen in VDRKO mice (n & 3
mice per group). B, In C2C12 myotubes, DIDS reversed the
1,25(OH)2D-mediated increase in uptake of
3H-25OHD3. cpm, counts
per minute.
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“happens” to 25OHD upon entry into the muscle fiber?
Bound toDBP, it could remain attached to actin (7). Upon
degradation of DBP (55), 25OHD may diffuse back into
the circulation, where it becomes available for biologi-
cal use. 25OHD may also be locally converted to
1,25(OH)2D as suggested the presence of functional
CYP27B1 in primary myotubes (Figure 2E). A recent
study has also shown thatmuscle fibers express CYP27B1
and that, together with VDR, it is up-regulated in regen-
erating fibers (14). This raises the intriguing possibility
thatVDRandCYP27B1play roles inmuscle regeneration,
a process that closely mimics muscle development.
Greater expressionofVDR inmuscles fromyoungmice
and inC2C12myoblasts suggests that VDRplays a role in
muscle development (Figures 1C and 5). There is evidence
to support this, such as the demonstration of smaller mus-
cle fibers and transcript changes in preweaned VDRKO
mice (56). This effect on fiber size may be ligand-depen-
dent. In humans, maternal vitamin D deficiency was as-
sociated with reduced arm-muscle area in offspring (57),
and in rats, smallermuscle fibers and altered expression of
developmental genes was noted in pups born to vitamin
D-deficient dams (58). In utero transfer of radiolabeled
25OHD across placenta and into muscle of rat embryos
also supports a role for vitamin D in embryonic muscle
development (59).
Themain limitation of this study is the focus onmurine
muscle. Although there is high interspecies homology in
the structure and ligand-binding properties of VDR (60),
differences exist in the metabolic rate, contractile speed,
and morphology of murine vs human muscle. To date,
only 1 study has examined the presence of VDR in human
muscle using the highly specific VDR-D6 antibody, and a
Table 1. Studies Investigating VDR in Skeletal Muscle
Study Species Model Methodology Findings
Neville and DeLuca (41) Rat (vit D def) Muscle extracts 3H-25D iv injection Proportion of 3H-25D localized to muscle
(#6%–8%)
Stumpf et al (42) Rat Muscle extracts 3H-1,25(OH)2D, autoradiography 3H-1,25(OH)2D not localized in muscle
Simpson et al (11) Rat, mouse G8, H9c2 cells; rat
longissimus
Equilibrium binding studies,
chromatography
VDR present; 50%–70% decrease
during differentiation; antiproliferative
effect of 1,25(OH)2D in muscle cells
Costa et al (61) Human Cloned muscle cells
(5 subjects)
24-Hydroxylase assay,
chromatography, 3H leucine, 3H
thymidine incorporation, binding
studies
VDR present; 1,25(OH)2D inhibited
protein and DNA synthesis in
myoblasts
Boland et al (62) Chick Muscle extracts Density gradient analysis, saturation
analysis
VDR present
Sandgren et al (63) Rat Muscle extracts Immunoradiometric assay VDR absent
Buitrago et al (64, 65) and
Boland et al (66)
Chick Muscle cells WB, IP, co-IP, transfection studies,
spectrofluorimetric analysis
VDR present; nongenomic VDR activities:
tyrosine phosphorylation of signaling
proteins (c-myc, c-Src, MAPK) and
calcium flux
Buitrago and Boland (67) Mouse C2C12 cells IHC, IP, co-IP, transfection VDR present; translocates to membrane
after 1,25(OH)2D (min); interacts with
membrane scaffolding protein,
caveolin-1
Endo et al (56) Mouse Muscle extracts;
C2C12 cells
PCR, NB VDR mRNA in 3-wk- but not 8-wk-old
mice; developmental differences in
VDRKO vs WT mice
Bischoff et al (13) Human Muscle extracts
(20 subjects)
IHC (VDR-9A7 Ab) VDR present, localized to nucleus;
decreases with age, no correlation
with 25OHD or 1,25(OH)2D
Ceglia et al (15) Human Muscle extracts
(4 subjects)
IHC (VDR-NR1I1 Ab; D-6 and 333C6a
Ab used as control); fiber-typing
VDR present; not specific for muscle
fiber type
Garcia et al (9) Mouse C2C12 cells PCR, IHC, WB (VDR-C20 Ab) VDR present; 1,25(OH)2D increased
nuclear VDR (d), antiproliferative,
promyogenic, larger myotubes
Wang and DeLuca (12) Human,
mouse, rat
Muscle extracts
(1 human
subject)
PCR, IHC, WB (VDR-D6 Ab) VDR mRNA at low level; protein not
detected (D6 Ab); 9A7 Ab not specific
Srikuea et al (14) Mouse C2C12 cells,
Muscle extracts
IHC, WB (VDR-H81 Ab), transfection,
BaCl2 muscle injury
VDR and CYP27B1 present and are
increased in regenerating fibers
Ceglia et al (16) Human,
!%65 yr
Muscle extracts
(12 subjects)
IHC (VDR-NR1I1 Ab) Subjects randomized to vitD3 (4000 IU/d)
increased myonuclear VDR and fiber
size
Girgis et al (10) Mouse C2C12 cells PCR, IHC, WB, luciferase reporter
studies
VDR and functional CYP27B1 present;
25OHD and 1,25(OH)2D
antiproliferative, antimyogenic, larger
myotubes
Abbreviations: IHC, immunohistochemistry; WB, Western blot; IP, immunoprecipitation; co-IP, co-immunoprecipitation; NB, Northern blot.
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single sample was used (12). Future studies examining
human muscle will be of great interest.
In summary, this study reports conditions necessary for
the detection of VDR in murine muscle on the basis of 4
different models.We confirm that muscle is a direct target
of vitamin Dwith an autoregulatory vitamin D-endocrine
system in primary myotubes and the 1,25(OH)2D-mod-
ulated uptake of 25OHD in WT myofibers, an effect
which is absent in VDRKO myofibers. A novel role for
VDR in the regulated uptake of 25OHD in muscle con-
firms its presence at this site; further studies are needed to
determine the biological significance andmechanisms un-
derlying this process.
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Vitamin D has been known for nearly a century to beessential for bone health because it can prevent and
cure endemic rickets and osteomalacia (1–3). Currently,
the complex implicationsof deficiencyor excess vitaminD
onbonemodeling and remodeling arewell documentedby
a wealth of preclinical and clinical studies (reviewed in 4).
The vitaminDreceptor (VDR) aswell as the key activating
(CYP27B1)or inactivating (CYP24A1) enzymesare, how-
ever, expressed inmany cells.Moreover, a very large num-
ber of genes—from zebra fish up to mice and man—are
under direct or indirect control of the active hormone,
1,25(OH)2D3. Therefore, it looks attractive to hypothe-
size that the vitaminDendocrine systemwouldhavemany
extraskeletal effects. Such hypothesis fits with the very
broad spectrum of activity of most ligands of nuclear re-
ceptors (1–3). Poor vitamin D status has also been asso-
ciatedwithmostmajor diseases ofmankind, ranging from
immune diseases and infections, cancer, diabetes, and the
metabolic syndrome, aswell as cardiovascular risk factors
and events, energy homeostasis, bile acid metabolism, to
(last but not least)muscle function and falls (1, 3, 5).How-
ever, following an extensive evaluation of these data, the
Institute of Medicine concluded, that “Scientific evidence
indicates that calciumandvitaminDplaykey roles inbone
health. The current evidence, however, does not support
other benefits” and “There is inconsistent evidence that
supplemental vitamin D reduces falls in postmenopausal
women and older men” (6). This conclusion was highly
debated because several meta-analyses concluded that vi-
taminD supplementation of elderly subjects decreased the
risk of falls by approximately 20% and improved proxi-
mal muscle strength of severely vitamin D–deficient (se-
rum 25OHD ! 10 ng/ml) subjects (7, 8).
Vitamin D’s direct action on muscle became doubtful
when a careful analysis ofVDRexpression in adult human
muscle as well as mouse skeletal and cardiac muscle, per-
formed in H. DeLuca’s laboratory (9), vitamin D receptor
showed only very low gene expression (10 000-fold lower
than in the intestine) without detectable protein expres-
sion even with a highly specific anti-VDR antibody, in
contrast with older publications using less stringent anti-
bodies (9). Therefore, any potential effect of vitamin D
metabolites onmuscle could at most be indirect given that
both genomic and potential nongenomic effects require
the presence of VDR.
In the current issue of Endocrinology, Girgis et al (10)
demonstrate that VDRprotein (using the same highly spe-
cific antibody) can be clearly demonstrated in adultmouse
skeletalmuscle, althoughonlywhenusing ahyperosmolar
lysis buffer. Such buffer releases VDR from its tight bind-
ing to DNA, as it has been demonstrated previously that
even unliganded VDR mainly resides in the nucleus. The
gene and protein expression of VDRwas higher in muscle
cell precursors (in vitro) comparedwith adultmaturemus-
cle and was also higher in muscle from younger than in
older animals (in vivo). Nevertheless, the expression was
still several-fold lower in skeletal muscle than in the in-
testine. Moreover, the authors confirmed the expression
as well as the functionality of cyp27b1 in muscle cell cul-
tures. The activity of the vitamin D receptor was also con-
firmed because both 25OHD3 and 1,25(OH)2D3 stimu-
lated the expression of VDR and Cyp24a1, both known
targets of VDR action, as well as the uptake of 25OHD in
muscle. Negative controls for all these end points were
obtained in VDR-null mouse tissue. All the data are in line
with decreasing VDR expression, as well as decreasing
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number of VDR binding sites in the cistrome and decreas-
ing transcriptome duringmaturation of other cells such as
osteoblasts (11) and osteoclasts. Indeed, the expression of
VDR is lost in multinucleated osteoclasts whereas
1,25(OH)2D3’s is a very potent stimulator of osteoclast
progenitors (12).
These novel data will clearly reopen the discussion on
muscle as a potential target for vitamin D’s action. The
gene and protein expression of VDR is also in line with
several other in vitro studies. Indeed, 1,25(OH)2D3 de-
creased proliferation and enhanced differentiation of
myocyte precursors, including the stimulation of follista-
tin and inhibition of myostatin (13) (Figure 1).Moreover,
VDR-null mice show a clear muscle phenotype, with
smaller muscle fiber size and abnormal expression of all
major muscle-specific genes including myogenin, myoD,
and Myf5 (14). Furthermore, cardioselective VDR dele-
tion (15) also causes similar cardiac hypertrophy and fi-
brosis as in systemic VDR-null mice (Table 1). Finally,
vitamin D deficiency accelerates muscle protein degrada-
tion by stimulation of the ubiquitin pathway in male rats
(16).
Do Girgis’ (10) observations in mouse muscle also ap-
ply to human skeletal, cardiac, and smoothmuscle? Care-
ful clinical observations indeed linked hypotonia, myop-
athy, and especially proximal muscle weakness to rickets
already in the early descriptions in the 17th century.More
recently, muscle weakness was confirmed in subjects with
inborn deficiency of CYP27B1 (hereditary pseudovitamin
D deficiency rickets (18)) and in patients with severe
chronic renal failure and deficiency of all vitamin D me-
tabolites. Severe muscle weakness, up to the point of need
for a wheel chair, also rapidly disappears when given
1,25(OH)2D3 (3). Randomized controlled trials, how-
ever, could not demonstrate beneficial effects of vitaminD
supplementation on either grip strength or proximal mus-
cle strength (except in patients with serum 25OHD lev-
els ! 10 ng/ml at baseline). Elegant in vivo 32P nuclear
magnetic resonance spectroscopy data, however, showed
more rapid energy (ATP) recovery after modest exercise,
concomitant with correction of complaints of severe mus-
cle weakness following vitamin D supplementation in de-
ficient Asian United Kingdom residents (5, 19). Finally,
the risk of falls could be reduced by approximately 20%
after vitamin D supplementation of elderly, mostly vita-
min D–deficient subjects, at least according to some (7, 8,
20) but not all meta-analyses (21). As for most ligands of
nuclear receptors, toomuchmay be equally deleterious as
too little. Indeed an increased risk of falls and fractures
Figure 1. Muscle gene regulation by the vitamin D endocrine system as revealed by in vitro and in vivo rodent studies.
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was observed during the first 3 months following a yearly
loading dose (500 000 IU of 25OHD3) (17).
Therefore, muscle may indeed be a real target for vita-
min D action but its mechanism of action may well be a
combination of indirect [eg, myocardial dysfunction of
vitamin D–deficient chicks could be corrected by calcium
alone (22)], and direct genomic actions (23, 24) (Figure 1)
or even nongenomic actions (24, 25).
The study ofGirgis et al (10)might generatemore ques-
tions than answers. Protein expression of other nuclear
receptors may also have to be reconsidered by using hy-
perosmolar conditions to better release such receptors
from the nucleus, and this may be especially relevant for
(un)liganded receptors residing permanently in the nu-
cleus, or for clinical situations whereby receptor expres-
sion in cancer tissues is crucial for therapeutic decisions. A
hyperosmolar lysis bufferwasalsoneeded tovisualizeheat
shock proteins. Tissue-specific deletion of VDR or
Cyp27B1, at early or late stage of muscle development or
conditional postnatal deletion may help to clarify mech-
anism(s) of action of the vitamin D endocrine system. The
Girgis study (10) also suggested that 1,25(OH)2D3 may
stimulate the uptake of 25OHD in muscle, thereby ad-
dressing the intriguing question of the storage site of vi-
tamin D (metabolites). Indeed, the summer accumulation
of vitaminD apparently enables surviving lack of sunlight
exposure during autumn and winter longer than expected
from the short half-life of only two weeks of the serum
pool of 25OHD.
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Expression of the Vitamin D Receptor in Skeletal
Muscle: Are We There Yet?
J. Wesley Pike
Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706
The diverse biological actions of the vitaminDhormone1,25-dihydroxyvitamin D3 (1,25(OH)2D3) that are
beyond its contribution to themaintenance ofmineralme-
tabolism are now well recognized (1). These actions in-
clude significant roles in skin maturation, protection, and
function, the immune system, cardiovascular activity,
neuromuscular function, bile acidmetabolism, xenobiotic
detoxification, muscle activity, and hepatic function (2).
They also include broad cellular growth control mecha-
nisms that include blockade of proliferation, prodifferen-
tiation, induced apoptosis, andother fundamental cellular
processes that may be of therapeutic relevance in cancer
(3). Many of these activities have been described over a
span of several decades both in cultured cells of specific
lineage origin and in vivo. In the latter case, these studies
have made frequent use of genetic strains of mice that are
either globally or tissue specifically deficient in the expres-
sionof the vitaminDreceptor (VDR), the centralmediator
of vitamin D action in all tissues (2, 4, 5). Perhaps most
importantly, the beneficial biological effects of vitamin D
in many of these systems appear to have translational and
clinical components as well, because clinical pathologies
associated with these systems frequently correlate with
vitamin D deficiency, and at least, a subset have been
shown to respond positively to increased vitaminD intake
(6). Accordingly, the actions of 1,25(OH)2D3 in many of
these tissues in humans are generally not in dispute.
Themechanism throughwhich vitaminDacts in tissues
centers on the presence and activity of the VDR, a tran-
scription factor that is activated by hormonal vitamin D
and functions at the level of the genome in a cell-specific
manner to regulate the transcription of genes (5). This
receptor is highly expressed in tissues, such as intestinal
epithelial cells and proximal and distal tubules of the kid-
ney, andmesenchymal lineage cells, such as chondrocytes,
early osteoblast precursors, mature osteoblasts, and os-
teocytes, and in many other cell types as well (7). Molec-
ularly cloned and the protein product studied over several
decades, many of the principles of the VDR’s modulatory
actions to regulate the expressionof specific genes are now
well established, most recently at the genome-wide level
(8–11). Although not fully understood, our advanced ap-
preciation of themechanisms throughwhich the VDRop-
erates at the genetic level stands in stark contrast to those
that have been proposed to account for the so called rapid,
nongenomic actions of the hormone, where the VDR or
other “receptors” have been suggested to regulate specific
membrane-associated activities in cells (12). Despite sug-
gestions to the contrary, both the mechanisms that under-
lie these latter activities and their relevance in vivo remain
tobedetermined, althoughconsiderablemechanistic prec-
edent has been established for nongenomic activity
through the study of nuclear receptors for estrogen, the
androgens, and progesterone.
With these issues in mind, it is not surprising that stud-
ies aimed at understanding the actions of the vitamin D
hormone in such tissues as the nervous system, the car-
diovascular system, and the skeletal muscle system have
focused upon detection of the VDR as an initial prereq-
uisite for defining a direct mechanism of action of the
hormone in these systems.Although thismayappear to the
outsider to be a relatively easy task, the VDR protein is
expressed at extremely low levels and thus is not easily
detected even in bone fide vitamin D-sensitive target tis-
sues. Therefore, it is even more difficult to identify the
receptor in atypical tissueswhere VDRabundancemay be
restricted to rare cell subtypes or is generally low for un-
known reasons. Accordingly, these features lead to more
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fundamental questions: Is the VDR expressed in a partic-
ular tissue above cellular background, can its activity(s) be
identified in unequivocal terms, is its activity localized to
a specific cell type and not to a contaminating or invading
cell type, and is it possible that the VDR manifests bio-
logical roles in tissues that are completely independent of
those that involve transcription? These questions need to
beansweredbefore excluding thepossibility that in certain
tissues vitamin D’s actions are indirect, perhaps through
the regulation of local or systemic modulators, such as
peptide or steroid-like hormones from other tissues or
through the maintenance of extracellular calcium and
phosphorus levels, which are known to impact muscle,
bone, and nerve cell function. What also must be consid-
ered is the possibility that VDR expression can be selec-
tively regulated in cell types that are temporally unique to
tissues and organs, such as those that occur during devel-
opment, growth, differentiation, and/or during physio-
logic states, such as pregnancy, lactation, and aging. Al-
ternatively, VDR expression may appear in a specific cell
type(s) as a consequence of disease. A final challenge is to
interpret the expression of the VDR in cell lines and in
primary cells in culture, where lineage relationships to the
originating tissue are often times uncertain and frequently
problematic. Efforts to identify the VDR in liver, cardio-
vascular tissues, skeletal muscle cells, and neurons of the
central nervous system are particularly prone to these lat-
ter issues, because the VDR is generally found in cell lines
derived from these tissues but has been difficult to detect
in the primary tissues.
In this current volume, Girgis et al (13) examine
whether theVDR is present in skeletalmuscle both in vitro
and in vivo and assess whether the receptor is capable of
mediating biological responses. In view of the numerous
and often conflicting studies that have attempted to ad-
dress this question over the years, as summarized, in part,
in table 1 of the manuscript, one would have hoped that
the current study would resolve these issues experimen-
tally once and for all. Although the observations are in-
teresting, however, this is really not the case. In short,
some of the major issues still remain major points of con-
troversy. Experiments in this study are initiated using the
mouseC2C12cell line, and earlymesenchymal lineage cell
has been employed by muscle biologists for decades to
study myoblast to myotube differentiation and by many
previous investigators to support the concept that muscle
cells contain the VDR (14–17). As in these earlier studies,
the present authors show that the VDR is indeed readily
expressed in this cell line (at the mRNA level and protein
levels) and regulated by 1,25(OH)2D3. Because the VDR
can be dynamically up-regulated in many cell lines pas-
saged in culture aswell as during differentiation, however,
these observations documented by Girgis et al (13) do not
really resolve the question of whether the VDR is ex-
pressed in skeletal muscle targets in vivo.
Thus, is this question answered in the current study?An
attempt ismade. The authors showusing traditional semi-
quantitative RT-PCR analysis that VDR transcripts are
detected, however, at concentrations 3–4 logs lower than
that found in the intestine. Unfortunately, this technique
does notmeasure theVDRprotein itself andperhapsmore
importantly, is many logs more sensitive than those that
do. Thus, it is not surprising that these investigators and
many before them have struggled to identify the VDR us-
ing Western blot analysis or through immunocytochem-
istry (see Ref. 13 and table therein). This seems to be high-
lighted by the Western blot analyses in the current work,
where it is unclear whether the immunoband detected in
normal adult skeletal muscle is in fact the VDR, given the
requirement for an unusual hyperosmolar (denaturing)
extraction buffer (18), the presence of additional bands in
a size range that is similar to the VDR, and the fact that
virtually all of the bands that are detected are absent in the
VDR-null control extract. With regard to the use of the
hyperosmolar buffer, although the authors suggest that it
may remove the VDR more efficiently from DNA, most
the VDR extracted here is not likely to be bound to the
genome, because normal levels of gene occupancy were
shownyears ago to be surprisingly low (!15%) in vitamin
D-sufficient animals (19). In addition, most nuclear re-
ceptors are known to be extracted efficiently in high salt
buffers. In the case of the ligand-freeVDR, concentrations
of 0.15MNaCl are generally sufficient (20, 21), although
higher levels (!0.3M) are necessary when the VDR is
bound to DNA via activation by 1,25(OH)2D3. In the
current case, the addition of detergents, such as Triton
X-100 andNP-40 (very similar nonionic detergents), only
increaseVDR sensitivity to extraction.One has towonder
whether it is technically feasible using Western blot anal-
ysis to detectVDRprotein in crude extracts ofmuscle such
as thesewhenVDR transcripts are present at 1/4284th the
concentration of those observed in the duodenum.
Interestingly, a recent series of well-controlled immu-
nocytochemical studies has been reported wherein VDR
was detected in a highly robust fashion in intestinal tissue
and other VDR-positive tissues (22–24). These experi-
ments, however, failed to detect the VDR in skeletal mus-
cle, numerous cardiovascular sites, including theheart and
liver, and in other cell types as well, suggesting its absence
in these tissues. Interestingly, these reports have been
widely used to call into question the presence of the VDR
in muscle. Ironically, however, they simply reiterate the
historical inability of investigators to detect the VDR in
muscle in studies using sucrose gradient analysis, hor-
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mone-binding assays, scintillation autoradiography, the
earliestWestern blot analyses, and finally various formsof
mRNA analysis, culminating in highly sensitive reverse
transcriptase, real time PCR approaches that have
spanned almost 4 decades. Perhaps the most important
lesson to be learned from the studies of DeLuca and co-
workers (22–24) is the absolute requirement for highly
robust positive andnegative controlswhen assessingVDR
levels in test tissues suchas themuscle. In the current study,
this does not appear to be the case, because the fluores-
cence intensity of signals generated from VDR-positive
tissue such as the intestine are not particularly remarkable
and the cellular and subcellular sources of the signals are
unclear. Even in themost recent studies (22–24), however,
the question of whether low levels of VDR in muscle and
other tissueswouldbedetectableby immunologicalmeans
should still be raised. Is it possible that mRNA levels and
VDR proteins levels might be strikingly discordant, and
thus the levels of receptor protein in muscle tissue are
higher thanwouldbepredictedas a result of low transcript
levels? The answer is of course yes; but if so, such a rela-
tionship needs to be demonstrated. What additional ob-
servations are made regarding the receptor in this study?
Perhaps the most important is the finding that the con-
centrations of the VDR in neonatal mouse muscle is much
higher than that found in adults. Although further explo-
ration is necessary, it is possible that this interesting dis-
covery could provide an important entre into defining the
mechanism through which vitamin D exerts its actions on
muscle in adults as well.
TheVDR functions in a traditional sense to regulate the
expression of genes by virtue of its ability to bind to sites
on DNA, to recruit coregulatory complexes that modify
chromatin structure and function, and to interact with
other transcription factors in aDNA-independentmanner
(5). In the current study, the authors show that both the
VDR and Cyp24a1 genes are modestly up-regulated by
1,25(OH)2D3, thereby establishing that this traditional
function is apparently intact in passaged primary myo-
tubes. Unfortunately, the regulation of these or other
genes by 1,25(OH)2D3 is not followed up by in vivo stud-
ies. Rather, the authors explore the possibility that
1,25(OH)2D3might stimulate the uptake of 25OHD3 into
isolated muscle myofibers, an interaction that has been
previously described in muscle, which occurs between the
vitamin D-binding protein-bound vitamin D metabolite
and membrane-bound endocytotic receptors megalin and
cubilin, and which maymediate storage of 25OHD3 (25).
Accordingly, the authors show that there is a modest in-
volvement of the VDR in this process in that pretreatment
of both myofibers as well as C2C12 cells with low levels
of 1,25(OH)2D3 are indeed stimulatory for uptake. Un-
fortunately, the nature of this stimulatory effect is entirely
obscure, because despite the suggestion that this phenom-
enon may represent a rapid nongenomic activity, the re-
quirement for a 3-hour hormone pretreatment of themyo-
fibers (and cells) is hardly the stuff of anongenomic action.
Because neither megalin nor cubilin are up-regulated, it
wouldappear that this activity is notdependentupon tran-
scription either. Clearly, further studies will be necessary
to facilitate an understanding of this proposed role for the
VDR in muscle tissue.
Thepresent studies highlight the difficulties of using the
presence of theVDR in cells and tissues as a centerpiece for
defining the mechanism that underlies the biological ac-
tions of vitaminD in nontraditional vitaminD-responsive
tissues. At this stage, hard experimental evidence will be
necessary to define a regulatory mechanism in muscle tis-
sue and to conclude that 1,25(OH)2D3 plays a direct
rather than an indirect biological role in this tissue, per-
haps through the regulation of extracellular phosphate
levels. These effects must also be distinguished from the
more subtle yet indirect mechanisms that have already
been shown to occur. For example, 1,25(OH)2D3 affects
bile acid metabolism in the liver not via a direct effect but
rather by inducing intestinal expression of fibroblast
growth factor 15, an endocrine fibroblast growth factor
that is rapidly transported via the portal system to the
liver, where its effects on bile acidmetabolism are actually
observed (26). They must also be distinguished from
mechanisms related to distinct VDR up-regulation during
a disease process. Accordingly, a recent study suggests a
direct action of 1,25(OH)2D3 in the liver centered on the
hormone’s ability to counter TGF!-induced liver fibrosis
(27). However, TGF! activates normally quiescent liver
stellate cells. Thus, the possibility exists that the VDR is
up-regulated during activation, and that the protein’s
presence is actually representative of a disease process
rather than a physiologicalmodel of normal hepatic tissue
response. Finally, studies must also be undertaken to
quantitate the levels of the VDR in specific cell types as
well. For example, although VDR-specific peptides have
recently been demonstrated in whole rat brain using mass
spectrometry, the starting material was derived from 20
separate mice (28). Clearly, additional details similar to
those generated recently will be necessary to interpret this
interesting result (29). Studies of this nature will be nec-
essary to understand 1,25(OH)2D3 action in muscle tis-
sues as well. Perhaps careful genetic deletion of the VDR
gene product in adult myocytes and/or their precursors
will be revealing, as has been accomplished in cardiac tis-
sue (30). These latter studies have provided supportive
evidence for the direct effects of vitamin D on the heart.
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There is no doubt that vitamin D is beneficial for the
maintenance of normal muscle form and function based
upon both animal models as well as overwhelming posi-
tive clinical experience (31). Unfortunately, the biological
effects observed inmice andmen do not really speak to the
mechanism through which the vitamin D hormone acts in
this tissue. Thus, resolution will likely be achieved using
creative basic approaches both in vitro and in vivo. For-
tunately, the biochemical, molecular biological, genetic,
and genomic techniques are now available such that this
issue should be resolved in the next few years.
Response to J.W. Pike by C.M. Girgis, N. Mokbel,
K.M. Cha, P.J. Houweling,M. Abboud, D.R. Fraser, R.S.
Mason, R.J. Clifton-Bligh, and J.E. Gunton
We thank Professor Pike for his comments above in
response to our work (13) and Professor Bouillon for his
comments in the “News and Views” (32). We agree that
clear detection of VDR in skeletal muscle has been con-
troversial due to a number of technical factors, including
protein extractionmethods, variability in differentmuscle
models, past problematic antibodies, and of course, the
low level of VDR that is present in mature muscle at base-
line. Our work shows clear absence of VDR in VDR
knockout mice by immunohistochemistry and Western
blotting, and perhaps more importantly, conclusive proof
of functional presence comes with the demonstration of a
novel physiological function, specifically the VDR-medi-
ated uptake of 25-hydroxyvitamin D in muscle fibers (ie,
nongenomic as indicated by inhibition using the chloride-
channel blocker 4,4=-diisothiocyanatostilbene-2,2=-disul-
fonic acid).We agree that the substantially higher levels of
VDR inmuscle of youngermice and immaturemuscle cells
is intriguing; this suggests the possibility for a pleiotropic
role for VDR in muscle and its potential activation after
muscle injury from relatively lowbaseline levels of expres-
sion. We hope that the findings of our study bring some
closure to this controversial field and may assist in future
work examining roles of VDR in muscle development,
regeneration, and 25-OHD uptake, ultimately justifying
the generationof a skeletalmuscle-specificVDRknockout
model.
Acknowledgments
Address all correspondence and requests for reprints to: Profes-
sor J. Wesley Pike, Department of Biochemistry, University of
Wisconsin-Madison, Hector F. Deluca Laboratories, Room
543D, 433 Babcock Drive, Madison, WI 53706. E-mail:
pike@biochem.wisc.edu.
This work was supported by National Institute of Arthritis
and Musculoskeletal and Skin Disease grant AR-045173 and
National Institute ofDiabetes andDigestive andKidneyDiseases
grant DK-072281 (to J.W.P.).
Disclosure Summary: The author has nothing to disclose.
References
1. Plum LA, DeLuca HF. Vitamin D, disease and therapeutic oppor-
tunities. Nat Rev Drug Discov. 2010;9:941–955.
2. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human
health: lessons from vitamin D receptor null mice. Endocr Rev.
2008;29:726–776.
3. Welsh J.Vitamin D and breast cancer: insights from animal models.
Am J Clin Nutr. 2004;80:1721S–1724S.
4. Pike JW, Meyer MB. Fundamentals of vitamin D hormone-regu-
lated gene expression. J Steroid Biochem Mol Biol. doi:10.1016/
j.jsbmb. 2013.11.004.
5. Pike JW, Lee SM, Meyer MB. Regulation of gene expression by
1,25-dihydroxyvitaminD3 in bone cells: exploiting new approaches
and defining new mechanisms. Bonekey Rep. 2014;3:482.
6. Girgis CM, Clifton-Bligh RJ, Turner N, Lau SL, Gunton JE. Effects
of vitamin D in skeletal muscle: falls, strength, athletic performance
and insulin sensitivity. Clin Endocrinol (Oxf). 2014;80:169–181.
7. HausslerMR,WhitfieldGK,Kaneko I, et al.Molecularmechanisms
of vitamin D action. Calcif Tissue Int. 2013;92:77–98.
8. Meyer MB, Goetsch PD, Pike JW. Genome-wide analysis of the
VDR/RXR cistrome in osteoblast cells provides new mechanistic
insight into the actions of the vitaminDhormone. J Steroid Biochem
Mol Biol. 2010;121:136–141.
9. MeyerMB,BenkuskyNA,LeeCH, Pike JW.Genomic determinants
of gene regulation by 1,25-dihydroxyvitamin D3 during osteoblast-
lineage cell differentiation. J Biol Chem. 2014;289:19539–19554.
10. Heikkinen S, Väisänen S, Pehkonen P, Seuter S, Benes V, Carlberg
C.Nuclear hormone 1", 25-dihydroxyvitamin D3 elicits a genome-
wide shift in the locations of VDR chromatin occupancy. Nucleic
Acids Res. 2011;39:9181–9193.
11. St John HC, Bishop KA, Meyer MB, et al. The osteoblast to osteo-
cyte transition: epigenetic changes and response to the vitamin D3
hormone. Mol Endocrinol. 2014;28:1150–1165.
12. Haussler MR, Jurutka PW, Mizwicki M, Norman AW. Vitamin D
receptor (VDR)-mediated actions of 1",25(OH)2vitamin D3:
genomic and non-genomic mechanisms. Best Pract Res Clin Endo-
crinol Metab. 2011;25:543–559.
13. Girgis CM, Mokbel N, Minn Cha K, et al. The vitamin D receptor
(VDR) is expressed in skeletal muscle of male mice and modulates
25-hydroxyvitamin D (25OHD) uptake in myofibers. Endocrinol-
ogy. 2014;155:3227–3237.
14. Okuno H, Kishimoto KN, Hatori M, Itoi E. 1",25-dihydroxyvita-
min D3 enhances fast-myosin heavy chain expression in differenti-
ated C2C12 myoblasts. Cell Biol Int. 2012;36:441–447.
15. Srikuea R, ZhangX, Park-SargeOK, Esser KA.VDRandCYP27B1
are expressed in C2C12 cells and regenerating skeletal muscle: po-
tential role in suppression of myoblast proliferation. Am J Physiol
Cell Physiol. 2012;303:C396–C405.
16. Garcia LA, King KK, Ferrini MG, Norris KC, Artaza JN.
1,25(OH)2vitaminD3 stimulatesmyogenic differentiation by inhib-
iting cell proliferation and modulating the expression of promyo-
genic growth factors and myostatin in C2C12 skeletal muscle cells.
Endocrinology. 2011;152:2976–2986.
17. Girgis CM, Clifton-Bligh RJ, Mokbel N, Cheng K, Gunton JE. Vi-
tamin D signaling regulates proliferation, differentiation, and myo-
tube size in C2C12 skeletal muscle cells. Endocrinology. 2014;155:
347–357.
18. Hizóh I, Sträter J, Schick CS, Kübler W, Haller C. Radiocontrast-
doi: 10.1210/en.2014-1624 endo.endojournals.org 3217
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 12 October 2014. at 00:34 For personal use only. No other uses without permission. . All rights reserved.
induced DNA fragmentation of renal tubular cells in vitro: role of
hypertonicity. Nephrol Dial Transplant. 1998;13:911–918.
19. Dokoh S, Pike JW, Chandler JS, Mancini JM, Haussler MR. An
improved radioreceptor assay for 1,25-dihydroxyvitamin D in hu-
man plasma. Anal Biochem. 1981;116:211–222.
20. Pike J. Interaction between 1,25-dihydroxyvitamin D3 receptors
and intestinal nuclei. Binding to nuclear constituents in vitro. J Biol
Chem. 1982;257:6766–6775.
21. Pike JW, Haussler MR. Association of 1,25-dihydroxyvitamin D3
with cultured 3T6 mouse fibroblasts. Cellular uptake and receptor-
mediated migration to the nucleus. J Biol Chem. 1983;258:8554–
8560.
22. Wang Y, Becklund BR, DeLuca HF. Identification of a highly spe-
cific and versatile vitamin D receptor antibody. Arch Biochem Bio-
phys. 2010;494:166–177.
23. Wang Y, DeLuca HF. Is the vitamin d receptor found in muscle?
Endocrinology. 2011;152:354–363.
24. Wang Y, Zhu J, DeLuca HF.Where is the vitamin D receptor?Arch
Biochem Biophys. 2012;523:123–133.
25. Abboud M, Puglisi DA, Davies BN, et al. Evidence for a specific
uptake and retention mechanism for 25-hydroxyvitamin D
(25OHD) in skeletal muscle cells. Endocrinology. 2013;154:3022–
3030.
26. Schmidt DR, Holmstrom SR, Fon Tacer K, Bookout AL, Kliewer
SA,Mangelsdorf DJ.Regulation of bile acid synthesis by fat-soluble
vitamins A and D. J Biol Chem. 2010;285:14486–14494.
27. DingN,YuRT, SubramaniamN, et al.AvitaminD receptor/SMAD
genomic circuit gates hepatic fibrotic response.Cell. 2013;153:601–
613.
28. Eyles DW, Liu PY, Josh P, Cui X. Intracellular distribution of the
vitamin D receptor in the brain: comparison with classic target tis-
sues and redistributionwith development.Neuroscience. 2014;268:
1–9.
29. CuiX, PelekanosM,LiuPY,BurneTH,McGrath JJ, EylesDW.The
vitamin D receptor in dopamine neurons; its presence in human
substantia nigra and its ontogenesis in rat midbrain.Neuroscience.
2013;236:77–87.
30. Chen S, LawCS, Grigsby CL, et al.Cardiomyocyte-specific deletion
of the vitamin D receptor gene results in cardiac hypertrophy. Cir-
culation. 2011;124:1838–1847.
31. GirgisCM,Clifton-BlighRJ,HamrickMW,HolickMF,Gunton JE.
The roles of vitamin D in skeletal muscle: form, function, and me-
tabolism. Endocr Rev. 2013;34:33–83.
32. Bouillon R, Gielen E, Vanderschueren D. Vitamin D receptor and
vitamin D action in muscle. Endocrinology. 2014;155:3210–3213.
3218 Pike VDR and Skeletal Muscle Endocrinology, September 2014, 155(9):3214–3218
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 12 October 2014. at 00:34 For personal use only. No other uses without permission. . All rights reserved.
Response to Counterpoint on: “The Vitamin D Receptor (VDR) is 
Expressed in Murine Skeletal Muscle and Modulates 25-
Hydroxyvitamin D (25OHD) Uptake in Myofibers” 
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Myriam Abboud, David R. Fraser, Rebecca S. Mason, Roderick J. Clifton-
Bligh, 
 Jenny E. Gunton 
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We thank Professor Bouillon for his comments in the "News and Views" 
and Professor Pike for his comments above. We agree that clear detection of 
VDR in skeletal muscle has been controversial due to a number of technical 
factors including protein extraction methods, variability in different muscle 
models, past problematic antibodies and of course, the low level of VDR 
that is present in mature muscle at baseline. Our work shows clear absence 
of VDR in VDR knockout mice by immunohistochemistry and Western 
blotting, and perhaps more importantly, conclusive proof of functional 
presence comes with the demonstration of a novel physiological function, 
specifically the VDR-mediated uptake of 25-hydroxyvitamin D in muscle 
fibers (i.e. non-genomic as indicated by inhibition using the chloride-channel 
blocker DIDS). We agree that the substantially higher levels of VDR in 
muscle of younger mice and immature muscle cells is intriguing; this 
suggests the possibility for a pleiotropic role for VDR in muscle and its 
potential activation following muscle injury from relatively low baseline 
levels of expression. We hope the findings of our study bring some closure 
to this controversial field and may assist in future work examining roles of 
VDR in muscle development, regeneration and 25-OHD uptake, ultimately 
justifying the generation of a skeletal muscle-specific VDR knockout model. 
Chapter 5 – Effects of vitamin D in muscle strength and                    
fibre size 
 
 
This chapter consists of a manuscript that was submitted for publication 
(November 2014). The primary author and PhD candidate, Christian Girgis, 
carried out the majority of experiments described in this work (>90%), drafted 
this manuscript and constructed figures. Figures and figure legends are found at 
the end of the manuscript. 
 
The main findings of this work include: 
• progressive weakness, demonstrated by grip strength testing, in whole-
body VDR knockout mice (VDRKO) and vitamin D deficient mice. 
• smaller muscle fibres and increased nuclei in muscles from VDRKO 
mice with dysregulation of myogenic regulatory factors, indicating 
impaired muscle maturation. 
• reduced expression of components of the calcium-handling apparatus in 
muscle of VDRKO and vitamin D deficient mice.  
• activation of myostatin and the E3-ubiquitin ligase MuRF1 in VDRKO 
and vitamin D deficient mice, suggesting activation of atrophy 
pathways and increased proteolysis in muscle in these models. 
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ABSTRACT 
Vitamin D deficiency is associated with muscle weakness, pain and atrophy. 
Serum vitamin D predicts muscle strength and age-related muscle changes. 
Here we examine the controversial question of whether vitamin D directly 
affects muscle function by characterizing the muscle phenotype of mice with 
deletion of vitamin D receptor (VDRKO) and mice with diet-induced vitamin D 
deficiency. VDRKO and vitamin D-deficient mice had significantly weaker 
grip strength than their controls. Weakness progressed with age and duration of 
vitamin D deficiency respectively. Histological assessment showed that 
VDRKO mice had muscle fibers that were significantly smaller in size and 
displayed hyper-nuclearity. Real time PCR (RT-PCR) also indicated muscle 
developmental changes in VDRKO mice with dysregulation of myogenic 
regulatory factors (MRFs) and increased myostatin in quadriceps muscle (>2-
fold). Vitamin D-deficient mice also showed increases in myostatin and the 
atrophy marker E3-ubiqutin ligase MuRF1. As a potential explanation for grip 
strength weakness, both groups of mice had down-regulation of genes encoding 
calcium-handling and sarco-endoplasmic reticulum calcium transport ATPase 
(Serca) channels. This is the first report of reduced strength, morphological and 
gene expression changes in VDRKO and vitamin D deficient mice where 
confounding by calcium, magnesium and phosphate have been excluded by 
direct testing. Although suggested in earlier in vitro work, this study is the first 
to report an in vivo association between vitamin D, myostatin and the regulation 
of muscle mass. These findings support a direct role for vitamin D in muscle 
function and corroborate earlier work on the presence of VDR in this tissue.    
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INTRODUCTION 
In addition to established effects in bone and mineral homeostasis, increasing 
evidence suggests that vitamin D exerts effects in skeletal muscle.(1) Muscle 
weakness and pain are prominent features of vitamin D deficiency that respond 
to replacement.(1) Serum 25(OH)-vitamin D (25OHD) levels correlate with 
muscle strength in healthy individuals and predict the risk of functional decline 
and sarcopenia in older populations.(2, 3) A cross-sectional observational study 
also reported a positive correlation between serum levels of 25OHD and 
myostatin, a negative regulator of muscle mass, in older men.(4)   
 
The biologically active form of vitamin D, 1,25(OH)2D, relies on the 
photochemical conversion of 7-dehydrocholesterol to vitamin D in skin by 
ultraviolet type-B radiation and subsequent hydroxylation steps. Active vitamin 
D then binds to its cognate receptor: the vitamin D receptor (VDR). VDR is a 
member of the nuclear receptor superfamily that regulates expression of many 
genes including those involved in calcium/phosphate homeostasis and cellular 
proliferation and differentiation.(1) The 1,25(OH)2D-VDR complex also exerts 
rapid, non-genomic effects on intracellular signaling and calcium flux.  
 
Precise mechanisms to explain vitamin D’s effects in muscle are unclear. 
Biochemical abnormalities associated with vitamin D deficiency, particularly 
altered serum phosphate and calcium levels, independently lead to muscle 
disease.(5) Whether skeletal muscle expresses VDR and may therefore be a 
direct target of 1,25(OH)2D has been controversial.(6-10) We recently reported 
that VDR is expressed in skeletal muscle and modulates the uptake of vitamin 
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D in this tissue.(11) Upon entry into muscle, vitamin D alters calcium flux by 
mechanisms involving protein kinase C and rapid inositol triphosphate (IP3)-
dependent calcium shifts from the sarcoplasmic reticulum to the cytosol, 
thereby potentially influencing muscle contraction and relaxation.(12, 13) Vitamin 
D treatment of cultured muscle cells leads to doubling in the size of 
differentiated myotubes(14) and opposing effects are seen following VDR 
knockdown by siRNA.(15) These in vitro effects rely on interaction between 
vitamin D signals and myostatin, a member of the TGF-β superfamily that 
negatively regulates muscle mass.(14, 16) However, in vivo studies examining 
direct effects of VDR in muscle function and fiber size are lacking. 
 
In this study, we examine the effect of vitamin D deficiency and deletion of 
VDR on grip strength, muscle bulk, fiber size and gene expression. In the 
absence of altered mineral levels following adequate dietary supplementation, 
these mice displayed a distinct muscle phenotype with morphological 
differences, reduced strength and altered gene expression. This provides further 
evidence in support of a functional role of vitamin D signaling in muscle, 
corroborating the presence of VDR in this tissue. 
 
MATERIALS AND METHODS 
Animals and Ethics  
Whole-body VDR knockout (VDRKO), heterozygous and wild-type (WT) 
mice were maintained on a γ-irradiated “rescue chow” (SF08-002, Specialty 
Feeds, Glen Forest, NSW) containing 2% calcium, 1.2% phosphorus, 0.2 g/g 
lactose and 1 IU vitamin D/g from weaning. Rescue chow is essential to 
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normalize the blood mineral ion levels of VDRKO mice.(17) These were male 
C57/BL6 mice, VDR knockout was generated by ablation of exon 3 as 
previously described (28) and the colony was maintained by successive 
heterozygous mating. We also induced vitamin D deficiency in a second group 
of male C57/BL6 mice by housing them under incandescent lighting and 
administering vitamin D-free diet (SF085-003, Specialty Feeds, Glen Forest, 
NSW) from 3 weeks age. This diet contains increased calcium (2%), 
magnesium (0.2%) and phosphorus (1.2%) to prevent abnormal mineral levels 
in association with vitamin D deficiency. Control vitamin D-replete mice 
received vitamin D (cholecalciferol) 2.2 IU/g, 1% calcium, 0.2% magnesium 
and 0.7% phosphorus (SF085-034, Specialty Feeds, Glen Forest, NSW). Mice 
were fed vitamin D-free and –replete diets and serum levels of vitamin D and 
related minerals were tested at various time-points. To examine effects of 
prolonged vitamin D deficiency, muscle mass, histology and gene expression of 
vitamin D deficient and replete mice were examined at 6 months of age. These 
parameters were examined at a younger age in VDRKO mice (7-8 weeks) as 
they have a reduced life span. Use of animals was approved by the Animals 
Ethics Committee of the Garvan Institute of Medical Research (AEC 12/26). 
All animals were sacrificed by general anesthesia followed by cervical 
dislocation. 
 
Serum parameters 
Serum calcium, phosphate and magnesium levels were measured using Roche 
reagents on a Roche Modular analyser. Serum 25OHD levels were measured by 
Diasorin Liaison assay (Royal North Shore Hospital, Sydney, Australia). 
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Grip Strength Measurement 
A grip strength meter (Columbus Instruments, OH, USA) was used to test 
mouse forearm grip strength as recorded in Newtons (N). Mice were held by 
the base of the tail and allowed to grip the trapeze with their front paws and 
then pulled with their body parallel to the floor. Each mouse was trialed 15 
times in sets of 3 with a short rest in between sets. The highest and lowest 
readings were excluded for each mouse and the remaining readings were 
averaged and corrected for individual body weight. Measurement of grip 
strength was blinded for group with the exception of VDRKO mice as their 
distinct phenotype (hairlessness and stunted growth) makes this impossible.(17) 
Heterozygous VDRKO mice were therefore included in grip strength testing 
blinded to genotype.    
 
Muscle histology 
Quadriceps muscles were isolated from VDRKO mice and their WT littermates 
(7-8 weeks of age), vitamin D deficient mice and their controls (6 months of 
age).  Upon isolation, muscles were rapidly frozen in isopentane (2-
methylbutane) cooled with liquid nitrogen. Frozen 8 µm muscle sections were 
cut using a Cryostat (Leica). Sections were incubated with Mayer’s 
hematoxylin solution for 4 mins, washed in deionized water, and then incubated 
with eosin solution for 4 min. Sections were then washed in deionized water, 
dehydrated in ethanol, and then mounted. Using ImageJ (National Institutes of 
Health), diameters of muscle fibers and nuclei per fiber were measured in ~ 150 
fibers per mouse.  
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Real-time PCR (RT-PCR) 
Total RNA was isolated from whole quadriceps muscle using TRIZOL Reagent 
(Sigma-Aldrich, Australia), as previously described.(18) cDNA was synthesized 
from 1 µg of total RNA using the Maxima First Strand cDNA synthesis kit 
(Thermo Scientific). RT-PCR was performed in 10 ul reactions using the 
SYBR Green master mix (Promega) within 384-well plates (ABI Prism 
7900HT Sequence Detection System). The amplification protocol included 10 
min at 95°C and 40 cycles of two-step PCR including melting for 15 sec at 
95°C and annealing for 1 min at 60°C. Triplicates were used for each sample. 
Primers were designed using Primer 3 and BLAST (National Library of 
Medicine) and obtained from Invitrogen. Every plate included house-keeping 
genes (TATA-box binding protein (Tbp), cyclophilin) for every sample. For 
each experiment, a house-keeping gene that did not differ significantly between 
groups was used to normalize CT (cycle threshold) values. CT is the number of 
PCR cycles at which fluorescence above background crosses a set threshold. 
Relative expression levels were calculated by comparing the logarithm of the 
difference of total cycle number and CT for specific groups (i.e. ΔΔCT).  
 
Statistical analyses 
Data are presented as means ± SEM. Statistical tests are Student’s t-tests 
conducted at a significance level of 5%. Statistical tests and graphs were 
performed using Excel and/or Prism (GraphPad Prism Version 6 for Windows; 
GraphPad Software, San Diego, CA, USA). 
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RESULTS 
Serum Values 
Serum calcium, magnesium and phosphate levels were measured in a subgroup 
of mice (Figures 1A, B). Due to adequate dietary supplementation, VDRKO 
and vitamin D-deficient mice did not display differences in mineral levels 
compared to their respective controls. Vitamin D deficiency was initially noted 
at 1 month following the commencement of the vitamin D-free diet and by 3 
months, these mice had no detectable 25OHD (Figure 1C).  
 
Grip Strength  
VDRKO and heterozygote mice were significantly weaker than WT controls 
with 43% and 30% reduction in grip strength respectively at 7 weeks of age 
(Figure 2A). At 14 weeks of age, the differences were greater at 48% and 40% 
reduction in grip strength respectively (p<0.005, Figure 2A). The effect of 
VDR ablation on grip strength was supported by a dose-response effect with a 
decline from WT to heterozygote to VDRKO mice at both ages (Figures 2A). 
Age-related decline in grip strength from 7 to 14 weeks was greatest in 
heterozygote mice (25%, p<0.005), followed by VDRKO and WT mice (18 and 
12%, both p<0.005). 
 
There were also differences, to a lesser extent, in vitamin D-deficient versus 
replete mice. After 7 weeks on vitamin D-free diet, mice were 15% weaker than 
controls (p<0.05, Figure 2B). At 10 weeks, vitamin D-deficient mice were 25% 
weaker than controls (p<0.05, Figure 2B).   
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Muscle Mass and Histology 
VDRKO mice had significantly lighter quadriceps muscles even after 
adjustment for total body mass (Figure 3C). They displayed smaller quadriceps 
muscle fibers (Figure 3 A, B, C D) and a higher nuclei to fiber ratio compared 
to WT littermates (Figure 4). These changes imply defects in the regulation of 
muscle fiber size and myocyte proliferation in the absence of VDR, 
respectively. Similar changes were seen in tibialis anterior muscles (data not 
shown), suggesting diffuse muscle defects in VDRKO mice. This staining, 
however, did not allow for differentiation between myonuclei and satellite cell 
nuclei. There were no histologic changes to indicate necrosis in muscle from 
VDRKO mice, nor was there an in increase in the proportion of central nuclei 
in fibers from VDRKO mice (i.e. an indication of fiber 
remodeling/regeneration). By contrast, quadriceps muscle mass proportionate 
to total body mass did not differ in mice with vitamin D deficiency (Figure 
5C). Muscle fiber size did not differ between vitamin D deficient and replete 
mice (Figure 5).  
 
Gene expression 
Differential expression of several groups of mRNAs was examined in the 
quadriceps muscles of VDRKO, vitamin D deficient mice and their controls 
(Figure 6). Myogenic regulatory factors MyoD and Myf5 were significantly 
upregulated in VDRKO mice (Figure 6A, p<0.05), consistent with impaired 
muscle development and maturity. Expression of Myostatin mRNA was greater 
than two-fold in VDRKO mice compared to WT littermates (Figure 6A, 
p<0.005), explaining the substantial reduction in fiber size and muscle mass 
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seen in these mice. To a lesser extent, vitamin D deficient mice also displayed a 
significant increase in Myostatin mRNA (Figure 6B, p<0.05). This was 
associated with increase in the E3-ubiqutin ligase MuRF1 (Figure 6B, 
p<0.005), suggesting upregulation of proteolysis and atrophy pathways in the 
muscles of these mice. Both vitamin D deficient and VDRKO mice showed 
significant down-regulation of calcium handling genes, specifically genes 
encoding Calbindin and sarcoendoplasmic reticulum calcium transport ATPase 
(Serca) channels (Figure 6, p<0.05). This supports a critical role for vitamin D 
in intramuscular calcium handling via genomic mechanisms in skeletal muscle.  
 
DISCUSSION  
This is the first study to examine muscle strength, histology and gene 
expression in VDRKO and vitamin D deficient mice with demonstration of 
normal serum calcium, phosphate and magnesium levels. By assessing 
function, morphology and mRNAs in these mouse models, we addressed the 
important question: does vitamin D directly alter muscle strength and size?   
 
Previous studies reported functional differences in VDRKO mice such as 
impaired swimming, motor coordination and reduced stride length compared to 
WT littermates.(19-21) Other studies reported impaired muscle contraction and 
recovery in vitamin D-deficient rats and chicks compared to their vitamin D-
replete counterparts.(22-24) With the exception of one study (25), these studies did 
not correct for associated biochemical abnormalities and could therefore not 
conclude direct effects of vitamin D. These studies also did not associate 
functional differences in vitamin D deficient or VDRKO mice with specific 
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morphologic changes in their skeletal muscle.  
 
On grip strength testing, vitamin D deficient and VDRKO mice were 
significantly weaker than their controls and this difference increased with 
duration of vitamin D deficiency and age. A stepwise decline in grip strength 
from WT to heterozygote to VDRKO mice strongly supports a role for VDR in 
muscle strength. Interestingly, differences in grip strength were greater in 
VDRKO versus WT than vitamin D deficient versus replete mice, perhaps 
explained by complete ablation of vitamin D signaling in the former. We 
hypothesized that muscle weakness in these mice may be related to defects in 
Ca2+ flux and intracellular handling during excitation-contraction coupling. 
Indeed, rapid, non-genomic effects of vitamin D on calcium handling in 
cultured muscle cells have been reported by the Boland group for over 30 
years.(12, 26, 27) In this study, we report that vitamin D also exerts genomic effects 
in the calcium-handling apparatus within skeletal muscle. Although this has 
been previously reported in tissues with classic vitamin D responses, namely 
intestine and kidney (28), this is the first time such an effect has been shown in 
skeletal muscle. Muscle from VDRKO and vitamin D deficient mice showed 
reduced mRNAs for the calcium-binding gene, Calbindin-28K, and SERCAs, 
potentially resulting in defective Ca2+ flux from sarcoplasmic reticulum (SR) 
into cytosol following excitation, impaired muscle contraction and reduced 
strength. Consistent with greater impairment in strength, VDRKO mice showed 
more pronounced down-regulation of these genes than vitamin D deficient mice 
compared to respective control groups. In vivo contractile studies may shed 
! 12!
further light on effects of vitamin D in muscle force, fatigue and recovery, all 
of which are intrinsically related to calcium signals.    
 
Muscles from VDRKO mice were significantly lighter, even after correction for 
lower body weight, than WT mice. On histology, VDRKO mice displayed 
smaller muscle fibers and had increased muscle nuclei, arising potentially from 
muscle fibers and/or satellite cells. A role for VDR in the regulation of muscle 
fiber size is supported by anabolic effects of 1,25(OH)2D in C2C12 myotubes 
and opposing growth-inhibitory effects following VDR knockdown in these 
cells.(15) Similarly, muscle hyper-nuclearity in the absence of VDR concurs 
with anti-proliferative effects of VDR in cultured muscle cells.(8, 14) In the 
notable study by Endo and colleagues, smaller muscle fibers were seen in mice 
with a different model of VDR deficiency (exon 2 deletion) and this progressed 
in the absence of a high-calcium/phosphorus rescue diet.(29) Our study is the 
first to demonstrate an in vivo role for VDR in muscle fiber size that is 
independent of phosphate or calcium levels. Increased expression of myogenic 
regulatory factors (MRFs) Myf5 and MyoD was also seen in adult VDRKO 
mice, supporting defects in myogenesis and post-natal muscle maturation in 
these mice. Most strikingly, Myostatin mRNA was greater than 2 fold higher in 
muscle from VDRKO mice, explaining the significant reduction in muscle 
mass and fiber size in these mice.  
 
Mice with vitamin D deficiency showed increased expression in the atrophy-
related gene MuRF1. This ubiquitin ligase triggers muscle protein degradation 
and is considered to play a role in pathological muscle wasting (30). However, 
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muscle fiber size and MAFBx, another ubiquitin ligase, were not significantly 
altered by dietary vitamin D deficiency. Interestingly, a modest increase in 
Myostatin mRNA was also seen, favoring the activation of atrophy-related 
mechanisms in vitamin D deficient mice despite the absence of morphologic 
changes. Possible explanations for this discrepancy are that a longer duration of 
vitamin D deficiency (> 6 months) may be necessary for atrophy-related 
mechanisms to lead to overt atrophy. Alternatively, normal mineral levels in 
these mice may have muted the overt development of muscle wasting in 
vitamin D deficiency. In support of this, the use of a high-calcium diet in 
Sprague-Dawley rats with vitamin D deficiency led to partial reversal in 
increased ubiquitin proteosomal activity in muscle.(31) However this study 
showed no change in the expression of myostatin and this may be related to the 
shorter duration of vitamin D deficiency in this study (i.e. 4 months).  It is 
therefore possible that vitamin D deficiency and associated calcium defects 
exert overlapping, interconnected effects in muscle atrophy via activation of the 
ubiquitin-proteosome and myostatin. 
 
Importantly, both models showed significant increases in myostatin expression. 
Myostatin, a member of the TGF-β superfamily which negatively regulates 
muscle mass, was first discovered in 1997.(32) A great deal of research has 
examined the immense potential of targeting myostatin or its receptor 
(ActRIIB) in the treatment of muscle wasting and sarcopenia.(33, 34) We have 
previously shown that treatment of cultured muscle cells with vitamin D results 
in pronounced inhibition of myostatin and subsequent doubling in myotube 
size.(14) The STRAMBO study displayed a significant positive correlation 
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between serum myostatin and 25OHD levels in older human subjects.(4) The 
current work advances the in vivo link between vitamin D signaling and 
myostatin in muscle and raises the pertinent question: may vitamin D present 
another pathway for myostatin inhibition and the reversal of muscle wasting?      
 
Differences in the muscle phenotypes of VDRKO versus vitamin D deficient 
mice reflect diverse effects of aberrant vitamin D signaling. Reduced muscle 
mass and smaller muscle fibers in mice with congenital ablation of VDR 
highlight the developmental role of vitamin D signaling. By contrast, changes 
seen in 6-month old mice with vitamin D deficiency may relate to the muscle 
effects of aging, as supported by the activation of the atrophy-related gene 
MuRF1 in this model. Conversely, VDR deficiency may also play a role in 
muscle aging as suggested by down-regulation of VDR in muscles of older 
subjects.(35) Vitamin D may also exert effects in muscle development. This is 
supported by the association of Vitamin D deficiency during pregnancy with 
reduced muscle fiber size in newborn offspring.(36, 37) These observations 
suggest that vitamin D signaling plays concerted roles in skeletal muscle at 
opposing ends of the age spectrum.  
 
In conclusion, this study demonstrates, for the first time, coordinated effects of 
vitamin D and VDR in muscle strength, morphology and gene expression, 
independent of systemic mineral changes. This provides additional proof that 
vitamin D directly targets skeletal muscle, a point of heated contention until 
now. The precise delineation of these effects, namely in muscle development 
and aging, will be the subject of future research. 
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FIGURE LEGENDS  
Figure 1 Serum Mineral and vitamin D levels A) Due to rescue diet, serum 
calcium, magnesium and phosphate levels were not significantly different 
between WT and VDRKO mice at 7 weeks age. B) After being on vitamin D-
free and replete diets for 3 months, serum calcium, magnesium and phosphate 
levels were not significantly different between these mice, owing to increased 
supplementation of these minerals. C) Serum 25(OH)Vitamin D levels dropped 
significantly after 1 month of the diet and was undetectable at 3 months (n= 4 
mice per group, error-bars SEM,  **p<0.005).  
 
Figure 2 Grip Strength Analysis A) At 7 and 14 weeks age, VDRKO and 
heterozygous mice displayed significantly reduced grip strength corrected for 
body weight. Age-related decline over this period was also more prominent in 
VDRKO and heterozygous mice (22% decline in grip strength) compared to 
WT littermates (12% decline in grip strength). B) At 7 weeks following 
commencement of vitamin D-free diet, vitamin D-deficient mice were 
significantly weaker than replete mice and this difference increased by 10 
weeks (n= 6-12 mice per group, error-bars SEM, *p<0.05, **p<0.005). 
 
Figure 3 Muscle Histology in VDRKO mice A, B) On H&E stain, VDRKO 
mice showed smaller muscle fibers than WT counterparts (quadriceps, 7 week-
old male mice, n= 5 per group). C) After correction for body mass, muscles 
remained significantly lighter in VDRKO mice. D) On ImageJ quantification, 
VDRKO muscles displayed ~ 30% reduction in fiber diameter (n = 5 mice per 
! 22!
group, 150 fibers analyzed per mouse, scale bars 200 µm, error-bars SEM, 
*p<0.05, **p<0.005). 
 
Figure 4 Muscle Histology in VDRKO mice A, B, C) Muscle fibers from 
VDRKO mice displayed a significant increase in nuclear number compared to 
WT mice. (n = 5 mice per group, 150 fibers analyzed per mouse, scale bars 50 
µm, error-bars SEM, *p<0.05, **p<0.005). 
 
Figure 5 Muscle Histology in Vitamin D deficient mice A, B) On H/E stain, 
there was no significant difference in muscle fiber size in vitamin D deficient 
versus replete mice. C) Quadriceps muscle mass, normalized to total body 
mass, did not differ between vitamin D deficient versus replete mice. D) On 
Image-J analysis, muscle fiber size was not significantly different (quadriceps, 
6-month old mice, n = 5 mice per group, 150 fibers analyzed per mouse, scale 
bars 100 µm).   
 
Figure 6 Gene Expression in Muscle from VDRKO and Vitamin D 
Deficient Mice A) VDRKO mice showed significant upregulation of mRNAs 
for myogenic regulatory factors,   >2-fold increase in Myostatin mRNA and 
significant reduction in Calbindin-28K, and genes encoding Serca2a and 2b 
mRNAs B) Vitamin D deficient mice showed upregulation of the atrophy 
marker MuRF1, modest increase in Myostatin mRNA and down-regulation of 
Calbindin-28K, Serca2a, 2b and 3 mRNAs. (n=6 mice per group, error-bars 
SEM, *p<0.05, **p<0.005). 
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Chapter 6 – Direct effects of vitamin D on bone mass 
 
 
 
This chapter consists of a research letter published online in Endocrinology in 
August 2013. The primary author and PhD candidate, Christian Girgis, drafted 
this letter in response to an original article by Yamamoto et al. on the bone 
phenotype of osteoblast-specific VDR knockout and whole-body VDR 
heterozygote mice. 
 
The main findings of this research letter include: 
• no difference in bone mineral density or bone mineral content of VDR 
heterozygote (VDR+/-) male mice and their littermates. 
• discrepancy with the findings of Yamamoto in which VDR 
heterozygote mice reportedly displayed increased bone density. 
• potential contribution of the different genetic models of VDR ablation 
(i.e. exon 3 versus exon 2) in altering bone phenotype.  
 
This research letter discusses the complexity of VDR’s effects in bone and 
raises the possibility that an integrated, inter-system approach in examining 
musculoskeletal roles of VDR may yield further information.  
 
Direct effects of VDR on bone mass 
Christian M Girgis, Sue Lynn Lau, Roderick J Clifton-Bligh, Jenny E Gunton 
Published online on Endocrinology website, August 2013 
 
Letter in response to: Yamamoto& Y,& Yoshizawa& T,& Fukuda& T& et& al.& Vitamin&D&
receptor& in& osteoblasts& is& a& negative& regulator& of& bone& mass& control.&
Endocrinology&2013;&154:1008J20&
 
We read with interest the study by Yamamoto and colleagues on the effects of 
osteoblast-specific VDR ablation on bone mass (1). 
 
Contrary to their finding of increased bone mass in systemic VDR heterozygotes 
(VDR+/-), our experiments have revealed no such difference. The offspring of 
chow-fed heterozygote pairs from the Boston VDRKO line formed the 
experimental litters. All offspring received high calcium, high phosphorus rescue 
diet from weaning. At DXA scanning at 27 weeks, there was no difference in 
weight, bone mineral density or content between 7 VDR heterozgote (VDR+/-) 
males and 14 WT littermates. (BMD: 0.058 vs 0.059 g/cm2 , p=0.7 and BMC: 
0.49 vs 0.50 g, p=0.6) A similar lack of difference was found between 11 female 
27 week  old VDR heterozygotes and 7 WT littermates, (BMD: 0.060 vs 0.060 
g/cm2, p=0.9 and BMC: 0.45 vs 0.48 g, p=0.5)   
 
We hypothesize that these contrasting findings may relate to differences in the 
genetic models. In the Boston strain of mice, exon 3 of VDR was deleted. It 
encodes the second zinc finger of the DNA-binding domain (2). The mice used 
in (1) (Tokyo strain) were generated by ablating exon 2 (the first zinc finger). 
The Tokyo strain expresses a truncated form of VDR which can bind 
1,25(OH)2D and thereby potentially exert biologic activity (3), even if traditional 
signaling through vitamin D response elements in gene promoters is prevented. 
Without ‘rescue’ diet, differences in survival time between homozygous Tokyo 
(15 weeks), Boston (6 months) and Leuven (12 months) VDRKO strains are 
noted, though direct comparisons between strains have not been performed.  
Genetic differences may therefore contribute to phenotypic variability between 
strains, for example, in the age of onset and extent of hypocalcaemia and bone 
abnormalities in relation to weaning.  
 
The question of how vitamin D directly affects bone is complex. In vitro studies 
demonstrate changes in osteoblast proliferation, differentiation and 
mineralization in VDR knockout mice (1). However, osteoclasts and 
chondrocytes also express VDR, CYP27B1 and CYP24A1 and display profound 
responses to VDR ablation or 1,25(OH)2D treatment (4). Effects of VDR on 
bone mass are therefore likely to result from intricate multi-cellular interactions 
rather than simply involve osteoblasts. 
 
Also, the stage of osteoblast differentiation directly influences effects of 
1,25(OH)2D on osteoblast activity. This has been nicely demonstrated in a study 
where osteoblasts isolated from neonatal mouse calvariae and juvenile mouse 
long bones showed different properties and responses to 1,25(OH)2D (5). VDR 
knockout at later stages of osteoblast differentiation (eg using Dmp (dentin 
matrix protein) 1-promoter Cre) may therefore result in a different phenotype 
from that described in this study. 
 
To add further complexity, VDR over-expression in osteoblasts also increases 
bone mass (6). This raises questions about VDR activity in the physiologic 
setting where its expression is tightly regulated. There may be a ‘window’ of 
activity for optimal bone homeostasis. 
 
The Yamamoto study adds very useful information to our understanding of the 
direct effects of VDR in bone mass but interesting and unresolved issues remain. 
A double osteoblast, osteoclast-specific VDR knockout mouse model may 
further enlighten the field. 
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Chapter 7 – Novel technique in satellite cell isolation 
 
 
 
This chapter consists of an original article published in Journal of Cellular 
Physiology in November 2014. The PhD candidate, Christian Girgis, was a co-
author on this publication and contributed to a specific component of this work 
(i.e. cell cycle analysis of Grb10 knockout primary muscle cells). 
 
The main findings of this original article include: 
• a novel technique for isolating pure populations of primary 
muscle/satellite cells using anti-CD56 (NCAM) cell staining. This 
technique was first described in this article and also used to isolate 
muscle cells from VDRKO and WT mice (discussed in Chapter 4). 
• differences in primary muscle cell proliferation, differentiation and 
GLUT4 translocation in the absence of growth-factor receptor-bound 
protein 10 (Grb10).  
  
 
Grb10 Deletion Enhances Muscle
Cell Proliferation, Differentiation
and GLUT4 Plasma Membrane
Translocation
NANCY MOKBEL,1* NOLAN J. HOFFMAN,1 CHRISTIAN M. GIRGIS,2,3 LEWIN SMALL,1
NIGEL TURNER,4 ROGER J. DALY,5 GREGORY J. COONEY,1* AND LOWENNA J. HOLT1
1 Diabetes and Obesity Research Program, The Garvan Institute of Medical Research, Sydney, New South Wales, Australia
2Immunology-Diabetes and Transcription Research Program, The Garvan Institute of Medical Research, Sydney, New South
Wales, Australia
3Faculty of Medicine, The University of Sydney, Sydney, New South Wales, Australia
4Department of Pharmacology, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
5Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia
Grb10 is an intracellular adaptor protein which binds directly to several growth factor receptors, including those for insulin and insulin-like
growth factor receptor-1 (IGF-1), and negatively regulates their actions. Grb10-ablated (Grb10-/-) mice exhibit improved whole body
glucose homeostasis and an increase in muscle mass associated speciﬁcally with an increase in myoﬁber number. This suggests that Grb10
may act as a negative regulator of myogenesis. In this study, we investigated in vitro, the molecular mechanisms underlying the increase in
muscle mass and the improved glucose metabolism. Primary muscle cells isolated from Grb10-/- mice exhibited increased rates of
proliferation and differentiation compared to primary cells isolated from wild-type mice. The improved proliferation capacity was
associated with an enhanced phosphorylation of Akt and ERK in the basal state and changes in the expression of key cell cycle progression
markers involved in regulating transition of cells from the G1 to S phase (e.g., retinoblastoma (Rb) and p21). The absence of Grb10 also
promoted a faster transition to a myogenin positive, differentiated state. Glucose uptake was higher in Grb10-/- primary myotubes in the
basal state and was associated with enhanced insulin signaling and an increase in GLUT4 translocation to the plasma membrane. These data
demonstrate an important role for Grb10 as a link betweenmuscle growth andmetabolismwith therapeutic implications for diseases, such
as muscle wasting and type 2 diabetes.
J. Cell. Physiol. 229: 1753–1764, 2014. © 2014 Wiley Periodicals, Inc.
Skeletal muscle is a highly dynamic tissue that makes up
25%–40% of our body weight (Janssen et al., 2000). It is capable
of increasing in size and improving in function after various
physiological stimuli (e.g., exercise, weight bearing), and
injuries. Muscle is also a major tissue contributing to energy
balance, and can be responsible for up to 80% of insulin-
stimulated glucose uptake and storage after a meal (DeFronzo
et al., 1985; Shulman et al., 1990). Change in muscle mass is one
of the factors shown to signiﬁcantly affect glucose homeostasis
andmetabolic health. An increase in muscle mass after exercise
training is associated with overall improved glucose utilization
and reduced insulin resistance (Srikanthan and Karlamangla,
2011). Conversely, reduced muscle bulk during aging and
severe myopathic diseases is associated with insulin resistance,
a risk factor for type 2 diabetes (Evans, 1997; Cruz Guzman
Odel et al., 2012). Thus, identifying factors or mechanisms that
regulate muscle growth, regeneration, and metabolism could
provide therapeutic targets to improve metabolic health, and
has implications for treatment of muscle diseases, and
maintaining general muscle function during aging.
The regenerative capacity of muscle is attributed to the
activation of a specialized population of cells termed “satellite
cells” that reside between the basal lamina and sarcolemma of
muscle ﬁbers. Muscle satellite cells share the same origin as
embryonic muscle precursor cells (Gros et al., 2005) and act as
adult stem cells in skeletal muscle. Therefore, they are
considered the major contributors to skeletal muscle growth
and regeneration in adults. Under normal conditions, satellite
cells are in a quiescent state (G0 phase), and in response to
trauma, injury, or stress, they become activated and enter
mitosis to proliferate then exit the cell cycle to differentiate and
form new ﬁbers (hyperplasia) or fuse to existing myoﬁbers
(hypertrophy) (Hawke and Garry, 2001). The main growth
factors that have been shown to regulate satellite cell
proliferation and differentiation include IGF-1 & IGF-2 (Duclos
et al., 1991; McFarland et al., 1993), the ﬁbroblast growth factor
(FGF) family (Bendall et al., 2007), hepatocyte growth factor
(HGF) (Maina et al., 1996; Tatsumi et al., 1998), and
transforming growth factor (TGF)-beta (Bischoff, 1990;
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Yablonka-Reuveni and Rivera, 1997). These growth factors
trigger a cascade of downstream signaling that phosphorylate
myogenic regulatory factors (MRF) leading to the regulation of
proliferation and/or differentiation of satellite cells (Yablonka-
Reuveni and Rivera, 1994; Sabourin and Rudnicki, 2000; Le
Grand and Rudnicki, 2007).
The Grb10 gene encodes for a growth factor receptor-
binding protein that is abundantly expressed in major insulin-
sensitive tissues such as muscle and adipose tissue, as well as
pancreas (Smith et al., 2007; Wang et al., 2007). Grb10 binds,
and negatively regulates signal output from the insulin receptor
(IR) (Liu and Roth, 1995;O’Neill et al., 1996; Laviola et al., 1997;
Ramos et al., 2006), and IGF-1 receptor (IGF-1R) (Liu and
Roth, 1995; Morrione et al., 1996; Laviola et al., 1997). Grb10
also interacts in vitro with other growth factor receptors such
as those for epidermal growth factor (EGF) (Ooi et al., 1995),
platelet-derived growth factor (PDGF), ﬁbroblast growth
factor (FGF), and HGF receptors (Wang et al., 1999; Holt and
Siddle, 2005; Liu et al., 2012), but the physiological relevance of
Grb10 binding in this context is unclear. Studies from our
laboratory and others have demonstrated that deletion of
Grb10 in mice results in improved glucose metabolism
mediated by enhanced insulin signaling and increased phos-
phorylation of insulin receptor substrate-1 (IRS1) in muscle
(Smith et al., 2007; Wang et al., 2007; Holt et al., 2009). More
recently, we have identiﬁed a novel role for Grb10 in regulating
muscle mass (Holt et al., 2012). Mice lacking Grb10 have
signiﬁcantly elevated muscle mass compared to wild-type
(WT). This is mainly due to hyperplasia, with no change in ﬁber
size or proportion. This model of hyper-muscularity is unlike
other models such as IGF-1 transgenic mice (Coleman
et al., 1995; Musaro et al., 2001) and myostatin knock-out mice
(McPherron et al., 1997), which exhibit both hyperplasia and
hypertrophy.
The knowledge of the role of Grb10 in muscle outside of
insulin signaling pathway regulation is limited. The aim of the
current study was to understand the mechanisms underlying
the increase in muscle mass and glucose homeostasis in the
Grb10-/-mice. Thus, we investigated the impact of Grb10
deletion on muscle cell proliferation, differentiation, and
glucose metabolism in an in vitro model of pure primary muscle
cells isolated from WT and Grb10-/- mice. The results
supported a role for Grb10 in playing a regulatory link between
muscle growth and metabolism.
Materials and Methods
Animal maintenance
Mice with homozygous deletion of Grb10 (Grb10-/-) have been
described previously in (Charalambous et al., 2003) and were
maintained on a mixed C57BL/6 x CBA background at the
Australian Bioresources (ABR) as described in Holt et al., 2012. All
animal studies were performed with the approval of the Garvan
Institute/St Vincent’s Hospital Animal Ethics Committee.
In vitro isolation and maintenance of mouse-derived
primary muscle cells
Mouse primary myoblast cell lines were established fromWT and
Grb10-/- mice using explant culture (Decary et al., 1997) with some
modiﬁcations as outlined below. Quadriceps muscles from four-
week-old mice were dissected out and rinsed in PBS containing
40mg/ml gentamicin. Muscle was cleaned from surrounding tissue,
fat, and vasculature, and then transferred into ~0.5–1.0ml of
plating media (DMEM/HAMS-F12 media 1:1, 40% v/v heat-
inactivated FBS (Thermo Fisher Scientiﬁc), 10% v/v amniomax,
40mg/ml gentamicin). The muscle was then cut into 1mm3 pieces
and placed as explants in culture dishes (Becton Dickinson) coated
with collagen–matrigel (DMEM/HAMS-F12 1:1. 0.17mg/ml colla-
gen type I (Becton Dickinson), 1/50 dilution of matrigel (Becton
Dickinson), 40mg/ml gentamicin). Dishes were kept in a humidiﬁed
chamber at 37 °C, 5% CO2 and after 48 h, when the explants had
sufﬁciently adhered, 2ml of myoblast media (DMEM/HAMS-F12
1:1, 10% v/v amniomax, 20% v/v FBS, 40mg/ml gentamicin) was
added. Once outgrowth from the explants was visible (day 2 or 3),
cells were gently washed twice with 1xPBS and detached using
TrypLE. The cells were then transferred and expanded in a T75
ﬂask. At 60%–70% conﬂuency, expanded cells were detached with
TrypLE and centrifuged at 300 g for 15min. Media was then
aspirated and the pellet frozen down in myoblast mediaþ 10%
DMSO. For differentiation of primary myoblasts into myotubes,
myoblast media was replaced with a differentiation media (DM)
(DMEM/HAMS-F12 1:1 media (12.5 nM glucose), antibiotics,
40mg/ml gentamicin, 3% heat-inactivated horse serum). Cells were
allowed to differentiate into mature myotubes over 6 days. For all
assays, a total of six clones fromWT and Grb10-/- mice was used,
and clones were maintained in the same culture media conditions
with similar passage number.
Puriﬁcation of satellite cells by FACS
Enrichment of primary muscle cells was achieved by FACS using a
Neural Adhesion Cell Marker/CD56 (NCAM/CD56) antibody
(MEM-188, Thermo Scientiﬁc/Pierce). Isolated primary cells were
left in culture for 48 h before sorting in order to enhance the
expression of cell surface markers. Cells were centrifuged at 300 g
for 1min, then the pellet washed with 1ml of FACS buffer (1 x
sterile PBSþ 0.1% BSA). The cell suspension was centrifuged at
300 g for 1min, and the pellet suspended in 100ml FACS buffer
containing NCAM/CD56 antibody, 1:10. Cells were incubated on
ice for 20min and were washed twice in FACS buffer in
preparation for sorting. Cell sorting was performed using a FACS
Aria U2 (Becton Dickinson) at 4 °C with a 100mm nozzle. To
eliminate false positive cells, the preparation was sorted against
auto ﬂuorescence parameters with a 530 nm ﬁlter. For all WT and
Grb10-/- clones included in this study, the top 20th percentile of
the NCAM/CD56 positive cells was collected containing the most
intensely staining NCAM/CD56 positive cells. All satellite cells
were used at low passage (1–9).
RNA isolation, cDNA synthesis and real time qPCR
Total RNA isolation from mouse tissues, primary cultured
myoblasts and myotubes was performed using the TRIZOL
Reagent1method (Sigma-Aldrich, Castle Hill, Australia) as per the
manufacturer’s instructions, followed by ethanol precipitation.
cDNA was synthesized from 1mg of total RNA using the
Omniscript RT Kit (200) (Qiagen, VIC, Australia) and Random
Primer 9 (New England Biolabs, MA). The intron-spanning primer
set used were as follows: for mouse Grb10 (UPL probe#63),
forward 50-CGGTTGCTCCTAGCTCCTT-30, reverse 50-
CTGAAGCCTGGAGGGAAAT-30, for mouse cyclophillin (UPL
probe# 108), forward 50-ATCTGCTCGCAATACCCTGT-30,
reverse 50-CTTGAAGGGGAATGAGGAAA, for mouse p21
(SYBR Green), forward 50-GCCTTAGCCCTCACTCTGTG-30,
reverse 50-AGGGCCCTACCGTCCTACTA-30. Data analysis was
performed using the comparative 2-delta Ct method and
normalized tocyclophilin transcript.
Immunohistochemical analysis
Cells grown on collagen/Matrigel coated plastic Thermanox
coverslips (Nunc, Rochester, NY) were ﬁxed and permeabilized in
3% PFA/0.1% Triton-X 100/PBS. Immunocytochemistry was
performed as previously described (Ilkovski et al., 2004). Imaging
was undertaken using a Zeiss AxioPlan1 upright microscope and a
Nikon Super Resolution Microscope N-SIM. Primary antibodies
used for immunohistochemical analysis were incubated overnight
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at 4 °C and included: PAX7 (1:50, Hybridoma Bank, UIOWA) and
MyoD (1:100, Santa Cruz). Antibodies incubated at room
temperature for 3 h included: sarcomeric actin (5C5 1:500, Sigma-
Aldrich), a-actinin 2 (4B3, 1:500,000, kindly provided by Prof.
Kathryn North, Institute of Neuroscience and Muscle Research,
Westmead, Australia) and total myosin heavy chain (MF 30,1:500,
Hybridoma Bank, UIOWA).
Immuno-blotting
Protein lysates were collected from primary myoblasts at day 2
(D2), myotubes at day 6 of differentiation (Diff 6) and muscle tissue
isolated fromWT and Grb10-/- mice. Samples from cells and tissue
were solubilized in a lysis buffer containing (4% SDS, 62.5mM
TrispH 6.8, 10% glycerol, 1:500 protease inhibitors cocktail).
Lysates collected from cells were left on ice for ~15min then
sonicated to shear chromosomal DNA. Muscle samples collected
fromWT and Grb10-/- mice were processed as described in (Hoy
et al., 2007). Primary antibodies used for immunoblotting included:
Grb10 antibody (K20, 1:1000, Santa Cruz), total retinoblastoma
(t-Rb) (1:1000, BD Pharmingen), phospho-retinoblastoma S807
(p-Rb) (1:1000,CST), total Akt (t-Akt) and phospho-Akt S473
(p-Akt) (1:1000, CST), total ERK (t-ERK) and phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) (p-ERK) (1:1000, CST), skeletal
actin 5C5 (1:2000, Sigma-Aldrich), vimentin (1:1000, Sigma-
Aldrich), myogenin (F5D, 1:1000, Hybridoma Bank, UIOWA),
b-tubulin (E7,1:1000, Hybridoma Bank, UIOWA).
In vitro proliferation assay
Cell proliferation rate was measured by a BrdU ELISA (Roche,
USA). Brieﬂy, satellite cells were seeded at "6000 cells/cm2 on
collagen–matrigel coated 96 well plates and pulsed with 10mM of
BrdU 2 h after seeding (T0) and incubated for 4 h. BrdU antibody
was used at 1:100 and ﬂuorescence was read at 570 nm using a
ﬂuorescent microtiter plate reader (Fluostar Omega-BMG
Labtech, Ortenberg, Germany). For the manual cell count, cells
were seeded at low density at"200 cells/cm2 and counted using a
haemocytometer at 24 h intervals.
Growth factor studies
Primary myoblasts and myotubes were serum starved for 4 h and
6 h respectively (baseline) followed by growth factor stimulation
with insulin (6min), IGF-1 (6min) and HGF (20min), and protein
lysates collected. Growth factors were used at concentrations:
insulin (100 nM, Actrapid Penﬁll, 100 IU units/ml), IGF-1 (10 ng/ml,
EAG-c03, Gropep, Adelaide, Australia), HGF (50 ng/ml, 130-093-
872, Miltenyi Biotech, Macquarie Park, Australia). These
concentrations were determined as optimal concentrations for
activation of Akt and ERK.
Glucose uptake assay
To assess the rate of glucose uptake in cells, differentiated primary
myotubes-Diff 6 were serum starved for 6 h in a media containing
DMEM/HAMS-F12 (6mM glucose). The assay was performed as
described in (Tan et al., 2010) with minor modiﬁcations outlined
below. Brieﬂy, cells were stimulated with insulin (100 nM) for
15min in Krebs buffer and for the ﬁnal 5min of stimulation 0.2mM
of 2-deoxyglucose (D3179-1G, Sigma-Aldrich)þ 10mCi/ml 1,2-3H
radioactively labelled 2-deoxyglucose (2DG, Perkin Elmer,
Massachusetts) was added to assess glucose uptake. After 5min
2DG stock was removed and lysis buffer (2% SDS, 125mM Tris-
HCl pH 6.8) was added. Speciﬁc activity (dpm 3H/pmole) of glucose
was read using a Beta counter (Beckman LS 6500) and results were
normalized to total protein content.
GLUT4 translocation assay
GLUT4 translocation assay was performed as described in
(Govers et al., 2004), (Shewan et al., 2003) with minor
modiﬁcations outlined below. Satellite cells were transduced
with HA-GLUT4 retrovirus and measurement of cell surface
Fig. 1. Assessment of satellite cell content in primary muscle cultures prior to purification with NCAM/CD56 antibody. (i&ii) Representative
images from WT and Grb10-/- primary muscle cells respectively showing ~20 and 40% of PAX7 positive cells compared to (iii&iv) the total
number of cells (shown by DAPI stain). The merged images (v&vi) show co-localisation of PAX7 positive cells (red) with total number of cells
(blue). Images were taken on a Zeiss Axioplan microscope with a 10x objective. Scale bar 50mm.
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HA-GLUT4 as a percentage of total cellular HA-GLUT4 was
performed. Differentiated myotubes were serum-starved for
4 h in 1:1 DMEM/HAMS-F12, and maintained in this medium
during subsequent treatments. Myotubes were stimulated with
100 nM insulin for the ﬁnal 20 min of serum starvation. All
values were expressed as a percentage of total GLUT4 that was
determined from anti-HA antibody labeling of permeabilized
cells.
Statistical analysis
All data presented are expressed as means# SEM where
appropriate. Statistical analysis was performed by two-way analysis
of variance (ANOVA) where appropriate using GraphPad Prism
Version 6. Unpaired t-tests, two tailed distribution, and unequal
variance were applied. Statistical signiﬁcance was set a priori
at P$ 0.05.
Results
Isolation and characterization of a highly myogenic
NCAM/CD56þ subpopulation of cells from mouse
skeletal muscle
Primary cells isolated from muscle of four-week-old WT and
Grb10-/- mice represent a highly enriched, but mixed, myogenic
cell population. Using PAX7, as a marker of satellite cells, we
demonstrated that ~20% and 40% respectively of WT and
Grb10-/- cells isolated are satellite cells (Fig. 1). To further
enrich for primary muscle cells, cells from these cultures were
sorted using FACS based on the expression of the neural cell
adhesion marker NCAM/CD56 previously described to be
expressed on muscle progenitor cells derived from porcine
(Wilschut et al., 2008) and human muscle (Meng et al., 2011).
To our knowledge, this is the ﬁrst paper describing the
puriﬁcation of murine muscle cells with the NCAM-CD56
Fig. 2. Isolation of a highly myogenic population of primary muscle cells using NCAM/CD56 cell surface marker. A) Positive staining for
NCAM/CD56 in primary murine muscle cells is shown on the histogram by a right shift (red peak) compared to unstained cells (grey peak).
B) (i) isolated NCAM/CD56 positive cells (red surface stain, arrow) are elongated in shape with a high nuclear to cytoplasmic ratio and (ii)
co-express MyoD (green nuclear stain, arrow), scale bar 10mm. C) NCAM/CD56 positive cells differentiate into mature multinucleated
myotubes as indicated by the co-expression of myosin heavy chain (yellow) and the Z-line marker a-actinin-2 (inset-striated pattern),
scale bar 50mm. D) Representative image from WT primary myoblasts following sorting with NCAM/CD56 antibody showing that the
majority of isolated cells are (i) Pax7 positive and (ii) MyoD positive when compared to (iii) total number of nuclei. (iv) Merged image. Scale
bar 50mm. E) Histogram representing percentage of PAX7 positive cells before and after purification with NCAM/CD56 antibody (n¼ 3 WT
& 3 Grb10-/- clones, three independent experiments).
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marker. FACS analysis demonstrates that NCAM/CD56 is
expressed in mouse primary muscle cells (Fig. 2A, red peak).
The isolated NCAM/CD56 positive population consists of
spindle-shaped cells with a reduced cytoplasmic volume typical
of satellite cells (Fig. 2B.i), and express the myogenic
transcription factor MyoD (Fig. 2B.ii), indicating that these cells
are actively proliferating. Differentiation of WT and Grb10-/-
NCAM/CD56 positive cells in low serum conditions (3% horse
serum) results in mature multinucleated primary myotubes as
revealed by the striation pattern for a-actinin2 (z-line marker)
(Fig. 2C, inset). To verify the purity of sorted cells,
immunoﬂuorescence against PAX7 and MyoD was performed
(Fig. 2D.i&ii) and the percentage of PAX7/MyoD positive cells
determined (Fig. 2D.iv), conﬁrming that our method results in
>95% purity (Fig. 2E). The fact that these cells co-express
MyoD indicates that they have been activated in culture.
Therefore, they will be referred to as activated satellite cells or
primary myoblasts henceforth.
Fig. 3. Grb10 is present in primary myoblasts and differentiated myotubes and is developmentally regulated in vivo. A) (i) Quantitative PCR
(qPCR) analysis showing expression of Grb10 mRNA in WT day 2 (D2) myoblasts and day 6 differentiated myotubes (Diff6) relative to
cyclophilin (n¼ 3WT, three independent experiments, *P< 0.05, t-test). (ii) Grb10 was also detected at the protein level in D2 myoblasts and
Diff6 myotubes. (iii) Expression profile of IGF-1R & IR in WT myoblasts and myotubes. B) (i) qPCR and (ii) Western blot analysis show that
Grb10 is highly expressed in new born pup muscle (P0) with levels decreasing as the muscle matures (3 wo, 3 mo), (n¼ 3 WT from each time
point, two independent experiments, ***P< 0.001, t-test), (iii) Expression profile of IGF-1R and IR in muscle frommice at stage P0, 3 wo and 3
mo.
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Grb10 is expressed in activated satellite cells and
expression levels in skeletal muscle decrease with muscle
maturity
To ascertain the expression of Grb10 in primary myoblasts and
differentiated myotubes in vitro, and to determine the
expression levels of Grb10 in maturing muscle in vivo, qPCR
and Western blot analysis were performed. Both methods
demonstrated that Grb10 is expressed in primary myoblasts
(D2) and differentiated myotubes (Diff6) in vitro (Fig. 3A.i&ii).
In vivo, Grb10 appeared to be developmentally regulated with
highest Grb10 expression levels detected by qPCR and
immunoblot in muscle of newborn pups and lower levels in
3 week old mice and 3 month old mice (Fig. 3B.i&ii). Two
known binding partners of Grb10, the IR and the IGF-1R, are
also expressed in myoblasts and myotubes (Fig. 3A.iii). In
muscle tissue, the expression pattern of these receptors
parallels that of Grb10 (Fig. 3B.iii).
Grb10 deletion enhances proliferation of primary muscle
cells and alters the expression of key cell cycle markers
To investigate the proliferative capacity of Grb10-/- primary
myoblasts, we examined the mean population doubling time
using both a manual cell count and BrdU incorporation assay.
After 48 h in culture, more Grb10-/- primary myoblasts were
detected compared to WT (Fig. 4A.i&ii). Manual cell count
demonstrated a twofold increase in Grb10-/- cell number
Fig. 4. Absence of Grb10 enhances muscle cell proliferation and alters the expression of key cell cycle markers. A) Brightfield images
showing a larger number of (ii) Grb10-/- cells compared to (i) WT after 48h in culture, scale bar 50m. B) Manual cell count of WT and Grb10-/-
cells at 48 and 96h. C) BrdU incorporation at 8, 24, and 48h (n¼ 3 WT & Grb10-/- clones, three independent experiments, *P<0.05, **P<0.01,
***P< 0.001, t-test). D) qPCR analysis of p21 mRNA (n¼ 3 WT & 3 Grb10-/- clones, three independent experiments, ***P< 0.001, t-test) E)
Representative Western blots from WT & Grb10-/- protein lysates at 48h blotted for p-Rb and total Rb. F) densitometry analysis of p-Rb in
Grb10-/- myoblasts compared to WT when normalised to total levels of Rb (t-Rb) (n¼ 3 WT & 3 Grb10-/- clones, two independent
experiments, *P< 0.05, t-test).
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(Fig. 4B, P< 0.05) that was also conﬁrmed by the BrdU assay
showing a signiﬁcant increase in BrdU incorporation at 8, 24,
and 48 h after pulsing with BrdU (Fig. 4C). To further
understand the molecular mechanisms leading to the increase
in cell proliferation, we measured markers of the G1-S cell
cycle checkpoint; namely p21 and its downstream target
retinoblastoma protein (Rb). qPCR analysis showed a
signiﬁcant decrease in p21 transcript levels in D2 Grb10-/-
myoblasts (Fig. 4D, P< 0.001) which was associated with a
twofold increase in phosphorylation of Rb (pRb) (Fig. 4E&F,
P< 0.05).
Grb10 deletion enhances Akt and ERK signaling in
primary myoblasts
To investigate a role for Grb10 in primary myoblast signaling,
we examined phosphorylation of the mitogenic signaling
pathway targets Akt and ERK. Following insulin stimulation,
there was no signiﬁcant difference in the response between
WT andGrb10-/- myoblasts for either p-Akt or p-ERK (Fig. 5A).
However, a modest difference in the phosphorylation of these
signaling proteins was observed between the two genotypes in
the basal state (growth factor-free media). To test the
response to well-established myogenic growth factors,
stimulation with IGF-1 and HGF was also performed. WT
myoblasts were responsive, with increased phosphorylation of
Akt and ERK in the presence of growth factors compared to
the basal state (1.8- or 7-fold increase of p-ERK for IGF-1 or
HGF respectively, and 2.9- or 2.6-fold increase of p-Akt for
IGF-1 or HGF respectively) (Fig. 5B). No signiﬁcant difference
was detected in the levels of p-ERK and p-Akt betweenWT and
Grb10-/-myoblasts following stimulation by either IGF-1 or
HGF (Fig. 5B). However, markedly higher levels of
phosphorylation of ERK (1/2) (p-ERK) and Akt (p-Akt) were
again seen in the basal state in Grb10-/- myoblasts compared to
WT (3- and 2.5-fold increase, respectively) (Fig. 5B).
Grb10 deletion produces faster transition to a myogenin-
positive state
To better understand the role of Grb10 during muscle
differentiation, the expression levels of Grb10 at early time
Fig. 5. Absence of Grb10 results in enhanced ERK and Akt signalling at baseline. A) Representative Western blot of ERK(1/2) and Akt on
protein lysates extracted fromWT and Grb10-/- myoblasts at baseline (6 h of serum starvation) and following insulin stimulation (n¼ 2 WT, 2
Grb10-/-, two independent experiments) with densitometry analysis. B) Representative Western blot of ERK(1/2) and Akt on protein lysates
extracted from WT and Grb10-/- myoblasts at baseline (6 h of serum starvation) and following stimulation with IGF-1 or HGF (n¼ 2 WT, 2
Grb10-/-, two independent experiments) with densitometry analysis.
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points of myoblast differentiation were determined. To induce
differentiation, cells were switched to differentiation media
(DM) and mRNA collected from WT cells after 1 (Diff1), 2
(Diff2) and 6 days (Diff6) of differentiation. qPCR showed an
increase in the level of Grb10 transcripts in differentiating
myoblasts, with levels peaking signiﬁcantly after 2 days of
differentiation (Fig. 6A, P< 0.05). Grb10 levels were lower in
mature myotubes (Diff6), but similar to previous results,
remained higher compared to undifferentiated myoblasts (D2).
Morphological assessment of Diff6 Grb10-/- myotubes showed
no apparent differences to WT, suggesting that Grb10-/- cells
are able to differentiate fully (Fig. 6B.i&ii). To assess the rate of
differentiation inWT andGrb10-/-myoblasts, subconﬂuentWT
and Grb10-/- myoblasts were switched to DM and pulsed with
BrdU at 12, 24 (Diff1), and 48 h (Diff2) of differentiation. The
percentage difference in BrdU incorporation relative to cells
growing in normal growth media (cells still cycling) was then
measured. After 12 h of switching to differentiation media, a
52% decrease in BrdU incorporation was observed in Grb10-/-
myoblasts compared to 27% in WT (Fig. 7A.i). A signiﬁcant
decrease in BrdU incorporation was observed at 24 h (Grb10-/-
65%, WT 43%) (Fig. 7A.ii). However, no difference was
observed between WT and Grb10-/- cells at 48 h (Diff2) of
differentiation(Grb10-/- 64%, WT 66%, Fig. 7A.iii). These
results indicate that when induced to differentiate, Grb10-/-
myoblasts can exit the cell cycle at a faster rate than WT cells,
but only for a short time interval. We then examined the
expression levels of myogenin, a marker of early differentiation.
Lysates from WT and Grb10-/- differentiating myoblasts were
collected 24 h (Diff1) after switching to DM (Fig. 7B), and
Western blot analysis of myogenin demonstrated a 2-fold
increase in expression levels in Grb10-/- myoblasts compared
to WT (Fig. 7C&D).
Grb10-/- primary myotubes display an increase in glucose
metabolism and GLUT4 content at the plasma
membrane
We evaluated the potential mechanisms by which Grb10
ablation impacts glucose uptake in muscle. H32-deoxyglucose
uptake in Diff6 differentiated myotubes was measured under
basal conditions, and following insulin stimulation. Grb10-/-
myotubes showed a 2-fold increase in glucose uptake under
both conditions (Fig. 8A) compared to WT. GLUT4
translocation assays were performed to investigate the
mechanisms underlying the increase in glucose uptake. Cell
surface HA-GLUT4 constituted ~25% of total HA-GLUT4
content in WT myotubes, while in Grb10-/-myotubes, it
represented 55% (Fig. 8B). No signiﬁcant difference in surface
HA-GLUT4 level was seen between WT and Grb10-/-
myotubes following insulin stimulation. Signaling pathways
were also examined. In the basal state, there was a tendency for
higher levels of p-ERK and p-Akt in Grb10-/- myotubes, and the
same was found following insulin stimulation (Fig. 8C,D).
Discussion
Factors that regulate muscle mass have the potential to offer
therapeutical beneﬁts in treating muscle diseases and
improving metabolic health. Our laboratory has recently
identiﬁed Grb10 as one such protein (Holt et al., 2012). In the
present study, we developed an in vitro model of pure primary
murine muscle cells to investigate the mode of action of Grb10
and provide insight into mechanisms that contribute to the
growth of muscle mass and the phenotype of improved insulin
action observed for Grb10 KO mice in vivo.
The satellite cell population in skeletal muscle is also
referred to as adult muscle stem cells. As well as having a
common origin with embryonic muscle precursor cells, they
share many cellular and molecular features, making them an
appropriate model for the study of muscle development in
vitro. However, such investigations require isolation of a highly
pure population of satellite cells to be able to speciﬁcally
evaluate muscle cell proliferation, differentiation, and
intracellular signaling cascades. Here, we provide a method
combining explant isolation with FACS to speciﬁcally enrich for
muscle satellite cells. To date, only two cell surface markers
(CD34 and alpha 7 integrin) have been used to purify mouse
muscle cells using FACS (Cooper et al., 1999; Beauchamp
et al., 2000; Ieronimakis et al., 2010). Based on studies using
human muscle (Meng et al., 2011), we investigated the use of
NCAM/CD56 as a marker for the isolation of muscle
progenitor cells from mouse tissue. NCAM/CD56 was initially
considered as a marker of Natural Killer (NK) cells (Hercend
et al., 1985; Jacobs et al., 1992) and later identiﬁed to be
expressed in a variety of tissues including brain, nerve, and
muscle (McClain and Edelman, 1982; Cunningham et al., 1987).
We have shown that NCAM/CD56 is expressed on primary
muscle cells from mouse tissue. Sorting with this marker
yielded over 95% PAX7/MyoD positive cells that can actively
engage in the terminal differentiation program (Fig. 2C). To our
knowledge, this is the ﬁrst paper describing the isolation of a
pure and highly myogenic population of primary myoblasts
from mouse tissue using this marker. Furthermore, we have
demonstrated the utility of this method for application to a
genetically modiﬁed mouse model, to facilitate comparative
studies of satellite cell function.We suggest that NCAM/CD56
cell surface marker can be considered by itself or in
combination with other established markers when isolating
primary muscle cells from mice.
While the role of Grb10 has been previously studied in the
context of adult muscle function, its role in myogenesis has
been unclear. We demonstrated that Grb10 protein is more
Fig. 6. Grb10 mRNA levels increase during early stages of
differentiation but Grb10 is dispensable for the formation of
myotubes. A) qPCR analysis of Grb10 mRNA isolated from WT
primary myoblasts (D2) and differentiating myotubes (Diff1, Diff2,
Diff6) (n¼ 3 WT & 3 Grb10-/- clones, three independent
experiments, *P< 0.05, t-test) normalised to cyclophilin. B)
Brightfield images of Diff6 (i) WT and (ii) Grb10-/- myotubes, scale
bar 50mm.
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highly expressed in activated satellite cells than in differentiated
myotubes. mRNA level did not correlate with protein, but this
could be attributable to post-transcriptional and/or post-
translational regulation of Grb10 (Hsu et al., 2011; Yu
et al., 2011). In addition, we showed in vivo that in skeletal
muscle, the highest expression for Grb10mRNA and protein is
at birth (P0), and these levels signiﬁcantly decrease during
muscle maturation to adulthood (3 months). These results are
consistent with previous work showing that Grb10 transcripts,
as well as other imprinted genes, are downregulated in adult
muscle compared to postnatal day ﬁve (P5) skeletal muscle
(Berg et al., 2011). The decline in Grb10 expression levels from
the postnatal to adult periodmay also be associatedwith a drop
in the proportion of satellite cells during postnatal muscle
growth. At birth, satellite cells represent ~30% of myocyte
nuclei, while they only constitute ~2%–7% of nuclei within adult
skeletal muscle (Hawke and Garry, 2001; Halevy et al., 2004).
Taken together, these results suggest that the expression of
this imprinted gene is retained in satellite cells and support a
role for Grb10 in early muscle development and satellite cell
function.
The hypermuscular phenotype of Grb10-/- mice is related to
an increase in muscle ﬁber number with no apparent changes in
ﬁber size or ﬁber type proportion (Holt et al., 2012). Fiber
number is thought to be established by birth (Ontell and
Kozeka, 1984) and is dependent on the number of available
Fig. 7. Deletion of Grb10 produces faster transition to a myogenin-positive state. A) Assessment of the difference in BrdU incorporation
after (i) 12 h, (ii) 24 h and (iii) 48 h of switching from growth media (GM) to differentiation media (DM) (n¼ 3 WT & three Grb10-/-, two
independent experiments, **P< 0.01, ***P< 0.001, t-test). B) (i) Representative bright field images of Diff1 WT and Grb10-/- differentiating
myotubes, scale bar 50mm. (ii) Western blotting of myogenin on protein lysates extracted from Diff1 WT and Grb10-/- myotubes. (iii)
Densitometry analysis of myogenin in WT and Grb10-/- Diff1 myotubes (P¼ 0.055, n¼ 3 WT & three Grb10-/-, two independent experiments).
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myogenic progenitor cells. Therefore, we hypothesized that
the increase in ﬁber number is likely due to an increase in the
proliferation of muscle progenitor cells during early stages of
muscle development. Studies have shown both positive
(O’Neill et al., 1996; Wang et al., 1999) and negative (Liu and
Roth, 1995; Morrione et al., 1997) roles for Grb10 in regulating
cellular proliferation. However, it is possible that these
differences result from the different cellular model examined
or the differences in experimental procedure. Our results
demonstrate that Grb10 acts as a negative regulator of muscle
cell proliferation. We show that Grb10-/- primary muscle cells
proliferate faster than WT cells by transitioning rapidly from
the G0 to the S (DNA synthesis) phase of the cell cycle.
Molecularly, the increased proliferative capacity of Grb10-/-
cells was associated with downregulation of p21 transcript
levels and hyperphosphorylation of Rb. Changes in p21 levels
and Rb activity are known to affect cell cycle dynamics, with
upregulation of p21 being associated with permanent cell cycle
arrest of muscle cells (Nevins, 1992; Sherr, 1996; Walsh
et al., 1996), whilst phosphorylation of Rb releases E2F from
the complex to enhance transition through the cell cycle
(Gottifredi et al., 2004). Our ﬁndings provide compelling
evidence that ablation of Grb10 in muscle cells stimulates the
proliferative potential. They are also consistent with those
described for myostatin ablated mice (myostatin-/-) where the
increase in muscle mass was associated with an enhanced
proliferative capacity of satellite cells and changes in cell cycle
markers (McPherron et al., 1997; Joulia et al., 2003;
McCroskery et al., 2003).
In addition to the changes we observed in cell cycle markers,
we also demonstrated that absence of Grb10 affects upstream
proteins in proliferation signaling pathways including Akt and
ERK. Phosphorylation of both Akt and ERK is markedly
enhanced in Grb10-/- myoblasts in the basal state. Stimulation
with growth factors IGF-1 or HGF in Grb10-/- myoblasts did
not further increase phosphorylation of these targets indicating
that Grb10-/- cells are near maximal phosphorylation even
under basal conditions. It is not known which signaling
molecules upstream of Akt and ERK are activated to maintain
this phosphorylation in the basal state, nor which growth factor
receptor is likely to be involved in triggering these effects.
Grb10 has an established role in binding the IR and IGFR (Liu
and Roth, 1995; Morrione et al., 1996; O’Neill et al., 1996;
Laviola et al., 1997; Ramos et al., 2006). Moreover there is
some evidence from in vitro studies showing that Grb10 binds
to FGFR and HGFR (Wang et al., 1999). Therefore it is likely
that any one or all of these growth factor receptors are
residually activated and could be involved in the enhanced basal
activation of Akt and ERK when the Grb10 interaction is
abolished.
In addition to the increase in cell proliferation, our data
demonstrate that Grb10 does not affect the ability of myoblasts
Fig. 8. Ablation of Grb10 results in an increase in glucose metabolism and insulin action A) Glucose uptake assay in WT and Grb10-/-
myotubes at baseline and following insulin stimulation (n¼ 3 WT & 3 Grb10-/- clones, *P< 0.05, 2 way Anova, five independent experiments).
B) Level of GLUT4 at the membrane at baseline (*P< 0.05, t-test) and following insulin stimulation. C) Representative Western blot of
signalling targets Akt and ERK at baseline and following insulin stimulation in Grb10-/- and WT myotubes. D) Densitometry analysis of p-Akt
and p-ERK in Grb10-/- and WT myotubes (n¼ 2 WT & 2 Grb10-/- clones).
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to differentiate, but rather impacts on when terminal
differentiation is initiated. Grb10 transcript levels peak during
early time points of differentiation suggesting that Grb10 may
be required to initiate differentiation. However, Grb10-/-
myoblasts do differentiate and form functional myotubes
similar in morphology and size to WT myotubes. It is known
that terminal differentiation requires permanent withdrawal
from cell cycle and is regulated by the expression of the early
differentiation marker myogenin (Kitzmann and Fernandez,
2001). Our studies from the BrdU labeling experiments show
that Grb10-/- myoblasts withdraw faster from the cell cycle
compared to WT. In addition, the molecular basis for the
increased withdrawal is due to an early increase in the
expression levels of myogenin. Taken together, these results
provide evidence that absence of Grb10 does not directly
modify the differentiation program; but rather provides an
environment that facilitates a faster differentiation of myoblasts
to myotubes. Based on the proliferation and differentiation
data presented here, we propose Grb10 as a regulator of
distinct intracellular signaling pathways involved in both
proliferation and differentiation of primary myoblasts.
Previous studies have demonstrated that Grb10-ablated
mice have an improved insulin action and improvedwhole body
glucose homeostasis compared toWTmice (Smith et al., 2007;
Wang et al., 2007). To investigate whetherGrb10 ablation has a
direct effect on muscle cell metabolism, glucose uptake was
investigated in differentiated myotubes from WT and Grb10-/-
cells. Our results demonstrated that Grb10-/- myotubes have a
twofold higher glucose uptake in the basal state compared to
WT. This improved glucose uptake in Grb10-/- myotubes was
accompanied by an increase in GLUT4 transporters at the
plasmamembrane and a tendency toward an enhanced Akt and
ERK signaling. Reduced GLUT4 translocation to the plasma
membrane is thought to be a major contributor to the defect in
glucose transport in skeletal muscles of insulin resistant and
type 2 diabetic patients (Ryder et al., 2000). Therefore, these
results provide further evidence that lack of Grb10 enhances
insulin signaling and glucose transport in myotubes in vitro and
supports in vivo data suggesting that improved insulin action in
Grb10-/- mice may be due to differences in muscle metabolism.
Myoblast proliferation and differentiation are early critical
processes that regulate muscle growth and also regeneration.
A defect in satellite cell proliferation or differentiation is
associated with different metabolic diseases including type II
diabetes and obesity, as well as with muscular diseases and with
reduced muscle mass during aging (Allbrook et al., 1971;
Purchas et al., 1985; Mozdziak et al., 1994; Aguiari et al., 2008).
In the current study, we developed and utilized an in vitro
model of highly puriﬁed primary muscle cells to study
mechanisms of action of Grb10 in muscle cells. We provide
evidence supporting a role for Grb10 as a factor that regulates
the balance between muscle cell proliferation and differentia-
tion via modulating signaling pathways and expression of key
cell cycle and differentiation markers (Fig. 9). In addition, we
demonstrated that absence of Grb10 increases glucose uptake
via enhanced translocation of GLUT4 transporters to the
plasma membrane. These data identify Grb10 as a potential
therapeutical target to improve glucose metabolism and
alleviate the reduction in muscle mass associated with muscle
disorders and aging.
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Chapter 8 – Clinical and therapeutic aspects of vitamin D, 
muscle and bone 
 
 
 
This chapter consists of 3 solicited review articles that were published in 2014. 
As primary author on these articles, the PhD candidate, Christian Girgis, 
conducted the literature reviews, analysed the evidence-base for the respective 
articles, prepared manuscripts/figures and reviewer responses.  
 
The article published in Clinical Endocrinology (Feb 2014: 80; 169–181) 
covers clinical studies, including observational and randomised controlled 
trials, on effects of vitamin D on a range of muscle outcomes, specifically falls, 
strength, athletic performance and metabolic function (i.e. insulin sensitivity). 
This is followed by description of mechanisms and translational data on 
vitamin D and muscle. 
 
The article published in Current Osteoporosis Reports (June 2014: 12; 142–
153) discusses novel therapies that target both muscle and bone, including 
activin signalling inhibitors, GH secretagogues and Vitamin D Receptor 
Agonists. The emerging notion that bone and muscle form a finely integrated 
unit is discussed here. 
 
The article published in Current Opinion in Clinical Nutrition and Metabolic 
Care (November 2014: 17; 546-550) discusses recent evidence on effects of 
vitamin D in muscle function in elderly subjects. The debate on optimal serum 
levels of vitamin D in the elderly is reviewed.  
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Effects of vitamin D in skeletal muscle: falls, strength, athletic
performance and insulin sensitivity
Christian M. Girgis*,†, Roderick J. Clifton-Bligh†,‡,§, Nigel Turner¶, Sue Lynn Lau*,†,** and
Jenny E. Gunton*,†,**,††
*Diabetes and Transcription Factors Group, Garvan Institute of Medical Research (GIMR), †Faculty of Medicine, University of
Sydney, ‡Department of Diabetes and Endocrinology, Royal North Shore Hospital, §Kolling Institute, University of Sydney,
¶Department of Pharmacology, School of Medical Sciences, University of New South Wales, **Department of Diabetes and
Endocrinology, Westmead Hospital, and ††St. Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia
Summary
Accompanying the high rates of vitamin D deficiency observed in
many countries, there is increasing interest in the physiological
functions of vitamin D. Vitamin D is recognized to exert extra-
skeletal actions in addition to its classic roles in bone and mineral
homeostasis. Here, we review the evidence for vitamin D’s actions
in muscle on the basis of observational studies, clinical trials and
basic research. Numerous observational studies link vitamin D
deficiency with muscle weakness and sarcopaenia. Randomized tri-
als predominantly support an effect of vitamin D supplementation
and the prevention of falls in older or institutionalized patients.
Studies have also examined the effect of vitamin D in athletic per-
formance, both inferentially by UV radiation and directly by vita-
min D supplementation. Effects of vitamin D in muscle metabolic
function, specifically insulin sensitivity, are also addressed in this
review. At a mechanistic level, animal studies have evaluated the
roles of vitamin D and associated minerals, calcium and phos-
phate, in muscle function. In vitro studies have identified molecu-
lar pathways by which vitamin D regulates muscle cell signalling
and gene expression. This review evaluates evidence for the various
roles of vitamin D in skeletal muscle and discusses controversies
that have made this a dynamic field of research.
(Received 25 October 2013; returned for revision 8 November
2013; finally revised 13 November 2013; accepted 15 November
2013)
Introduction
Long before the discovery of vitamin D, the sun was revered as
a source of physical strength and vitality. In ancient Greece,
heliotherapy (sun exposure) was prescribed as a cure for ‘weak
and flabby muscles’.1 Sun exposure was considered a perfor-
mance enhancer; ancient Olympians were instructed to train in
sunlight to increase their muscle size.1
It was in 1922 that the American physician, Alfred Hess, real-
ized that children with rickets had profound muscle weakness
and that direct sunlight exposure improved their ‘general vigour
and nutrition’.2 Adolf Windhaus was awarded the 1928 Nobel
prize for his work on sterols, including the discovery of the chem-
ical structure of vitamins D2, D3 and 7-dehydro-cholesterol.
3 The
name ‘vitamin D’ is a historical misnomer. The active form, cal-
citriol, is a hormone; it is synthesized in humans, undergoes auto-
crine regulation and it interacts with a nuclear receptor.4
Following the photochemical conversion of 7-dehydrocholesterol
to vitamin D under the influence of UV radiation, this molecule
circulates bound to vitamin D-binding protein (DBP) and under-
goes two hydroxylation steps, firstly in the liver to form 25(OH)
Vitamin D (25OHD) and subsequently in the kidney to form
1,25(OH)2Vitamin D (1,25(OH)2D) by the 1-alpha-hydroxylase
enzyme (encoded by CYP27B1). 1,25(OH)2D is the biologically
active form that binds to the vitamin D receptor (VDR) to regu-
late gene expression, with major effects on calcium and mineral
homeostasis.4 1,25(OH)2D regulates its own catabolism via
upregulation of the expression of CYP24A1 gene (which encodes
24-hydroxylase). Although VDR is present in cell types involved
in mineral homeostasis, it is present in other cell types, suggesting
that there may be nontraditional roles of vitamin D.
Vitamin D deficiency is now recognized to be common. In
Australia, 31% of participants in a study of 11 247 adults were
deficient (25OHD < 50 nM)5, and an incidence of 41% was
recently reported in the United States.6 Other parts of the world,
such as Asia, India and the Middle East, have also reported high
rates of vitamin D deficiency.4 With increasing recognition of
this pandemic, a plethora of observational studies have associ-
ated deficiency with several conditions including autoimmune
diseases, diabetes, cancer and muscle weakness.7
A direct link between vitamin D deficiency and muscle
weakness was first described in the 1960s. In adults with
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osteomalacia, muscle strength improved following supplementa-
tion.8 Whether this improvement represented a direct effect on
muscle or an indirect result of vitamin D-mediated changes in
calcium homeostasis was unclear. In the years since this paper,
clinical studies examining the effects of vitamin D on muscle
performance, mass and the risk of falls in various populations
have emerged.9,10 There are also a variety of studies that have
examined mechanisms responsible for vitamin D’s effects in
muscle. However, controversy remains regarding the significance
of this research and whether the VDR is expressed in adult
muscle.11–13 In this review, we will cover the clinical evidence
for effects of vitamin D in skeletal muscle function and potential
mechanisms underlying a role for vitamin D at this site.
Vitamin D and muscle function in older populations
Low muscle mass (sarcopaenia) is characteristic of the ageing
process and is associated with a greater risk of disability, falls
and mortality in older people.14 Vitamin D deficiency is com-
mon in the elderly and institutionalized and may contribute to
sarcopaenia.15 Reduced capacity for UV-mediated vitamin D
synthesis in older skin may be partly responsible. Additionally,
VDR expression in human muscle declines with age.11 This may
render the muscles of elderly individuals more vulnerable to low
vitamin D levels. Higher serum levels may be required to achieve
comparable physiological effects. In this section, we discuss
observational studies linking vitamin D deficiency and muscle
dysfunction in elderly subjects and interventional studies exam-
ining potential effects of vitamin D supplementation in the risk
of falls and muscle weakness.
Observational studies
Several authors report an association between baseline 25OHD
and subsequent falls risk in elderly people. In a prospective, lon-
gitudinal study of 1600 elderly women living in assisted care,
Flicker and colleagues found a 20% reduction in falls risk over
!150 days with a doubling of 25OHD levels.16 Similarly,
amongst 1231 people over age 65, those with 25OHD levels
<25 nM were more likely to have recurrent falls in the subse-
quent year (OR 1"78 for ≥2 falls).17
Prospective studies have also reported an association between
baseline 25OHD levels and declining muscle function. In a
Dutch study of 1000 subjects over age 65, baseline 25OHD level
<50 nM correlated with a greater 3-year decline in physical per-
formance (sum score of walking test, chair stands and tandem
stand i.e. ability to stand with feet in tandem position with eyes
closed for 10 s).18 The 3-year risk of sarcopaenia in older sub-
jects was two times greater with baseline 25OHD levels
<25 nM.15
However, not all studies confirm these associations19 and
despite adjustments, potential confounding factors exist. Low
baseline 25OHD levels may be a marker of pre-existing frailty,
as the frail elderly are less likely to spend time outdoors,
exposed to UV radiation. Malnutrition is common in the
elderly; 40% of those living in institutions are at risk.20 Dietary
deficiencies may contribute simultaneously to low vitamin D
and to frailty. Factors not considered in adjustment models may
confound data interpretation, making interventional studies
important.
Intervention studies
Many studies have examined the effect of exposure to UV radia-
tion or vitamin D supplementation in the prevention of falls
and muscle strength in older individuals.
Amongst 602 residents of aged-care facilities living in Sydney,
Australia, those who increased sunlight exposure had fewer falls
than those randomized to the control group over 12 months
(incidence rate ratio 0"52, P = 0"01).21 However, compliance
with sunlight exposure was poor (26%), and no effect was
observed on intention-to-treat analysis.
Several studies reported beneficial effects of vitamin D on
falls. Amongst 625 older residents of assisted-living facilities,
those who received calcium (600 mg daily) and ergocalciferol
(initially 10 000 IU weekly, then 1000 IU daily) for 2 years
were less likely to ever fall than those receiving calcium alone.22
Similarly, in 122 older women in geriatric care, calcium
(1200 mg/day) and cholecalciferol (800 IU/day) caused a 49%
reduction in falls during the 12-week treatment vs the preced-
ing 6-weeks, vs calcium alone.23 Those who fell most had the
greatest benefit. Other studies have also suggested benefits in
at-risk individuals such as less active older women24 and those
suffering stroke.25
Not all studies, however, are concordant.26,27 A randomized
study of 5292 subjects ≥70 years showed no benefit with chole-
calciferol (800 IU daily) in the reduction of falls over
26–62 months.27 However, in both negative studies,26,27 patients
had recently sustained minimal-trauma fracture or were at risk
of fracture, suggesting impaired mobility and falls were not the
primary study end-point.
One study suggested that ‘mega-doses’ increased falls risk. An
annual oral dose of 500 000 IU of cholecalciferol increased falls
in 2256 community-dwelling older women, particularly in the
3 months following the dose (incidence rate ratio 1"31 compared
to placebo).28 The mechanism was unclear as serum levels were
not toxic. As the vitamin D system is autoregulated by induction
of 24-hydroyxlase which inactivates 25OHD and 1,25OHD, we
speculate that large single doses of cholecalciferol may result in
excess 24-hydroxylase induction, rapidly degrading the adminis-
tered dose and potentially contributing to subsequent deficiency.
Regarding muscle performance, studies show improved lower
limb strength following vitamin D supplementation in institu-
tionalized29 and community-dwelling older individuals.30 Those
with baseline 25-OHD levels <50 nM had the greatest benefits.
However, a study of single mega-dose therapy (300 000 IU) in
243 frail, older patients did not improve performance even
amongst those with baseline levels <30 nM.31 For a detailed list
of studies examining vitamin D supplementation and falls, we
refer readers to Tables 4 and 5 in a recent review.4
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Meta-analyses
In the widely cited meta-analysis by Bischoff-Ferrari, a dose-
dependent effect of vitamin D supplementation in the reduction
in falls was found when examining eight trials and 2426 elderly
individuals.32 Compared with placebo, higher doses of vitamin
D (700–1000 IU) reduced falls risk by 19%, but lower doses had
no effect. Likewise, people who achieved serum 25OHD concen-
trations ≥60 nM reduced falls by 23%, but those who achieved
concentrations ≤60 nM had no effect.
The recent Institute of Medicine report criticized this meta-
analysis for inconsistencies in study inclusion, perceived errors
in statistical analysis and reliance on two studies to produce the
positive effect, one of which was reportedly not well-powered.33
On reanalysis with two statistical alterations, the positive effect
was not found.
The most recent and largest meta-analysis of 45 782 people,
mainly elderly females, found a significant reduction in falls risk
amongst those randomized to vitamin D supplementation (OR
0"86 for ≥1 fall).34 There was no difference between higher
(>800 IU) vs lower doses. Vitamin D was effective in both com-
munity-dwelling and institutionalized people with cholecalciferol
or ergocalciferol. Reduction in falls was most prominent in
patients who were deficient at baseline and with calcium
co-administration. In studies included in this meta-analysis, the
calcium doses ranged from 500 to 1200 mg daily and elemental
calcium and calcium carbonate were used.
Meta-analyses dealing with vitamin D and muscle strength are
limited by substantial study heterogeneity in design, including in
the parameters of muscle function.31 A recent meta-analysis that
assessed 17 RCTs involving 5072 participants reported no effect
on grip strength or proximal lower limb strength in adults with
25OHD levels >25 nM.10 However, on pooling data from two
studies on vitamin D-deficient adults (i.e. 25OHD < 25 nM), a
large effect on hip muscle strength was found although the
studies used different measures.
Summary
Although observational studies link falls, muscle weakness and
sarcopaenia with vitamin D deficiency, randomized intervention-
al trials have yielded conflicting results. This may be explained
by the heterogeneity in study design, variability in treatment
dose, duration and the different analyses of falls and muscle
function. Nevertheless, the data generally support a benefit of
vitamin D supplementation in reducing falls amongst at-risk
populations, specifically those with vitamin D deficiency and a
history of falls.34 On this basis, we suggest the use of vitamin D
in combination with calcium at a daily dose of at least 500 mg
for falls prevention in older people with baseline vitamin D defi-
ciency. The dose of vitamin D supplementation and target
25OHD levels are controversial. Whilst the Institute of Medicine
recommends 25OHD target levels of 50 nM and daily vitamin D
doses of 800 IU d in older adults (>70 years),33 the US Endo-
crine society advocates higher serum target level of 75 nM and
daily doses of at least 1500–2000 IU in this age group.35 Those
targets are based on skeletal and biochemical outcomes, and the
evidence for muscle outcomes does not particularly favour one
target over the other. It appears that single-dose mega-therapy is
not beneficial for muscle function, and we recommend daily
therapy in favour of intermittent mega-dosing.
Vitamin D and muscle function in the young
Children with rickets, a condition characterized by chronic vita-
min D deficiency, display profound muscle weakness and hypo-
tonia. Similarly, those affected with the rare condition type II
vitamin D dependent rickets display muscle weakness in associa-
tion with mutations in the VDR.36 These observations suggest
that together with a critical role in bone mineralization and
metaphyseal fusion, vitamin D is important in muscle develop-
ment.
Beyond the developmental stage, adults with osteomalacia dis-
play proximal myopathy characterized by proximal weakness,
pain, a ‘waddling gait’ and difficulty rising from a seated or
squat position.8,37
Here, we review evidence for a role of vitamin D in muscle
function and mass in those not yet affected by age-related mus-
cle loss.
Physical performance
There is extensive literature dating back to the 1930s reporting
significant improvements in physical performance following
exposure to UV radiation. Although these studies do not directly
refer to vitamin D, UV-mediated changes in vitamin D status
may have played a role in muscle function amongst study partic-
ipants. In 1938, a Russian group reported significant improve-
ments in 100-m sprint times amongst students receiving UV
radiation (7"4% vs 1"7% improvement in controls).38 In 1944, a
German group found that medical students receiving UV radia-
tion over 6 weeks had a 13% improvement in performance on a
bicycle ergometer.39 In a study from USA, 11 male students
experienced a 19% increase in cardiovascular fitness following a
course of UV radiation.40
Contemporary studies have reported surprisingly high rates of
vitamin D deficiency amongst athletes, including Middle-Eastern
sportsmen (58% deficient),41 professional British athletes
(57%)42 and Australian gymnasts (33%).43 However, studies
examining vitamin D supplementation in athletes are sparse. In
a study of thirty UK athletes randomized to cholecalciferol
20000, 40000 IU or placebo once per week for 12 weeks, despite
significant increases in 25OHD levels at 6 and 12 weeks in the
active arms, there was no significant improvement in muscle
performance.42 In a larger study including 61 male athletes and
30 healthy male nonathletes in the UK, cholecalciferol (5000 IU/
day) led to significant improvements in 10-m sprint times and
vertical jump over the 8-week period, with no improvement in
the placebo group.44 Baseline 25OHD levels were lower in this
study than in the previous one (mean approximately 40 vs
50 nM), and higher 25OHD levels were achieved (mean 103 vs
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approximately 85–91 nM), possibly explaining the discrepancy.
With the potential involvement of vitamin D in metabolic path-
ways,45 athletes may require a higher intake to ensure adequate
availability for muscle metabolism and physical performance.
Once again, there are suggestions that high-dose supplemental
vitamin D does not improve muscle function compared with
daily lower doses.42,44
A study of 14 recreationally active subjects found an associa-
tion between baseline vitamin D levels and muscle recovery,
assessed by leg isometric force following a bout of intense
exercise.46 Pre-exercise 25OHD levels predicted immediate and
persistent muscle weakness (i.e. 48 and 72 h postexercise), but
there was no correlation at 24 h. Interestingly, 25OHD levels
initially increased (by approximately 5 nM) and then decreased
following exercise, and the authors hypothesized this was due to
exercise-related shifts in cytokine and protein levels.
In nonathletes, supplementation studies have yielded mixed
results. Amongst 69 adolescent females, those randomized to
receive 150 000 IU ergocalciferol orally every 3 months for
1 year demonstrated significant improvements in movement effi-
ciency, a composite of jump height and velocity measured by
mechanography, compared with baseline.47 Additionally, higher
baseline 25OHD correlated with greater jumping velocity.
In another study of 179 vitamin D-deficient adolescent
females in Lebanon, those randomized to receive cholecalciferol
(doses 1400 or 14 000 IU weekly) did not improve grip
strength.48 Adequate 25OHD levels were achieved in the high-
dose group but not in the low-dose group (! 95, 40 nM, respec-
tively, placebo 40 nM), implying that increases in lean mass and
bone mineral content seen in both groups vs placebo at 1 year
were not directly due to serum 25OHD levels.
In a case–control study, 55 veiled Arabic women with severe
vitamin D deficiency (mean 25OHD 7 nM) were weaker on all
tested parameters of muscle function than 22 Danish women with
higher levels (47 nM).49 Following vitamin D repletion (IM ergo-
calciferol: 100 000 IU per week for 1 month then monthly for
5 months and 400–600 IU orally daily), the Arabic women had
significant improvements in muscle function and pain at 3 and
6 months. This may have been due to improvement in related bio-
chemical defects and does not prove a direct role for vitamin D. In
any case, mega-dose supplementation was helpful in this group.
Therefore, vitamin D deficiency is common in young popula-
tions, and vitamin D supplementation may improve physical
performance in athletes depending on the dose.42,44 Such an
effect is less clear is nonathletic populations.47,48
Myalgia
Studies examining a putative association between vitamin D
deficiency and myalgia (i.e. muscle pain) have generally been
small, observational and potentially confounded.
Vitamin D deficiency was reported in 93% of individuals with
persistent, nonspecific musculoskeletal pain.50 Significantly, more
frequent occurrence of 25OHD level <20 nM was found in 40
premenopausal women with fibromyalgia compared with 37
age-matched controls.51 These studies were observational and
potentially confounded by factors such as physical activity,
smoking and body mass index (BMI).
A single randomized trial of ergocalciferol supplementation
(50 000 IU weekly for 3 months) in 50 subjects with 25O-
HD < 50 nM failed to demonstrate improvement in pain scores
compared with baseline or placebo.52 As the study was adequately
powered to detect a significant change in pain, results would sug-
gest that high-dose supplementation has no benefit in the manage-
ment of generalized pain in the absence of osteomalacia. Therefore,
despite an association between vitamin D deficiency and myalgia,
the single RCT addressing this question shows no effect.
Vitamin D receptor (VDR) polymorphisms
Vitamin D receptor is the nuclear receptor to which 1,25
(OH)2D binds to regulate gene expression. Several VDR poly-
morphisms exist that are associated with a range of biological
effects, including bone mineral density and muscle function.53
The FokI polymorphism, found in approximately 35% of Cauca-
sians,53 is a T/C transition in exon 2 that results in a shorter
protein with enhanced transactivation capacity. Although this
greater activity might suggest improved muscle strength, the
FokI polymorphism is in fact associated with reduced muscle
strength. In 107 patients with chronic obstructive pulmonary
disease (COPD), homozygosity was associated with reduced
quadriceps strength compared with heterozygosity.54 In another
study, the Fok I genotype associated with reduced muscle mass
and sarcopaenia in 302 Caucasian men aged 58–93 years.55
The BsmI polymorphism affects the 3′ region, which is impor-
tant in the regulation of gene expression. It is reported in
approximately 40% of Caucasians.53 In studies of older individu-
als, the bb genotype was associated with greater strength and
reduced risk of falls. Amongst 121 healthy women >70 years, the
bb genotype was linked to higher quadriceps and wrist strength
compared with the BB genotype.56 In two population-based
studies from Italy and the UK, the bb genotype of the BsmI
polymorphism appeared to protect against falls.57
However, in younger people, studies link the bb genotype to
reduced strength. Amongst 175 women (20–39 years), bb geno-
type associated with lower hamstring strength and lower fat-free
mass compared with the BB genotype.58 In a Chinese study of
109 female university students, bb genotype was associated with
significantly lower peak torque in concentric knee flexors.59
Whilst these polymorphisms are interesting, the associations
are not consistent and lack mechanistic explanation. Larger stud-
ies to assess the associations are needed. Importantly, polymor-
phisms of other components of the vitamin D system may also
be relevant: DBP polymorphisms have been associated with dif-
ferent responses to vitamin D3 supplementation
60
, and CYP27B1
polymorphisms have been linked to a greater risk of osteopo-
rotic fracture.61
Mechanisms linking vitamin D and muscle function
A variety of mechanisms by which vitamin D impacts on muscle
cells and fibres have been elucidated. This research includes the
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description of muscle morphology in vitamin D-deficient sub-
jects, signalling pathways by which vitamin D effects muscle cells
in vitro, and in vivo studies that have sought to delineate effects
and mechanisms of aberrant vitamin D signalling on muscle
function. These have been summarized in Fig. 1.
Changes in muscle morphology
Several reports dating back to the 1970s described striking mor-
phological changes in the skeletal muscle of subjects with osteo-
malacia, likely related to severe vitamin D deficiency.62 The
main change described is atrophy of the type 2 (i.e. fast twitch)
muscle fibres with some reports of scattered necrosis and
derangement of the intermyofibrillar network.63
These changes appear to be reversible. Eleven patients with a
condition described as ‘bone loss of ageing’ displayed significant
increases in the proportion and cross-sectional size of fast-twitch
type IIa fibres of the vastus lateralis following treatment with the
vitamin D analogue, 1a-OHD3 and calcium for 3–6 months.
64
Interestingly, vitamin D supplementation resulted in changes to
the oxidative capacity of muscle – succinate dehydrogenase
activity and total phosphorylase activity were low at baseline and
increased with treatment whilst lactate dehydrogenase activity, a
measure of anaerobic metabolism, did not change.64
At a functional level, Sato and colleagues suggested that the
reduction in falls in a group of 48 women with poststroke hemi-
plegia who received vitamin D2 (1000 IU daily) supplementation
could be explained by the increase in the proportion and diame-
ter of type II muscle fibres at 1 year.25 A recent study also impli-
cates improved mitochondrial function as a possible mechanism
in the prevention of falls by vitamin D.45 In twelve individuals
with severe vitamin D deficiency (<15 nM), 10–12 weeks of
treatment with cholecalciferol 20 000 IU on alternate days
resulted in improved muscle mitochondrial function, as assessed
by NMR spectroscopy.
There is an association between fatty infiltration of skeletal
muscle and vitamin D deficiency. In 90 postpubertal females in
California, the proportion of quadriceps muscle fat, assessed by
computed tomography (CT), was strongly inversely correlated
with serum 25OHD levels, independent of body mass or subcu-
taneous and visceral fat.65 Similar findings were reported in 20
older subjects who received MRI (magnetic resonance imaging)
of the thigh.66 Interestingly, selective and near total fatty degen-
eration of at least one muscle was observed amongst 55% of
patients with 25OHD <50 nM.66
These studies raise the interesting possibility that vitamin D
deficiency may increase the deposition of intramyocellular lipids,
either directly or potentially as a consequence of the reduced
physical activity or via reduced muscle mitochondrial capacity.
As defects in mitochondrial fuel metabolism and increases in
intramuscular lipids are thought to play a role in the pathogene-
sis of skeletal muscle insulin resistance,67 these findings may
potentially explain the association between vitamin D deficiency
and insulin resistance.
VDR and muscle
The presence of the VDR in avian, murine and human muscle
cells is described by immunohistochemistry, Western blot and
detection of VDR mRNA by RT-PCR.68–70 However, a recent
paper suggested that the VDR is not expressed in skeletal, car-
diac or smooth muscle.12 Differences in experimental conditions
and the possibility of tight protein binding of VDR to DNA
may have accounted for this finding. Another possible explana-
tion is that VDR is expressed at low levels in resting muscle but
is activated by particular conditions. In support of this, a recent
paper reported that VDR expression increases following muscle
injury in mice.13 Interestingly, this paper also reported the pres-
ence of 1-alphahydroxylase (CYP27B1) in muscle and that it too
is activated during muscle injury. These findings support the
intriguing possibility that VDR and CYP27B1 play roles in mus-
cle regeneration and that muscle possesses the capacity for local
production of 1,25(OH)2D.
More recently, a pilot study linked vitamin D supplementa-
tion (4000 IU/day for 4 months) with an increase in muscle
VDR expression and fibre size in older, mobility-limited
women.71 Although this was a small study and the specificity of
the particular antibody used is unclear (VDR-NR1I1), this study
provides tantalizing evidence that vitamin D may influence mus-
cle fibre size in humans by upregulating local VDR expression.
Vitamin D receptor defects also influence muscle function.
Mice with congenital absence of VDR display a number of defi-
cits in muscle function. On forced swim tests, they display more
sinking episodes and fatigue compared with wild-type mice.72
These changes are probably largely related to impaired muscle
development with generalized atrophy of muscle fibres in this
mouse model.73 One important caveat is that these mouse mod-
els of VDR defects also display secondary biochemical abnormal-
ities in calcium, phosphate and parathyroid hormone that could
affect muscle function.
One study examined the precise aetiology of vitamin D defi-
ciency myopathy by rendering rats vitamin D, phosphorus and
calcium deficient by dietary methods.74 Phosphorus levels corre-
lated independently with the reduction in soleus muscle force in
these rats, and phosphorus repletion in the presence of persis-
tent vitamin D deficiency resulted in complete restoration in
slow-twitch muscle force.74 Another study reported that calciumFig. 1 Potential effects of vitamin D on muscle cells.
© 2013 John Wiley & Sons Ltd
Clinical Endocrinology (2014), 80, 169–181
Effects of vitamin D in skeletal muscle 173
was predominantly important in the type 2 muscle fibre atrophy
and the muscle protein degradation seen in vitamin D-deficient
rats.75 Although calcium repletion mostly corrected these abnor-
malities, persistent vitamin D deficiency was itself associated
with a degree of muscle fibre atrophy.
It therefore appears that muscle defects are due, in part, to
vitamin D deficiency but predominantly to the associated hypo-
calcaemia and hypophosphataemia. Repletion with vitamin D
remains the most effective treatment as it corrects all of those
defects.49,76
Vitamin D and intracellular pathways in muscle
A variety of molecular pathways by which vitamin D may affect
muscle cells have been elucidated. These effects may be rapid,
occurring within seconds to minutes of vitamin D treatment
and include the release of calcium from intracellular stores and
its subsequent entry via voltage-gated membrane channels.4 This
suggests a role for vitamin D in the calcium-mediated functions
of muscle, namely contraction, plasticity, mitochondrial func-
tion, insulin signalling and fuel handling. Whilst evidence for a
link between vitamin D and mitochondrial function is only
recent,45 potential alterations in muscle substrate metabolism
may help explain the occurrence of insulin resistance,77 intra-
muscular fatty deposition65 and muscle weakness49 in vitamin
D-deficient subjects. Serum 25OHD levels correlate with recov-
ery rates of phospho-creatinine muscle stores after exercise, sug-
gesting a broader link with ATP production and oxidative
function.45
Vitamin D could lead to delayed effects on muscle via gene
expression. This involves binding of the 1,25OHD-VDR-RXR
(retinoid X-receptor) complex to vitamin D response elements
of DNA and includes effects in the expression of contractile pro-
teins and myogenic transcription factors which influence muscle
development.73
More recently, it has emerged that skeletal muscle serves a
storage site for 25OHD.78 Skeletal muscle was found to express
megalin and cubulin, proteins necessary for the endocytic inter-
nalization of DBP-bound 25OHD and muscle fibres were noted
to retain substantially higher proportions of tritium-labelled
25OHD than bone cells.
Therefore, evolving research points to both rapid and genomic
effects of vitamin D in skeletal muscle and its storage at this site
that may have a range of effects that remain unknown at this time.
Vitamin D and insulin sensitivity
Apart from the generation of force, skeletal muscle is a highly
metabolic tissue that responds to a range of hormones including
growth hormone, IGF-1, corticosteroids and insulin. Under nor-
mal physiological conditions, skeletal muscle is responsible for
approximately 85% of whole-body insulin-mediated glucose
uptake79 and is therefore of primary importance to insulin resis-
tance. In this section, we discuss the evidence linking vitamin D
deficiency with insulin resistance and the broader implications
for the pathogenesis of type 2 diabetes.
Observational studies
Amongst 808 nondiabetic participants of the Framingham
Offspring Study, plasma 25OHD was inversely associated with
fasting insulin concentrations and homeostasis model assessment
of insulin resistance (i.e. HOMA-IR) after adjustment for age,
sex and BMI (summarized in Table 1).80 A similar association
between 25OHD and HOMA-IR was found in 712 subjects at
risk of diabetes.81 HOMA is a mathematical model, based on
data from physiological studies, which is used to estimate insulin
resistance (HOMA-IR) and insulin sensitivity (HOMA-S). In a
group of 126 healthy young adults, there was a significant asso-
ciation between 25OHD and insulin sensitivity assessed by
hyperglycaemic clamps, after adjustment for a range of factors
including BMI.82
Prospective studies show an association between baseline
25OHD levels and the long-term risk of developing insulin resis-
tance (Table 1). In a study of 5200 participants, a 25 nM incre-
ment in baseline serum 25OHD levels was associated with a
24% reduced 5-year risk of diabetes.77 A positive and indepen-
dent association with HOMA-S at 5 years was also reported
(r = 0"16, P < 0"001).
These observational studies suggest, but do not prove, a causal
or directional relationship between vitamin D status and insulin
resistance. Multiple possible confounders exist. In particular,
adiposity has an independent inverse association with 25OHD,
in many (though not all) studies.83 This may relate to storage of
fat-soluble compounds, the avoidance of sunlight exposure and
outdoor activity amongst potentially self-conscious obese indi-
viduals. Adiposity is a key factor in insulin resistance. Other
potential confounders include physical activity, parathyroid hor-
mone levels, serum calcium and dietary intake, all of which may
influence or reflect 25OHD levels and also independently influ-
ence insulin sensitivity.
Interventional studies
In people without diabetes or underlying insulin resistance,
there is no clear evidence that vitamin D supplementation
results in improved insulin sensitivity (summarized in Table 2).
However, limited evidence suggests that subjects at risk of diabe-
tes may benefit. At-risk subjects randomized to receive various
regimens of cholecalciferol and calcium over 6 weeks–3 years,
displayed significant improvements in insulin sensitivity, secre-
tion and/or the disposition index (an integrated measure of
insulin secretion and action).84–86
The evidence is mixed for subjects with established diabetes.
In a recent trial of 90 diabetic subjects, those randomized to
receive daily vitamin D (1000 IU) in fortified yoghurt demon-
strated improved glycaemic control and insulin resistance
(HOMA-IR) vs those receiving plain yoghurt.87 Importantly, an
inverse correlation was observed between changes in serum
25OHD and HOMA-IR in this study.
As summarized in Table 2, the large number of small inter-
ventional studies in different populations with baseline vitamin
D status, using different modes of supplementation, creates
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difficulty in drawing definite conclusions. Methods of assessing
insulin sensitivity range from measuring fasting insulin to eugly-
caemic–hyperinsulinaemic clamps. Whilst insulin resistance is a
factor in the genesis of type 2 diabetes, there is a complex inter-
action between glucose and insulin levels, with glycaemic out-
comes reflecting the relationship between both insulin resistance
and insulin secretory capacity.
Thus, the question of whether vitamin D supplementation is
effective in the amelioration of insulin resistance, and with partic-
ular respect to a role in muscle, remains unanswered. A number of
large clinical trials are currently underway, which may defini-
tively answer this question (e.g. NCT00736632, NCT01354964,
NCT01315366).
Potential mechanisms
Mouse models of type 2 diabetes show improvements in insulin
sensitivity following treatment with 1aOHD3.
4 In vitro studies
help to explain this link. 1,25D leads to increased expression of
insulin receptors and amelioration of insulin resistance via
effects on Akt and insulin receptor phosphorylation.88 Nonge-
nomic effects of vitamin D may also be important. In addition
to intracellular calcium regulation, vitamin D leads to the release
of arachidonic acid, a polyunsaturated fatty acid, from the cell
membrane and into the cytoplasm of muscle cells.89 This further
links vitamin D with insulin sensitivity as does the possibility
that vitamin D may influence caveolin-I,90 a scaffolding protein
within the membrane that plays roles in metabolism.
Conclusions
Our understanding of the role of vitamin D in skeletal muscle
results from the combined efforts of basic scientists and clinical
researchers (summarized in Table 3). Reports of profound muscle
weakness in children with rickets more than 80 years ago and
more recent descriptions of muscle weakness and myalgia in
adults with severe vitamin D deficiency have provided prima facie
evidence of a role for vitamin D in muscle. Although historical lit-
erature reports substantial improvements in physical performance
amongst athletes exposed to UV irradiation, a direct association
with vitamin D status was not established in these early studies
and remains to be substantiated by contemporary research.
Amongst older individuals, studies examining the effect of
vitamin D on strength and falls have had mixed results. The
general consensus is that correction of vitamin D deficiency is
beneficial in preventing falls, in combination with calcium sup-
plementation and with the recommended aim of achieving
serum 25OHD levels of >50 nM according to the IOM or
>75 nM according to the US Endocrine society.
Animal studies have demonstrated that congenital lack of the
VDR and models of vitamin D deficiency are associated with
defects in muscle function. From these studies, it has been diffi-
cult to dissect the individual contribution of vitamin D signal-
ling to muscle function, distinct from its role in mineral
homeostasis. At a molecular level, muscle cells show both rapid
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and delayed responses to the active form of vitamin D,
1,25OH2D, that provides mechanistic support for these clinical
and animal studies. Recent research showing the activation of
VDR in regenerating muscle and the storage of 25OHD in skele-
tal muscle raise intriguing questions regarding its unknown roles
at this site. In conclusion, vitamin D supplementation prevents
falls in susceptible populations, vitamin D pathways regulate
muscle development in animal models and vitamin D signalling
alters various molecular pathways in cultured muscle cells. Fur-
ther clinical and translational studies are needed and will be of
particular interest in muscle training, insulin resistance and
muscle regeneration.
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Abstract Musculoskeletal diseases are highly prevalent with
staggering annual health care costs across the globe. The com-
binedwasting of muscle (sarcopenia) and bone (osteoporosis)—
both in normal aging and pathologic states—can lead to vastly
compounded risk for fracture in patients. Until now, our thera-
peutic approach to the prevention of such fractures has focused
solely on bone, but our increasing understanding of the inter-
connected biology of muscle and bone has begun to shift our
treatment paradigm for musculoskeletal disease. Targeting path-
ways that centrally regulate both bone and muscle (eg, GH/IGF-
1, sex steroids, etc.) and newly emerging pathways that might
facilitate communication between these 2 tissues (eg, activin/
myostatin) might allow a greater therapeutic benefit and/or
previously unanticipated means by which to treat these frail
patients and prevent fracture. In this review, we will discuss a
number of therapies currently under development that aim to
treat musculoskeletal disease in precisely such a holistic fashion.
Keywords Muscle . Bone . Anabolic agents . Osteoporosis .
Sarcopenia
Introduction
Musculoskeletal diseases are highly prevalent, affecting up to
1 in every 2 individuals in western countries [1, 2]. Moreover,
the annual cost of these diseases is staggering, estimated at
nearly 8 % GDP in USA ($850 billion) and an even greater
proportion of GDP in other countries (eg, 10 % GDP or $4.5
billion in Australia). As the world’s population ages, the
sequelae of musculoskeletal wasting, falls, and fractures are
a highly concerning health problem; not only for their finan-
cial impact, but as well for the significant increases in patient
morbidity, the need for assisted care, and mortality [3]. Falls/
fractures represent the common end-point in the age-related
involution of bone (osteoporosis) and muscle (sarcopenia)
[4••]. In this regard, the combined wasting of muscle and
bone—both in normal aging and pathologic states—can lead
to vastly compounded risk for fracture in patients. Reduced
muscle mass can lead to poor balance and falls, and these falls
are then more likely to result in fractures due to the osteopo-
rotic bone’s inability to withstand load.
Until now, our therapeutic approach to the prevention of
low-energy fracture has focused solely on bone. While osteo-
porosis has been clearly defined, sarcopenia and its end-points
remain open to debate [5]. Sarcopenia has been provisionally
defined on the basis of anthropomorphic parameters (appen-
dicular lean mass relative to height or corrected for body
weight/fat mass) [6], performance-based parameters (lower
limb strength, timed up and go test, walking speed) or a
combination of both (lower limb strength/leg lean mass on
DXA) [7]. The unclear relationship between muscle mass and
function and sex-specific differences highlight difficulties in
reaching a consensus definition that corresponds to clear
outcomes.
A paradigm shift may be underway with increasing recog-
nition of the interaction of 2 adjacent tissues, bone andmuscle.
As we are becoming increasingly aware, these interactions are
not merely at their anatomic interface or related to mechanical
effects of muscle loading on bone function. Rather, bone-
muscle interaction encapsulates an intimate relationship, in
which bone and muscle communicate via complex paracrine
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and endocrine signals to coordinate their growth and devel-
opment from their earliest embryologic stages to involution,
as well as to adapt in response to loading and injury [8••].
Research in bone-muscle interactions opens an immense field
of potential therapeutic targets and the possibility of address-
ing osteoporosis and sarcopenia as a single disorder, rather
than parallel pathologies, and may present the possibility of a
way to ‘treat 2 birds with 1 stone.’ In this review, we will
discuss factors involved in bone-muscle interactions and their
therapeutic implications.
Muscle and Bone Development
The musculoskeletal system grows, functions, and ages as a
finely coordinated unit. Muscle and bone are derived from a
commonmesenchymal progenitor during embryogenesis, and
their development is closely coordinated by the action of
myriad overlapping genes and growth factors [9, 10•]. In
addition to these biochemical cues—and likely intertwined
with them—mechanical force from developing muscle drives
periosteal bone growth, bone density, and bone geometry;
even during embryogenesis. Evidence of this integral associ-
ation of bone andmuscle during development can be observed
in various mouse models, in which mice with paralyzed or
nonfunctional muscle display severe impairments in bone
development and mineralization [11, 12]. Likewise, children
with Duchenne muscular dystrophy (DMD) and cerebral pal-
sy are also known to have abnormal bones and a higher
fracture risk [13, 14].
The close coordination of bone and muscle development in
mammals continues into adult life, driven in large part by sex
steroids and the growth hormone/insulin-like growth factor-1
(GH/IGF-1) axis, which will be discussed in detail later. In
puberty, the accumulation of lean mass precedes gains in bone
mass, and skeletal muscle area determines cortical bone area
[15, 16]. A similar link exists in aging adults, in whom lean
mass is lost before bone mass, and again, muscle parameters
correlate tightly with loss of bone mineral density [17, 18].
Muscle, therefore, seems to “set the pace” for both bone
growth and involution—a point that may be key in consider-
ing our approach to treating musculoskeletal disease.
One possible explanation for the apparently dominant role
of muscle in coordinating bone mass is that muscle loading
induces a cascade of biomechanical signals necessary for bone
growth and remodeling. In support of this notion, individuals
exposed to a gravity-free environment, such as astronauts,
experience dramatic bone loss due to lack of muscle loading
[19]. However, this “mechanostat theory,” as it is commonly
known, presents an incomplete picture of bone-muscle inter-
actions. Importantly, appendicular muscle mass correlates
with bone cortical thickness even at remote sites and not just
adjacent, mechanically loaded bone [20••], suggesting
additional paracrine or endocrine cross talk, by which bone
and muscle coordinate their mass.
Further support for bone-muscle cross talk can be observed
in fracture repair, where it has been repeatedly demonstrated
that the presence of healthy muscle tissue is a positive factor
for fracture healing. For example, the use of muscle flaps in
the treatment of open fractures results in faster rates of bone
healing in both mice and humans [21, 22]. In addition, the rate
of nonunion is markedly higher in fractures associated with
acute compartment syndrome, where muscle viability is com-
promised [23]. In this regard, skeletal muscle may represent a
kind of “second periosteum”, providing trophic factors, mor-
phogens, and even cells to aid bone repair. Several myokines
with potential effects on bone have been proposed, including
myostatin, interleukin 6 (IL6), fibroblast growth factor 2
(FGF2), and matrix metalloproteinase 2 (MMP2), amongst
others [24–26]. Communication between bone and muscle is
likely bi-directional, and bone may also ‘talk back’ to muscle
via a range of osteokines, such as FGF21 produced by osteo-
cytes and other factors [27••]. Additionally, common path-
ways such as GH/IGF-1, sex steroids and Wnt signaling can
centrally coordinate the bone-muscle unit during development
and adaptation to mechanical stimuli [20••, 28].
Thus, a complex interplay of mechanical, endocrine, and
paracrine signals exists between muscle and bone that serves
to coordinate their mass and function throughout life. In the
following sections, we will discuss some of these common
pathways that have been, or are currently being investigated,
as possible targets to treat musculoskeletal diseases.
Unraveling the individual effects of these pathways and stim-
uli poses significant experimental challenges. However,
achieving a more thorough understanding of the biochemical
links that intertwine bone and muscle physiology is critical for
the discovery of therapeutic targets that may lead to a more
holistic approach to musculoskeletal disease.
Growth Hormone (GH) and GH Secretagogues
GH plays a fundamental role in bone and muscle growth
during childhood and puberty. It also exerts important effects
throughout life in glucose and lipid metabolism [29], body
composition and bone mineralization [30]. GH is secreted in a
pulsatile manner by the pituitary gland and acts by specific
growth hormone receptors (GHR) in peripheral tissues, or
indirectly through induction of insulin-like growth factor-1
(IGF-1) [31••]. Circulating IGF-1 is produced mainly in the
liver, but it is also produced locally in numerous peripheral
tissues, including muscle during exercise [32] and regenera-
tion [33]. GH/IGF-1 signaling is complex and tissue-specific,
involving JAK/STAT, PI3K, and ERK pathways [34, 35].
Effects of GH in muscle cell proliferation, fiber size and fiber
type depend on IGF-1, whilst effects on insulin sensitivity are
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IGF-1-independent [31••]. In bone, GH/IGF-1 promotes oste-
oblast proliferation and differentiation, inhibits osteoclast ac-
tivity, and modulates renal 1α-hydroxylase, (which activates
25-OH-Vitamin D) and phosphate reabsorption [36–39].
Patients with GH deficiency or congenital mutations of GH
signaling display short stature, impaired muscle development,
and failure of epiphyseal fusion, which respond to GH or IGF-
1 replacement, respectively [40]. Even in healthy, GH-replete
patients, serum GH and IGF-1 levels decline during aging and
are correlated with losses in muscle, bone, and an increased
risk of osteoporotic fracture [41]. Furthermore, muscle levels
of growth hormone receptor (GHR) drop in proportion to
reduced muscle fiber size in older adults [42], and bone
responsiveness to IGF-1 also decreases with age [43]. Given
these correlates, its central role in postnatal growth, and ex-
amples of effective treatment in pathologic states, GH would
seem a logical therapeutic for musculoskeletal disease.
However, treatment of older adults with recombinant hu-
man growth hormone (rhGH) to reverse age-related changes
inmuscle, bone, and fat is controversial. In the landmark study
by Rudman and colleagues, 12 older men treated with rhGH
for 6 months showed increases in lean mass (8.8 %) and
lumbar bone density (1.6 %), reduced fat mass (14.4 %), and
no change in femoral neck bone density [44]. These results
were consistent with effects of GH treatment in adults with
hypopituitarism [45] and sparked intense interest in GH as an
‘anti-aging’ therapy. However, subsequent studies and a meta-
analysis of 18 randomized controlled trials reported more
modest changes in lean mass, inconsistent effects in bone
density and physical function, and a number of side effects
of rhGH treatment in older patients, including arthralgias,
edema, carpal tunnel syndrome, and diabetes [46–48]. It
should be noted that these studies were generally small, the
treatment durationwas short (~ 6months) and follow-up times
and rhGH dosing were variable.
Additional concerns surround the possibility that GH ther-
apy might increase mortality. Reduced GH/IGF-1 signaling
has been demonstrated to increase lifespan in worms, flies,
and rodents [49]. A similar observation can be made in
humans, where GH deficiency and resistance are associated
with advanced longevity [40], and short individuals are more
likely to live longer than tall individuals from the same pop-
ulation [50]. Conversely, acromegaly (GH-secretory pituitary
adenoma) leads to increased mortality due to cardiovascular
disease and cancer. The question of whether GH therapy
increases mortality has yet to be adequately addressed.
Despite this uncertainty, equivocal effects in body compo-
sition, and reported side effects (eg, edema, diabetes), a multi-
billion dollar industry based on the off-label use of rhGH as
anti-aging therapy has emerged in the US. The case of an
86 year-old male with Crohn’s disease who developed meta-
static colon cancer 7 years after commencing rhGH for anti-
aging is concerning [51]. The tumor showed greater
expression of IGF-1 receptor, suggesting a direct link with
rhGH. Larger and longer-term studies are needed to determine
the risk: benefit ratio of rhGH in elderly patients, its functional
effects in osteoporosis and sarcopenia, and address long-term
safety concerns. Proteins involved in tissue-specific GH/IGF-
1 signaling in muscle and bone, such as Grb10 [52], SOCS
proteins, and local isoforms of IGF and IGF binding proteins
(IGFBP) [53] may provide future therapeutic targets that
could circumvent undesirable side effects of GH therapy.
Another alternative to rhGH therapy is the use of GH
secretagogues. In principle, these agents are “more physiolog-
ical” than administration of rhGH, as they result in pulsatile—
rather than prolonged—elevation of GH and preserve nega-
tive feedback by IGF-1. Small studies of GH secretagogues
(including GHRH-1,44-amide and ghrelin mimetic MK-677)
confirmed increases in GH and IGF-1 levels, showed im-
provements in lean mass, no change in bone density, and
inconsistent effects in physical function [54, 55]. In the largest
clinical trial of a GH secretagogue, 395 older individuals were
randomized to capromorelin or placebo for a planned 2-year
period [56]. The trial was ceased prematurely as significant
increases in weight gain (1.4 kg at 6 months) offset improve-
ments in lean body mass. This probably resulted from an
appetite-stimulating effect of this drug, a ghrelin mimetic.
Interestingly, 2 of 6 functional parameters improved signifi-
cantly by 12 months, namely tandem walking and stair
climbing [56], but older patients in this trial were healthy with
mild functional decline. It remains to be seen whether GH
secretagogues demonstrate similar functional effects, or im-
provements in bone parameters, in a more frail population.
Androgens
Sex steroids are another critical player in regulating growth
that might serve as a potential bone-muscle therapeutic, in
particular, androgens. Apart from their established effects in
the reproductive system, androgens exert anabolic effects in
muscle and bone—the former being quite easy to appreciate in
professional bodybuilders. The mechanisms by which andro-
gens exert their anabolic actions in muscle and bone are
complex and extend beyond simply androgen receptor (AR)
activation in these tissues. In bone, testosterone must first be
converted to estrogen (aromatization) to exert effects on oste-
oclast activity via estrogen receptors [57]. In muscle, testos-
terone stimulates protein synthesis, leads to muscle fiber hy-
pertrophy, and increases myonuclei and satellite cell number,
suggesting effects on pluripotent precursors [58].
Clinically, men with classic hypogonadism develop muscle
wasting and osteoporosis that are reversible with testosterone
therapy [59••]. HIV-positive men and glucocorticoid-treated
men also display increases in lean mass and muscle strength
following testosterone supplementation [60]. Elderly males
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with reduced testosterone levels are more likely to have
muscle/bone loss and a higher fracture risk [61], but testoster-
one replacement is controversial in this group. Studies dem-
onstrate significant increases in lumbar BMD in older men
receiving testosterone [62, 63]. This effect was more pro-
nounced in those receiving intramuscular rather than transder-
mal formulations, and in general, there was no improvement
in femoral neck BMD. Despite increases in lean mass, effects
of testosterone on muscle strength are heterogeneous with a
tendency to improved leg/knee extension and handgrip
strength [63]. In 1 randomized trial of frail, older men, trans-
dermal testosterone led to improved physical function and
increased fat-free mass after 6 months [64]. However, no
clinical trials have evaluated the effects of testosterone on hard
outcomes such as falls or fractures.
There are also safety concerns about long-term use of
testosterone in vulnerable, older patients. In particular, data
on cardiovascular events and prostate cancer are limited; trials
are also not sufficiently powered to assess such effects [65•].
The risk of obstructive sleep apnea and polycythemia in
individuals using testosterone is also higher. In 2003, the
Institute of Medicine (IOM) reported that the existing
evidence-base was so equivocal that it could not even recom-
mend large-scale clinical trials without better short-term evi-
dence [66]. However, the US Endocrine Society advocates an
individualized approach in the consideration of testosterone
therapy in older men [59••]. Despite the uncertainty, prescrip-
tion sales of testosterone in the US have grown by about 25 %
annually between 1993 and 2002, suggesting that increasing
proportions of older males are using these medications [66].
Selective Androgen Receptor Modulators (SARMs)
The ‘holy grail’ of decades of preclinical research has been a
highly tissue selective and safe agent that does not inhibit
gonadotropins [67•]. Selective Androgen Receptor Modula-
tors (SARMs) have been developed to produce anabolic ef-
fects in muscle and bone without the dose-limiting androgenic
effects associated with testosterone (eg, prostate growth, acne,
oily skin). These compounds achieve tissue selectivity by
differences in gene regulation, tissue distribution, and local
interactions with aromatase and 5-alpha-reductase [60]. In
general, nonsteroidal SARMs (eg, aryl propionamides, quin-
olines) have greater AR specificity, oral bioavailability, and
tissue selectivity than their steroidal counterparts (eg, 17-
alpha-methyl-testosterone, 19-nortestosterone) and have,
therefore, progressed further. Andarine (also known as 8 or
S-4) has been described as the ideal SARM due to single daily
dosing, complete oral bioavailability and a wealth of preclin-
ical data reporting anabolic muscle and bone effects [68].
Early clinical data were also encouraging, and a related com-
pound, Ostarine (GTx-024, enobosarm), showed increases in
lean mass and physical function in elderly men, postmeno-
pausal women, and cancer patients in randomized controlled
trials [69, 70•]. There was no improvement in BMD, but this
may have been due to the relatively short study period of
3 months [69]. A phase III trial is currently underway for
Ostarine, focusing on cancer cachexia in particular. Another
agent, LGD-4033, increased lean mass and strength in healthy
males after 3 weeks [71], and according to the company,
increased bone mass in preclinical studies (www.ligand.
com/). A phase II trial for this agent is currently in
development for disorders associated with muscle wasting
(eg, cancer, fracture). Other nonsteroidal SARMs such as
BMS-564929 and LGD-2941 are currently in phase I trials
for age-related functional decline.
The first steroidal SARM to enter clinical trials, MK-0773,
showed increases in lean mass but no change in physical
function or bone mineral content over 6 months in women
aged >65 years [72•]. It has now entered a phase II trial for
sarcopenia. Clinical data on the efficacy and safety of SARMs
continues to emerge, and they hold great promise as anabolic
and function-promoting agents in a range of musculoskeletal
conditions. However, functional outcomes and long-term side
effects of these agents remain to be seen.
Vitamin D
In addition to sex steroids, a number of other hormone path-
ways impinge on bone and muscle development and may
present viable therapeutic targets to treat musculoskeletal
diseases. Vitamin D is one such hormone, and while its impor-
tance in bone physiology is quite well established, our under-
standing of its involvement inmuscle physiology and function
is only emerging. The biologically active form of vitamin D,
1,25(OH)2D, is a bona fide hormone that binds to a nuclear
receptor (VDR), regulates gene expression, and exerts effects
on mineral homeostasis, tissue development, and cell cycle
[73•]. Effects of vitamin D in bone and muscle are mainly
indirect, resulting from effects on calcium and phosphate
homeostasis [74, 75]. In bone, direct effects of vitamin D are
also possible, as both osteoblasts and osteocytes express VDR
[76•]. Osteoblast VDR inhibits bone mineralization to pre-
serve normal serum calcium levels [77] and consistent with
this, osteoblast-specific VDR knockout mice display in-
creased bone density [78]. Conversely, VDR overexpression
in osteoblasts and osteocytes protects against the bone effects
of vitamin D deficiency [79]. By contrast, whether the VDR is
expressed in muscle remains controversial, but studies in
cultured muscle cells and VDR knockout mice suggest that
vitamin D signaling does play a role in muscle differentiation
and fiber size regulation [80, 81].
In humans, severe vitamin D deficiency leads to osteoma-
lacia and muscle weakness due to type II muscle fiber atrophy
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[73•]. Vitamin D deficiency is common in the elderly, owing
to both nutritional deficits and lack of sun exposure, and has
been associated with falls, sarcopenia, and osteoporosis [82,
83]. One study even observed a reduction in the levels of VDR
inmuscle with age, suggesting an even greater vulnerability of
older individuals to low vitamin D levels [84].
Randomized trials have demonstrated that vitamin D sup-
plementation reduces the risk of falls and fractures in older,
institutionalized individuals [85, 86]. However, the effects of
vitamin D supplementation are less clear amongst those living
in the community. Although vitamin D supplementation may
increase femoral neck and hip BMD in such individuals, this
effect is small and not associated with reduction in fracture
risk [87, 88]. Interestingly, vitamin D supplementation may
increase muscle fiber size in frail, older patients [89•],
confirming effects demonstrated at a cellular level [81].
Whether these effects on fiber size translate into any function-
al benefit (eg, muscle strength or improved physical perfor-
mance measures) is not clear without standardized end points
for muscle function in these trials [73•, 89•].
While generally well tolerated, a greater incidence of kid-
ney stones and increased falls and fractures have been report-
ed in individuals receiving mega-doses of vitamin D [87, 90•].
Such reports have raised questions and vigorous debate about
what precisely constitutes vitamin D sufficiency, and safe
doses to achieve positive benefit from vitamin D. Indeed,
discord persists regarding recommendations for vitamin D.
For example, the IOM recommends 25 OHD target levels of
50 nmol/L and daily vitamin D doses of 800 IU in older adults
(> 70 years) [91•]. The USEndocrine society advocates higher
serum target level of 75 nmol/L and daily doses of at least
1500–2000 IU in this age-group [92•]. Perhaps most attractive
for treating musculoskeletal disease because of its availability
and ease of use, the ongoing uncertainty regarding risks and
benefits of vitamin D supplementation, together with contin-
ued controversy regarding optimal serum levels, point to a
need for further study; especially in the context of its potential
effects on skeletal muscle.
Exercise and Nutrition
Perhaps the simplest of all possible therapies to treat—or in
this case, even more importantly, prevent—musculoskeletal
disease is also one of the most difficult to implement. For
many years, health professionals have been advising patients
with osteoporosis to engage in weight-bearing exercise. The
benefits of exercise in elderly patients are quite clear: im-
proved muscle tone and balance to prevent falls and attenua-
tion of bone loss, particularly at the femoral neck [93, 94].
Sufferers of chronic diseases, such as breast cancer, may also
prevent muscle and bone loss by regular strength training and
exercise [95]. Unfortunately, the positive effects of exercise on
bone and muscle can only be maintained through continued
engagement in the activity; a fact with which many of us who
sit at desks and write papers about musculoskeletal therapies
are all too familiar. For example, a study of premenopausal
women demonstrated that 6 months after ceasing regular
exercise, positive effects in muscle strength and BMD were
lost [96]. An additional confounder in recommending exer-
cise, there is no clear consensus on the type, intensity, or
duration of exercise that is most effective. However, regular
walking has shown positive effects on muscle and bone in
elderly individuals [93]. Even low magnitude mechanical
signals have been demonstrated to have positive effects on
bone and muscle [97], providing an encouraging prospect for
those who have restricted mobility due to prior injury or
concomitant disease. Electrical muscle stimulation may also
prevent muscle and bone loss, as demonstrated in patients
with spinal cord injury [98].
Nutrition provides substrates necessary for bonematrix and
mineral (protein, calcium, magnesium, phosphate) and muscle
accretion (protein). Nutrition is of particular concern in the
elderly, where malnutrition affects up to 40 % of those living
in institutions. Moreover, 20 % of older individuals in the
USA consume inadequate protein, as defined by <0.66 g/kg/
actual body weight per day [99, 100]. Although an association
between dietary protein intake and lean mass exists [101], the
use of protein supplementation to reduce sarcopenia is con-
troversial. Small trials suggest that 25–30 g of high-quality
protein is necessary to maximize skeletal muscle protein syn-
thesis [102]. However, a meta-analysis of 62 trials found no
improvement in physical function in elderly patients on high-
energy protein supplements [103].
Another concern has been the co-occurrence of muscle
wasting and visceral adiposity, known as “sarcopenic obesi-
ty”. This is associated with functional disability and osteopo-
rosis, possibly related to adipocyte infiltration in bone and
muscle and subsequent pro-inflammatory state [8••]. The ad-
dition of exercise training to energy restriction preserves mus-
cle mass during periods of weight loss in older adults [104].
Activin signaling inhibitors, discussed below, show promising
results in the reduction of fat mass whilst increasing lean mass
[105].
The use of calcium supplements and their benefit in bone
health is similarly controversial. Calcium supplements may
lead to small benefits in bone mineral density, but they do not
clearly reduce fracture risk and their effects do not persist
beyond their duration of use [106]. A potentially increased
risk of myocardial infarcts with calcium supplements have
also called the benefits of calcium supplementation into ques-
tion [107]. Taken together, exercise, and dietary interventions
would seem to produce equivocal results, at best, in elderly
patients with existing osteoporosis and sarcopenia. However,
their value as both preventative and concurrent approaches to
help maintain bone and muscle mass should not be
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overlooked, especially given the additional health benefits of
exercise and proper nutrition in other organ systems (eg,
cardiovascular).
Activin Signaling Inhibitors
In addition to the more ‘classical’ pathways involved in mus-
cle and bone development discussed already, recent studies
have suggested that the activin signaling pathway—well
known for the suppressive effects of myostatin on muscle
mass—may represent another shared pathway between mus-
cle and bone. Myostatin is a member of the TGF-β superfam-
ily and a muscle-derived hormone that was first discovered in
1997 [108]. Myostatin deficiency results in increased muscle
mass in several species, including humans [108, 109]. Con-
versely, increases in myostatin may partially explain the mus-
cle wasting observed in patients with chronic diseases such as
renal failure [110], HIV [111], and chronic obstructive pul-
monary disease [112]. Myostatin exerts these effects on mus-
cle by binding to a transmembrane receptor, activin receptor
IIB (ActRIIB), ultimately activating Smad family proteins and
downstream signals that lead to muscle protein breakdown via
the ubiquitin-proteasome system. There is also a closely relat-
ed ActRIIA that binds additional activin ligands (but can
weakly bind myostatin) and shares some functional overlap
with ActRIIB in muscle [113, 114]. More recently, the activin
signaling pathway has also been shown to affect bone devel-
opment and remodeling. Polymorphisms in the myostatin
gene are associated with peak bone mineral density [115].
Myostatin knockout mice display increased BMD and bone
mineral content (BMC) [24, 116] and greater callus size
following osteotomy [117]. These anabolic effects on bone
were predominantly believed to be related to increased me-
chanical loading, secondary to increased skeletal muscle
mass. However, direct effects of activin/myostatin on bone
are also possible, as bonemarrow stromal cells and osteoblasts
express activin receptors, and modulating the pathway in vitro
appears to affect bone cell differentiation [118•, 119•].
The activin signaling pathway is an attractive therapeutic
target for musculoskeletal disease, given the evidence to sug-
gest that it might function to negatively regulate both bone and
muscle mass. Indeed, several inhibitors of this pathway have
already been developed, including myostatin-neutralizing
antibodies/propeptide, recombinant follistatin (an endogenous
inhibitor that binds and sequesters ligands), follistatin deriva-
tives, and soluble activin receptors [114]. Mice treated with
such agents demonstrated substantial increases in muscle
mass and strength [26, 118•]. Positive effects on muscle mass
were also reported in mouse models of androgen deficiency
[120], muscular dystrophy [121], and cancer cachexia [122].
In addition to the expected effects on skeletal muscle,
ActRIIB-Fc also increased bone formation rates and bone
mineral density in mice and demonstrated direct effects on
osteoblast activity [118•, 123•]. Similar bone anabolic re-
sponses were also seen in primates administered soluble
ActRIIA [124]. Interestingly, a myostatin propeptide had no
effect on bone parameters in mice, despite increasing muscle
mass [125•]. This difference in tissue response highlights the
possibility that specific components in the pathway could be
exploited therapeutically to achieve different benefits (eg,
bone and muscle anabolic, only muscle anabolic, etc.), de-
pending on the disease context.
In addition to these preclinical studies, inhibitors of the
activin signaling pathway have also been tested in human
phase 1 and 2 trials. A recombinant human myostatin anti-
body (MYO-029, Stamulumab) was found to be generally
safe in healthy individuals (NCT00563810) and adults with
muscular dystrophy [126]. Although MYO-029 resulted in
improved contraction in single muscle fibers [127], increases
in muscle mass on DXA were not statistically significant.
Moreover, no improvement in muscle strength was observed
in 116 patients with muscular dystrophy [126], although this
study was not adequately powered to detect changes in muscle
function. In a double-blind, placebo-controlled study of 48
postmenopausal women, a single dose of ACE-031 (soluble
ActRIIB decoy receptor) resulted in significant increases in
leanmass (3.3%) and thigh muscle volume (5.1%) on DEXA
and MRI after 1 month [128•]. Although grip strength was
measured at baseline, changes following treatment were not
reported. ACE-031 also resulted in a significant increase in
bone-specific ALP and decrease in C-telopeptide, indicating
increased bone remodeling. The company reported a signifi-
cant 3.4% increase in bonemineral density (BMD) at 113 days
in a phase 1b trial of 60 postmenopausal women on ACE-031
(www.acceleron.pharma.com/), although this trial has not
been published or subject to peer review.
Targeting this pathway is not without its issues however.
First noted in trials of children with DMD (NCT01099761,
clinicaltrials.gov) and postmenopausal women receiving
higher doses of ACE-031 [128•], side effects include nose-
bleeds and skin telangiectasia. Although not serious in itself,
this phenomenon does raise concerns about unrecognized,
systemic effects of ActRIIB inhibition. Other off-target effects
include significant reduction in serum FSH levels (43 %) after
a single dose of ACE-031 (3 mg/kg), most likely related to
suppression of activin/GnRH signaling [128•], and alteration
of fat mass and metabolism [105]. In this regard, antibodies
directed against activin receptors could potentially offer a
means to avoid off target effects seen with soluble receptor
administration by allowing more specific targeting of IIA vs
IIB receptor and varied blockade kinetics. A recent study
showed that a novel anti-ActRIIA antibody (BYM338) was
twice as effective as a myostatin-specific inhibitor (D76A) in
increasingmusclemass inmice [129•]. The effect of BYM338
was partly myostatin-independent as confirmed by its effects
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in myostatin mutant mice. Interestingly, BYM338 also result-
ed in increases in muscle IGF-1 and prevented glucocorticoid-
induced muscle wasting by reducing levels of E3 ubiquitin
ligases, MAFbx, and MuRF1.
Clinical studies of various activin pathway inhibitors are
still in their infancy, but they have yielded promising results
for the therapeutic potential of modulating this pathway to
treat musculoskeletal disease. Larger, prospective studies are,
of course, necessary to establish the long-term safety and
efficacy of these agents.
Myokines and Future Directions
In addition to myostatin, a number of recent studies have
demonstrated other muscle-secreted factors—termed
myokines—that can serve as paracrine/endocrine factors to
influence other organ systems, including bone. These
myokines include myostatin, LIF, IL-6, IL-7, BDNF, IGF-1,
FGF-2, FSTL-1, and irisin [25]. Given that we have already
discussed therapeutics targeted at 2 of these myokines
(myostatin and IGF-1, albeit secondary to GH), it is likely
that further study of muscle-bone interactions will reveal other
myokines as candidate therapeutic targets to treat musculo-
skeletal disease.
Importantly, many of these myokines could impact bone
and muscle secondarily, through actions on other tissues and
organs, as the interconnectedness of bone and muscle extends
well beyond just one another. In recent years, endocrine
pathways have been elucidated that connect bone metabolism
to the pancreas, fat, and brain; all organs also interconnected
with muscle. It is not unreasonable to suspect that impinging
upon a “middle man” could exert profound effects on muscle
and/or bone. One such example can be envisaged for the
myokine IL-6, which has been demonstrated to increase the
secretion of insulin from the pancreas [130]. Insulin could
then feed into the bone–pancreas endocrine loop to exert
secondary effects upon bone [27••]. Such systems biology-
based approaches to understanding the interaction of muscle
and bone—with each other and other organs—could even
result in treatments for musculoskeletal disease that target
entirely different organ systems to exert their effect on muscle
and bone (eg, CNS or fat). This represents a truly exciting
future direction for study.
Conclusions
Osteoporosis and sarcopenia are closely related conditions
characterized by age-related involution of the bone-muscle
unit. Functionally, this progressive muscle and bone loss leads
to falls, fractures, deconditioning, and further muscle wasting,
all of which can be exacerbated by additional disease
pathology. While previous efforts to reduce fracture were
heavily geared toward treating bone as a separate organ, our
increasing understanding of bone-muscle interactions has
highlighted that targeting the bone-muscle unit as a whole
may break this ‘vicious cycle’ of musculoskeletal atrophy
even more effectively. There has been significant progress in
the development of novel anabolic agents for bone and mus-
cle, most notably SARMs and activin pathway inhibitors, and
exciting new opportunities for targeting myokines may be on
the horizon.
Developing therapeutic treatments to holistically treat
musculoskeletal disease is not without significant challenge
however, and one of the largest hurdles is related neither to
the targets nor their biology. Rather, it lies within the
definition of the condition itself; sarcopenia and its end-
points are poorly defined. Moreover, functional outcomes
and markers are needed to clarify a positive outcome in the
‘musculoskeletal unit’ and guide efficacy trials. These
topics are under vigorous debate and are of critical impor-
tance for advancing musculoskeletal therapeutics. As with
any therapeutic development, safety has also been a concern.
Telangiectasia, bleeding, and gonadotropin suppression in
patients on activin pathway inhibitors highlight our incom-
plete understanding of systemic activin/myostatin signaling
[128•]. Similar issues have been overcome for other pathways,
however. To avoid undesirable systemic effects of androgens,
SARMs selectively target muscle and bone. Concerns of
nonphysiological GH levels, and possible related side effects,
with GH administration have been addressed with GH secre-
tagogues, which preserve IGF-1-mediated negative feedback
of GH [60]. Finally, systems biology-based research may
prompt us to consider other tissues that participate in bone-
muscle interactions, such as fat and nerves, as future potential
therapeutic targets [8••]. Collaborative efforts by basic scien-
tists, clinicians, and industry are needed to address these
complex issues and energize the clinical development of novel
bone-muscle therapies.
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 CURRENTOPINION Vitamin D and muscle function in the elderly: the
elixir of youth?
Christian M. Girgisa,b
Purpose of review
Circumstantial evidence suggests that vitamin D deficiency may contribute to age-related changes in
skeletal muscle. This review discusses recent clinical trials examining effects of vitamin D on muscle function
in the elderly, and poses the important question: can vitamin D reverse muscle ageing?
Recent findings
Observational studies report an association between vitamin D and muscle atrophy/weakness in elderly
subjects. Interventional studies suggest that frail, elderly subjects may benefit from vitamin D
supplementation by displaying reduced falls, improved muscle function and increased muscle fibre size.
However, meta-analyses do not report convincing effects of vitamin D in the elderly. This may be because
of multiple factors including lack of standardized endpoints for muscle function, variable study design and
different doses of vitamin D supplementation amongst these studies. The evidence base is therefore
inconsistent.
Summary
Vitamin D deficiency may exacerbate ageing of skeletal muscle. However, current evidence that vitamin D
supplementation reverses age-related muscle dysfunction is equivocal and does not justify stringent
vitamin D targets in the elderly. Until these issues are clarified, the safest option is to aim for conservative
vitamin D targets that are sufficient for normal calcium homeostasis.
Keywords
falls, muscle weakness, sarcopaenia, vitamin D
INTRODUCTION
Vitamin D deficiency is highly prevalent in elderly
subjects, affecting up to 50% of those living in
institutions [1] and in the community [2] [that is
deficiency defined as 25 hydroxy vitamin D
(25OHD) levels<50 nmol/l, 20ng/ml]. Elderly indi-
viduals are at risk of vitamin D deficiency owing to
intrinsic age-related changes in vitamin D synthesis
[3], reduced exposure to sunlight and malnutrition,
which is rife amongst those living in institutions
[2,4]. The active form of vitamin D [1,25(OH)2D]
binds to a nuclear receptor, vitamin D receptor
(VDR), to mediate effects in calcium homeostasis
in addition to wide-ranging extracalcaemic effects
(e.g. in tissue development, cell cycle regulation).
The expression of VDR declines with age in skeletal
muscle and vitamin D deficiency is associated with
age-related involution of muscle in elderly subjects
[3]. However, the precise role of vitamin D in the
ageing process is unclear. In this review, clinical
studies seeking to clarify the relation between
vitamin D and muscle function in the elderly and
potential mechanisms will be discussed. Muscle
function is a broad entity and individual com-
ponents including muscle mass, strength, func-
tional parameters and falls will be reviewed.
Controversies in this field will be discussed together
with conflicting guidelines for vitamin D supple-
mentation in the elderly.
OBSERVATIONAL STUDIES
Observational studies report an association between
vitamin D, muscle function and physical perform-
ance in the elderly. In two recent studies from the
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REVIEW
Netherlands, serum 25OHD levels less than
75nmol/l (20ng/ml) correlated with impairments
in gait and the ability to conduct activities of daily
living in older individuals [5&]. In individuals who
had recently experienced a fall, vitamin D levels
correlated with classical parameters of physical
function (e.g. timed-up-and-go test) and vitamin
D deficiency was very common (i.e. 44% of study
participants) [6].
Associations between specific tests of muscle
function – such as grip strength testing – and vita-
min D levels in the elderly are not consistently
found [6,7&]. This may relate to the predominant
involvement of proximal muscles in vitamin D
deficiency and the possibility that vitamin D has a
more generalized effect in coordinating muscle
function, balance and well-being.
Low vitaminD levels are associated with reduced
muscle mass, a condition referred to as sarcopaenia
[8,9]. This association is specific to appendicular lean
mass rather than whole lean mass, supporting
vitamin D’s predominant effect in proximal limb
muscles [8]. However, no association was found
between vitamin D intake and muscle mass in two
studies [8,10], raising doubts as towhether vitaminD
supplementation may increase muscle mass.
Vitamin D levels associated with optimalmuscle
function in the elderly are not clearly defined. One
study suggested that 25OHD level of 75nmol/l
(30ng/ml) in elderly men was associated with better
physical performance than lower levels [5&]. A larger
study of "1500 community-dwelling older men
found that a vitamin D range of 50–75nmol/l
(20–30ng/ml) correlated with significantly better
physical performance and reduced falls than lower
levels [7&]. No additional benefit was seen in those
with levels higher than 75nmol/l (30ng/ml). In fact,
further analysis of this study found a higher inci-
dence of fractures in those with levels higher than
72nmol/l (29ng/ml) compared with those in the
intermediate range of 60–72nmol/l (24–29ng/ml),
suggesting a U-shaped association between vitamin
D and fracture incidence [11]. This increased frac-
ture risk was not related to a greater incidence of falls
or changes in bone mineral density, raising ques-
tions about potential mechanisms for this finding.
Although these studies support an association
between vitamin D and muscle strength, they are
not equipped to establish a cause-and-effect
relationship. Their cross-sectional nature and the
possible presence of confounding factors, not
included in adjustment models, are limitations.
Vitamin D deficiency is also associated with frailty,
a syndrome characterized by the combination of
reduced muscle strength, impaired gait and exhaus-
tion in older individuals [7&]. It may therefore be
difficult to disentangle direct effects of vitamin D in
muscle function, independent of its association
with frailty. Interventional studies may clarify these
issues and more clearly examine the relation
between vitamin D and muscle function.
INTERVENTIONAL STUDIES
Several studies have examined effects of sunlight
exposure and vitamin D supplementation in the
prevention of falls and muscle strength in older
individuals [12,13]. These studies generally support
effects of vitamin D supplementation in vulnerable
elderly populations. For example, in institutional-
ized elderly subjects, daily sunlight exposure
reduced falls [14] and the daily consumption of
fortified bread (containing vitamin D 5000 IU,
calcium 320mg) improved locomotion and reduced
general pain compared with baseline [15]. However,
these studies were limited by poor compliance [14],
lack of a control group [15] and increases in serum
vitamin D levels were not demonstrated [15].
Apart from general improvements in physical
performance, muscle strength has also been shown
to respond to vitamin D supplementation. In older,
institutionalized subjects, 6 months of vitamin D
supplementation led to increases in hip flexor and
knee extensor strength ("20–25%) [16]. Similar
KEY POINTS
! Vitamin D deficiency is associated with muscle
weakness, age-related muscle loss (that is sarcopaenia)
and functional decline in the elderly. Vitamin D
supplementation may reduce falls and improve muscle
function in frail elderly people, particularly those living
in institutions.
! Randomized controlled trials and meta-analyses do not
demonstrate a convincing effect of vitamin D
supplementation in muscle function in the elderly. This
may be because of heterogeneity in study design,
variability in vitamin D supplementation regimens and
different vitamin D assays amongst the studies. Future
studies should use standardized measures of proximal
muscle function, rather than grip strength, to assess
effects of vitamin D.
! Vitamin D is a marker of general health. Establishing
direct effects of vitamin D in muscle function in the
elderly may be confounded by its potential effects in
general health and frailty.
! Until muscle outcomes of vitamin D and its therapeutic
window are clarified, a conservative approach aiming
for vitamin D levels that maintain normal calcium
homeostasis is the safest option (that is serum vitamin D
>50nmol/l, 20ng/ml).
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increases in proximal muscle strength were demon-
strated in community-dwelling subjects, predomi-
nantly in those who were weakest at baseline [17].
Impairments in balance may also respond to
vitamin D supplementation, thereby reducing the
incidence of falls [18]. This effect in falls is seen
predominantly in the institutionalized elderly
[12,13], whereas healthy, postmenopausal women
showed no change in grip strength or falls risk in
response to vitamin D supplementation (400 and
1000 IU/day) [19]. Therefore, an individualized
approach to vitaminD supplementation, depending
on a subject’s baseline muscle function, may
be necessary.
From a mechanistic viewpoint, vitamin D
supplementation (4000 IU/day) was found to
increase muscle fibre size and expression of vitamin
D receptor within muscle nuclei of frail older
women with baseline vitamin D deficiency [20&&].
This did not translate to tangible improvements in
muscle function, possibly because of the short study
duration of 4 months. In another study, vitamin D
supplementation improved muscle mitochondrial
function in deficient subjects, explaining improve-
ments in muscle fatigue reported in this study [21].
Megadoses of vitamin D are not recommended.
In a study of 243 frail, older patients, megadose
vitamin D (300000 IU) did not improve perform-
ance even amongst those with baseline levels less
than 30nmol/l (12ng/ml) [22]. An annual oral dose
of 500000 IU increased falls in 2256 community
dwelling older women, particularly in the 3 months
following the dose (incidence rate ratio 1.31 com-
pared with placebo) [23]. One potential explanation
is that sudden improvement inmuscle function and
increased physical activity following supplement-
ation led to an increased risk of falling. Alterna-
tively, supraphysiologic levels of vitamin D may
be deleterious to muscle function by inducing
muscle protein breakdown via calpain proteolytic
pathways [24].
Vitamin D’s positive effects in skeletal muscle
may be limited by its dose-dependent effect in
increasing serum calcium levels. To support this, a
vitamin D analogue with lower calcaemic potency,
eldecalcitol, increased bone mineral density,
reduced falls/fractures and improved lower limb
muscle power in older individuals [25&,26]. The
use of vitamin D analogues may present a viable
option for optimizing muscle function in the eld-
erly, but this needs further evaluation.
In summary, recent studies suggest that moder-
ate-dose daily vitamin D supplementation reduces
falls and improves muscle function in vulnerable
elderly subjects such as the institutionalized and
those with baseline weakness.
META-ANALYSES
In a widely cited meta-analysis, vitamin D supple-
mentation was found to reduce falls amongst 2426
elderly individuals from eight trials [27]. Higher
doses (700–1000 IU) reduced falls risk by 19%, but
lower doses had no effect. Likewise, people who
achieved serum 25OHD concentrations 60nmol/l
(24ng/ml) or higher reduced falls by 23%, but those
who achieved concentrations 60nmol/l (24ng/ml)
or lower had no effect. This meta-analysis was
criticized by the recent Institute of Medicine report
for inconsistencies in study inclusion, perceived
errors in statistical analysis and reliance on two
studies to produce the positive effect, one of which
was reportedly not well powered [28]. On reanalysis
with two statistical alterations, the positive effect
was not found.
Another meta-analysis including 45782 people,
mainly elderly females, found a significant reduc-
tion in falls amongst those randomized to vitamin D
supplementation (odds ratio 0.86 for #1 fall) [29].
The effect was most prominent in those who were
deficient at baseline and with calcium co-adminis-
tration. However, the effect was not related to the
dose or form of vitamin D supplementation (that is
D2 versus D3) or the target population (community
dwelling versus institutionalized subjects).
Meta-analyses dealing with vitamin D and
muscle strength are limited by substantial hetero-
geneity in study design, including the parameters
of muscle function. A recent meta-analysis that
assessed 17 randomized controlled trials (RCTs)
involving 5072 participants reported no effect on
grip strength or proximal lower limb strength in
adults with 25OHD levels higher than 25nmol/l
(10ng/ml) [30]. However, on pooling data from
two studies on vitamin D-deficient adults (that is
25OHD <25nmol, 10ng/ml), an effect on hip
muscle strength was found, although the studies
used different measures.
More recently, an umbrella review collectively
assessed more than 250 reviews and meta-analyses
on vitamin D, exploring its effects in 137 outcomes
[31&&]. From these studies, evidence that vitamin D
supplementation reduced nonvertebral fractures
and improved muscle strength was suggestive but
not convincing (P values 0.04 and 0.02, respec-
tively). In general, no effect was seen in falls or
fractures, raising doubts about vitamin D’s widely
accepted effects.
An important consideration is that vitamin D is
a marker of general health [32]. Therefore, effects of
vitamin D in muscle function may be indirectly
related to improvements in general well-being
[15,32]. Moreover, these studies lack uniformity in
parameters of muscle function, reporting of falls,
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vitamin D supplementation regimens and study
populations. Commercially available vitamin D
assays also differ substantially in their estimation
of serum levels [33]. This heterogeneity complicates
the collective assessment of these studies, leading to
the lack of a clear and convincing effect of vitaminD
in muscle function in the elderly.
GUIDELINES
In the absence of clearly established muscle out-
comes, guidelines for vitamin D supplementation
in the elderly are conflicting. In a recent report, the
US Institute of Medicine recommended 25OHD tar-
get levels of 50nmol/l and daily vitamin D doses of
800 IU/day in older adults (>70 years) [28]. How-
ever, the US Endocrine Society advocated a higher
serum target level of 75nmol/l and daily doses of at
least 1500–2000 IU in this age group [34]. Similar
targets were recommended by the American
Geriatrics Society to prevent falls and fractures in
frail, elderly subjects [35]. The society also recom-
mended a total daily intake of 4000 IU of vitamin D
from all sources [35]. However, evidence to support
this higher target is lacking and studies hint that
adverse effects may occur with excessive doses of
vitamin D [11,23]. Until these issues are clarified,
this author’s practice is to aim for vitamin D levels
sufficient to normalize calcium homeostasis, an
unequivocal benefit of vitamin D. On the basis of
RCT evidence, this corresponds to a serum vitamin
D level of 50nmol/l (20ng/ml) in the majority of
individuals [36&]. This can usually be achieved by a
daily oral intake of"800 IU vitamin D3 [36&]. Higher
dosesmay be necessary in the initial stage of treating
vitamin D deficiency and a daily maintenance dose
of 1000 IU is considered well tolerated. Achieving
this target poses a formidable task, as 50% of elderly
individuals fall short of these levels [1,2].
CONCLUSION
Although observational studies link falls, muscle
weakness and sarcopaenia with vitamin D deficiency
[5&], interventional trials and meta-analyses have
yielded conflicting results [29,30,31&&]. A number
of confounding factors suchasheterogeneity in study
design, variability in treatment dose and analyses of
muscle functionmayexplain the lackof a convincing
effect. Some studies suggest that vitamin D supple-
mentation may reduce the risk of falls and improve
muscle function in more vulnerable elderly people,
such as the institutionalized or those who are prone
to falls [12,13,16]. Other studies suggest that exces-
sive doses of vitamin Dmay have adverse effects and
precipitate falls and fractures in frail elderly people
[11,23]. On the basis of these conflicting data,
vitamin D cannot be considered the ‘elixir of youth’
with regards to skeletal muscle and stringent guide-
lines for vitamin D supplementation are premature.
At this time, conservative vitaminD targets aiming to
preserve calcium homeostasis are the safest option
(>50nmol/l, 20ng/ml).
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Chapter 9 – Vitamin D, bone-muscle interactions and  
metabolic effects 
 
 
 
This chapter consists of 3 published review articles. The PhD candidate, 
Christian Girgis, was primary author on one of these manuscripts and second-
author on the other two.  
 
The manuscript published in Molecular and Cellular Endocrinology discusses 
biomolecular effects of vitamin D in muscle-bone interactions and evidence for 
specific roles throughout the life of the musculoskeletal systems: development, 
injury and ageing. The therapeutic potential of the vitamin D endocrine system 
in subjects with sarcopaenia and osteoporosis is discussed.  
 
The manuscript published in Bone discusses mechanisms underlying bone and 
muscle interactions, humoural and endocrine factors responsible for their cross-
talk and purported effects of vitamin D in integrating the musculoskeletal 
system. 
 
 The article published in Nutrition and Dietary Supplements discusses clinical 
evidence on effects of vitamin D and the anti-oxidant, vitamin C, in the 
prevention and treatment of type 2 diabetes mellitus. This is then followed by a 
discussion of potential mechanisms by which vitamins C and D may alter 
skeletal muscle insulin sensitivity. 
 
Manuscript layout and referencing style differ between these articles, 
depending on specific journal requirements.   
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A B S T R A C T
Beyond the established effects of muscle loading on bone, a complex network of hormones and growth
factors integrates these adjacent tissues. One such hormone, vitamin D, exerts broad-ranging effects in
muscle and bone calcium handling, differentiation and development. Vitamin D also modulates muscle
and bone-derived hormones, potentially facilitating cross-talk between these tissues. In the clinical setting,
vitamin D deficiency or mutations of the vitamin D receptor result in generalized atrophy of muscle and
bone, suggesting coordinated effects of vitamin D at these sites. In this review, we discuss emerging ev-
idence that vitamin D exerts specific effects throughout the life of the musculoskeletal system – in
development, aging and injury. From this holistic viewpoint, we offer new insights into an old debate:
whether vitamin D’s effects in the musculoskeletal system are direct via local VDR signals or indirect via
its systemic effects in calcium and phosphate homeostasis.
© 2015 Elsevier Ireland Ltd. All rights reserved.
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Introduction
The link between vitamin D andmusculoskeletal function is long-
standing. In the first description of rickets four centuries ago,Whistler
reported the combination of “flexible, waxy” bones and “flabby, tone-
less” muscles in young children (Whistler, 1645). Adults with vitamin
D deficiency also display concurrent defects in bone and muscle,
characterized by osteomalacia (i.e. reduced bone mineral) and type
2muscle fiber atrophy (Girgis et al., 2013). These conditions are also
seen in subjects with mutations of the vitamin D receptor (VDR),
suggesting local genomic effects of vitamin D in the muscle–bone
unit.
Studies have elucidated a range of effects of vitamin D in bone
and muscle cells and transgenic mouse models have shed light on
potential interconnected vitamin D signals between these tissues
(Garcia et al., 2011; Girgis et al., 2014b; Lam et al., 2014; van Driel
et al., 2006). Concurrently, we are becoming increasingly aware that
muscle and bone interact to form a finely coordinated unit
(DiGirolamo et al., 2013). This notion is supported not only by effects
of muscle loading on bone function but also the emergence of mul-
tiple paracrine/endocrine factors that facilitate cross-talk between
these tissues. Bone and muscle arise together from embryonic me-
soderm, grow together throughout puberty and atrophy during aging.
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The search for biomechanical and endocrine cues responsible for
this life-long synchrony of muscle and bone is underway.
Vitamin D is one endocrine system that may integrate bone and
muscle function. Clinically, vitamin D levels predict the rate of func-
tional decline, fracture risk and bone mass in young and old
individuals (Sohl et al., 2013;Ward et al., 2010). At a molecular level,
muscle and bone both express the 1-alpha-hydroxylase enzyme,
encoded by Cyp27b1, facilitating the local synthesis of the bioactive
hormone, 1,25(OH)2D (Anderson et al., 2005; Girgis et al., 2014b;
Srikuea et al., 2012). Regulated by local and systemic vitamin D
signals, bone is the major depot for calcium, an essential mineral
in muscle contraction, morphology and plasticity. Conversely, skel-
etal muscle is emerging as a major storage site for vitamin D from
where it may diffuse back into the circulation or possibly, into ad-
jacent bone, following specific signals (Abboud et al., 2013; Girgis
et al., 2014d). Thus, vitamin D may have complementary effects in
bone and muscle, further supporting the integration of these two
tissues.
In this review, we will discuss key events in the life of the mus-
culoskeletal system – development, aging and injury – and evidence
for integrated effects of vitamin D at these times. Wewill cover areas
of controversy, particularly whether vitamin D’s effects in the mus-
culoskeletal system are mainly indirect via systemic calcium and
phosphate levels or direct via local VDR, the presence of which is
debated in muscle. Finally, potential therapeutic implications of this
field and outstanding questions will be raised.
Vitamin D and musculoskeletal development
The VDRmakes its first appearance in the fetal rat at day 13 ges-
tation (Johnson et al., 1996). At this stage, it resides within the
condensing mesenchyme of the vertebral column and by day 17,
within osteoblasts and proliferating, hypertrophic chondrocytes. Mes-
enchymal stem cells (MSCs) express VDR (Artaza and Norris, 2009).
In various studies, 1,25(OH)2D results in nuclear translocation of VDR
in MSCs and induction of myogenic and osteogenic pathways by
effects in TGF-beta and bone matrix proteins ALP, bone sialoprotein
(BSP) and osteopontin (Artaza and Norris, 2009; Honda et al., 2013;
Mostafa et al., 2012). MSCs also express 1-alpha-hydroxylase
(Cyp27b1). Inhibition of this enzyme reverses the effects of 25OHD
in human MSCs including its anti-proliferative, pro-differentiation
and anti-apoptotic activity (Geng et al., 2011b). Therefore, effects
of vitamin D in MSCs and the presence of vitamin D signaling com-
ponents in these primordial cells provide prima facie evidence for
vitamin D’s role in musculoskeletal development.
Vitamin D exerts a range of in vitro effects in committed myo-
blasts and osteoblasts. These effects vary widely depending on the
particular cell model used (van Driel et al., 2006; Yamaguchi and
Weitzmann, 2012), the stage of cellular differentiation (Tanaka et al.,
2014), origin of primary cells (Yang et al., 2013) and species (Thomas
et al., 2000; van Driel and van Leeuwen, 2014). In general, 1,25(OH)2D
stimulates bone formation and mineralization in human osteo-
blasts by effects in Wnt and B-catenin pathways (Fretz et al., 2007)
and the subsequent expression of RUNX2, osteocalcin, osteopontin
and matrix Gla protein (Prince et al., 2001; van Driel et al., 2006;
Zhang et al., 1997). By contrast, 1,25(OH)2D inhibits bone forma-
tion and mineralization in cultures of murine osteoblasts due to
suppression of the same osteogenic markers (Shi et al., 2007;
Yamaguchi andWeitzmann, 2012) and leads to increases in themin-
eralization inhibitor pyrophosphate (Drissi et al., 2002; Lieben et al.,
2012). This discrepancy between responses of murine and human
osteoblasts to vitamin Dmay result from different extracellular con-
ditions including phosphate or cytokine levels or species-specific
VDR cistromic interactions (Pike et al., 2014).
C2C12 muscle cells also respond to vitamin D by increased ex-
pression and nuclear translocation of VDR (Garcia et al., 2011; Girgis
et al., 2014b). In addition to anti-proliferative effects due to altered
cell cycle activity, vitamin D intriguingly leads to a doubling in the
size of C2C12myotubes by profound inhibition of myostatin (Garcia
et al., 2011; Girgis et al., 2014b). Conversely, knockdown of VDR and
CYP27B1 results in increased proliferation, impaired differentia-
tion and myotube maturation in C212 and G8 cells (Srikuea et al.,
2012; Tanaka et al., 2014). Together, these studies support a direct
role for vitamin D signaling in bone and muscle cells but present
a mixed picture of its effects. Under certain conditions, vitamin D
has an anabolic effect in bone and muscle cells, promoting miner-
alization and myotube growth. However, the physiologic relevance
of these findings is unclear and a limitation inherent to these studies
is the isolated assessment of bone and muscle cells without ac-
counting for interactions. Cross-culture studies would be helpful in
assessing integrated effects of vitamin D in bone and muscle cell
differentiation.
Despite the early presence of VDR in the developing embryo, the
clinical features of rickets develop after weaning (Li et al., 1997;
Yoshizawa et al., 1997). These features including growth plate defects,
increased osteoid (i.e. unmineralized bone), and generalized atrophy
of type I and II muscle fibers are seen in VDRKOmice at day 35 (Endo
et al., 2003; Li et al., 1997). However, subtle changes are seen prior
to weaning including expansion of the growth plate (Li et al., 1997),
smaller muscle fibers and altered expression of myogenic regula-
tory factors at day 15 (Endo et al., 2003). Interestingly, another
VDRKOmodel – generated by ablation of exon 2 – showed no mus-
culoskeletal defects prior to weaning (Yoshizawa et al., 1997),
possibly due to the presence of a truncated form of VDR with po-
tential biologic activity in thesemice (Bula et al., 2005). This suggests
non-classical signaling may be responsible for pre-weaning mus-
culoskeletal effects of VDR.
In humans, subtle differences in fetal bone development are
observed in association with maternal vitamin D deficiency
(Ioannou et al., 2012; Mahon et al., 2010). Maternal vitamin D
status is indirectly associated with fetal bone mineral content via
methylation at 4 sites of the RXRA in umbilical cord tissue (Harvey
et al., 2014; Jaenisch and Bird, 2003). This indicates a novel epi-
genetic role for vitamin D in embryonic skeletal development.
VDR may also prepare bone during embryogenesis for post-natal
mineralization by enhancing production of mature matrix vesicles
rather than directly increasing mineral deposition (Woeckel et al.,
2010).
Vitamin D may also regulate muscle fiber size during develop-
ment. In humans, maternal vitamin D deficiency is associated with
reduced arm-muscle area in newborn offspring (Krishnaveni et al.,
2011). In rats born to vitamin D deficient dams, smaller muscle fibers
were seen in association with altered expression of genes in-
volved in protein catabolism, differentiation and the cytoskeleton
(Max et al., 2013). These effects are not restricted to mammals as
European sea bass treated with dietary 25OHD after hatching also
demonstrate dose-dependent increases inmuscle fiber size andmyo-
genic gene expression (Alami-Durante et al., 2011). Growth-
promoting effects of vitamin D in muscle may potentially enhance
loading on bone and stimulate bone mass. In addition, skeletal
muscle may represent a reservoir for vitamin D from where it may
diffuse to adjacent bone during embryogenesis. In support of this,
a study from 1986 reported the in utero transfer of radiolabeled
25OHD across the placenta and into the skeletal muscle of rat
embryos (Clements and Fraser, 1988). More recently, we reported
a direct effect of VDR in the uptake of 25OHD into muscle fibers
(Girgis et al., 2014d). Human studies also support the notion that
vitamin D may be taken up and utilized by the musculoskeletal
system during growth. Reductions in serum vitamin D levels con-
current with increases in leanmusclemass and bonemineral content
during puberty have been reported (Breen et al., 2011; Willis et al.,
2007).
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Vitamin D directly alters growth plate fusion. Cyp27b1-KO mice
display persistent abnormalities in long bone growth even after cor-
recting their mineral levels (Dardenne et al., 2003). Chondrocyte-
specific VDR knockout mice displayed an intriguing phenotype with
transient impairment in osteoclastogenesis, reduced vascular in-
vasion of the growth plate and increased serum phosphate
(Masuyama et al., 2006). This elegantly demonstrates the role of VDR
in regulating interactions between chondrocytes, osteoblasts and
endothelial cells in growth plate fusion and systemic mineral levels.
Mechanical loading is also important for growth plate fusion (Mirtz
et al., 2011) and effects of vitamin D in muscle fiber size and mass
may thereby play an indirect role in growth plate physiology.
In summary, evidence suggests that vitamin D plays a subtle role
in prenatal musculoskeletal development that has perhaps been ob-
scured by overwhelming evidence in support of a predominantly
post-natal effect. VDR appears at an early stage in the developing
embryo and is expressed by MSCs, osteoblasts and myoblasts, all
of which are responsive to vitamin D (Artaza and Norris, 2009). In
vitro studies report growth-promoting effects of vitamin D in
myotubes and maturation of matrix vesicles in osteoblasts (Girgis
et al., 2014b; Woeckel et al., 2010). In vivo studies support subtle
musculoskeletal changes in pre-weaned VDRKOmice (Li et al., 1997).
However, pre-weaning effects of VDRKO are not consistently found
(Yoshizawa et al., 1997) and VDR activity in muscle/bone precur-
sor cells is confounded by its increased expression following cell
isolation (Girgis et al., 2014d). Therefore further research is re-
quired to clarify these questions. If confirmed, a role for VDR in
musculoskeletal development would be consistent with its known
pleiotropic effects in other tissues (Lin et al., 2002). For further dis-
cussion on development effects of vitamin D on bone, we refer
readers to the following review (van Driel and van Leeuwen, 2014).
Vitamin D and musculoskeletal involution
Vitamin D deficiency is common in elderly and institutional-
ized subjects and may contribute to age-related involution of bone
(osteoporosis) andmuscle (sarcopenia) (Sohl et al., 2013; Visser et al.,
2003). Vitamin D levels predict the risk of functional decline, loss
of muscle mass and osteoporotic fracture in elderly subjects, all of
which have devastating effects by increasing morbidity, the need
for assisted-care and mortality (Sohl et al., 2013). Elderly individu-
als are also at risk of vitamin D deficiency due to intrinsic age-
related changes in vitamin D synthesis, reduced exposure to sunlight
and malnutrition, which is rife among those living in institutions
(Girgis, 2014).
VDR expression in muscle and bone declines with age (Bischoff
et al., 2001; Montero-Odasso and Duque, 2005), rendering the mus-
culoskeletal system more vulnerable to low vitamin D levels in the
elderly. In addition, Cyp27b1 levels drop in aged bone cells andMSCs,
blunting their responses to 25OHD (Anderson et al., 2005; Geng et al.,
2011a). Clinically, 25OHD levels correlate more tightly with bone
parameters in the elderly than 1,25(OH)2D, also supporting an effect
of Cyp27b1 in skeletal aging (Anderson et al., 2013). By contrast,
muscle mass correlates tighter with 1,25(OH)2D (Marantes et al.,
2011), suggesting a lesser role for Cyp27b1 in this tissue.
Vitamin D also affects age-related musculoskeletal atrophy, a
complex process that involves involution and adipose infiltration
of the muscle–bone unit (Schellinger et al., 2001; Visser et al., 2005).
Vitamin D deficiency activates pathways responsible for muscle
atrophy by increasing protein turnover via activation of the ubiquitin-
proteasome system, ubiquitin ligases (MAFBx and MuRF1), FoxO
signaling and TGF-beta signaling (Bhat et al., 2013; Bonaldo and
Sandri, 2013). These features are only partly reversible following
correction of serum calcium, suggesting a direct VDR effect. Con-
versely, treatment of muscle cells with 1,25(OH)2D increasesmyotube
size by effects on TGF-beta signaling (Garcia et al., 2011; Girgis et al.,
2014b) and prevents free fatty acid (FFA)-induced atrophy by effects
on Akt/c-Jun N-terminal kinase (cJNK) (Zhou et al., 2008). However,
at supra-physiological doses, vitamin D may induce muscle protein
breakdown by activating calpain proteolytic pathways, a mecha-
nism that has been studied for its potential to tenderize beef from
aged cattle (Montgomery et al., 2004).
Age-related decline in bone mineral density and mass involves
increased osteoclastogenesis, mismatch in RANKL:OPG activity and
proteasomal degradation of bone morphogenetic signaling pro-
teins (Cao et al., 2005; Guo et al., 2008). 1,25(OH)2D exerts anti-
aging effects in bone marrow pluripotent stem cells by inducing
osteogenesis (Duque et al., 2004), delaying replicative senescence
(Klotz et al., 2012) and modulating cell survival proteins FoxO, Sirt1
and sestrins (An et al., 2010; Eelen et al., 2013). In osteoblasts,
1,25(OH)2D upregulates cystathionine beta-synthase (CBS)
(Kriebitzsch et al., 2011), a key enzyme that catalyzes homocyste-
ine and thereby exerts positive effects on bone strength and collagen
cross-linking in aging (van Meurs et al., 2004). This effect is sup-
ported by an inverse relationship between serum vitamin D and
homocysteine levels in human subjects (Amer and Qayyum, 2014)
and importantly, the discovery of a VDRE in the CBS gene in pre-
osteoblastic MC3T3-E1 cells (Kriebitzsch et al., 2011).
Adipose infiltration is another pertinent factor inmuscle and bone
aging. Clinical studies report an inverse correlation between serum
vitamin D levels, muscle adiposity and poor functional outcomes
(Gilsanz et al., 2010; Redzic et al., 2014; Tagliafico et al., 2010). In
muscle cells, low-doses of 1,25(OH)2D (10−11 and 10−13 M) mimick-
ing deficiency result in upregulation of PPARγ2 and formation of lipid
droplets while higher doses (10−7 and 10−9 M) inhibited trans-
differentiation (Ryan et al., 2013). Similarly in bone, 1,25(OH)2D
inhibits marrow adipogenesis by reducing expression of PPARγ2 and
has concomitant pro-osteogenic effects on bone marrow stem cells
(Duque et al., 2004; Kelly and Gimble, 1998). Therefore vitamin D
and PPARγ2 signaling are related in muscle and bone and this link
requires further evaluation for its tissue-modulatory effects.
Clinical studies show that vitamin D supplementation reduces
(Bischoff-Ferrari et al., 2005; Broe et al., 2007), increases (Sanders
et al., 2010) or has no effect on the risk of falls and fractures (Girgis
et al., 2014c), functional endpoints of musculoskeletal aging. The
musculoskeletal systemmay respond dose-dependently to vitamin
D with a U-shaped curve. Individuals with high and low serum
vitamin D levels were found to have the highest risk of fracture and
frailty compared to those with intermediate levels (60–70 nmol/l)
(Bleicher et al., 2014; Ensrud et al., 2010). Likewise, single mega-
doses of vitamin D (500,000 IU) increased the risk of falls and
fractures (Sanders et al., 2010) while daily supplementation at lower
doses had favorable effects in bonemineral density andmuscle fiber
size in older individuals (Ceglia et al., 2013; Reid et al., 2013).
However, these effects did not translate to improvements in muscle
function or fracture incidence possibly due to the dose-limiting
calcemic effect of vitamin D. By contrast, a 1,25(OH)2D analog with
lower calcemic potency, eldecalcitol increased bonemineral density,
reduced falls/fractures and improved lower limb muscle power in
older individuals (Iwamoto and Sato, 2014; Matsumoto et al., 2011).
These findings may result from tissue-specific activation of VDR in
bone and muscle, an effect that has been recently observed follow-
ing vitamin D supplementation (Ceglia et al., 2013).
In summary, serum vitamin D and musculoskeletal VDR decline
with age concurrent with the physiological involution of muscle and
bone. Effects of vitamin D deficiency overlap with those of aging,
including adipose-tissue infiltration, activation of proteolytic path-
ways in muscle, osteoclastogenesis and increased mineral turnover
in bone. Evidence also suggests that musculoskeletal aging re-
sponds to vitamin D at a cellular level and in human clinical studies.
These findings raise an important question for future consider-
ation: can therapies targeting VDR reverse musculoskeletal aging?
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Vitamin D and musculoskeletal injury
We are becoming increasingly aware of the interconnected re-
sponses of muscle and bone to injury. Fractures associated with
muscle injury are more likely to undergo non-union (Reverte et al.,
2011) and conversely, the use of muscle flaps to treat open frac-
tures leads to improved bone healing (Harry et al., 2008). In this
regard, skeletal muscle may represent a kind of “second perios-
teum”, providing trophic factors, morphogens and cells to aid bone
repair.
Vitamin D may also integrate the combined response to injury.
Serum 25OHD levels drop in the curative phase of a fracture and
increased 24,25OHD levels correlate with fracture healing (Ettehad
et al., 2014; Seo and Norman, 1997). This suggests that vitamin D
is being utilized and metabolized by healing bone. To support this,
fracture callus displays increased Cyp24a1 activity and 24,25(OH)2D
notably improves fracture repair in mice and chickens (Seo and
Norman, 1997). This may relate to known effects of 24,25(OH)2D
in the differentiation and maturation of growth plate chondrocytes
via a putative membrane receptor in fracture callus (St-Arnaud and
Naja, 2011). 1,25(OH)2D may also play an independent role follow-
ing fracture via regulation of a range of genes involved in bone
remodeling (Ormsby et al., 2013) and neovascularization (Wang et al.,
1996). Although polymorphisms in the vitamin D-binding protein
(DBP) are associated with osteoporosis (Al-oanzi et al., 2008), local
administration of DBP did not alter healing in a rodent model of
fracture (Sun et al., 2009).
Similar to bone, reductions in serum 25OHD levels are seen in
humans directly following muscle injury and baseline vitamin D
levels correlate with faster recovery in muscle function (Barker et al.,
2013). Studies in mice and rats demonstrate substantial increases
in the expression of VDR and Cyp27b1 following injury (Girgis et al.,
2014e; Srikuea et al., 2012; Stratos et al., 2013). This has been re-
ported in variousmuscle injurymodels including intramuscular BaCl2
or Notexin administration (Girgis et al., 2014e; Srikuea et al., 2012)
and freeze-crush injury (Stratos et al., 2013). Importantly, in-
creased VDR is localized to regenerating muscle fibers and not
dependent on other cell types such as inflammatory or satellite cells
seen in injury (Srikuea et al., 2012). Vitamin D supplementation also
reduces muscle injury due to high-intensity exercise or crush injury
in rats (Choi et al., 2013; Stratos et al., 2013). Mechanisms include
reduced activation of stress-related proteins (p38 MAPK, ERK1/2,
IKK, IkappaB), reduced expression of inflammatory cytokines (TNF-
alpha, IL-6) and increased muscle fiber turnover (Choi et al., 2013).
As such, vitamin D leads to faster recovery of contractile force
in the injured muscle. At a cellular level, increases in VEGF and
FGF-1 – classic factors involved in tissue regeneration and
neovascularization – were seen in C2C12 myoblasts treated with
1,25(OH)2D, suggesting additional pathways by which vitamin D
modulates muscle regeneration (Garcia et al., 2013). An important
question is whether vitamin D also affects muscle fibrosis follow-
ing injury. This is suggested by recently described effects of VDR
in hepatic stellate cells and liver injury via pathways relevant to
muscle (TGF-beta/SMAD) (Ding et al., 2013), but is yet to be ad-
dressed in this tissue.
These intriguing effects of vitamin D in bone and muscle injury
highlight the need to examine models that integrate these com-
ponents. In particular, potential effects of vitamin D on paracrine
factors and morphogens crossing between muscle and bone during
injury and the common activation of regeneration pathways at both
sites need to be addressed.
Effects on muscle and bone: direct or indirect?
The extent to which vitamin D directly affects the musculoskel-
etal system versus its indirect actions via calcium and phosphate
homeostasis is a matter of ongoing debate. This is further compli-
cated by controversy regarding the presence of VDR in muscle.
Overwhelming evidence supports a predominantly indirect effect.
This includes the observation that musculoskeletal defects in vitamin
D deficiency or VDR ablation coincide with altered serum mineral
levels and are reversed by correcting these levels (Bhat et al., 2013;
Li et al., 1998; Schubert and DeLuca, 2010). In addition, sole ex-
pression of VDR in the intestine reverses the skeletal phenotype of
VDRKO mice, highlighting its central role in the enteric absorp-
tion of calcium and phosphate (Xue and Fleet, 2009). However, there
is evidence to suggest direct effects of vitamin D inmuscle and bone,
potentially working in parallel or complementary to its systemic
effects.
The first, perhaps weakest, line of evidence is that vitamin D
exerts a range of effects in cultured bone and muscle cells. Genomic
effects of 1,25(OH)2D-VDR alter muscle and bone cell prolifera-
tion, differentiation, remodeling and regeneration (Girgis et al.,
2014b; Tanaka et al., 2014; van Driel et al., 2006; Yang et al., 2013).
Rapid effects in calcium handling and cellular proliferation occur
via diverse signaling pathways including c-Src, MAPK, protein kinase
C, phospholipases and voltage-gated ion channels (Buitrago et al.,
2003; Morelli et al., 2001; Wali et al., 2003). Receptors modulat-
ing these effects include membrane-bound VDR and non-classical
proteins such as protein-disulfide isomerase-associated 3 protein
(Pdia3) and membrane associated rapid response-binding protein
(MARSS) (Nemere et al., 1998). However the physiological rele-
vance of these in vitro studies is questionable and VDR levels increase
during cell isolation, possibly augmenting its activity in culture
(Bhalla et al., 1987; Girgis et al., 2014d).
Mice with aberrant vitamin D signaling continue to display subtle
musculoskeletal defects even after correction of mineral defects.
Smaller muscle fibers and changes in osteoblast number, mineral
apposition rate and bone volume persist in VDRKO mice on rescue
diets (Endo et al., 2003; Panda et al., 2004). However, upon trans-
planting femora from VDRKO bone mice into WT mice, they
paradoxically form more bone (Tanaka and Seino, 2004). This raises
the possibility that extra-skeletal signals, potentially originating from
muscle, maymodulate bone effects of VDR. Interestingly, lack of VDR
in bone protects VDRKO mice from the more severe skeletal phe-
notype seen in intestine-specific VDRKO mice (Lieben et al., 2012).
However, intestine-specific VDRKO mice showed normal calcium
and phosphate levels, presumably at the expense of bone. These ob-
servations support complex interactions in local and systemic VDR
signaling in modulating bone and calcium levels.
Transgenic mouse models have shed further light on local effects
of VDR in bone. These effects vary depending on the differentia-
tion stage of osteoblasts, systemic calcium levels and the particular
promoter-based Cremodel used (e.g. osteoalcin, collagen 1-promoter)
(Eisman and Bouillon, 2014). VDR overexpression in mature osteo-
blasts (OSVDRmodel, osteoalcin promoter) enhances bone formation,
reduces bone resorption and protects against bone loss due to
vitamin D deficiency (Baldock et al., 2006; Gardiner et al., 2000; Lam
et al., 2014). These mice respond to mechanical loading by increas-
ing bone formation and mineralization (Anderson et al., 2013),
suggesting an intriguing interaction between muscle and bone
through osteoblast VDR. This effect may occur by activation of Wnt
co-receptor LRP5, a transcription factor with a central role in bone
mechano-transduction (Bonewald, 2007; Shi et al., 2007), sup-
ported by the presence of a putative VDRE in the LRP5 gene (Fretz
et al., 2007). Alternatively, 1,25(OH)2D may alter mechano-
transduction via non-genomic mechanisms, suggested by its VDR-
independent effect on nitric oxide (NO) production by osteoblasts
(Willems et al., 2012).
In immature osteoblasts, VDR signaling may have the opposite
effect in stimulating bone resorption and reducing bone mass, as
suggested by a knockout model using the collagen 1-promoter
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(Yamamoto et al., 2013). In osteocytes (terminally-differentiated os-
teoblasts), VDR plays a more systemic role in inhibiting
mineralization to preserve normal serum calcium levels (Lieben et al.,
2012).
By contrast, whether VDR is expressed in muscle remains con-
troversial (Bischoff et al., 2001; Ceglia et al., 2010, 2013; Srikuea et al.,
2012; Wang and DeLuca, 2011). Differences in experimental con-
ditions, the presence of problematic VDR antibodies and altered
expression of VDR throughout muscle differentiation/aging explain
this controversy (Girgis et al., 2014d). We have recently reported
that age is a major determinant in VDR detection in muscle (Girgis
et al., 2014d). Significantly higher levels of VDR are found in muscle
of young mice. In adult mice, marked increases in VDR following
muscle injury are also seen, supporting a predominantly pleiotro-
pic role in this tissue (Choi et al., 2013; Srikuea et al., 2012; Stratos
et al., 2013).
Although effects of vitamin D in the musculoskeletal system are
mainly indirect, VDR acts locally to regulate bone mass, mineral-
ization and responses to muscle loading. These effects may
complement systemic vitamin D activity and may be either ana-
bolic or catabolic depending on the calcemic status and stage of bone
cell differentiation. Further research is needed to characterize the
complex nature of these interactions and therapeutic implications.
Vitamin D and muscle-bone signals
Under various stimuli, muscle and bone produce a range of hor-
mones that facilitate cross-talk between these tissues. Vitamin D
may regulate such factors, thereby indirectly affecting muscle–
bone interactions (Fig. 1).
One such factor, osteocalcin is produced by osteoblasts, regu-
lated by vitamin D and its gene contains a well-established VDRE
(Morrison et al., 1989; Terpening et al., 1991). Apart from being
a primary marker of bone formation, osteocalcin in its
undecarboxylated form participates in glucose homeostasis and
forms the basis of a putative bone–pancreas endocrine loop (Clemens
and Karsenty, 2011). Osteocalcin also has potential effects in skel-
etal muscle by altering insulin sensitivity (Clemens and Karsenty,
2011), muscle mitochondrial function (Clemens and Karsenty, 2011)
and lower limb strength in older women (Levinger et al., 2014).
Sclerostin is another potential link. This factor, secreted by
osteocytes, regulates the osteogenic response to muscle loading
and, interestingly, responds to vitamin D supplementation
(Dawson-Hughes et al., 2014; Tu et al., 2012). Similarly, FGF23 is a
vitamin D-responsive phosphaturic hormone produced by bone cells
that has effects on cardiac and smooth muscle, suggesting poten-
tial effects in skeletal muscle (Six et al., 2014; Touchberry et al., 2013).
Vitamin D supplementation has been shown to alter IL-6
(Schleithoff et al., 2006), an inflammatory cytokine and hormone
produced by skeletal muscle following contraction and exercise
(Pedersen and Febbraio, 2008). In addition to its role in glucose ho-
meostasis via fat and liver, IL6 stimulates bone resorption and IL6-
related cytokines, Oncostatin M and ciliary neurotrophic factor
(CNTF), alters osteoblast differentiation and bone strength (Johnson
et al., 2013, 2014). Alterations in IL6 may also explain age-related
inflammation and skeletal muscle defects in vitamin D-deficient
older individuals (Sanders et al., 2014).
Myostatin, a member of the TGF-beta superfamily and a muscle-
derived hormone, has been linked to vitamin D in cultured muscle
cells and in a human study (Girgis et al., 2014b; Szulc et al., 2012).
Myostatin negatively regulates muscle mass by effects on Smad
family proteins and the ubiquitin–proteasome system and affects
bone mass directly (via activin receptors) and indirectly (by muscle
loading) (Bowser et al., 2013; Elkasrawy and Hamrick, 2010). Vitamin
D has a profound inhibitory effect on myostatin expression in cul-
tured muscle cells, an intriguing connection which explains the
doubling in myotube size in response to 1,25(OH)2D (Girgis et al.,
2014b). Another member of the TGF-beta family, follistatin en-
hances 1,25(OH)2D-simtulatedmineralization in osteoblasts (Woeckel
et al., 2013) and is also regulated by vitamin D inmuscle cells (Garcia
et al., 2011).
Therefore, vitamin D is associated with several bone andmuscle-
derived hormones, suggesting indirect links in muscle–bone cross-
talk. While these links are tenuous, they require further evaluation
and present interesting lines of enquiry. These links have been sum-
marized in Fig. 1.
Conclusions
In his seminal publication on the cure of rickets by sunlight, the
American physician Alfred Hess remarked that “although we have
realized the importance of sunlight in the growth of plant life, we
have [until now] accorded it too little significance in the develop-
ment of animal life” (Hess, 1922). Since this time, we have made
major advances in understanding the biologic activity of the “sun-
shine hormone”, 1,25(OH)2D, and its system-wide effects in mineral
homeostasis, organ development, fibrosis and cell cycle regula-
tion. We are also becoming increasingly aware of the interconnected
biology of muscle and bone and the search for unifying factors to
explain this connection has clear implications to future therapies
(Girgis et al., 2014a).
Vitamin D is one such factor that potentially integrates bone and
muscle. To support this contention, in vitro studies demonstrate a
range of rapid and genomic effects of vitamin D in differentiation,
bone mineralization and muscle fiber size (Girgis et al., 2014b;
Tanaka et al., 2014; van Driel et al., 2006; Yang et al., 2013). Fol-
lowing injury, the muscle–bone unit displays heightened sensitivity
to vitamin D with local up-regulation of Cyp27b1, VDR and asso-
ciated reductions in serum 25OHD levels (Ettehad et al., 2014; Seo
and Norman, 1997; Srikuea et al., 2012). In contrast, the aging
muscle–bone unit displays reduction in local VDR in association with
activated proteolytic pathways in muscle, increased bone resorp-
tion and adipose-tissue infiltration by common effects on PPARγ2
(Bhat et al., 2013; Duque et al., 2004; Ryan et al., 2013).
A central question that has perplexed this field for many years
is whether effects of vitamin D in bone and muscle are entirely in-
direct – via calcium and phosphate homeostasis – or partly direct
by local VDR. This is especially controversial in muscle where the
presence of VDR is debated and in bone, where transgenic mouse
models have not presented a clear picture of VDR’s local effects
(Eisman and Bouillon, 2014). The latter highlights the complexityFig. 1. Putative mechanisms by which vitamin Dmodulates bone–muscle cross-talk.
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of local and inter-system VDR signals in modulating tissue re-
sponses. Another question is whether vitamin D’s effects in bone
and muscle are truly integrated or rather independent. In support
of the former, osteoblast VDRmodulates the effect of muscle loading
on bone (Anderson et al., 2013) and vitamin D, sequestered within
muscle fibers, may diffuse to adjacent bone under the influence of
local stimuli (Abboud et al., 2013). Furthermore, vitamin D regu-
lates paracrine factors considered to facilitate bone–muscle cross-
talk – osteocalcin and, possibly, IL6 and myostatin (Morrison et al.,
1989; Schleithoff et al., 2006; Szulc et al., 2012). Perhaps the most
compelling evidence of an inter-connected response is seen in elderly
patients receiving the vitamin D analog eldecalcitol. They demon-
strated parallel improvements in muscle and bone parameters with
associated functional outcomes (Iwamoto and Sato, 2014;Matsumoto
et al., 2011).
Taken together, these studies corroborate the intimate relation
between bone and muscle and add to vitamin D’s burgeoning rep-
ertoire of extra-skeletal effects. Future studies are needed to unravel
mechanisms in tissue-modulatory, pleiotropic effects of vitamin D
and to explore the therapeutic potential of targeting this pathway
in musculoskeletal disorders.
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Beyond the established roles of vitaminD in bone andmineral homeostasis, we are becoming increasingly aware
of its diverse effects in skeletal muscle. Subjects with severe vitamin D deﬁciency or mutations of the vitamin D
receptor develop generalized atrophy ofmuscle and bone, suggesting coordinated effects of vitamin D inmuscu-
loskeletal physiology. At a mechanistic level, vitamin D exerts wide-ranging effects in muscle and bone calcium
handling, differentiation and development. Vitamin D alsomodulatesmuscle and bone-derived hormones, facil-
itating cross-talk between these tissues. In this review, we discuss emerging evidence that vitamin D regulates
bone andmuscle in a direct, integrated fashion, positioning the vitamin D pathway as a potential therapeutic tar-
get for musculoskeletal diseases.
This article is part of a Special Issue entitled “Muscle Bone Interactions”.
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Introduction
Bone and muscle serve obvious and critical functions in our
structure, strength and motion. In addition, bone serves as the major
reservoir for calcium which is vital for the regulation of blood calcium
levels. This tight regulation of serum calcium is an absolute requirement
for normal neurological function.Muscles are not usually thought of as a
reservoir, but they contain up to 80% of stored carbohydrates in healthy
individuals and may contain a surprising amount of lipid in trained
athletes, and in the obese. Emerging evidence also suggests that skele-
tal muscle may be a storage site of 25(OH)vitamin D (25D), a process
that relies on innate vitamin D signaling components and transport car-
riers within muscle cells [1,2].
Diseases of themusculoskeletal system are becomingmore common
with increasing longevity and adiposity of the population in many
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countries around the world. Loss of muscle mass (sarcopenia) and
decreased bone density (osteopenia or osteoporosis) with subsequent
fractures cause much of the frailty and disability of aging, with enor-
mous societal and economic costs. This has been estimated at $850
billion dollars a year in the USA [3].
During fetal life, post-natally and in adulthood, muscle mass and
bonemass are linked. This link is mediated in part via direct mechanical
interactions, and also via tissue cross-talk between muscle and bone.
Bones weaken with decreased muscle use in people and in animals.
Examples occur in humans with congenital myotonic dystrophy and
with other hereditary muscle disorders. These groups of people are
born with thin long-bones, relating to severely impaired fetal muscle
movements [4,5]. Bone mass and strength are rapidly lost in people
with denervating neurological injuries, e.g. spinal cord lesions, and
in astronauts who spend prolonged periods of time in a gravity-free
environment.
In the opposite direction, bones may also regulate muscle function
via a range of osteokines, such as ﬁbroblast growth factor (FGF)-21
which is produced by osteocytes, and other factors [6]. Osteocytes
are osteoblasts which have become completely surrounded by bone-
matrix. Additionally, common pathways such as growth hormone/
insulin-like growth factor (IGF)-1, sex steroids and Wnt-signaling may
centrally coordinate the bone–muscle unit during development and ad-
aptation to mechanical stimuli [7].
Vitamin D represents another pathway by which muscle and bone
may interact. Individuals with vitamin D deﬁciency and rickets display
concurrent defects in muscle and bone. Mutations in vitamin D sig-
naling are also associated with generalized underdevelopment of the
musculoskeletal system. These observations suggest an integrated role
of vitamin D in muscle/bone health. Potential mechanisms may relate
to effects of vitamin D in the expression of myokines and osteokines
(i.e. muscle and bone-derived hormones) or regulation of mechano-
stimulatory processes.
This review presents evidence for a holistic role of vitamin D in the
musculoskeletal system beyond its established roles in skeletal health
alone. While evidence for such an integrated role is slowly emerging,
there is hope that the vitamin D pathway may present therapeutic tar-
gets for the treatment of musculoskeletal disease [8].
Development and regulation of bone and muscle
Bone and skeletal muscle both develop during early fetal life from
the somatic mesoderm in close physical association with each other.
This has been the subject of excellent reviews, including [6,9].
Bone forms sequentially, initially by the condensation of mesenchy-
mal precursors at future skeletal sites and then by differentiation into
chondrocytes to form a cartilage anlage (i.e. endochondral bone) or
directly into osteoblasts (i.e. intramembranous bone). This early process
relies on positional and mechanical cues [6]. Once formed, bone
undergoes continual remodelling throughout life in response to me-
chanical loads and in order to repair microdamage and adapt to chang-
ing mechanical requirements. This relies on the coordinated action of
bone cells: bone resorption by osteoclasts, then subsequent bonematrix
formation andmineralization by osteoblasts. Osteocytes are sensitive to
mechanical forces and may initiate adaptation through regulation of
both bone resorption and formation.
During embryogenesis, myogenic differentiation occurs adjacent
and concurrent to skeletal development. Myogenesis is speciﬁed by
the master regulator Pax3 in fetal and neonatal life and by Pax7 in
later life. In the trunk and limbs, mesodermal precursor cells under
the control of Pax3 become committed to myogenic lineage and differ-
entiate and fuse to form multinucleated syncytia under the control of
external signals such as MyoD and Myf5 [10]. These syncytia grow
with fusion of additional myoblasts and ultimately, nascent myotubes
develop into mature, multinucleated muscle ﬁbers. Not all myoblasts
fuse. A subset of myogenic precursors instead form a reservoir of
Myf5/MyoD-expressing cells that remain on the periphery of myoﬁbers
as a source of new muscle cells during postnatal growth and regenera-
tion [11]. These are known as satellite cells [12–15].
The linked developmental origins of muscle and bone suggest
the possibility that common signaling pathways or networks may regu-
late their mass. To support this, mice with genetic defects in muscle de-
velopment (MyoD knockout) display profound impairments in bone
development andmineralization [16]. Signals responsible for coordinat-
ed muscle/bone development include FGFs, transforming growth fac-
tors (TGFs), IGF-1 and other morphogens [17].
Muscle and bone mass are both increased by anabolic exercise and
are both decreased by disuse. The changes in mass with exercise or
with disuse are mediated by some of the same factors. As well as the di-
rect mechanical interactions between muscle and bone, there is further
evidence that muscles may indirectly regulate bone repair following
fracture. Covering fractures with muscle ﬂaps, even with immobiliza-
tion is well recognized to improve healing of traumatic factures [18,
19]. Conversely, injury to overlyingmuscle impairs fracture healing [20].
The vitamin D receptor (VDR) makes an early appearance during
musculoskeletal development. In the fetal rat, it is found at day 13 of
gestation [21] within the condensing mesenchyme of the vertebral
column. By day 17, the VDR resides within osteoblasts and proliferating
chondrocytes. Despite the early embryologic presence of the VDR,
defects in vitamin D signaling do not lead to clinical features of rickets
until after birth [22]. The skeletal phenotype is most manifest after
weaning, coincidingwith development of hypocalcemia andhyperpara-
thyroidism in VDR knockout (VDRKO) mice. Abnormal growth plate
development, impaired bone mineralization and muscle ﬁber atrophy
are seen at day 35 [22,23]. However, subtle changes are noted in pre-
weaned VDRKO mice. These include growth plate enlargement [22]
and smaller muscle ﬁbers at day 15 [23]. These effects occur prior to
the onset of abnormal calcium and phosphate levels, suggesting a direct
albeit subtle role for VDR in musculoskeletal growth.
Vitamin D
Vitamin D synthesis and signaling are the subject of many reviews
[24]. Brieﬂy, vitamin D may be synthesized in the body by conversion
of 7-dehydrocholesterol in the skin upon ultraviolet (UV) light expo-
sure, or obtained from the diet, where it is mainly in fatty ﬁsh or in
supplemented foods. Because humans can synthesize vitamin D, it is ac-
tually not a classic vitamin, but has retained the name for historical
reasons.
VitaminD is then hydroxylated in the liver into 25-hydroxyvitaminD
(25D). This is the main form of circulating vitamin D and it is measured
to assess adequacy of overall vitamin D status. However, the major
active hormone is 1,25-dihydroxyvitaminD (1,25D). This binds to the vi-
tamin D receptor (VDR), a member of the nuclear steroid hormone re-
ceptor superfamily. VDR usually heterodimerizes with the retinoid X
receptor (RXR) although it can homodimerize with a second VDR. The
receptor dimer, when ligand activated, classically translocates to the nu-
cleus, binds to vitamin D response elements (VDRE) in theDNA and reg-
ulates transcription [25].
There are hundreds of well-characterized targets for activated VDR
in the genome. Recent use of RNA-sequencing combined with chroma-
tin immunoprecipitation (ChIP) has given new power to examine genes
regulated by vitamin D in non-classic target tissues such as liver [26]
and bone cells [27] although this technology has not yet been applied
to muscle.
Vitamin D in bone
Vitamin D has long-recognized actions in both bone and muscle
[28–30]. The classical consequence of vitamin D deﬁciency is a defect
of bone mineralization, causing rickets in children and osteomalacia in
adults. However, vitamin D has been linked more to active calcium
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absorption from the intestine than to locally stimulatemineralization of
the newly formed bonematrix, the osteoid. The active vitaminDmetab-
olite, 1,25D binds to VDR in intestinal cells and stimulates formation of
calbindin which binds calcium and inﬂuences the calcium channels. It is
generally assumed that bone mineralization is mostly a passive process
when sufﬁcient calcium and phosphate are available. Besides active cal-
cium absorption, passive diffusion through the intestinal wall also is
possible, depending on the calcium gradient.
The study of knockout mice has largely conﬁrmed this concept.
Mice with genetic deletion of VDR may display reversal of rickets/
osteomalacia when supplied with a diet very high in calcium and lac-
tose; “rescue diet”. Similarly, rickets can be healed in childrenwith a ge-
netic defect in the VDR; vitamin D dependent rickets type 2. However,
VDRKO mice have atrophic muscle ﬁbers and changes in osteoblast
number, mineral apposition rate and bone volume despite rescue diet,
resulting in lower longitudinal growth and a smaller skeleton [23,31].
In recent years, our understanding of vitaminD signaling in bonehas
expanded to include direct vitamin D signaling in bone cells. Mouse
models have enabled the delineation of direct effects of vitamin D. In
mice, overexpression of VDR restricted to mature osteoblasts increases
bone formation, reduces bone resorption and inhibits bone loss related
to vitamin D deﬁciency [32,33]. Recent data suggests that these mice
respondmore actively tomechanical loading by increasing bone forma-
tion and mineralization [34], a ﬁnding consistent with greater cortical
bone mass and size in mice with elevated osteoblastic VDR levels,
under normal or vitamin D-deﬁcient conditions [32,33]. The muscle
phenotype of these mice has not been reported.
The direct effects of vitamin D in bone may be differentiation stage
speciﬁc. VDR signaling in immature osteoblasts may have the opposite
effect, stimulating bone resorption and reducing bone mass, as demon-
strated in a knockout model using the collagen 1-promoter [35]. More-
over, vitamin D treatment of early committed osteoblastic cells is
inhibitory, reducing cell activity and number [36]. In contrast, vitamin
D levels have been reported to be inversely related to serum sclerostin
levels. Sclerostin is a marker of osteocyte mechano-sensing, and an
active suppressor of WNT-mediated mechanical stimulation of bone
formation by terminally differentiated osteocytes [37]. These stage-
speciﬁc effects may relate in part to vitamin D's regulation of WNT sig-
naling in the osteoblastic lineage [36]. The osteoblast-speciﬁc VDR-null
mouse suggests that VDR plays a more systemic role in inhibiting min-
eralization in order to maintain serum calcium levels [38]. The direct
role of VDR in osteocytes appears to be regulation of their development
by effects on osteoprotegerin and maintaining calcium levels during
deﬁciency [39]. Therefore, local effects of vitamin D in bone may com-
plement systemic vitamin D effects andmay be anabolic or catabolic de-
pending on the calcemic status and stage of bone cell differentiation.
Vitamin D in muscle and potential effects on bone mass
The link between the effects of vitamin D signaling in muscle/bone
has long been appreciated. There are many potential factors which
may play a role in mediating this interaction, some of which are shown
in Fig. 1.
Indeed, one of the major components of vitamin-D deﬁciency-
related increases in fracture rates is due to muscle weakness and falls.
The greatest effects are evident in those with lowest vitamin D levels
[40,41]. In addition, vitamin D status is associated with physical perfor-
mance in epidemiological studies. Vitamin D deﬁciency can predict a
decline in physical performance after 3 years [42,43]. According to the
study of Need et al. [44], the calcium absorption starts to decrease
and the alkaline phosphatase as a sign of deﬁcient mineralization starts
to rise when serum 25D is below 20 nmol/l. Physical performance
decreases when serum 25D falls below 50 nmol/l, but the decrease ac-
celerates when 25D is below 30 nmol/l [42].
A meta-analysis of randomized clinical trials has conﬁrmed that
vitamin D supplementation can decrease the incidence of falls [45],
although this remains controversial. However, the appreciation of
muscle-bone cross-talk continues to increase, and evidence is emerging
of a role for vitaminD in this axis [46]. Co-regulation of bone andmuscle
by vitamin D is evident in co-existence of osteoporosis and sarcopenia
in the elderly, vitamin D deﬁcient population [40,47–49].
Interestingly, the notion of direct humoral interactions between
bone and muscle has also been supported by studies such as those of
myostatin, a powerful inhibitor of muscle growth (reviewed in [50]),
which also has powerful effects upon bone mass and fracture healing,
independent of the changes inmuscle strength [51,52]. Vitamin D treat-
ment decreases myostatin in cultured muscle cells, suggesting a poten-
tial relationship between these pathways in vivo.
Vitamin D-related signals have also been implicated in muscle bone
interactions [53]. Osteoglycin, produced by muscle cells under the con-
trol of vitamin D, regulates osteoblastic activity [53].
Vitamin D in muscle
We reviewed the roles of vitamin D in muscle in 2013 and 2014 [40,
41] and others have published excellent reviews on this area [28,54].
Whether vitamin D receptor is expressed in muscle has been a contro-
versial question, made more difﬁcult by the low level of expression of
VDR in myocytes after neonatal life. However, by RNA, Western immu-
noblot and by immunohistochemistry, VDR is present at low levels in
cultured C2C12myotubes [55] and normalmurinemuscle [56]. VDR ex-
pression is typically much higher in cell lines and isolated myocytes
than in primary muscle. VDR expression is also signiﬁcantly higher in
neonatal muscle and declines with age at this site. This further supports
developmental roles of VDR in muscle.
It has been long-recognized that vitamin D deﬁciency is associated
with muscle weakness, particularly proximal muscle weakness, and
that this resolves with correction of deﬁciency. There are non-speciﬁc
electromyographic (EMG) features which resolve with correction of
deﬁciency (reviewed in [40]). In biopsy studies, most of which are
non-randomized, people with deﬁciency have preferential loss of type
2 muscle ﬁbers which improves with supplementation [57,58]. In chil-
dren with rickets and adults with osteomalacia, muscle weakness can
Fig. 1. Potential vitamin D mediated mechanisms of bone–muscle cross-talk.
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be extreme [40]. In the people with vitamin D pathway mutations,
weakness is also a clinical feature prior to treatment. However,
in these cases, and in severe vitamin D deﬁciency, the situation is
frequently confounded by other factors such as hypocalcemia or
hypophosphatemia [59].
In addition, in people, it is challenging to control for sunlight anddiet
exposure; ‘healthier’ individuals may have better diets and undertake
more outdoor activities, and have correspondingly better muscle and
bone function. For this reason, it is useful to turn to animalmodels to ex-
amine the question of bone–muscle interactions and vitamin D.
Mice with mutations in vitamin D receptor are weak and can have
low bone mass and less longitudinal growth. However, these ﬁndings
are confounded by the altered calcium and phosphate status of the
mice. Studies of VDR-null mice where phosphate and calcium are ag-
gressively replaced with a ‘rescue diet’ may result in near-normal
bone phenotype [60,61]. However, there can be more subtle residual
effects, suggesting persistent and local effects of VDR ablation in bone,
including in heterozygous VDR-null mice [61]. Epidemiological studies
show associations between vitamin D deﬁciency and poor physical
performance, assessed by a walking test, 5 chair stands, and a balance
test [42].
Potential muscle to bone vitamin D cross-talk
Even with use of rescue diet, there is decrease in the size of muscle
ﬁbers in mice lacking VDR [23]. This suggests that the effect on muscle
is more likely to be a VDR effect rather than a calcium or phosphate ef-
fect. On ‘rescue diet’ the bonemass changes in VDRnullmice are smaller
than those changes seen in muscle mass and strength measures. This
suggests that there may be a muscle-related or hormonal factor that is
stimulating bone mass in VDR-null muscle.
Myostatin is a hormone secreted frommuscle. Its role is to inhibit in-
creasedmuscle mass, hence its name. It is a member of the TGFβ super-
family which acts on activin receptors and SMADs. Vitamin D inhibits
myostatin production from muscle cells, for example C2C12 cells [62],
and vitamin D treatment doubles myotube size in these cells [55]. De-
creased myostatin is associated with greater bone mass [63] (Fig. 1).
Vitamin D may regulate responses to muscle injury and regenera-
tion. Serum 25D levels drop directly following muscle injury, which
may partly be due to the fall in vitamin D binding protein after trauma
[64]. Baseline levels correlate directly with muscle recovery [65]. Stud-
ies in rodents demonstrate substantial increases in the expression of
Vdr and Cyp27B1 following injury [66–68]. This has been found both
in models of chemical injury [66,68], and a freeze–crushmodel of phys-
ical injury [67]. Increased VDR is directly localized to regeneratingmus-
cle ﬁbers [66]. Vitamin D supplementation also reduces muscle injury
due to high-intensity exercise in rats and humans [69,70]. At a cellular
level, it increases VEGF and FGF1; both factors involved in tissue regen-
eration and neovascularization. Thiswas seen in C2C12myoblasts treat-
ed with 1,25D, and VEGF and FGF1 are potential pathways by which
vitamin Dmay modulate muscle regeneration [71]. An important ques-
tion is whether vitamin D also affects muscle ﬁbrosis following injury.
This is suggested by recently described effects of VDR in hepatic stellate
cells and liver injury via pathways relevant to muscle (TGF-B/SMAD)
[72], but is yet to be addressed in this tissue.
Vitamin D is known to stimulate local vascular endothelial growth
factor (VEGF) and IGF-1 (Fig. 1) production in muscle. Both factors are
well known to have potential beneﬁcial effects in bone. How large a
contribution muscle vitamin D action makes to circulating levels of ei-
ther hormone is not clear.
Another potential muscle factor which is regulated by vitamin D is
IL-6 (interleukin-6). It is produced following exercise or contraction. It
stimulates bone resorption, andmay alter bone strength. It is decreased
by vitamin D [73].
Potential bone to muscle vitamin D cross-talk
The osteocyte cell line MLO-Y4 expresses muscle anabolic factors
IGF-1, MGF and VEGF after mechanical loading [74]. Osteocalcin
which is produced by osteoblasts has recently come to a new light for
its role in regulating beta-cell function [75]. Its classic use is as a marker
of bone formation. It is regulated by vitamin D and its gene contains
a vitamin D response element (VDRE) indicating direct regulation by vi-
tamin D [2]. It has potential effects in muscle, in which it alters mito-
chondrial function, insulin sensitivity [75], and possibly strength in
women.
Sclerostin is secreted by mature osteocytes during completion of
osteon formation. It inhibits bone formation. Mutations in the SOST
gene, coding for sclerostin, cause sclerosteosis with undetectable or
low sclerostin levels, increased bone formation, very high bone mass
and neurological impairments due to entrapment of nerves [37].
Sclerostin antibodies have a potential for exciting use in the treatment
of osteoporosis. Sclerostin secretion by osteocytes increases in response
to bedrest and decreases with muscle loading [76]. Serum levels in-
crease in people treated with vitamin D [77]. FGF23 is another vitamin
D responsive hormone produced by bone which may have positive ef-
fects on cardiac and smooth muscle [78]. The effects on skeletal muscle
are the subject of current investigation.
Conclusions
In addition to established roles in calcium and phosphate homeosta-
sis, vitamin D plays a vital role in musculoskeletal health. People with
severe vitamin D deﬁciency display the combination of reduced bone
mineral density and muscle wasting. Mechanistic studies demonstrate
a range of rapid and genomic effects of vitamin D on cell differentiation,
bone mineralization and muscle ﬁber size [53,55,79,80]. Vitamin D
may also exert effects in bone and muscle injury. Following injury,
these tissues display heightened sensitivity to vitamin D with local up-
regulation of Cyp27b1, VDR and associated reductions in serum 25D
levels [66,81,82]. We are also becoming increasingly aware of the inter-
connected biology ofmuscle and bone. The search for unifying factors to
explain this connection has clear implications to future therapies [8]. Vi-
tamin D appears to be one of these factors integrating bone andmuscle.
To support this, vitamin D exerts effects in a range of bone and muscle-
derived hormones, including osteocalcin, sclerostin, IL-6 andmyostatin,
and may thereby modulate bone–muscle cross-talk.
Taken together, these studies conﬁrm the intimate relation between
bone and muscle and add to vitamin D's increasing repertoire of extra-
skeletal effects. Future studies are needed to unravel mechanisms in-
volved in vitamin D's tissue-modulatory, pleiotropic effects and explore
the therapeutic potential of targeting this pathway in musculoskeletal
disease.
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Abstract: Scurvy and rickets are largely considered historical diseases in developed countries. 
However, deficiencies in vitamins C and D are re-emerging due to increased consumption of 
processed foods and reduced fresh foods in the Western diet, as well as to an indoor seden-
tary lifestyle away from sun exposure. These dietary and lifestyle factors also predispose one 
to diabetes and metabolic syndrome. Our understanding of the potential roles of vitamin C 
(an antioxidant) and vitamin D (a biologically active hormone) in disease is increasing. In 
this review, we present observational, interventional, and mechanistic studies that examine the 
potential links between vitamins C and D in reversing defects in glucose homeostasis and the 
prevention of type 2 diabetes. Studies suggest an association between vitamin C deficiency and 
diabetes. An association between vitamin D and insulin resistance has been well described; 
however, the role of vitamin C and D supplementation in diabetes and its prevention requires 
further controlled trials.
Keywords: glucose homeostasis, diabetes, insulin resistance, vitamin C, vitamin D
Introduction
Nutrients play essential roles in health and the prevention of disease. Nutrients, 
including vitamins, are vital to cardiovascular health (ie, vitamin B1), nerve func-
tion (ie, vitamins B6 and B12), the production of red blood cells (ie, folate and 
vitamin B12), and coagulation (ie, vitamin K), among many other functions.1 Scurvy 
and rickets were largely thought to be conditions of historical interest in developed 
countries; however, deficiency in vitamins C and D are re-emerging due to increas-
ingly inadequate carbohydrate- and fat-based Western diets and sedentary, indoor 
living.1 These same phenomena are contributing to the surging prevalence of obesity, 
metabolic syndrome, and diabetes. Early evidence suggests that vitamin D deficiency 
may contribute to diabetes, and that vitamin D repletion may ameliorate abnormal 
glucose homeostasis. Low vitamin C is associated with an increased risk of the future 
development of diabetes. It is likely that low vitamin C is a marker of a less healthy 
lifestyle, a well-known risk factor for diabetes.
Vitamin C is an antioxidant, and the structural similarity between vitamin C and 
glucose makes it of interest in diabetes.2 Oxidative stress can lead to disturbed glucose 
metabolism and hyperglycemia.3 Therefore, a benefit of antioxidants to prevent diabetes 
or to achieve positive outcomes in type 2 diabetes mellitus (T2DM) is biologically 
plausible.
Vitamin D plays a vital role in whole-body calcium homeostasis by exerting classic 
effects on the duodenum, bone, and kidney.4,5 Vitamin D may also alter intracellular 
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calcium signals and thus plays a role in pancreatic insulin 
secretion and insulin sensitivity, both of which relate to 
calcium levels. It therefore has potential in the prevention 
of T2DM. The role of vitamin D in insulin resistance has 
been studied extensively, and vitamin C is another vitamin 
for which studies have demonstrated significant associations 
with diabetes.6,7 This review explores the observational, inter-
ventional, and mechanistic studies that address the effects of 
vitamins C and D in T2DM.
Effects of vitamin C in diabetes
Physiology and vitamin C deficiency
Vitamin C, also known as ascorbic acid, is a cofactor in 
multiple enzymatic reactions including collagen synthesis.8 
Humans are unable to produce vitamin C due to the absence 
of the enzyme, L-gulonolactone oxidase, which catalyzes the 
final step in the synthesis of ascorbic acid;9 therefore, it is an 
essential nutrient in humans. Vitamin C acts as a reducing 
agent in free radical-mediated oxidation processes; therefore, 
it can act as an antioxidant.9 Deficiency of vitamin C results 
in the defective formation of collagen and connective tissues 
in the skin, cartilage, dentine, bone, and blood vessels.
In its most severe form, vitamin C deficiency results 
in scurvy, which is uncommon in developed nations due 
to the inclusion of fresh fruits and vegetables in the diet.1 
Nevertheless, lesser degrees of vitamin C deficiency were 
found to be common among healthy adults in the United 
States (National Health and Nutrition Examination Survey 
[NHANES] 2003–2004: 7.1%).10 Smokers and people in 
lower-income groups were at increased risk of deficiency. Other 
classic risk factors include alcoholism and renal failure.
Though diabetes is not traditionally considered a risk 
factor for vitamin C deficiency, patients with diabetes should 
all receive dietary advice about healthy eating and vitamin C 
dietary sources, including fresh fruits and vegetables. The 
recommended dietary intake of vitamin C is 45 mg per day 
for adults.1 There are some data suggesting that people with 
diabetes may have increased cellular uptake and turnover of 
vitamin C that would necessitate increased intake, and they 
also have an increased risk of deficiency.11
Observational studies
The effects of vitamin C in diabetes have been an area of 
interest for over 50 years. A review of 23 observational studies 
looking at the vitamin C status of people with diabetes pub-
lished between 1935 and 1996 found that people with diabetes 
have at least 30% lower vitamin C concentrations than do 
people without diabetes.11 However, there was heterogeneity 
among the studies in terms of the methods used to measure 
vitamin C status, and subjects were unmatched on important 
covariates such as dietary intake of vitamin C, sex, smoking 
status, and acute illness. 
Observational data from NHANES 1988–1994 identified 
that people with newly diagnosed diabetes had significantly 
lower serum vitamin C concentrations than did people with-
out diabetes; however, no difference was seen after adjust-
ing for the dietary intake of vitamin C.6 On the other hand, 
among those with a similar dietary intake of vitamin C, those 
with diabetes of 2 months to 25 years’ duration did have 
lower levels of vitamin C when compared to controls.6,12,13 
In the Finnish Mobile Clinic Health Examination Survey 
conducted during 1966–1972, the association between low 
vitamin C levels and diabetes was also not demonstrated to 
be due to low dietary vitamin C.14 This prospective study 
estimated total habitual food consumption in the previous 
year, and it examined the incidence of diabetes during a 
23-year follow-up period. About 380 cases of diabetes were 
identified, but vitamin C intake was not associated with the 
risk of T2DM.
In a cross-sectional study where dietary vitamin C intake 
was the same, lower vitamin C levels in people with diabetes 
were seen as a consequence of diabetes itself and not due 
to the inadequate dietary intake of vitamin C.15 In a nested 
case-control study in Korea,16 there was no difference in 
dietary vitamin C intake between those with diabetes and 
controls matched for age, sex, drinking status, and smoking 
status. Interestingly, however, nonsmoking individuals with 
a new diagnosis of T2DM had lower serum vitamin C levels 
(22.3p16.8 Mmol/L) than did controls (26.3p17.0 Mmol/L) 
(P0.01).16 Among smokers, there was no difference between 
serum vitamin C levels in those with diabetes and controls. 
Therefore, smoking – a known trigger of vitamin C deficiency 
– appears to modify the association between vitamin C and 
diabetes incidence.
An English population-based prospective cohort study 
of 25,639 volunteer participants demonstrated a strong 
inverse association between plasma vitamin C levels and 
incident diabetes after 8–12 years with a dose–response 
effect.17 A 29% reduction was found in diabetes risk per 
19.87 Mmol/L (0.35 mg/dL) change in vitamin C level, which 
was adjusted for important covariates including the use of 
vitamin supplements. However, vitamin C may actually be 
a marker of other protective factors found in fruits and veg-
etables that may decrease the risk of T2DM.18
An association between vitamin C levels and glycemic 
control was assessed in a cross-sectional study of people 
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with diabetes, which identified a weak, negative correlation 
between hemoglobin A1c (HbA1c) and vitamin C levels.
19 
The relationship between vitamin C and glucose levels was 
also demonstrated in a large sample of US adults without 
a history of diabetes from NHANES 2003–2006, in which 
serum vitamin C concentrations were inversely associated 
with HbA1c levels.
20 An observational study on the use of 
vitamin C supplements demonstrated that a significantly 
lower risk of diabetes was associated with the use of daily 
vitamin C supplements when compared to nonusage.21 The 
potential benefit of a vitamin C supplement was limited to 
those who did not take a multivitamin or those who had a 
lower dietary intake of vitamin C. However, the observational 
nature could not demonstrate a cause-and-effect relation, nor 
could confounding be excluded, such as health-conscious 
users of supplements being less likely to develop disease. To 
rectify this, a post hoc analysis from the SU.VI.MAX study,22 
a randomized trial to assess the effects of a combination of 
vitamins and minerals including vitamin C, was performed. 
Plasma concentrations of vitamin C were inversely (P0.046) 
associated with fasting plasma glucose levels; however, over 
the follow-up period of 7.5 years, supplementation had no 
effect on age-adjusted fasting plasma glucose levels.
Observational studies have suggested that people with 
T2DM have lower vitamin C levels, and this was not 
explained by differences in dietary vitamin C intake when 
compared to people without diabetes. There may be an asso-
ciation between lower vitamin C levels and the subsequent 
development of diabetes, as well as higher glucose levels.
Interventional studies
In three intervention studies of vitamin C supplementation 
in T2DM, an improvement was seen in fasting glucose and 
HbA1c levels, but only with a higher dose supplementation of 
2,000 mg of vitamin C per day for 90 days, with no improve-
ment observed after 2 months of 500 mg daily vitamin C 
supplementation, nor with short-term supplementation over 
2 weeks.23–25 This finding may be due to an inadequate 
increase in vitamin C levels in diabetes with standard 
supplementation doses or of brief duration. The difficulty 
with interpreting the vitamin C intervention studies is the 
use of study populations with adequate vitamin C levels, 
which significantly decreases the likelihood of observing 
any effects of the intervention.26,27 Another randomized 
controlled trial28 demonstrated that supplementation with 
800 mg per day for 4 weeks in people with T2DM and low 
plasma vitamin C levels (40 Mmol/L) at baseline was insuf-
ficient for replenishing serum levels to what is seen in healthy 
subjects (80 Mmol/L). The lower vitamin C levels achieved 
could have explained the lack of improvement in measures 
of insulin resistance in the supplemented group.
The addition of vitamin C supplementation to standard 
therapy was assessed in 70 patients treated with metformin 
for T2DM who were randomized to 500 mg twice daily of 
vitamin C or placebo for 12 weeks.29 Those given vitamin C 
were identified to have lower HbA1c, fasting, and postmeal 
blood glucose levels when compared to the placebo group, 
despite all being treated with metformin.
Apart from the impact on glycemic control, antioxidant 
supplementation has been studied for the prevention of 
complications of diabetes. An improvement in neuropathic 
symptoms (but not in objective signs of neuropathy) and 
decreased odds of retinopathy were seen with the use of a 
combination of vitamin supplements including vitamin C.30,31 
The impact of high dietary vitamin C and supplementation 
has been demonstrated to have variable effects on cardiovas-
cular complications in diabetes.32,33
Interventional studies with vitamin C supplements 
have not consistently demonstrated improvements in gly-
cemic control in T2DM. Vitamin C as an antioxidant could 
reduce the risk of complications of T2DM; however, excess 
supplementation may increase the risk of cardiovascular 
disease.32
Potential mechanisms
The significance of vitamin C in T2DM has been sug-
gested by the hypothesis that hyperglycemia inhibits the 
cellular uptake of dehydroascorbic acid (DHA), which is 
the oxidized transportable form of vitamin C.34,35 In the red 
blood cell, glucose strongly inhibits the uptake of DHA; 
therefore, hyperglycemia in diabetes would be expected to 
cause vitamin C deficiency within the cell.35 DHA uptake 
into the cells is accomplished through glucose transporters, 
GLUT1 and GLUT3, which transport DHA in competition 
with glucose,36,37 and this effect may be overcome by a large 
intake of vitamin C.38
The mechanisms for reduced vitamin C levels in dia-
betes are suggested by animal studies. A study of rats with 
streptozotocin-induced diabetes39 demonstrated a decrease in 
serum levels of vitamin C and the increased urinary excretion 
of vitamin C when compared to the levels obtained prior to 
the induction of diabetes in the same rats, suggesting that 
the renal reabsorption of vitamin C is reduced in diabetes. 
Another study of diabetic rats12 demonstrated an increased 
turnover of vitamin C, and this finding was most likely due 
to the increased oxidation of ascorbate to DHA in tissue 
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mitochondria. Furthermore, a human study of vitamin C 
turnover, measured by the rate of reduction of DHA to ascorbic 
acid, indicated that this turnover was higher in a group of 
people with diabetes than in volunteers without diabetes.12 
This higher turnover of vitamin C in diabetes may underlie the 
need for higher dietary vitamin C requirements in diabetes.
Significant benefits of vitamin C supplementation have 
been demonstrated in an animal model of T2DM. Vitamin C 
supplementation in ob/ob mice caused significant reduc-
tions in food intake, plasma glucose, HbA1c levels, plasma 
glucose levels, and insulin concentrations when compared 
with untreated control ob/ob mice.40 The total insulin content 
and the extent of insulin glycation in the pancreas of ob/ob 
mice also decreased after vitamin C supplementation. These 
parameters did not change with vitamin C supplementation 
in lean mice.
The biological mechanisms underlying lower vitamin C 
levels in people with diabetes includes decreased cellular 
uptake, increased urinary losses, and increased metabolic 
turnover of vitamin C in diabetes. These mechanisms sug-
gest higher dietary vitamin C requirements in diabetes, along 
with the benefits of supplementation, as seen in a mouse 
model of T2DM.
Effects of vitamin D in diabetes
Vitamin D physiology
The name “vitamin D” is a historical misnomer because a 
vitamin, by definition, is something that we cannot synthe-
size ourselves. The active form of vitamin D, calcitriol, is 
synthesized in humans, and is a hormone that undergoes 
autocrine regulation. Vitamin D is synthesized from choles-
terol precursors. Moreover, 7-dehydrocholesterol is converted 
to vitamin D in the skin following exposure to ultraviolet 
radiation. This molecule binds to vitamin D-binding protein 
(DBP) and undergoes hydroxylation in two stages: firstly, in 
the liver to form 25-OH vitamin D (25OHD); and secondly, 
in the kidney to form 1,25(OH)2vitamin D (1,25[OH]2D). In 
its active form, vitamin D (1,25[OH]2D) has predominant 
effects in calcium and mineral homeostasis by interacting 
with the vitamin D receptor (VDR).4 The VDR is present in 
tissues involved in calcium/phosphate homeostasis (ie, the 
intestine, bone, kidney), and it is present at lower levels in 
other tissues, suggesting the nonclassical roles of vitamin D 
(eg, in glucose homeostasis).
Observational studies
The potential effects of vitamin D on insulin sensitivity and 
glucose tolerance have been the subject of a recent review.5 
In 808 subjects without diabetes, plasma 25OHD correlated 
inversely with fasting insulin levels and Homeostasis Model 
Assessment of Insulin Resistance (HOMA-IR) scores 
after adjusting for sex, age, and body mass index (BMI).41 
A similar link between HOMA-IR and 25OHD was found 
in 712 prediabetic subjects.42 HOMA used data from physi-
ological studies to derive equations to assess insulin resis-
tance (HOMA-IR) and insulin sensitivity (HOMA-S) from 
matched fasting insulin and glucose samples.43 In an elegant 
study of healthy adults,44 there was a significant association 
between 25OHD and insulin sensitivity assessed by hyper-
glycemic clamps, after adjusting for BMI and a range of 
other factors.
Prospective studies have demonstrated that 25OHD levels 
correlate with the long-term risk of insulin resistance. In a 
study of 5,200 participants, a 25 nmol/L increment in baseline 
serum 25OHD levels correlated with a 24% reduced risk of 
developing diabetes over 5 years, although this was a nonlin-
ear relation.45 Furthermore, a meta-analysis of 21 prospective 
studies identified a linear trend for each 10 nmol/L increment 
in 25OHD levels to be associated with a 4% lower risk of 
T2DM (95% confidence interval [CI]: 3–6; P for a linear 
trend, 0.0001).46 An independent association with HOMA-S 
at 5 years was also found (r0.16; P0.001). Furthermore, 
vitamin D status and T2DM were inversely associated in 
multiple observational studies.46–52
In the Women’s Health Study,53 dietary vitamin D was 
inversely associated with metabolic syndrome, but this 
was related to total calcium intake. The Nurses’ Health 
Study48 showed that there was a decrease in the relative 
risk of incident diabetes of 0.87 (95% CI: 0.75–1.00; P for 
trend 0.04) among those on high-dose vitamin D supple-
ments (800 IU daily), as compared to those on low-dose 
vitamin D supplements (400 IU daily); this was also seen 
with calcium intake.
Studies have demonstrated an association between 
vitamin D and insulin resistance, which is significant for the 
risk of developing T2DM. Although suggestive, these obser-
vational studies do not prove a causal relationship between 
vitamin D and insulin resistance. A number of factors may 
confound this link, such as adiposity.54 Obese individuals 
may avoid sun exposure, and vitamin D (a lipophilic com-
pound) may be trapped in adipose tissue, resulting in serum 
deficiency. Obesity is also a major determinant of insulin 
resistance. Other confounders include parathyroid hormone 
levels,55 calcium levels, physical activity, and diet. These 
may influence vitamin D and independently alter insulin 
sensitivity.
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Interventional studies
In the absence of insulin resistance, vitamin D supple-
mentation does not alter insulin sensitivity.7,56–58 However, 
some evidence indicates that subjects with prediabetes 
may benefit. At-risk subjects receiving various regimens 
of vitamin D and calcium over 6 weeks to 3 years showed 
significant improvements in insulin secretion, sensitivity, 
and/or the disposition index (a marker of insulin secretion/
activity).7,59–61
The evidence that vitamin D improves glycemic control 
in subjects with established diabetes is mixed. In a recent 
trial,62 90 subjects with diabetes were randomized to daily 
vitamin D (1,000 IU), taken in fortified yogurt; these subjects 
showed better glycemic control and reduced insulin resistance 
(HOMA-IR) when compared to subjects on plain yogurt. 
Importantly, serum vitamin D levels and HOMA-IR scores 
correlated inversely in this study. Another three studies of 
vitamin D supplementation of 3 weeks to 3 months’ duration 
have demonstrated positive effects on HbA1c levels, insulin 
resistance, and insulin secretion compared to placebo, while 
other studies have shown no benefit from brief supplementa-
tion with low doses of vitamin D, nor with high doses of over 
6 months’ duration.63–67
Small interventional studies examining different popula-
tions with variable vitamin D levels, using different regimens of 
supplementation, make it difficult to draw definite conclusions. 
Parameters of insulin sensitivity are variable, ranging from 
measuring fasting insulin to hyperinsulinemic–euglycemic 
clamps. While insulin resistance leads to diabetes, a complex 
interaction between glucose and insulin levels exists. Glycemic 
outcomes reflect the interplay between insulin resistance and 
insulin secretion by pancreatic beta-cells.
Therefore, whether vitamin D supplementation results in 
clear improvement in diabetes remains unclear. A randomized 
controlled trial of two doses of vitamin D supplementation 
(5,000 IU versus 400 IU daily) did not demonstrate improved 
glucose levels in pregnancy, despite another study showing 
a link between vitamin D levels and the subsequent risk of 
gestational diabetes.68,69 Large trials are currently underway in 
other populations, which may definitively resolve this ques-
tion (eg, NCT01354964, NCT01315366, NCT00736632, 
and Pittas et al70).
Potential mechanisms
Mouse models of diabetes demonstrate improvements in 
insulin sensitivity following the administration of 1AOHD3.4 
This vitamin D analog is automatically 25-hydroxylated 
in the liver, forming calcitriol, and it bypasses normal 
endocrine regulation of the activation process. An in vitro 
study has shown that 1,25(OH)2D increases insulin receptor 
expression and insulin signaling via Akt and insulin receptor 
phosphorylation.71 Nongenomic, rapid effects of vitamin D 
may also play a role. Apart from calcium regulation, vitamin 
D leads to the release of arachidonic acid, a polyunsaturated 
fatty acid, from the cell membrane and into the muscle cell 
cytoplasm.72 This links vitamin D with insulin sensitivity, as 
does the possibility that vitamin D may modulate caveolin-
I,73 a scaffolding protein within the membrane that exerts its 
effects in metabolism.
Pancreatic beta-cells, responsible for insulin secretion, 
express components of the vitamin D pathway, including 
1A-hydroxylase enzyme, a vitamin D-dependent calcium-
binding protein (calbindin), and the VDR.74 Vitamin D 
treatment increases insulin secretion in vitamin D-defi-
cient rodents and cultured pancreatic cells. This effect 
occurs via intracellular calcium signals and altered gene 
expression, but its physiological significance is unclear. 
Animal models and in vitro studies provide potential 
mechanisms for the associations between vitamin D and 
insulin resistance.
Summary points 
v  Observational studies indicate a link between deficien-
cies in vitamins C and D and the prevalence of type 2 
diabetes.
v  There is biological plausibility for the effects of 
vitamins C and D in glucose homeostasis. Vitamin C 
prevents oxidative stress and is known to interact with 
glucose transporters, potential mechanisms by which it 
may also alter glucose homeostasis. Vitamin D may affect 
calcium handling in pancreatic beta-cells and skeletal 
muscle, thereby affecting insulin secretion and sensitivity, 
respectively.
v  Randomized controlled trials have not clearly demon-
strated the effects of vitamins C and D in the preven-
tion or treatment of diabetes. This is due to a range of 
factors, including heterogeneity in study design and 
endpoints, and the lack of standardized supplementation 
regimens. Further research will address the impact of 
these nutrients in glucose homeostasis.
Conclusion
The relationship between diabetes and vitamins C and D 
have been demonstrated by human and animal studies. The 
limitation of observational studies is that confounders can-
not be excluded to explain the relationship between vitamin 
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deficiency and diabetes outcomes. Interventional studies 
that are randomized provide the best evidence for a benefit 
of supplementation, with serum vitamin levels indicating 
variations in the dietary intake of vitamin C and the levels of 
sun exposure for vitamin D. Animal models can provide an 
indication of the mechanisms that underlie these associations; 
however, metabolic processes in animals are not directly 
translated in humans.
Vitamin C levels are lower among people with T2DM 
and not completely explained by a difference in dietary 
vitamin C intake. A number of mechanisms underlying the 
decrease in vitamin C levels and increased requirements 
in T2DM have been proposed.75 Consequently, the dietary 
requirements or the need for supplementation of vitamin C 
may be greater in people with diabetes. However, studies 
of vitamin C supplements alone or in combination have not 
demonstrated sufficient benefit to support a recommenda-
tion for routine supplementation, nor higher target serum 
vitamin C levels, in people with T2DM. Further studies 
are needed to determine if vitamin C supplementation 
may play a role in minimizing the risk of complications 
of diabetes.
While strong links between vitamin D and diabetes have 
been demonstrated, it remains to be determined whether this 
is by cause or association. Increasing endogenous levels of 
vitamins C and D can be achieved by dietary modifications, 
and in the case of vitamin D, also by judicious sun exposure.76 
The availability of supplements enables a convenient 
method of reaching a prespecified serum vitamin C and D 
level. However, as with many other nutrients, the maximum 
health benefit is probably obtained by achieving the recom-
mended daily intake of vitamin C as part of a balanced diet, 
and maintaining vitamin D status by regular sun exposure. 
Further studies – in particular, randomized controlled 
trials – are needed to determine if there is a benefit of rou-
tine supplementation with these vitamins in diabetes or for 
its prevention.
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Chapter 10 – Discussion, conclusions and future directions 
 
This thesis demonstrated that skeletal muscle responds directly to vitamin D via 
its receptor (VDR) in this tissue. To reach this conclusion, different models of 
murine muscle and experimental techniques were employed. The presence of 
VDR was demonstrated in immortalised and primary muscle cells, muscle fibres 
and whole muscle tissue (16, 17). Effects of VDR on muscle cell differentiation, 
the regulation of muscle fibre size and strength, and the uptake of 25OHD within 
muscle fibres were demonstrated (17). These novel effects, in themselves, 
provide compelling evidence of functional vitamin D signalling in skeletal 
muscle and serve to clarify the controversy on VDR’s presence in muscle.  
 
Vitamin D and cultured muscle cells 
The C2C12 line is an established in vitro model of skeletal muscle, originally 
derived from satellite cells of dystrophic murine muscle. These cells were shown 
to express VDR mRNA and protein. VDR expression, together with the classic 
target gene CYP24A1, were activated in dose- and time-dependent manners by 
1,25(OH)2D (i.e. 1- 100 nM, 8-24 hrs respectively). Luciferase reporter studies 
also demonstrated the presence of functional CYP27B1 in these cells, explaining 
demonstrated increases in VDR and CYP24A1 in response to 25OHD. Similar 
effects were also demonstrated in primary muscle cells, corroborating these 
findings from C2C12 cells. To obtain a pure population of primary cells, they 
were isolated from healthy quadriceps muscle of 4 week-old mice and sorted for 
the specific myogenic cell-surface marker, CD56. The development of this novel 
technique occurred as part of these doctoral studies, and the original article has 
therefore been added (24).  
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 Three distinct effects of treating C2C12 cells with 1,25(OH)2D were 
demonstrated: (1) inhibition of proliferation, (2) inhibition of myotube formation 
during serum starvation, and (3) increased size of individual myotubes. VDR 
stimulation was demonstrated at various time-points during this study, indicating 
its role in the transcriptional regulation of muscle development. Although anti-
proliferative effects of vitamin D have been reported, including in muscle cells, 
for over thirty years, precise mechanisms are unclear (27-29). This thesis 
demonstrated a significant increase in the proportion of quiescent muscle cells in 
response to 1,25(OH)2D, associated changes in cell cycle genes (ATM, myc, Rb, 
cyclin D1) and post-translational phosphorylation of Rb (16). This effect was not 
associated with an increase in cell death. 
 
To suppress C2C12 myotube formation, 1,25(OH)2D directly altered myogenic 
regulatory factors myogenin, myf5 and desmin which were down-regulated 
following serum starvation (16). However, Garcia and colleagues reported an 
opposite effect of 1,25(OH)2D in stimulating myotube formation when cells were 
not exposed to serum starvation (30). This discrepancy is interesting and 
suggests interconnected effects of 1,25(OH)2D with myogenic regulatory factors 
and endogenous Insulin-like Growth Factors (IGFs), the latter being essential in 
myogenesis due to prolonged confluent culture (31, 32). 
 
Together, the anti-proliferative and myotube-inhibitory effects of 1,25(OH)2D 
may indicate the promotion of cell quiescence and protection from senescence. 
Such an effect of vitamin D has been demonstrated in human mesenchymal stem 
cells (33) and is relevant to muscle stem cells as their ability to maintain 
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quiescence determines their self-renewing capacity (34). 1,25(OH)2D had no 
effect on necrotic or apoptotic C2C12 cells in this study (16). However, previous 
studies have reported modulatory effects of VDR on cell survival via regulation 
of FoxO and Sestrins (35, 36). 
 
Both 25OHD and 1,25(OH)2D exerted anabolic effects on C2C12 cells with 
doubling of myotube size (37). Mechanistically, 1,25(OH)2D led to pronounced 
down-regulation of myostatin, a negative regulator of muscle mass and a 
member of the TGF-β superfamily. This novel finding occurs within the broader 
context of VDR’s emerging links with TGF-β, particularly in mesenchymal stem 
cells (38), skin (39) and in liver (40). In hepatic stellate cells, fascinating 
interactions between VDR and TGF-β at a cistromic level mediate the response 
to fibrosis (40). To assess whether similar effects may be responsible for VDR’s 
anabolic effect in muscle cells, chromatin immunoprecipitation (ChIP) studies 
are necessary to examine potential vitamin D response elements (VDREs) in the 
myostatin gene or the presence of co-regulated genes. Separate pathways may 
also be responsible for vitamin D’s effect on myotube size. In the study by Zhou 
et al, vitamin D had a protective effect against free fatty acid (FFA)-induced 
C2C12 myotube atrophy by interacting with insulin signalling components IRS-1 
and Akt phosphorylation (41). 
 
Cultured muscle cells provide prima facie evidence for the presence of VDR in 
skeletal muscle. These studies purport novel effects of vitamin D signalling on 
muscle development via biologically plausible pathways including TGF-β, cell 
cycle genes and myogenic regulatory factors by genomic and post-translational 
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mechanisms (16). Whilst these in vitro findings are intriguing, they are not 
conclusive and therefore prompted examination of VDR in muscle using in vivo 
models.  
 
Vitamin D receptor and skeletal muscle 
Skeletal muscle expresses a range of nuclear receptors that play vital roles in 
metabolism (42), mitochondrial function and exercise (43). However the 
presence of VDR in muscle has been controversial for many years. This is due to 
a number of confounding factors including the use of variable muscle models 
(i.e. cultured muscle cells vs. whole muscle), differences in the specificity of 
VDR antibodies and protein extraction methods. Previous studies assessing the 
presence of VDR in muscle have been summarised in table 2 of the literature 
review included with this thesis (Chapter 2) and recently published (2). 
 
To circumvent these technical issues and comprehensively address this 
controversy, this thesis employed three different techniques (i.e. RT-PCR, 
western blot, immunohistochemistry) to examine VDR in four muscle models 
(i.e. C2C12, primary muscle cells, muscle fibres and whole muscle) (17). The 
highly specific VDR-D6 antibody was used in addition to positive and negative 
controls (i.e. intestine/kidney and muscle from VDRKO mice, respectively).  
 
VDR transcript was detected in whole muscle but at substantially lower levels 
than the classic site of VDR activity, the duodenum (~ 4000-fold lower) (17). 
Following standard tissue lysis, VDR protein was not detected in muscle from 
mature mice consistent with previous reports using the same antibody (44). 
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However, following hyperosmolar lysis, VDR was detectable in mature muscle 
but at substantially lower levels than in duodenum and kidney. Hyperosmolar 
lysis may be necessary for the release of DNA-bound proteins including VDR 
and is more effective in protein unfolding and denaturation (45, 46). In addition, 
detection of VDR in whole muscle required longer exposure time on western blot 
(15 mins) and greater protein per sample (50 µg vs. 10 µg for duodenum). By 
describing specific conditions for the detection of VDR in murine muscle, this 
thesis both confirms the technical basis for this long-standing controversy and 
seeks to resolve it. 
  
Further efforts to examine VDR’s presence in muscle focused on its potential 
functions in this tissue.  Primary muscle fibres responded to physiological doses 
of 1,25(OH)2D by significantly increasing their uptake of 3H-25OHD3 (17). This 
effect was absent in muscle fibres from VDRKO mice and reversed by DIDS, a 
chloride channel blocker and classic inhibitor of VDR non-genomic effects. 
Together, these data indicate a non-genomic role for VDR in the ligand-mediated 
uptake of 25OHD into muscle.  
 
Neville and De Luca first raised the possibility that muscle stores vitamin D in 
1966 (47). These authors reported that a significant proportion of 3H-25OHD3 
localised within muscle following its intravenous administration in deficient rats 
(47). More recently, Abboud and colleagues demonstrated that vitamin D uptake 
in muscle is time-dependent and relies on the local activity of megalin and 
cubilin, endocytic receptors of the vitamin D binding protein (DBP) (48). This 
thesis advances these findings by demonstrating a modulatory role for VDR in 
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1,25(OH)2D-mediated uptake of 25OHD in muscle (17). These data also suggest 
that VDR rapidly regulates megalin and cubulin in muscle to produce these 
effects. A related nuclear receptor, RXR, modulates these endocytic receptors at 
other sites (49), supporting similar mechanisms in muscle. 
 
The significance of vitamin D uptake in muscle is unclear. Bound to DBP, 
25OHD could be stored in muscle attached to actin and thereby escape hepatic 
catabolism (48). Upon degradation of DBP, 25OHD may then diffuse back into 
the circulation (50), or be converted locally to 1,25(OH)2D as suggested the 
presence of functional CYP27B1 in primary myotubes (17). This cycling of 
vitamin D between muscle and the circulation, dependent upon the local 
activities of DBP and VDR, may determine the half-life and biologic activity of 
25OHD. This effect may also respond to exercise, with increases in 25OHD 
uptake in muscle and its subsequent recirculation potentially explaining the 
higher serum levels of vitamin D found following activity (48, 51). Conversely, 
increases in serum vitamin D may lead to its enhanced uptake by muscle, 
increases in local mitochondrial function and improved physical performance 
(52). Vitamin D uptake may also play a role in muscle development. In support 
of this, radiolabelled 25OHD has been shown to cross the placenta in late 
gestation and thereafter, reside preferentially in the muscle of rat embryos (53).  
 
Expression of VDR in muscle was significantly greater in young mice and there 
was a sequential drop in levels of muscle VDR from birth (17). In 3 week-old 
mice, VDR was localised clearly within nuclei and cytoplasm of muscle fibres. 
Similarly, C2C12 myoblasts showed greater levels of VDR than fully 
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differentiated myotubes. These findings support a developmental role for VDR in 
muscle, corroborating earlier work presented in this thesis on effects of 
1,25(OH)2D on C2C12 muscle cell differentiation (16). Together these data 
prompted further evaluation of direct in vivo effects of VDR on muscle 
morphology and strength. 
 
Vitamin D, muscle strength and morphology 
In a manuscript submitted for publication and included in this thesis, the muscle 
phenotypes of VDRKO and vitamin D deficient mice were characterised. These 
different models allowed systematic assessment of effects of the vitamin D 
pathway whilst correcting associated biochemical abnormalities by dietary 
supplementation. The former model (VDRKO) relies on congenital whole-body 
ablation of VDR (exon 3) to examine global effects of vitamin D signalling (54). 
Vitamin D deficiency was induced in a second group of mice by housing them 
under incandescent, UV-free lighting and administering vitamin D-free diet 
(SF085-003, Specialty Feeds, Glen Forest, NSW) from 3 weeks age. 
 
On grip strength testing, vitamin D deficient and VDRKO mice were 
significantly weaker than their controls and this difference progressed with 
duration of vitamin D deficiency and age. A stepwise decline in grip strength 
from WT to heterozygote to VDRKO mice strongly supported a role for VDR in 
muscle strength. Interestingly, differences in grip strength were greater in 
VDRKO vs. WT than vitamin D deficient vs. replete mice, possibly explained by 
complete ablation of vitamin D signalling in the KO model. A potential 
mechanism for weakness in these mice includes altered calcium handling within 
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muscle fibres. In support of this, mRNA expression of calcium-handling genes, 
specifically Calbindin-28K and sarcoendoplasmic reticulum calcium transport 
ATPase (SERCA) channels, were significantly reduced in VDRKO and vitamin 
D deficient mice. SERCA channels are essential for the release of Ca2+ into the 
cytosol and the subsequent process by which muscle contraction occurs via the 
interaction of troponin-tropomyosin complex and actin filaments (2). The Boland 
group has previously shown that 1,25(OH)2D exerts rapid, non-genomic effects 
on calcium handling by muscle cells (55, 56). However, this thesis reports, for 
the first time, novel genomic effects of vitamin D on altering the calcium-
handling apparatus in muscle. With reduced levels of these calcium-handling 
components in muscle, reduced Ca2+ entry into the cytosol during excitation-
contraction coupling may lead to defects in muscle contraction and reduced 
strength. Other explanations for the reduced strength seen in these mice may 
include effects of vitamin D on the expression of muscle contractile proteins (57, 
58) and extracellular matrix proteins (59). Therefore the relationship between 
vitamin D and muscle strength is potentially multifactorial and requires further 
examination. In vivo contractile studies may shed light on effects of vitamin D on 
muscle force, fatigue and recovery.  
 
In addition to functional effects, this thesis demonstrates that vitamin D also 
exerts critical effects on muscle mass. VDRKO mice had significantly lighter 
muscles, even after correction for their lower body weight, and ~ 30% reduction 
in muscle fibre size. This was associated with other developmental changes 
including muscle fibre hyper-nuclearity and dysregulation of myogenic 
regulatory factors (MRFs). Although Endo et al reported similar findings in 
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VDRKO mice before weaning (60), this thesis describes a significant muscle 
phenotype in adult VDRKO mice, generated by ablation of exon 3 rather than 2, 
on rescue diet and with unaltered mineral levels. These in vivo findings concur 
with earlier studies in which vitamin D treatment exerted opposing effects by 
inhibiting proliferation and increasing myotube size in C2C12 cells (16).  By 
contrast, vitamin D deficient mice did not display significant changes in muscle 
mass or fibre size. Differences in these models – congenital ablation of VDR 
versus prolonged vitamin D deficiency in the post-natal setting – may account 
for this discrepancy. In the absence of altered calcium and phosphorus defects, 
vitamin D’s predominant effect in muscle mass and morphology may relate to 
development and pre-natal myogenesis. Observational data support this 
conclusion. Children born to vitamin D-deficient mothers displayed significantly 
smaller arm-muscle area (61). Administration of vitamin D to European sea bass, 
directly after hatching, resulted in dose-dependent increases in white muscle 
fibre size and altered expression of muscle developmental genes (62). To further 
support this developmental role, the first appearance of VDR during 
embryogenesis is within mesoderm, the structure from which muscle and bone 
arise (63). VDR is also expressed within mesenchymal stem cells and immature 
myoblasts, both of which respond in vitro to vitamin D (38).  
 
 
Evidence that vitamin D plays a clear role in fetal musculoskeletal development 
may have clinical implications in the recommended daily intake of vitamin D in 
pregnant women. Recent evidence also links maternal vitamin D levels with 
methylation at 4 sites of the RXR-A (retinoid X-receptor alpha) in umbilical cord 
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tissue, suggesting an intriguing epigenetic role for vitamin D in development via 
alterations in the heterodimeric partner of VDR (64, 65). If confirmed, a role for 
VDR in musculoskeletal development would be consistent with its known 
pleiotropic effects in other tissues (66).   
 
Observational data also suggest that vitamin D plays a role in musculoskeletal 
ageing. Serum levels of vitamin D predict the risk of functional decline, loss of 
muscle mass and osteoporotic fracture in elderly subjects (67). VDR levels in 
muscle and bone decline with age (68, 69), rendering the musculoskeletal system 
more vulnerable to low vitamin D levels in the elderly. In this thesis, mice placed 
on a vitamin D deficient diet for 6 months showed upregulation of the atrophy 
marker, MuRF1 and a modest increase in the TGF-β myostatin. However, 
another ubiquitin ligase, MAFbx, was not altered and muscle mass and fibre size 
were not significantly different between vitamin D deficient and replete mice. A 
longer duration of vitamin D deficiency (> 6 months) may be necessary for 
atrophy-related mechanisms to lead to overt atrophy. It is also possible that 
normal mineral levels in the vitamin D deficient mice may have prevented the 
development of muscle wasting. A recent study supports the presence of 
complementary effects of vitamin D and calcium deficiency on muscle fibre 
atrophy (15). Sprague-Dawley rats with vitamin D deficiency showed partial 
reversal in parameters of muscle atrophy and reduced activation of the ubiquitin 
proteosome in muscle in response to a high-calcium diet (15).  
 
Musculoskeletal ageing may also result, in part, from interactions between 
Vitamin D, FGF23 and its co-factor klotho. Premature ageing seen in FGF23 
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knockout mice, including osteopaenia, sarcopaenia and atherosclerosis, was 
completely reversed by ablation of 1α-hydroxylase (70). This suggests that, at a 
tissue level, 1,25(OH)2D mediates age-related responses to FGF23. Klotho 
deficient mice also display premature ageing (71) and klotho levels are reduced 
in FGF23 KO mice (70), leading the authors to posit vitamin D as the common 
humoural pathway mediating these age-related effects (70). Interestingly, klotho 
deficient subjects display similar functional defects to VDRKO and vitamin D 
deficient mice with reduced grip strength and impaired running endurance (72, 
73). Alterations in TGF-β and Wnt signalling leading to muscle wasting may be 
responsible for these effects in klotho deficient mice (71, 74). On the basis of 
these similarities, it is intriguing to speculate whether vitamin D and klotho may 
play interdependent and connected effects on skeletal muscle morphology and 
function during ageing. 
 
By examining the muscle phenotype of VDRKO and vitamin D deficient mice, 
this thesis reports novel effects of vitamin D signalling on muscle development 
and ageing. Effects on grip strength, calcium handling, muscle fibre size and 
developmental gene expression are described here, further confirming the local 
expression and diverse functional effects of VDR in skeletal muscle. 
 
Future directions  
This work has raised several questions beyond the original scope of this thesis. A 
fascinating link between vitamin D and myostatin has been reported (2, 16, 17). 
Myostatin is a highly conserved member of the TGF-β superfamily which 
negatively regulates muscle mass (75). Genetic inactivation of myostatin leads to 
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marked increase in muscle mass in mammalian species including humans (76) 
and conversely, increases in myostatin may explain muscle wasting seen in 
chronic diseases such as renal failure, HIV, and emphysema (26). Muscle cells 
treated with 1,25(OH)2D showed pronounced 10-fold down-regulation of 
myostatin mRNA with a doubling in myotube size (16). Conversely, VDRKO 
mice showed two-fold increase in myostatin expression, associated with 30 % 
reduction in muscle fibre size. Together, these findings raise the pertinent 
question of whether targeting VDR may be a viable therapeutic mechanism to 
inhibit myostatin and reverse disorders of muscle wasting. Already, intense 
efforts are underway in the search for effective mysotatin inhibitors and decoy 
molecules for ActRIIB (i.e. the myostatin receptor) and these are at phase I-II 
clinical trials (26). In this thesis, increases in myostatin in vitamin D deficient 
mice were not clinically significant and in vitro doses of 1,25(OH)2D leading to 
myostatin inhibition were supra-physiological. Therefore the use of VDR 
analogues, such as calcipotriol, may be more effective in addressing this 
important question. Such agents would allow greater stimulation of VDR for its 
potential tissue-modulatory effects whilst avoiding hypercalcaemia.  
 
Molecular effects of vitamin D on muscle ageing are also an open question. 
Striking similarities in the phenotype of VDRKO and klotho deficient mice, such 
as reduced survival, osteopaenia/sarcopaenia, muscle weakness and reduced 
body mass raise the possibility that these pathways intersect in ageing (54, 71), 
warranting further research. Another feature of muscle ageing is a decline in the 
number and function of muscle stem cells responsible for the reduced 
regenerative capacity of old muscle (77). Two observations in this thesis suggest 
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that vitamin D signalling may play critical roles in muscle stem cell function 
(known as satellite cells). Firstly, significantly higher VDR levels in muscles of 
newborn and 3-week old mice correspond with a higher proportion of satellite 
cells at these ages (i.e. 30% of muscle cells compared to 3% in adult mice) (17, 
77). Secondly, using a novel technique to isolate muscle precursor cells (24), this 
thesis shows that VDR expression was significantly higher in these cells than in 
whole muscle and that these cells express functional CYP27B1 (17). However 
precise in vivo effects of vitamin D on satellite cell function, in particular relating 
to quiescence, differentiation and survival, remain unknown and will be 
addressed in future studies.  
 
Another component of muscle ageing is the progressive infiltration of muscle 
with adipose tissue. Interestingly, clinical studies report an association between 
vitamin D deficiency, muscle adiposity and poor functional outcomes (78-80). In 
muscle cells, 1,25(OH)2D exerts dose-dependent inverse effects on PPARγ2 
expression and adipose transdifferentiation (81). Therefore, adipose tissue may 
represent an important piece of the puzzle in determining vitamin D’s role in 
muscle ageing (82). 
 
Although the VDRKO mouse model has greatly advanced our knowledge of 
diverse biological effects of the vitamin D-endocrine system (83), there are 
inherent limitations to this model. Global effects of VDR ablation such as growth 
restriction, hairlessness, and hyperparathyroidism may confound the examination 
of tissue-specific effects. Conditional, muscle-specific deletion of VDR is 
therefore necessary to confirm the local effects of vitamin D that have been 
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reported in thesis. A similar approach has been taken by generating mice with 
cardiomyocyte-specific ablation of VDR. These mice display severe cardiac 
hypertrophy in response to an adrenergic stimulus, similar to the phenotype seen 
in whole-body VDRKO mice (84). Similar studies are currently underway, 
employing Cre-lox recombinase technology for VDR deletion in skeletal muscle. 
 
Concluding remarks 
This thesis reports the unequivocal presence of VDR in skeletal muscle and 
provides closure to this long-standing controversy. This thesis elucidates direct 
effects of vitamin D on muscle function relating to development, fibre 
morphology, strength and local uptake of 25OHD. These findings provide hope 
that the vitamin D endocrine system may be a potential therapeutic target for 
diseases of muscle wasting, sarcopaenia and acquired myopathies. 
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